annual report image hiv virusgsk annual report gsk scienceled global healthcare company strategic report new ceo discusses measuring performance performance managing risk new longterm priorities see pages see pages create innovation performance longterm value three businesses see pages see pages industry trends three businesses together contribute trust priority see pages see pages new longterm priorities financial review innovation performance trust see pages see pages cover image cautionary statement years developing first hiv see inside back cover document medicine research treatment cautionary statement regarding prevention hiv continues remain forwardlooking statements forefront helping people living hiv driving innovation working communities world ggsskk aannnnuuaall rreeppoorrtt ssttrraatteeggiicc rreeppoorrtt ggoovveerrnnaannccee aanndd rreemmuunneerraattiioonn ffiinnaanncciiaall ssttaatteemmeennttss iinnvveessttoorr iinnffoorrmmaattiioonn financial performance bn bn aer aer group turnover cer new product salesb cer bn bn aer aer total operating profit cer adjusted operating profit cer p p aer aer total earnings per share cer adjusted earnings per share cer bn bn bn p net cash flow free cash flow dividends declared dividend operating activities per share strategic report remuneration report investor information glance chairmans annual statement quarterly trend chairmans statement annual report remuneration five year record ceos statement remuneration policy summary product development pipeline create longterm value product competition financial statements industry trends intellectual property longterm priorities directors statement principal risks uncertainties measure success responsibilities share capital control manage risk independent auditors report dividends pharmaceuticals financial statements financial calendar vaccines notes financial statements annual general meeting consumer healthcare financial statements tax information shareholders trust glaxosmithkline plc prepared shareholder services contacts group financial review uk gaap us law regulation group companies governance glossary terms chairmans governance statement board footnotes corporate executive team aer growth rates represent growth actual exchange rates use number adjusted nonifrs measures leadership effectiveness report performance business described including adjusted results free cash flow nominations committee report cer growth rates measures used management planning reporting purposes may accountability directly comparable similarly described measures used companies adjusted results exclude audit risk committee report number items presented management believes adjusted results allow key trends factors driving performance easily clearly identified shareholders nonifrs measures may relations stakeholders considered addition substitute superior information presented accordance ifrs science committee report reconciliation total results adjusted results set corporate responsibility b defined new products follows pharmaceuticals relvarbreo ellipta incruse ellipta anoro committee report ellipta arnuity ellipta eperzantanzeum nucala tivicay triumeq vaccines menveo bexsero shingrix gsk annual report gsk glance purpose three global businesses help people feel better live longer goal one worlds innovative best performing trusted healthcare companies strategy immune system tcells attacking cancer cell bring differentiated highquality needed healthcare products many people possible three global businesses scientific technical knowhow talented people values expectations values expectations heart everything form important part culture values expectations patient focus courage herpes zoster virus shingles transparency accountability respect development integrity teamwork novamin key technology sensodyne repair protect gsk annual report strategic report governance remuneration financial statements investor information three global businesses pharmaceuticals leading positions group turnover respiratory hiv focused new longterm priorities read vaccines innovation see pages broadest portfolio group turnover leading position meningitis performance opportunity shingles see pages read trust see pages consumer healthcare category leadership group turnover respiratory pain relief oral health read gsk annual report chairmans statement board believes renewed focus innovation enable gsk capitalise opportunities industry drive longterm value investors philip hampton chairman pleased report another year cash generation remains key focus financial reporting good performance sales earnings board pleased see board mindful need growth important new product increased free cash flow year provide clear financial reports approvals continued cash returns approved dividend p per share reviewed aspects financial reporting shareholders line expectations expect framework made changes ensure remain line latest regulatory following emma walmsleys appointment noted first letter shareholders requirements best practice ceo april board two years ago cash dividends industry commercial structures conducted review companys excess free cash flow generation reporting requirements sometimes lead strategy management context still case board complexity reporting would operating environment industry established policy achieving like make great efforts simplify dynamics global healthcare july time cash dividend cover range clarify possible emma presented new strategy x x since investment growth investors setting longterm priorities opportunities funded least board changes year three main headings innovation part cash retentions business continue bring new skills performance trust top priority capabilities board year culture improve performance welcomed dr laurie glimcher central ensuring longterm delivery pharmaceuticals business seek independent nonexecutive director strategy developing culture growth pharmaceuticals rd scientific medical expert years rewards high performance board believes renewed focus agm professor sir roy anderson also seeks build values innovation enable gsk capitalise joined board stepdown company board pleased see opportunities industry thank roy excellent contribution employees support marked drive longterm value investors special areas scientific increase employee engagement early progress strategy scores past knowledge also broadly encouraging board closely instances commercial practices dr patrick vallance also step engaged management delivery disappointing leading board end march leave gsk become chief scientific regulatory intervention board capital allocation adviser uk government patrick focused improving framework company new capital fine leader board colleague culture control environment allocation framework help shape sir andrew witty dr moncef slaoui strategic priorities improving pipeline executive team stepped long careers new pharmaceutical products main following announcement emma company thanked priority company potential new ceo board involved last letter marked improvement performance top executive appointments dr hal new science committee made good also invest behind key products barron new chief scientific officer progress last year crucial vaccines business expect president rd joined board enter important phase pipeline drive growth coming years new president global pharmaceutical vaccines activities addition may invest pharmaceuticals luke miels new next years dr barron consumer joint venture partner chief digital technology officer working closely committee novartis decides exercise option karenann terrell board taken sell interests us dividends keen interest balance would like thank gsks employees represent allocation capital external recruits development partners hard work throughout board mindful value many internal succession planning shareholders customers shareholders attach dividends continued support look framework material acquisitions forward successful lower priority would meet strict returns criteria philip hampton chairman gsk annual report strategic report governance remuneration financial statements investor information ceos statement ambition drive highperformance culture putting science heart gsk remaining true values purpose help people feel better live longer emma walmsley chief executive officer longterm priorities im delighted introducing gsks consumer healthcare sales driven annual report first ceo power brands continued innovation see outpace market growth sales since starting role become new gsk innovations represented increasingly clear performance see healthcare industry remains attractive approximately turnover sector entering period significant total earnings per share p trust see change bringing challenges accounting charges billion opportunities addition despite improved related us tax reform adjusted delivery recent years also clear earnings per share aer cer several areas company need p three businesses strengthened group adjusted operating margin improved pharmaceuticals see thats july set three longterm reflecting effective management costs priorities everyone company successful integrations new focused innovation performance businesses vaccines consumer vaccines see trust believe priorities enable healthcare us focus areas improve renewed emphasis cost consumer see allow us respond effectively cash discipline pleased operating environment focus us healthcare see free cash flow year delivering improved performance billion improvement better returns shareholders million previous year short long term well met expectation paying dividend broader societal contribution pence per share performance expect deliver group sales billion pipeline progress actual rates constant exchange towards end received rates cer growth across three approvals three key new products businesses first time group shingrix new vaccine represents sales reached billion new standard prevention year shingles juluca first series new pharmaceutical vaccine product drug regimens hiv reduces sales billion continued number drugs patients take strong performances hiv living longer becoming medicines tivicay triumeq ellipta chronic disease trelegy ellipta portfolio biologic medicine nucala first day inhaler respiratory meningitis vaccines combine three medicines one device treat chronic obstructive pulmonary performance new products disease copd great demonstration achieve commercial organisation focus successfully launch clear focus new products bring significant benefits patients continue maximise current portfolio footnote use number adjusted nonifrs measures report performance described gsk annual report ceos statement continued clear need strengthen hal one three senior leaders pharmaceutical business pipeline appointed executive team last year ultimately drive sustainable luke miels joined new president longterm growth company pharmaceuticals responsible driving performance commercial set organisation work closely refocusing rd organisation hal ensure alignment rd four areas two world karenann terrell also joined us new leader respiratory hiv two role chief digital technology potential areas oncology immuno officer karenann joins time inflammation pipeline potential overlap healthcare areas innovative early technology never apparent next years continue receive potentially transformative role data number key assets ensure gsk forefront inform progress exciting new opportunity new external appointments made number changes delighted appointed dr hal senior leadership year barron chief scientific officer promoting great internal talent president rd joins us bringing fresh expertise outside calico alphabetfunded company company spent many years roche genentech gained exceptional performance values based culture reputation leading highly productive ambition drive highperformance rd teams would like thank dr patrick culture putting science heart vallance outgoing president rd gsk remaining true values contribution last years purpose help people feel ensuring smooth transition better live longer long history hal wish well new role tackling worlds biggest health uk governments chief scientific adviser challenges commitment improving uniquely qualified global health responsible business continue leadership corporate executive team e mma walmsley imon dingemans karenann terrell chief executive officer chief financial officer chief digital technology officer dr hal barron n ick hirons claire thomas c hief scientific officer senior vice president global ethics senior vice president president rd compliance human resources roger connor brian mcnamara p hil thomson president global manufacturing ceo gsk consumer healthcare president global affairs supply l uke miels dan troy luc debruyne president global pharmaceuticals senior vice president president global vaccines avid redfern general counsel chief strategy officer see pages gsk annual report strategic report governance remuneration financial statements investor information great people commitment foundational gsks culture technology revolutionising healthcare year conducted new global employee survey aligned priorities pleased see meaningful improvement new frontiers innovation genomics employee engagement scores creating major opportunities us patients important driver performance outlook ability apply new technology also maximising huge given momentum seeing across rd activities creating amount data within gsk applying new products recent launches major opportunity gsk currently artificial intelligence machine operating performance improvements across industry almost learning allow us identify driving benefit us tax medicines entering trials fail never patterns would almost reform increasingly confident reach patients part impossible identify using traditional ability deliver outlook incomplete understanding methods model right mid high single digit growth adjusted link biological patient population find eps cagr cer target drug human disease clinical trials reduce could see generic competition pursuing drug targets human eliminate need studies advair us guidance genetic evidence support cases predict outcomes year reflects aside advair indication estimated double virtual patient allowing us expect face significant generic probability developing safe effectively manage diversity erosion us mids effective medicines improve within clinical trials align research development population demographics analysing finally want say thank gsk productivity recent years clinical trials last ten years employees partners customers approximately gsks new work especially gsk connecting bringing targets supported human support first year ceo life patient data genomics genetic evidence also gsk much look forward working wearable devices social media one first companies make beyond deliver emerging sources ensuring multimillion pound investment uk longterm priorities improved leverage opportunities biobank support generation performance gsk presented new genetic sequencing data half million volunteers information generated groundbreaking health resource provide vital insights hope inform support development transformative medicines emma walmsley chief executive officer footnote use number adjusted nonifrs image wellcome images measures report performance described gsk annual report create longterm value scienceled global healthcare company three businesses common aim improving health describe resources rely business activities span lifecycle product create longterm value shareholders society resources talented people st distrib ute returns invest scientific r e e ar c h ein r e scientific pharmaceuticals v e l technical knowhow p e n effective capital allocation g vaccines purpose n e n e ati r external collaborations e r e erciali v e consumer n u healthcare e c n n supply chain pr fit uring ct uf n longterm priorities values expectations innovation patient focus courage transparency accountability performance respect development trust integrity teamwork gsk annual report strategic report governance remuneration financial statements investor information industry trends longterm priorities measure success manage risk value create shareholders aim deliver sustained industryleading growth competitive costs margins cash flow distribute capital shareholders create value form dividends p p invest scientific research total earnings per share adjusted earnings per share invested billion research development bring new medicines vaccines bn p consumer healthcare products patients payers consumers strategic business development including external partnerships dividends declared dividend per share joint ventures supports inhouse scientific research patients consumers generate revenue profit aim bring differentiated highquality needed healthcare products many people possible generate revenue executing new product launches brilliantly sales existing portfolios three businesses bn bn integrated strategy one pl enables us drive competitive costs margins cash flow across company packs medicine vaccines sold consumer healthcare sold products made reinvest distribute returns employees society part capital allocation framework reinvest three businesses also provide want run company responsibly ethically returns shareholders form dividends modern employer strong employee engagement make positive contribution communities operate creating employment working suppliers paying tax bn employees cash tax paid footnote use number adjusted nonifrs measures report performance described gsk annual report industry trends create longterm value operating fastchanging environment potential growth outline key opportunities challenges influence new longterm priorities global healthcare market growing healthcare industry entering strategic response global pharmaceutical sales period significant change bringing strategy designed respond billion month rolling basis opportunities challenges life changing environment bring september expectancy increases demographic differentiated highquality needed september north america changes supporting market healthcare products many people remains largest pharmaceutical growth contributing pressures possible three global market share global sales healthcare sector particularly businesses scientific technical global vaccine sales totalled approximately pricing access knowhow talented people billion challenges new industry new longterm priorities sales consumer healthcare markets advances science technology innovation performance trust gsk operates total approximately transforming way scientists help us deliver strategy billion research diseases likely improve patients diagnosed treated future positive demographics demographic change increasing life expectancy advances science expanding global population driving technology disruption demand healthcare products growing prosperity changing diets better understanding human biology lifestyles also fuelling demand genomics changing way healthcare products especially scientists research diseases chronic conditions ability develop novel treatments respiratory disease patients advances digital technology data analytics enabling pricing access researchers explore interpret everlarger volumes biological data increasing demand healthcare partly much faster technology led demographic change continues also central way people put pressure government gain information compare payer budgets impacting buy healthcare products developing developed markets including europe us public privately funded organisations looking ways address affordability medicines ims data internal data gsk annual report strategic report governance remuneration financial statements investor information longterm priorities measure success manage risk societal expectations companies expected behave greater integrity fairness transparency make positive contribution society companies sustainable must create longterm value stakeholders including shareholders genericisation competition employees customers communities patent protection applies pharmaceutical medicines patents expire challenges upheld competition authorities patients payers gain access generic alternatives lower priced generic competition often results lower sales patented products regulatory political environment healthcare highly regulated industry reflecting public expectations products comply stringent levels quality safety efficacy globally changing national politics impacting operating environment particularly governments often making healthcare priority see summary impact brexit gsk longterm priorities innovation performance trust gsk annual report longterm priorities create longterm value industry trends innovation strong patient payer focused pipeline competitive claims labels brilliant execution launches gsk annual report strategic report governance remuneration financial statements investor information measure success manage risk innovation read innovation innovation pharmaceuticals see pages innovation vaccines see pages innovation consumer healthcare see pages ggsskk aannnnuuaall rreeppoorrtt longterm priorities create longterm value industry trends performance sustained industryleading growth competitive costs margin cash flow ggsskk aannnnuuaall rreeppoorrtt ssttrraatteeggiicc rreeppoorrtt ggoovveerrnnaannccee aanndd rreemmuunneerraattiioonn ffiinnaanncciiaall ssttaatteemmeennttss iinnvveessttoorr iinnffoorrmmaattiioonn measure success manage risk performance read performance performance pharmaceuticals see pages performance vaccines see pages performance consumer healthcare see pages ggsskk aannnnuuaall rreeppoorrtt longterm priorities create longterm value industry trends trust maximising social impact ensuring reliable supply highquality products many people possible highly engaged employees ggsskk aannnnuuaall rreeppoorrtt ssttrraatteeggiicc rreeppoorrtt ggoovveerrnnaannccee aanndd rreemmuunneerraattiioonn ffiinnaanncciiaall ssttaatteemmeennttss iinnvveessttoorr iinnffoorrmmaattiioonn measure success manage risk trust read trust across three businesses addressing global health sustainable access science highquality products see pages see pages modern employer ethical conduct environmental sustainability see pages see pages gsk annual report measure success create longterm value industry trends longterm priorities identified ten operating key performance indicators kpis track progress new group turnover longterm priorities aer bn cer innovation innovation sales pipeline value progress performance turnover profit cash flow market growth aer cer share top talent key roles trust supply service levels employee engagement corporate reputation provide performance data operating kpis reporting externally due commercial sensitivities planning publish data performed operating kpis group turnover year increased aer cer billion growth delivered three businesses pay performance remuneration policy used reward performance pharmaceuticals sales aer cer reflecting continued strong growth new respiratory hiv products executives includes measures linked kpis partly offset declines older respiratory products vaccines sales see pages aer cer reflecting strong performance meningitis influenza vaccines consumer healthcare sales grew aer cer reflecting strong performance power brands pain oral health categories partly offset impact continued competitive pressures us allergy category broader market slowdown operating profit margin earnings per share bn p total total bn p adjustedc adjustedc growth growth total adjusted aer cer total adjusted aer cer b b b b performed performed total operating profit billion higher aer basis increase total earnings per share reflected reduced impact higher cer charges arising revaluations liabilities contingent consideration put options associated groups hiv adjusted operating profit billion higher aer consumer healthcare businesses benefit swiss tax reform basis higher cer adjusted operating margin improved performance relevant businesses partly offset percentage points higher percentage points charges arising us tax reform higher cer basis reflected improved operating leverage driven sales growth together favourable mix continued tight adjusted earnings per share p aer cer control ongoing costs across three businesses line guidance provided july linked remuneration gsk annual report strategic report governance remuneration financial statements investor information manage risk new productinnovation sales free cash flow bn bn growth definition definition identified series new pharmaceutical vaccine calculation free cash flow described products expected deliver least billion revenues reconciliation provided per annum cer basis full list products included performed definition provided increased free cash flow million investing performed priority review voucher approximately million sales new pharmaceutical vaccine products billion inventory primarily support new launches increase aer cer represented approximately pharmaceuticals vaccines turnover year exchange rates equivalent value sales billion linked remuneration linked remuneration dividends declared employee engagement bn favourable responses global employee survey dividends description measure employee engagement twice annually inviting gsk employees participate global employee survey engagement kpi based favourable responses four questions pride company feeling valued employee opportunity meaningful challenging work recommending gsk great place work employees participated performed new survey engagement score set baseline future improvement score represented declared dividends shareholders increase three four questions directly comparable p per share giving total return billion year footnotes revised include contingent consideration payments b djusted results exclude significant legal charges per revised definition prior year figures revised c w e use number adjusted nonifrs measures report performance business described including adjusted results free cash flow cer growth rates nonifrs measures may considered addition substitute superior information presented accordance ifrs includes special dividend gsk annual report manage risk create longterm value industry trends longterm priorities measure success principal risks regularly reviewed cet list principal risks managed across group including assessment change risk year due macro events mitigating gsk activities gsk exposure macro post risk description assessment mitigating activities environment mitigation patient safety macro environment remained unchanged patient safety regulation good pharmacovigilance practices failure appropriately collect review follow report adverse events potential remaining consistent sources act relevant findings gsk exposure level remained unchanged risk timely manner maintained appropriate level continued strong oversight developing capabilities detect safety issues making key safety processes standards simpler effective product quality macro risk level remained unchanged continuing industrylevel regulatory scrutiny data integrity drug failure comply current good manufacturing practices inadequate controls governance shortages expectation timely communication quality supply chain covering supplier issues authorities standards manufacturing distribution gsk exposure level remained unchanged risk products maintained appropriate level effective response external inspections continuous improvement data integrity programmes quality management system financial controls reporting macro risk level remained unchanged due material increase financial reporting requirements failure comply current tax law incurring significant losses due treasury activities gsk exposure level reduced due strong risk failure report accurate financial information management governance approach compliance accounting standards embedding system changes controls standardisation applicable legislation process simplification antibribery corruption abac macro risk level increased due stringent abac laws rise enforcement regulators failure gsk employees complementary workers third parties comply gsk exposure level remained unchanged enhanced abac principles standards well use data better inform business decisions strengthened applicable legislation management abac risk third party network introduced improved abac standard clarifying stance expected behaviours government investigations regarding china business operations ongoing see commercial practices macro risk level increased due greater competitive pressure increased regulatory enforcement expansion failure engage commercial activities consistent letter spirit digital marketing laws regulations still evolving law industry groups requirements gsk exposure level remained unchanged continued relating marketing communications develop robust controls mature commercial practices medicines associated therapeutic order apply appropriate oversight assurance across areas appropriate interactions healthcare markets increased digital capability across gsk professionals hcps patients legitimate transparent transfer value enhanced internal controls mitigate risk gsk annual report strategic report governance remuneration financial statements investor information arrows key increased risk change risk decreased risk gsk exposure macro post risk description assessment mitigating activities environment mitigation research practices macro risk level remained unchanged despite evolving regulation continuing industrylevel regulatory scrutiny failure adequately conduct ethical sound preclinical clinical research addition failure data integrity engage scientific activities consistent gsk exposure level remained unchanged risk letter spirit law industry maintained appropriate level groups requirements failure secure strengthened governance structure includes enterprise adequate patent protection gsks products wide management risk enables better information sharing increased focus systems data analytics third party oversight tpo macro environment remained unchanged industry continues vigilant thirdparty risks global sourcing failure maintain adequate governance oversight thirdparty relationships failure supply consumer investor expectations mature third parties meet contractual regulatory gsk exposure level reduced following rollout confidentiality obligations tpo programme risk assessed third parties directly engage enable us identify manage risks consistently proportionately improvement plans place required insights programme informed sourcing processes mitigate risk environment health safety macro risk level increased due greater emphasis sustainability ehss environment antimicrobial resistance increasing emerging market regulation potential impact eu chemicals failure manage environment health safety legislation greater use third parties develop sustainability risks line objectives policies relevant laws regulations pipeline assets gsk exposure level remained unchanged due continued execution enterprise strategy strengthening ehss controls information protection macro risk level continued increase threat pharmaceutical business industry generally became risk gsk business activities information becomes disclosed authorised see sophisticated targeted evidenced wannacry information systems fail available notpetya global incidents new regulations corrupted typically cybersecurity introduced including eu general data protection regulation threats although accident malicious insider despite gsk exposure level remained unchanged action may contributory causes also due development programme safeguard includes risk failure collect secure use personal information accordance data cyberattacks protect critical information privacy laws systems ability balance demands regulation digital transformation involves increased data collection analysis supply chain crisis macro risk level remained unchanged ongoing stringent management regulation continued us focus contract manufacturers outside useu increasing data integrity expectations failure deliver continuous supply compliant finished products inability respond effectively gsk exposure level reduced due improved risk crisis incident timely manner recover management supplier portfolio progress completing sustain critical operations including key supply remediation programmes improvements supply chains crisis continuity management framework information see pages see viability statement gsk annual report oncology immune system tcells attacking cancer cell gsk annual report strategic report governance remuneration financial statements investor information pharmaceuticals pharmaceuticals business broad portfolio innovative established medicines focused developing new medicines respiratory hiv oncology immunoinflammation discovery research exploring areas pharmaceuticals sales aer two significant cer reflecting continued strong pharmaceutical approvals trelegy ellipta growth nucala ellipta portfolio provides three medicines respiratory tivicay triumeq day single inhaler treat copd dave oncology scientist uk hiv juluca first drug regimen oncedaily joined forces partners rapidly single pill hiv helps reduce evolve science immunooncology one amount medicines patients need area working increasing ability bodys immune system help detect pharmaceuticals turnover attack cancer cells respiratory hiv immunoinflammation established pharmaceuticals total fran cancer survivor gsk employee whats next innovation pharmaceuticals see pages performance pharmaceuticals see pages report trust priority footnote across three businesses use number adjusted nonifrs measures report performance see pages described gsk annual report pharmaceuticals innovation priority strengthen pharmaceuticals business focusing fewer assets improving rd commercial interface brilliant execution launches pharmaceuticals business continues created integrated grow global leaders competitive pharmaceuticals business respiratory hiv two significantly strengthening existing bestinclass medicines approved trelegy partnership rd commercial ellipta oncedaily triple therapy made several significant chronic obstructive pulmonary disease leadership appointments including copd single inhaler juluca hal barron chief scientific officer first twodrug regimen oncedaily single president rd luke miels pill hiv also made important president global pharmaceuticals progress across pipeline assets highly respected leaders track record bringing new medicines delivering bestinclass innovation market respiratory need focus medicines leader respiratory greatest potential back stop medicine nearly years remain projects following review forefront scientific research drug development process area offering innovative medicines aimed focusing priority assets two areas treating patients symptoms reducing world leaders respiratory risk disease worsening hiv two potential areas oncology immunoinflammation trelegy ellipta ensure sufficient funding year gained us resource priority areas european regulatory approval trelegy medicines gsk ellipta new oncedaily triple therapy support patients strengthen copd single inhaler launch existing business long term adds portfolio oncedaily inhaled terminated preclinical respiratory medicines broadest clinical programmes included industry ending collaboration janssen also achieved positive headline results biologics sirukumab starting trelegy ellipta phase iii impact process identifying new owner study patient study found rare disease gene therapy medicines oncedaily triple therapy achieved significant reductions moderatesevere exacerbations copd patients compared two oncedaily dual medicines ellipta portfolio submitted additional regulatory filings supported impact data aim expanding patient population trelegy ellipta copd also investigating efficacy safety trelegy ellipta phase iii study captain treatment patients asthma gsk annual report strategic report governance remuneration financial statements investor information respiratory assets juluca continue lead respiratory biologics november received us fda strategy action believe nucala mepolizumab offers approval juluca oncedaily single highly competitive profile received pill dr regimen hiv juluca combines scientific innovation fda approval additional indication dolutegravir rilpivirine edurant heart gsk mepolizumab first targeted janssen medicine complete treatment uncontrolled eosinophilic regimen treating hiv adults highest priority granulomatosis polyangiitis egpa virologically suppressed build next wave also submitted regulatory file resistance sword studies mepolizumab treatment copd patients phase iii trials growth company showed juluca achieved noninferior viral priority respiratory assets suppression compared traditional also target copd phase ii drug regimens purchase trials danirixin firstinclass oral use priority review voucher cxcr antagonist nemiralisib accelerated approval us highly selective firstinclass following june submission phosphatidylinositol kinase delta european medicines agency ema pik inhibitor regulatory approval expect hiv response longstanding commitment hiv assets hiv investigating new paradigms dr clinical trial programme dr hal barron treatment prevention cure chief scientific officer dolutegravir number one core agent consists eight phase iii clinical trials president rd globally success tivicay two completed sword studies support approval juluca triumeq offers important benefits four studies due report wide range patients used without need booster showed superior efficacy five different clinical dolutegravir lamivudine studies generally well tolerated investigated versus traditional drug high barrier resistance regimen treatmentnaive hiv patients interactions commonly used gemini studies medications tango trial patients achieved viral suppression tenofovir alafenamide today due advances antiretroviral fumarate tafbased regimen therapy art people living hiv near normal life expectancies compared longacting dr cabotegravir general population may spend rilpivirine investigated decades hiv treatment innovative administration every four weeks virally research drug regimens dr suppressed adults hiv infection initiated response physician atlas flair addition patient demand reduce longterm atlas study started investigate art exposure administration every two months also two phase iii studies began evaluate cabotegravir longacting monotherapy prevention hiv trials conducted publicprivate funding collaboration gsk annual report pharmaceuticals continued oncology immunoinflammation oncology focused delivering immunoinflammatory diseases transformational therapies lengthen relatively common chronic debilitating lives patients cancer conditions remains made significant progress emerging significant unmet medical need portfolio next generation therapies discover next breakthrough immune areas immunooncology cell therapy mediated diseases focusing epigenetics transformational medicines could potentially alter course inflammatory monoclonal antibody disease induce sustainable remission bcma potential target number tumour types including relapsed received approval us eu refractory multiple myeloma promising new subcutaneous sc formulation early results suggest highly competitive benlysta treatment systemic lupus profile compared existing approved erythematosus enables either home read pharmaceuticals treatments multiple myeloma hospital administration medicine pipeline pages granted european prime fda also received approval japan breakthrough status potentially resulting use benlysta first time faster review regulatory authorities two phase ii immunoinflammation filed priority assets monoclonal exercised option gain antibody blocks effect anti exclusive global licence adaptimmune granulocytemacrophage colony stimulating investigational spear factor gmcsf rheumatoid arthritis tcell receptor targeting nyeso osteoarthritis receptor granted european prime fda interacting protein rip kinase inhibitor breakthrough status another oncology psoriasis ulcerative colitis therapy first investigational rheumatoid arthritis inducible tcell costimulator icos agonist future pipeline optionality antibody enter human clinical trials outside core therapy areas assets phase iii trials number promising programmes including two latestage priority assets oral daprodustat phase iii trials anaemia associated chronic renal disease antisap therapy amyloidosis currently phase ii strengthening ensuring strong partnership rd commercial rd commercial functions priority us interface help ensure deliver differentiated medicines competitive profiles robust evidence plans compete effectively todays dynamic market single strategy across rd commercial ensure alignment focus across business simplifying processes eliminate complexity parallel strengthening commercial medical resource drive performance gsk annual report strategic report governance remuneration financial statements investor information accelerating priority assets new technology frontiers strategy action improving pace medicines digital technology impact development enhancing speedto every part business goal clinical decision making changes harness developments datarich governance adapting way informationbased medicine accelerate design conduct clinical trials drug discovery development drive business forward support acceleration established new board committee global scientific collaborations remain key innovation experts science committee ensure year joined forces two emerging scientific medical external companies harness artificial knowledge integrated strategic intelligence ai exscientia uk specialist planning addition new development machinelearning insilico medicine advisory committee provide board us leader ailed drug discovery strategic guidance aspects also cofounded privatepublic current future development activity accelerating therapies opportunities full consideration emerging trends medicine atom consortium based alternative approaches see us aims cut preclinical cancer information drug discovery six years one early research infrastructure using supercomputers analyse data around discovery performance units failed rd programmes aim dpus project accountability finding patterns vital clues aid budgets encourages competitive successful future development dimension proposed areas discovery also supporting uk biobank ground research capital allocation breaking initiative generate anonymised genetic sequence data volunteer participants deliver insights people greater risk disease addition continue work open targets programme supports open access search engine searches evaluates integrates biologic genetic disease data drug discovery development regulatory drug discovery preclinical clinical trials review manufacturing compounds one approved number volunteers drug phase phase ii phase iii years years years source pharmaceuticals research manufacturers america yrevocsiderp elfi yrotaluger dettimbus noitacilppa gurd wen dettimbus ecnallievrus gnitekramtsop digital technology transform many aspects develop new medicines interact customers karenann terrell chief digital technology officer gsk annual report pharmaceuticals continued performance pharmaceuticals sales aer cer reflecting continued strong growth new respiratory hiv products performance summary immunoinflammation sales million aer cer pharmaceuticals turnover year million aer cer sales established pharmaceuticals us total sales million million declining aer aer cer primarily driven cer reflecting three percentage new respiratory hiv products point impact recent divestments europe sales million noncore assets aer cer reflecting continued transition respiratory pharmaceuticals operating margin portfolio generic competition kivexa percentage points disposal romanian aer percentage points distribution business international sales cer primarily reflecting increased rd million aer investment including using priority cer review voucher q lower operating margin also reflected increased respiratory sales aer investment new product support well cer million new respiratory continued impact lower prices products recorded combined sales particularly respiratory partly offset million offsetting favourable product mix primarily decline seretideadvair driven growth hiv sales hiv sales increased aer cer continued cost reduction benefit million year growth groups pharmaceuticals driven continued increases restructuring programme market share triumeq tivicay partly offset impact generic competition epzicomkivexa particularly affecting european market delivering world ambitious commercial efforts asthma medicine relvarbreo class capability focused driving continuous growth ellipta focus target customer priority brands largest groups helped medicine become markets notably us rd first new respiratory portfolio teams continue generate evidence billion brand helping clinical trials support right four million patients year patients medicine well differentiation brands strategic use data analytics enabled us optimise role engagement training salesforce helped make sure knowledge disease strategy competitive environment led truly competitive customer engagement day one launch gsk annual report strategic report governance remuneration financial statements investor information outlook creating simpler competitive supply chain strategy action five years expect simplifying manufacturing low singledigit cagr sales supply chain achieve competitive strong sales new exchange rates despite higher level sustainable performance delivering products show divestments period strong results fundamentals safety originally expected strong performances quality service well improved achieve great things new medicines together financial performance focused focused disciplined cost management expected fewer priorities removing waste making enable business achieve things simpler current plans address operating margin low percentage productivity improvement procurement range exchange rates savings working supplier base even automatically substitutable prioritise fewer strategic supplier generic version advair launched relationships track reduce us suppliers approximately leveraging scale standardising driving performance specifications use fewer bespoke profitable sustainable growth materials improving cost goods continue invest manufacturing refocused pharmaceuticals luke miels network advanced manufacturing business make stronger president global pharmaceuticals technologies potential competitive order deliver improved improve product quality reducing sustainable returns leadership material waste lead times new luke miels simplified capacity work continuous commercial management structure processing well advanced reshaped operations deployed could reduce cost goods aggressively reallocating resources long term areas best able deliver profitable sustainable growth returns digital transformation much focus new medicines goal apply digital technology major markets delivers truly competitive customer engagement drive better performance changes making drive sharper prioritisation simpler portfolio investment area underpinned faster decision making effective appointment karenann terrell capital allocation strong focus chief digital technology officer execution joined september help drive digital transformation programme began streamlining across three businesses pharmaceuticals products portfolio exiting divesting noncore across pharmaceuticals business brands track reach using new technologies improve goal fewer brands performance increased focus included announcing end improving customer experience manufacture sale type diabetes includes customercentric integrated therapy eperzantanzeum campaigns personalised content expect end addition help healthcare professionals deliver announced strategic review better patient outcomes drive cephalosporins antibiotics business preference brands option sell restructuring emerging markets business improve growth profitability sustainability continuing ensure access patients need medicines simplifying geographies reducing organisational layers simplifying cost structures including moving export model markets support faster aligned execution footnote use number adjusted nonifrs measures report performance described gsk annual report shingles herpes zoster virus shingles gsk annual report strategic report governance remuneration financial statements investor information virginie laboratory technician vaccines rd new vaccine shingrix represents significant advance vaccine technology clinically demonstrated strong sustained immune response efficacy shingles painful complications alain shingles sufferer gsk employee vaccines vaccines business broad portfolio innovative pipeline vaccines help protect people throughout life deliver two million vaccine doses per day people living countries vaccines sales aer year received us fda whats next cer primarily driven meningitis approval shingrix new vaccine vaccines bexsero growing across represents new standard innovation regions menveo us europe prevention shingles vaccines higher sales influenza products see pages vaccines turnover primarily us europe meningitis influenza performance shingles vaccines established vaccines see pages total report trust priority footnote across three businesses use number adjusted nonifrs measures report performance see pages described gsk annual report vaccines innovation advanced science technology platform capability enables us discover develop vaccines help protect people countries serious diseases vaccines strategy bring following approval us food differentiated highquality needed drug administration fda october vaccines many people possible competitive position global scale well shingrix strengthened positioned take advantage changing recommendations us centers demographics vaccines longterm disease control preventions assets without volatility patent cliffs cdcs advisory committee provides opportunities invest immunization practices acip naming lifecycle management improve preferred shingles vaccine adults competitive profile existing vaccines aged recommendation better meet patient needs includes revaccinating previously received competitor vaccine focus finding new candidate meaning million people us vaccines help protect people eligible shingrix vaccine ages disease pipeline candidate vaccines currently january received positive development believe core opinion european medicines competitive advantage expertise agencys emas committee medicinal technology platforms facilitates products human use shingrix development effective vaccines results regulatory filings shingrix australia japan also innovation action due addition december announced new data confirming received regulatory approval safety efficacy shingrix immuno us canada shingrix compromised autologous haematopoietic efficacy believe stem cell transplant patients provides step change prevention commercial manufacturing rd shingles anticipate could drive teams worked closely together onethird vaccines growth ensure shingrix launch executed people flawlessly taking staged approach infected varicella zoster global launch order manage virus causes shingles one three strong anticipated demand develop shingles lifetime reliable supply breakthrough shingles painful potentially vaccine science serious condition shingrix developed specifically overcome agerelated decline immunity first shingles vaccine combine nonlive antigen trigger targeted immune response specifically designed adjuvant system asb make response strong sustained adjuvant also used rtss vaccine prevention malaria children gsk annual report strategic report governance remuneration financial statements investor information delivering bestinclass innovation developed malaria vaccine candidate received positive strategy action aiming develop assets opinion european medicines best class investment unique agency ema see global vaccines technology platforms including adjuvants rd organisation delivering competitive advantage new technology frontiers targeting new emerging remaining supported unique medical needs new technologies including technology platforms adjuvant systems structural vaccinology meningitis synthetic vaccine platforms talented people focus maintain gsks helping us move beyond observation meningococcal meningitis market experimentation methods vaccine developing vaccines leadership licensed candidate development create vaccines design meet existing vaccines aim broaden age made antigens delivery range meningococcal vaccines systems adjuvants help emerging needs us demonstrate impact increase immune systems response infants well meningococcal carriage vaccine adolescents february granted breakthrough designation gsk innovating adjuvant bexsero children aged years systems years unique also working new formulations approach led development including fully liquid presentation several adjuvant systems families tetravalent vaccine menacwy menveo use combination adjuvants expected enter phase ii clinical achieve better immune response trials results phase iii fundamental next generation study booster menveo vaccines portfolio emmanuel hanon expected also committed selfamplifying mrna sam senior vice president developing single vaccine tackles technology uses human body head rd vaccines five common serogroups factory produce vaccines b c w sam require traditional vaccine reflecting active lifecycle management production methods could potentially vaccines strategically enable us produce vaccines plan assets commercial journey quickly simply early final clinical trials onwards continue stages data variety animal expand target populations protection models show sam performs well way aim extend patient benefits increase use vaccines external partnerships leader helping prevent meningococcal disease collaboration central innovation around external scientific line approach supporting collaborations extensive study examine candidate vaccines developed meningococcal b vaccine reduces partnership collaborations enable spread meningococcal bacteria vaccines scientists global teenagers herd immunity rd centres us belgium italy involves vaccinating teenagers learn experts stay close south australia high incidence emerging technologies example meningococcal b disease involved phase ii trial priority assets hiv vaccine group ngos pharmaceutical companies led building gsks existing respiratory us national institutes health leadership position pharmaceuticals business number candidate vaccines targeting respiratory diseases include candidate vaccine chronic obstructive pulmonary disease copd began phase ii proof concept study europe growth drivers respiratory portfolio respiratory syncytial virus rsv candidates different approaches tailored age group also research collaboration focused read vaccines tuberculosis candidate pipeline vaccine currently phase ii trials gsk annual report vaccines continued performance demand worldleading meningitis portfolio contributed aer cer increase vaccines sales performance summary following launches argentina belgium bexsero available vaccines sales grew aer cer countries vaccines broad age million primarily driven indication provides competitive advantage meningitis vaccines bexsero growing europe us offers across regions menveo us fastest series completion two doses europe higher sales influenza administered one month products primarily us europe menveo sales grew aer cer vaccines operating margin primarily driven impact favourable percentage points aer yearonyear cdc stockpile movements percentage points higher cer partly offset supply constraints basis primarily driven improved international product mix benefit settlement lost thirdparty supply volume together influenza continued restructuring integration fluarixflulaval sales aer benefits partly offset cer million reflecting strong increased sga selling general sales execution primarily us administration resources support higher demand europe business growth new launches shingles increased supply chain costs shingrix recorded initial sales lower royalty income distributors million us meningitis fda approval favourable meningitis sales grew aer cer acip recommendations million bexsero sales growth aer cer driven new national immunisation programmes private market sales regional tenders europe well growing demand us together strong private market sales international global demand million doses meningitis b vaccine bexsero bexsero distributed since launch bexsero developed using reverse image meningococcal vaccinology decodes serogroup b bacteria genome sequence meningitis b commonly known selects effective protein meningitis b candidates use vaccine bexsero part national immunisation programmes uk andorra ireland italy us bexsero current market share represents approximately adolescent market gsk annual report strategic report governance remuneration financial statements investor information established vaccines driving performance profitable strategy action established vaccines growth driven sustainable growth hepatitis vaccines mainly due competitor supply shortage us year decided discontinue focused higher demand boostrix rotarix number commercially available maintaining launch cervarix china first vaccines within established vaccines cervical cancer vaccine approved portfolio low volume leadership position launched country also contributed medical needs met vaccines meningitis vaccines towards growth favourable yearon year cdc stockpile movements infanrix creating simpler competitive executing pediarix us growth supply chain partly offset increasing competitive global vaccines network includes shingrix launch pressures infanrix pediarix vaccine manufacturing sites countries flawlessly us europe lower synflorix sales international presence enables us driven lower pricing developing manufacture vaccines greater countries capacity efficiency flexibility aim keep critical production steps inhouse wherever possible outlook continue focus removing five years expect complexity supply chain since mid high singledigit cagr sales reduced number different exchange rates strong launch packs increased shingrix key priority believe manufacturing flexibility simplified vaccine could one biggest standardised product offerings luc debruyne growth drivers support commercial strategy president global vaccines period still targeting operating profit margin least process analytical robustness exchange rates process improvements analytical robustness enabled us produce bexsero vaccine efficiently due new pyrogen test approved several countries improved assay robustness eliminated failures also demonstrated feasibility increasing yields reducing failure rates two four antigen manufacturing processes synflorix process robustness programme completed continued deliver good results enabling us manufacture product without major losses transaction savings excellent execution acceleration integration implementation plan across rd manufacturing global support functions commercial network procurement helped vaccines business deliver million novartis integration savings target footnote use number adjusted nonifrs measures report performance described gsk annual report oral health novamin key technology sensodyne repair protect gsk annual report strategic report governance remuneration financial statements investor information consumer healthcare consumer healthcare business develops markets consumerpreferred expertrecommended brands oral health pain relief respiratory nutrition gastrointestinal skin health consumer healthcare sales consumer healthcare turnover aer cer strong performance wellness power brands across wellness oral health oral health partly offset competitive nutrition pressures us allergy category skin health darren principal scientist sales new gsk innovations product total oral health rd uk introductions within last three years novamin technology sensodyne repair rolling basis represented approximately protect seeks forms protective layer sales period notable footnote sensitive areas teeth helping relieve pain sensitive teeth launches several line use number adjusted nonifrs extensions sensodyne including measures report performance described next generation sensodyne rapid relief sensodyne deep clean well voltaren mess parodontax launched flonase sensimist us continued global rollout flonase otc overthecounter van sensitive teeth sufferer whats next innovation consumer healthcare see pages performance consumer healthcare see pages report trust priority across three businesses see pages gsk annual report consumer healthcare innovation priorities execute brilliant product launches build strong differentiated pipeline consumerled sciencebased innovations claims continued demonstrate also introduced sensodyne deep ability innovate within consumer clean toothpaste number markets healthcare market harnessing gsks provides deep clean sensitive scientific technical expertise alongside teeth using small particle silica delivers deep consumer insights proportion longlasting freshness novel sales innovations launched within coolant technology last three years approximately key innovation launched included several key launches voltaren mess cap makes product easier less delivering bestinclass innovation messy apply addressing one key consumer barriers using topical new sensodyne rapid relief latest painreliever unique innovative premium extension billion packaging assessed extensively sensodyne brand launched new consumer sensory testing successfully markets laboratories rollout continues developed ukbased oral health innovation hub launched parodontax brand designed provide fast relief tooth clinically proven help prevent bleeding sensitivity supported clinical gums gingivitis first time studies active ingredient stannous us fluoride seals layer beneath surface tooth enamel known dentine aided special polymer clinical data shows result relief pain sensitivity within little seconds consumer insightdriven innovation new eno cooling antacid creates instant cooling sensation taken scientists developed formulation create cooling effect research consumer sensory labs showed consumers believe feeling cool internally helps soothe heartburn eno cooling launched india one many consumerled innovations created following research three consumer sensory facilities india uk us gsk annual report strategic report governance remuneration financial statements investor information continued see success emerging market opportunities strategy action switch programme flonase sensimist successfully changing prescription emerging markets continue key medicine overthecounter opportunity area growth consumer deliver differentiated product us enhancing offering healthcare increased products consumers allergy market also emerging market rd investment continued global rollout flonase focus particular china combining consumer launching several markets indiabased innovation hubs insights scientific including canada spain czech continue identify local consumer republic switching flonase retailer insights underpin product technical excellence prescriptiononly overthecounter development marketing ensuring recognised growing consumer demand remain locally relevant competitive greater personal control healthcare india example discovered nearly half indigestion treatments building industryleading use home remedies using insight capabilities developed launched new variant eno antacid using popular continued invest understanding ajwain herb contributed strong meeting consumers retail brand growth customers needs expanding international network consumer sensory external innovation richard slater shopper science laboratories head rd new labs opening uk singapore continue look beyond gsk gsk consumer healthcare stateoftheart facilities additional innovation opportunities differentiate gsk retailer feedback saw significant increase showing scientific approach proportion pipeline coming shopper insight customer collaboration outside company identified puts us ahead competitors possible partnerships formally reviewed proposals integrated global innovation hubs entered partnerships colocating rd commercial increased external focus along experts continue ensure strong internal science capabilities innovation sciencebased ensures able develop consumerled breadth deliver strong competitive pipeline network also keeps us step consumerled sciencebased innovation local regional trends weather app theraflusponsored weather app boosts sales kept us consumers informed local cold flu levels boosted sales gsk brand teamed weather channel create theraflu cold flu tracker part launch campaign theraflu expressmax caplets reflecting social media conversations app gave likely cold flu levels users areas advising treat symptoms theraflu almost million unique visitors exposed theraflu messaging via tracker brands sponsorship weather channel sparked significant rise sales among app users peak flu season gsk annual report consumer healthcare continued performance strong performance power brands across wellness oral health helped drive growth performance summary category basis sales wellness grew aer cer million consumer healthcare sales grew reflecting strong performance aer cer million voltaren cold flu seasonal strong performance power brands products partly offsetting weaker across wellness oral health performance us allergy products partly offset competitive pressures oral health sales grew aer cer us allergy category impacting flonase million sensodyne sales otc well lower sales tail brands continuing drive performance nutrition across nutrition skin health sales grew aer declined cer categories addition reported growth million adversely impacted impacted disposal nigeria sale nigeria beverages business beverages business q implementation gst well implementation goods service continued competitive pressures tax gst india july net effects horlicks india skin health sales grew partly offset benefit aer flat cer million comparison impact consumer healthcare operating margin demonetisation india q percentage points aer divestment gst demonetisation percentage points higher combined reduce overall consumer cer basis reflecting tight control costs healthcare cer growth approximately integration synergies principally sga one percentage point partly offset increased investment sales new gsk innovations product power brands introductions within last three years rolling basis represented approximately outlook sales period notable launches several line five years expect extensions sensodyne including low mid singledigit cagr sales next generation sensodyne rapid relief exchange rates expect sensodyne deep clean well operating margin voltaren mess parodontax exchange rates also launched flonase sensimist us continued global rollout flonase otc footnote use number adjusted nonifrs measures report performance described gsk annual report strategic report governance remuneration financial statements investor information driving performance profitable industry partnerships strategy action sustainable growth collaboration core aspects took significant steps innovation signed partnership consumer strengthen performance google bring digital advertising healthcare market longer term increasing focus data platform inhouse enabling us best performing brands priority better target relevant content consumers evolves investing markets drive efficiency marketing digital capabilities campaigns formed another partnership power brands alimama marketing forming groundbreaking strategy focusing resources media arm chinese technology group seven power brands regional core alibaba partnership helps us identify partnerships continue brands continued deliver power potential consumers gain deeper meet changing brands including sensodyne voltaren understanding online shopping panadol theraflu significantly behaviour reach consumer needs outperformed market high single right advertising appropriate time digit growth sensodyne continued drive continued prioritise building performance reporting growth relationships healthcare professionals aer cer strong marketbeating hcps whose recommendations delivery regions following rollout key introducing new consumers next generation sensodyne rapid brands seventy per cent consumer relief launch pronamel strong trial sensodyne us example bright driven dentist recommendation pain relief sales aer deployed new customer cer driven significantly voltaren relationship management platform across saw growth across regions benefiting markets hcp field forces brian mcnamara ceo gsk consumer healthcare momentum hour variant system upgrade enables us strong instore marketing activation engaging relevant science expansion expert detailing strong based dialogue hcps performances international markets concentrate best performers creating simpler competitive announced divestment smaller supply chain nutrition brands including maxinutrition uk continued improve consumer health supply chain across digital transformation quality safety service cost simplified network announced invested strongly digital plans exit three sites since transformation programme intended streamlined number contract boost sales datadriven manufacturers cmos use marketing new ecommerce sales channels reduce complexity supply chain digitally powered innovations supply chain successfully unlock efficiency savings example supported strong growth optimising generate deploy highermargin power brands digital content extracting value improvements across productivity media mix procurement systems ensuring robust reliable supply drive digital transformation appointed first consumer healthcare chief digital officer established digital advisory board external digital marketing data ecommerce experts also revised core training programmes build digital ecommerce capabilities across sales marketing general management teams ggsskk aannnnuuaall rreeppoorrtt trust maximising social impact ensuring reliable supply highquality products many people possible highly engaged employees ggsskk aannnnuuaall rreeppoorrtt strategic report governance remuneration financial statements investor information earning detail progress made addressing trust global health needs science creating sustainable access highquality products responsible business modern employer practices creating longterm value later year launch set stakeholders longterm commitments describing investors patients consumers actions taking demonstrate employees communities rightly expect continuing commitment deliver companies consider social societal value seek well financial impact seek establish clear ambitious targets drive create value long term investing impact progress three areas balanced set longterm priorities addressing global health needs innovation performance trust science across three businesses deliver financial returns creating sustainable access broader contribution society highquality products responsible business focusing impact modern employer practices long history tackling also continue seek transparent worlds biggest health challenges trusted engagement scientific biggest impact use medical communities address scientific technical knowhow environmental impact maintain address global health needs like hiv ethical standards conduct malaria support sustainable business access highquality products must also responsible business section reports progress modern employer practices support areas detail available talented people give best responsible business supplement available wwwgskcomresponsibility three businesses contribute towards trust priority pharmaceuticals vaccines consumer healthcare hiv drug dolutegravir vaccines business developed early consumer healthcare made available brazil first line malaria vaccine candidate business launching fiveyear treatment people living hiv received positive scientific opinion partnership smile train provide never received treatment via european medicines agency funding support expertise help national health programme also recommendation pilot implementation children living cleft lip palate available first line treatment world health organization lead full productive life botswana gsk annual report trust continued addressing using science technology tackle global health biggest global health challenges delivering leading scientific medical engagement science aim use science work open lab tres cantos spain collaboratively transparently supported seven new projects run partners scientific community external scientists since develop new medicines vaccines opened year consumer healthcare products tres cantos facility supported greatest need phase clinical trials new candidate drug tb phase ii studies expected global health impact begin also began late stage preclinical studies molecule biggest contribution make potential shorten tb treatment improve health globally focus funding bill melinda diseases impacting people around gates foundation world specific scientific received fda approval technological expertise respiratory juluca see important hiv oncology immunoinflammation milestone hiv care provides vaccines also important role new treatment option could make play tackling biggest significant difference people living global health challenges including malaria hiv receive lifelong treatment see case study tuberculosis tb chronic condition also neglected tropical diseases ntds hiv drug dolutegravir made available commercial market brazil botswana created global health unit added essential medicines list drive integrated approach across russia business innovate deliver part commitment eliminate medicines vaccines tackle control ntds gsk donated nearly biggest global health challenges eight billion albendazole tablets since malaria ntds reach million people lymphatic filariasis lf intestinal worms april togo became first african country eliminate lf public health problem seven countries later year helping pharmaceuticals business following successful phase iii trials beat malaria late stage development tafenoquine supporting plans singledose treatment pvivax malaria pilot malaria vaccine implementation common south asia horn programmes subsaharan africa africa latin america approved proud working together first new treatment path ministries p vivax malaria years health kenya ghana malawi stakeholders ensure vaccines business developed successful implementation pilot malaria vaccine candidate programmes parallel gsk received positive scientific opinion preparing implementation ema recommendation phase iv programme starting pilot implementation manufacturing activities gsk donate first million doses rtss vaccine support pilot programmes subsaharan africa gsk annual report strategic report governance remuneration financial statements investor information preparing future health threats also share anonymised patientlevel committed preparing data interventional phase iiv clinical strategy action global health threats emergencies trials within six months publication late maintain reserve capacity respond listed trials created future influenza pandemic wwwclinicalstudydatarequestcom global health unit collaborating development platform use external researchers universal influenza vaccine candidate since started initiative drive innovation research proposals requesting gsk fighting antibiotic resistance delivery medicines data approved declining effectiveness antibiotics vaccines tackle due extensive use misuse sales marketing practices becoming major public health crisis introduced policy stop global health challenges paying hcps speak prescribers important work malaria pharmaceutical industry governments prescription medicines vaccines believe policy find creative ways incentivise improved transparency trust reward new research development feedback scientific experts antibiotics support ways reduce important scientific dialogue resistance gsk reduced early ranked number intent policy transparent one large pharmaceutical scientific dialogue engagement companies access medicine experts interests foundations first antimicrobial resistance working develop new medicines amr benchmark assessed improve care patients pharmaceuticals generics biotech phil thomson address feedback company responses amr president global affairs consulted hcps decided pharmaceuticals pipeline gepotidacin change policy allow fair first new class antibiotics market value payments made expected progress phase iii clinical gsk expert researchers hcps research vaccines also play critical speak science behind role avoiding need antibiotics products disease clinical practice preventing bacterial viral limited number gsk sponsored infections medicalled meetings promote responsible antibiotics use believe change best trained healthcare interest patients helps effective professionals hcps areas transparent scientific dialogue allowing appropriate antibiotics use prescribing hcps share new science guidelines primary focus remains internal medical experts speaking leading scientific products pay hcps medical engagement talk products outside approved medicalled scientific workshop believe important trusted symposium transparent engagement continued strengthen scientific medical communities online resources inhouse medical transparency clinical trial data capabilities provide bespoke product gsk one companies information hcps using publishes clinical study reports whether existing channels increased overall positive negative end interactions customers reports publicly digital interactions growing available clinical study register gsk eliminated use individual addition result summaries sales targets pharmaceutical trials reflecting longstanding vaccines sales representatives commitment clinical trial transparency change implemented year ranked number one us expanded alltrials transparency index markets globally today sales representatives incentivised based selling competency broader business performance gsk annual report trust continued sustainable expanding access highquality medicines access vaccines consumer healthcare products people benefit use highquality products committed widening access world intellectual property highquality products organization wipo international embedding equitable pricing federation pharmaceutical manufacturers strategy using innovative business models associations ifpma launched ensuring products adhere new partnership called patinformed high quality safety standards facilitate access medicine patent information gsk played instrumental pricing role development partnership catalysed equitable pricing strategy medicines commitment make information vaccines based country patent portfolio freely available disease area product type patients also understand payer patient ability pay since capped concerns affordability developed prices patented medicines markets prices new medicines least developed countries vaccines reflect goal work western europe long best interests patients manufacturing costs covered shareholders balance reward vaccine doses go innovation access affordability least developed low middleincome us negotiate payers gain countries lowest vaccine prices favourable placement formularies lists offered organisations gavi products covered health insurers vaccine alliance supports pharmacy benefit managers patients poorer countries generally lower outofpocket costs company committed tenyear price medicines preferred treatment freeze support countries transitioning formulary gsk patient gavi financing assistance programme provided prescribed medicines vaccines patients reducing child mortality launched fiveyear partnership save children aim saving lives one million children poorest countries approach end five years reached million children countries lifesaving interventions partnership also created distributed potentially lifesaving medicine chlorhexidine gel benefited newborns next phase gsk save children partnership continue address child mortality launch image ilan godfrey save children gsk annual report strategic report governance remuneration financial statements investor information europe engage governments track risks quality safety payers balance access standards global risk register strategy action affordability working towards performed audits sustainable health systems support trials conducted us reliable supply daily ongoing innovation third parties enhanced policy priority across three management human safety information partnerships support access gsk products trained relevant businesses staff safeguard people take invest communities around products involved world product cash donations clinical research charitable giving totalled reliability supply million make reliable supply daily priority since reinvested across three businesses profits sales pharmaceuticals significant improvements achieved consumer healthcare products pharmaceutical supply performance least developed countries ldcs instrumental million total strengthening enabling growth key therapy areas local healthcare infrastructure roger connor partnerships amref health africa well ensuring launch new president global manufacturing care international save children products went plan improvements supply result essential capabilitybuilding helped train frontline infrastructure investments made health workers helping us exceed supply chain improve safety quality goal reaching million people well consistent focus meeting new programmes botswana patient business needs cameroon namibia training performance management frontline health workers beyond ldcs supply performance vaccines continued improve grew cleft surgery cost little manufacturing output left untreated children underpinned strong financial struggle eat breathe speak properly performance maintained focus leaving isolated communities safety delivering vaccines ongoing health issues early high quality standards also consumer healthcare business continued invest capacity updating launching fiveyear partnership older facilities building new capacity smile train provide funding support support longterm growth ambition expertise help children living cleft lip palate lead full across consumer healthcare supply productive life chain implemented new ways working including core business commitment quality planning processes improve service safety levels increased steadily significantly benchmark charitable giving totalled follow strict quality management well fmcg competitors million million system comply regulations consumer healthcare product good manufacturing practice launches supplied time regulatory inspections held continue strive higher targets manufacturing sites majority product supply maintaining resulted zero minor observations quality safety standards committed addressing issues raised inspections part continuous improvement programme regulatory authorities accepted proposed plans corrective actions product inkind cash management time pulse gsk annual report trust continued modern attract retain best talent committed employer modern employer driving high levels employee engagement staff engaged talent development part conversation put strong focus holding open made number key inclusive conversations appointments corporate executive encouraging leaders employees team identified significant gsk roles share ownership delivery supported development top talent strategy also focused creating included changing approximately safe inclusive workplace top manager roles everyone gsk feel able inspired promoting existing talent realise potential hiring externally bring fresh ideas skills leadership roles engagement also launched new employee performance system individual objectives senior leaders across gsk playing linked priorities pivotal role engaging people behind innovation performance trust strategy initiatives new gskwide bonus system reflect new lets talk programme see case study progress priorities october senior overall business performance leaders attended threeday conference encourage regular consistent deepen understanding performance development strategy priorities develop conversations effective tools inspire teams trained around people support promotion first second delivering performance line leadership addition cultural change gsk leaders shared knowledge helped improve colleagues performance strong values purpose coaching programmes fundamental way operate central year graduates development highperformance postgraduates joined future leaders valuesbased culture alignment esprit development programmes people behind longterm business gsk ranked third guardian priorities part approach uk graduate employers made evolving gsks culture retained top ten times top graduate reinforced values introducing employers four new expectations guide behaviour employees courage accountability development teamwork engaging strategic success relies survey questions aligned employees ability engage employees behind new priorities results strategy gsks longterm priorities discussed leaders employees identify priority focus areas plan conduct survey twice year people took part gsks global employee survey best ever response new lets talk programme rate employee engagement score encourages employees discuss key setting issues share views ideas baseline year improvement strengthening gsk leaders across employees recommend gsk business hosted conversations great place work since teams range topics feedback previous survey proud insights collated shared work us employees senior leaders help shape future organisation gsk annual report strategic report governance remuneration financial statements investor information diverse inclusive workplace early ranked st uk stonewall workplace equality index strategy action hampton alexander review top lgbt inclusive ftse companies found gsk employers uk gsk familyfriendly eighthhighest proportion women committed removing barriers policies key success board line increasing understanding ensuring ftse average female factor drive employee disabilities representation among executive committee opportunities disability confidence engagement members direct reports network employee resource group continuing focus improving employee members across number coming years overall countries support global proportion women management disability council driving change roles gsk promoting disability confidence women made half new graduates esprit participants health wellbeing new apprentices science technology engineering roles women committed providing health traditionally underrepresented programmes services help people lead healthy lives made published data gender pay programmes claire thomas gap uk first time following services available top countries senior vice president new legislation gender pay gap human resources permanent ukbased gsk employees covering employees globally mean outperforming national partnership prevention programme average continue offers employees family review pay equity global level members access preventive healthcare services immunisations cancer screening little extra accelerating difference cost expanded programme programme provided coaching asia pacific region prepared support highperforming female extend europe managers around began programme reportable injury illness rate promoted compared women per hours worked across gsk period compared rate women management comparable leading companies us diverse reverse mentoring sector remained low provides leaders opportunity svpvp several years learn junior employee director different background help leaders manager flexible lifefriendly practices develop inclusive leadership skills total mentoring pairs gsk familyfriendly policies employees gender number place key success factor drive employee male female total seven nationalities represented engagement us board board executive committee increased maternity leave mothers management seventyeight nationalities make weeks introduced weeks total future leaders graduate programme paid parental leave parents adoptive people completed parents partners bond management senior managers defined companies act strategic report directors emerging leaders programme singapore new baby also raised commitment report regulations includes persons develop asia leadership pipeline familyfriendly policies across top responsible planning directing controlling activities company strategically significant part global lgbt council continued markets example pakistan company board including directors engage people across gsk lgbt revised maternity policy eligible undertakings included consolidated accounts issues supported lgbt employees increase fully paid maternity employee resource group spectrum leave days employee also seeking improve worklife members across countries around balance range flexibility models world across markets uk offer taxfree holiday programme enables employees sacrifice part salary exchange ten days extra holiday programme usage rate among eligible employees based benchmarking data pharmaceutical safety group gsk annual report trust continued ethical aim run business ethically conduct environmentally sustainable way environmental sustainability ethical conduct working third parties expect suppliers third strive build valuesbased culture parties comply standards training people standards ethics labour rights health safety expect encouraging reporting environment end concerns acting swiftly deployed rollout third transparently issues occur party oversight programme third parties expect remainder living values completed early provide mandatory annual training risk assessments third parties values code conduct help conducted employees complementary workers improvements plans agreed since manage ethical dilemmas put programme began based values practice work initial risk assessment living values training emphasises third parties underwent extensive zero tolerance bribery corruption independent assessments highlights commitment issues standardised programme enables product quality data protection us identify manage third party risks explains key risks effectively embedded employees complementary processes use engage workers completed training suppliers people additional training antibribery corruption help conducted third party audits manage specific risks inherent health safety ethics environment roles responsibilities labour rights audits quality processes assess well values embedded conducted around identify unsatisfactory areas values maturity assessments engage third parties develop past two years improvement plans track progress significant issues remain unresolved employees disciplined reporting investigating concerns may suspend terminate work breakdown types policy violation speak campaign raised third party awareness multiple channels offer people within outside gsk human rights voice concerns ask questions signatory un global independent third party compact committed confidentially anonymously preferred upholding universal declaration year received reports human rights core labour reviewed standards set international formal investigations initiated labour organization ilo expanded information act employees fail adhere human rights expectations living policies employees training completion marketing values training particularly around labour code conduct promotional activities disciplined policy violations rights supply chain also held attendance local work including failing workshop senior managers build payroll r iog lau tla ioti sns complete mandatory living understanding labour rights risks g ano dd sm tra ibn uu tf ia oc nt uring policy v tra al iu ne ins g nd ta imn eti b sr oib ery n c eo mrr pu lp ot yi eo en identify team training requirements practices violations received documented warning continued monitor existing suppliers received verbal warnings screen new suppliers included dismissed standardised labour rights clauses third agreed leave voluntarily party contracts updated supplier portal human rights policy information labour rights support compliance gsk annual report strategic report governance remuneration financial statements investor information environmental sustainability also platform gsk water supplier exchange encourage suppliers continue seek ways use less water aim minimise environmental share best practices sustainability operations supply chain impact every stage value chain recognise outstanding performance use products extending access products annual supplier environmental reduced water use since people sustainability awards water use increased driven growth vaccines business carbon use products also overall carbon footprint made significant impact scope end scope emissions direct emissions majority patient pharmaceutical consumer healthcare operations scope emissions use propellantbased inhaler ventolin manufacturing sites completed water supply chain use propellant greenhouse gas risk assessments line water products released use reducing impact stewardship standard sites propellant complex continue developing plans address risks operational emissions scope research feasible solutions identified may include reduced compared issue including changing way working local communities previous year result manufacture reduce amount stakeholders efforts enhance water continuing focus energy efficiency propellant used maintaining efficacy stewardship prioritise sites areas measures purchasing renewable safety patients water stress energy since baseline reduced annual carbon emissions gsks new generation inhaler products waste energy use saving cumulative using ellipta device developed since cut operational waste million tonnes coe launched dry powder inhalers producing less hazardous dpis release greenhouse waste less nonhazardous waste scope emissions fell gas emissions certified however progress towards million tonnes coe assessment respiratory inhaler target slowed amount waste however portfolio carbon trust showed produced remained baseline year result lifecycle carbon footprint therefore increased novartis integration increasing dpi around times lower focus reclaiming waste sales propellantbased inhalers propellantbased inhaler one reuse recycling recovery engage suppliers drive months treatment improvement example encourage around sites worldwide suppliers monitor disclose achieved zero waste landfill performance ecodesk external tonnes operational waste resource offers benchmarking ended landfill less information helps develop recycled incinerated improvement plans recover energy carbon emissions plus intensity ratios per regulations tonnes coea b scope emissions scope emissions data available scope emissions may intensity ratios scope emissionssales revenue tonnes coem scope fte tonnes coefte carbon emissions calculated according greenhouse gas protocol corporate accounting reporting standard revised edition b data included former novartis sites emissions headcount recently available scope data publish data online late one months treatment dose propellant inhaler carbon footprint kg coe per pack compared dose oncedaily ellipta dpi carbon footprint kg coe per pack ggsskk aannnnuuaall rreeppoorrtt group financial review continued group financial review section cfos statement approach brexit approach tax viability statement reporting framework noncontrolling interests viiv healthcare group turnover total results adjusted results cash generation conversion financial position resources critical accounting policies treasury policies gsk annual report strategic report governance remuneration financial statements investor information group financial review continued make progress delivering strategy financial goals set financial architecture simon dingemans chief financial officer results reflect continued focus due magnitude charges related execution including driving growth impact us tax cuts jobs existing products recent launches act enacted excluded controlling costs tightly help build better adjusted results operating leverage across group gsk continues present total also investing behind future growth adjusted results tables drivers improving cash generation commentaries provided increase capacity support reconciliation two investment dividends pay shareholders sales growth financial architecture three businesses delivered using financial architecture growth ensure delivery strategic priorities innovation performance pharmaceuticals sales aer trust translate clear financial goals cer growth hiv products embed across group ellipta portfolio nucala offsetting decline sales seretide goals targeted delivering advair established pharmaceuticals viability statement stronger growth sales improved well drag divestments viability statement sets innovation across three businesses assessment prospects driving earnings per share faster sales vaccines generated significant group next three years better operating leverage growth meningitis flu portfolios presented tight cost control continued financial benefited increased demand efficiencies converting established vaccines finished year earnings cash either overall vaccines sales aer reinvested business returned cer shareholders critically goals need consumer healthcare delivered growth delivered right way consistent aer cer reflecting strong values objective building performance power brands trust gsk pain oral health categories partly using architecture offset impact continued competitive goals help create stepchange pressures us allergy category alignment operations across three broader market slowdown across key fully integrated businesses including categories addition reported growth new endtoend emphasis cost cash impacted divestment capital discipline nigerian beverages business implementation goods reporting framework service tax india reporting framework described detail following operating leverage detailed review made changes total operating margin core results renamed sales compared adjusted results include increased margin reflected primarily ordinary course legal charges lower accounting charges related remeasurement liabilities contingent consideration put options preferential dividends footnote use number adjusted nonifrs measures report performance business described including adjusted results free cash flow cer growth rates nonifrs measures may considered addition substitute superior information presented accordance ifrs gsk annual report group financial review continued capital allocation framework key priorities capital pharmaceuticals pipeline invest business consumer healthcare put option innovation vaccines capacity improved p per share dividend expected performance cash shareholder returns focus rebuilding free cash flow time generation target x x cover returning dividend growth trust transactions strict discipline returns adjusted operating margin us tax reform contingent consideration percentage points higher enactment us tax cuts jobs end gsk liabilities percentage points higher act december expected contingent consideration payments cer basis reflected improved positive impact future tax billion billion related operating leverage driven sales growth earnings gsks us businesses estimated present value future favourable mix three primarily due reduction federal payments shionogi viiv healthcare businesses together benefit corporation tax rates january payments shionogi calculated vaccines settlement lost third party expected benefit group quarter based highteens supply volume favourable yearonyear effective tax rate adjusted profits percentage revenues relevant comparison inventory adjustments two three percentage points products principally dolutegravir tight control ongoing costs across intend apply flexibility cash discounted fair value total future three businesses also contributed along benefits reforms provide payments reflecting current expectations benefits restructuring accordance capital allocation total future sales products integration partly offset framework details provided note increases rd investment including contingent consideration liabilities enactment new law charge million priority resulted number additional charges free cash flow review voucher utilised hiv well reduced total earnings net cash inflow operating activities continuing price pressure particularly million billion free cash flow group respiratory supply chain investments charges represent managements billion compared billion work maintain tight control costs estimates impact us tax reform sterling increase across group included supply chain group based information currently reflected improved operating profit efficiencies mixture site closures available information detailed performance positive currency benefit consolidating manufacturing supplier application act becomes available reduced cash spending restructuring base simplifying global distribution assumptions underlying estimates capital expenditures partly offset logistics network also could change consequent adjustments increased working capital mainly due stepping focus procurement charges taken could building inventory advance new new global organisation material impact results group product launches financial efficiency earnings per share net debt financial efficiency remains priority total eps p p net debt end amounted successfully refinancing maturing debt increase reflected primarily lower billion billion lower allowed us hold net accounting charges related end reduction primarily financing costs relatively flat year remeasurement liabilities attributable improved free cash flow continue focus protecting contingent consideration put options billion disposal proceeds credit profile funding flexibility preferential dividends billion together translation benefit billion sterling value adjusted eps p aer nonsterling denominated debt cer reflecting improved operating offsetting cash dividends paid leverage delivered earnings growth shareholders year billion faster sales growth gsk annual report strategic report governance remuneration financial statements investor information capital allocation framework event substitutable generic approach brexit priorities use capital version advair introduced us remain presented july market group expects evaluated impact brexit focused three particular priorities adjusted eps growth cer business operations including investing business delivering cash based expected decline supply chain quality oversight returns shareholders dividends us advair sales priority maintain continuity potentially accessing strategic event midyear introduction gsks supply medicines vaccines acquisitions would strengthen substitutable generic competitor advair health products patients business subject meeting strict us group expects fullyear consumers uk eu set returns criteria establishing us advair sales around million first priority investing business uncertainty remains future cer us adjusted eps flat identified primary focus relationship uk cer strengthening pharmaceuticals business eu result agreed particular rd pipeline also scenarios reflect benefit us riskbased approach mitigation across confirmed attractiveness accepting tax reform expected effective organisation implementation consumer healthcare put option tax rate adjusted profits contingency plan underway exercised continuing expand able give guidance total since january immediate capacity key product lines across results reliably forecast certain focus supply chains includes vaccines business material elements total results expanding ability eu uk conduct retesting certification strengthen allocate capital future fair value movements medicines transferring marketing ensure allocating funding contingent consideration put options authorisations registered uk attractive returns returns shareholders eu entity updating packaging available implemented clearer maintained ordinary packaging leaflets amending framework created new board dividend p line commitment manufacturing importation licences govern allocation capital made shareholders time securing additional warehousing businesses closed novartis transaction early currently anticipate cost expanded use cash flow gsk recognises importance implement necessary based return metrics beyond individual dividends shareholders aims changes could million project assessments distribute regular dividend payments next two three years able create fully integrated business determined primarily reference subsequent ongoing additional costs units pharmaceuticals vaccines free cash flow generated business approximately million per year consumer healthcare able funding investment necessary including additional customs duties apply consistent cash return support groups future growth transaction administration costs invested capital croic methodology charges represent estimates prioritise investment across group board intends maintain dividend impact brexit based information whole compare returns current level p per share currently available information three integrated businesses subject material change external changes business allocate capital environment performance expectations required brexit becomes also regularly benchmark time free cash flow strengthens available assumptions underlying peers relevant three intend build free cash flow cover estimates could change businesses annual dividend target range consequent adjustments either x returning dividend guidance growth additional costs expect expect continued progress incur continue adjust including sales growth contributions fuller review financial results plans expected financial impact new recent product launches hiv set pages negotiations regulations develop respiratory vaccines delivering necessary complex expectation adjusted eps changes march ambitious growth dependent number factors potentially disruptive short term including particular uncertainties relating support efforts secure status timing extent potential generic quo transition period minimise competition advair us simon dingemans disruption longer term continue believe brexit chief financial officer material impact business gsk annual report group financial review continued approach tax understand understand responsibility pay total tax rate also reflected appropriate amount tax fully reassessment estimates uncertain responsibility pay support efforts ensure companies tax positions following settlement appropriate amount appropriately transparent number open issues tax authorities tax affairs managed tax important various jurisdictions tax element economic contribution tax risk managed set policies bring countries operate financially efficient procedures ensure consistency engage artificial tax compliance tax legislation audit delivering arrangements without business risk committee board commercial substance seek sustainable tax rate responsible approving tax policies avoid tax use tax havens risk management approach transactions would fully disclose tax authority zero tolerance seek maintain open positive approach tax evasion facilitation relationships governments tax tax evasion authorities worldwide welcome constructive debate taxation policy substantial business employment presence many countries seen enactment significant around globe pay significant reforms tax laws multiple jurisdictions amount tax including corporation expect continued focus business taxes well tax tax reform future driven associated employees oecds base erosion profit time responsibility shifting beps project european shareholders financially efficient commission initiatives fiscal state deliver sustainable tax rate part aid investigations outputs approach look align investment oecd beps projects clarified strategies countries important principle tax paid already substantial economic activity profits throughout supply chain government policies promote profitmaking activity takes place regimes attractive business gsk supports beps proposals investment rd activity particular implementation transparent intent available oecds recommendations country relevant tax payers examples include country reporting including exchange uk patent box research data tax authorities development expenditure credit data validated existing information group corporate tax charge held taxpayers support ability million million ensure multinational groups pay profits million appropriate amount tax million representing effective tax rate detailed tax implications brexit made cash dependent outcome negotiations tax payments million year uk eu therefore million addition currently unknown however continue taxes pay profits pay duties work closely abpi bia levies transactional employment taxes analyse potential implications adjusted tax rate industry order highlight key focus areas subject material government part brexit changes product mix negotiations direct tax implications material changes tax regulations laws particular expected limited countries operate gsk indirect implications following impact us tax reform may significant including potential groups effective adjusted tax rate customs duty costs additional next several years expected transaction administrative costs region associated managing import export obligations movement groups total tax rate goods uk eu higher approach brexit set adjusted tax rate affected impact us swiss tax reforms approach tax set detail explained note together within public policy positions section footnote transactionrelated charges arising website details use number adjusted nonifrs groups put option liabilities corporate tax charges year set measures report performance business described gsk annual report strategic report governance remuneration financial statements investor information viability statement accordance provision c revision code following hypothetical downside scenarios evaluated gsk assessed prospects company longer scenario business performance risks include key period months required going concern performance risks including lower sales new products provision directors confirm reasonable possible impact generic alternative seretideadvair expectation gsk continue operate meets liabilities us intensifying competition hiv market greater adverse fall due next three years directors assessment impact generic competition competitive launches made reference gsks current position gsk products well possible supply manufacturing prospects strategy boards risk appetite gsks challenges principal risks managed detailed pages strategic report scenario external macroeconomic risks scenario reflects incremental risks business driven outside factors board reviews internal controls risk management intense competition increased pricing pressure policies approves governance structure code us europe well potential impact material conduct also appraises approves major financing investment negative changes macroeconomic healthcare licensing decisions evaluates monitors performance environment prospects gsk whole focus largely improving scenario principal risks scenario includes severe longterm financial performance delivery company assessment potential loss impact principal risks three business strategies aligned innovation performance related patient safety product quality supply chain continuity trust priorities well antibribery corruption consequent regulatory board reviews gsks strategy makes significant capital actions fines could fundamentally threaten investment decisions long term time horizon based operations risks managed mitigating activities multiyear assessment return capital performance described pages company three business units market opportunity scenario put option exercise scenario evaluates pharmaceutical vaccines consumer healthcare sectors additional funding requirements assuming earliest potential approach aligned gsks model achieving balanced exercise outstanding put options held partners growth investing high quality innovative products patients hiv consumer healthcare businesses consumers healthcare providers however since many internal external parameters become increasingly unpredictable three year review also makes certain assumptions longer time horizons gsk focuses detailed bottomup plan normal level capital recycling likely occur considers whether three year cycle plan reviewed least annually additional financing facilities required respective level directors approve business forecasts showing expected funding flexibility headroom financial impact directors believe three year assessment results stress testing show certain combinations period viability statement appropriate aligns hypothetical scenarios could increase funding demands companys well established business planning processes gsk require mitigating changes groups funding strategy balance long term nature investments pharmaceutical however light liquidity available group based vaccines consumer healthcare sectors assessment analysis directors reasonable expectation even period analysis near term business performance stress tests described company able realistically visible continue operation meet liabilities fall due plan stress tested series robust operational three year period assessment principal risk downside scenarios part boards review risk downside scenarios consider gsks cash flows sustainability dividends funding strategy insurance provision recovery well key financial ratios period metrics subject sensitivity analysis involves flexing number main assumptions underlying forecasts individually combination along mitigating actions could realistically taken avoid reduce impact occurrence underlying risk gsk annual report group financial review continued reporting framework presentation group results contingent consideration group financial review discusses operating financial gsk recognised significant liability contingent performance group cash flows financial position consideration million december fair value resources compare results year primarily discounted basis million represented estimated results preceding year present value future amounts payable shionogi relating viiv healthcare discounted payments shionogi use number adjusted nonifrs measures report calculated based sales performance life performance business measures used relevant products principally dolutegravir described management planning reporting purposes discussions effect required ifrs accounting treatment gsk presentations investment analysts rating agencies recognises fair value liabilities balance sheet may directly comparable similarly described remeasurement charges reflected immediately operating measures used companies nonifrs measures may income charges adjusted total results present considered addition substitute superior adjusted results gsk make cash payments future information presented accordance ifrs discharge liability recorded profit total results loss account future earnings total reported results represent groups overall performance however results contain material unusual non free cash flow operational items may obscure key trends factors adjusted free cash flow longer reported determining groups operational performance result free cash flow definition amended include also report adjusted results nonifrs measure contingent consideration payments made period adjusted results free cash flow nonifrs measure defined announced april change financial reporting net cash inflow operating activities less capital expenditure framework press release core results contingent consideration payments net interest dividends paid renamed adjusted results instead legal charges noncontrolling interests plus proceeds sale property expenses significant legal charges expenses excluded plant equipment dividends received joint ventures order present adjusted results legal charges associates used management planning reporting expenses included adjusted results significant legal charges purposes discussions presentations investment expenses arising settlement litigation analysts rating agencies free cash flow growth calculated government investigation normal course reported basis reconciliation net cash inflow materially larger regularly occurring individual matters operations free cash flow presented also include certain major legacy legal matters new free cash flow conversion significant legal matters excluded order present adjusted free cash flow conversion free cash flow percentage results disclosed time total earnings result enactment us tax cuts jobs act december gsk recorded charges initial application working capital conversion cycle reduced total earnings billion set working capital conversion cycle calculated number due magnitude gsk reported charges days sales outstanding plus days inventory outstanding less adjusting items obscure key trends days purchases outstanding groups operational performance year cer aer growth adjusted results exclude following items total results order illustrate underlying performance practice amortisation impairment intangible assets excluding computer discuss results terms constant exchange rate cer growth software goodwill major restructuring costs including represents growth calculated exchange rates used costs following material acquisitions significant legal charges net determine results overseas companies sterling insurance recoveries expenses settlement litigation remained unchanged used previous year cer government investigations transactionrelated accounting represents growth constant exchange rates aer adjustments significant acquisitions items including represents growth actual exchange rates disposals associates products businesses operating income royalty income together tax effects items impact enactment us tax cuts jobs act gsk believes adjusted results representative performance groups operations allow key trends factors driving performance easily clearly identified shareholders definition adjusted results set also aligns groups results majority peer companies report earnings reconciliations total adjusted results set including detailed breakdowns key adjusting items provided shareholders ensure full visibility transparency assess groups performance gsk annual report strategic report governance remuneration financial statements investor information noncontrolling interests viiv healthcare trading profit allocations contingent consideration payable posttax basis viiv healthcare subsidiary group shionogi december million december operating results turnover operating profit profit tax million expected paid within one year included within group income statement portion exit rights earnings allocated noncontrolling interests owned shareholders line respective equity pfizer may request ipo viiv healthcare time shareholdings pfizer shionogi either gsk consent ipo offering shareholders including gsk also entitled preferential dividends completed within nine months pfizer could require gsk acquire determined performance certain products shareholding original agreements gsk shareholder contributed relative performance unconditional right long made subsequent distribution products changes time proportion overall earnings shareholders withhold consent exercise viiv healthcare allocated shareholder change pfizer put options result accordance ifrs gsk particular increasing sales tivicay triumeq recognise liability put option balance sheet favourable impact proportion preferential dividends q gsk notified pfizer irrevocably given allocated gsk gsk entitled approximately right accordingly recognised liability put option adjusted earnings viiv healthcare groups balance sheet initial value million remeasurements liabilities preferential dividends consistent revised treatment end q allocated pfizer shionogi included within adjusting gsk also recognised liabilities future preferential dividends items operating income anticipated become payable pfizer shionogi groups balance sheet acquisitionrelated arrangements closing balances liabilities related pfizers shareholding part agreement reached acquire shionogis interest follows former shionogiviiv healthcare joint venture viiv healthcare agreed pay additional consideration shionogi contingent performance products developed pfizer put option joint venture principally dolutegravir liability pfizer preferential dividend contingent consideration estimated recognised groups balance sheet date acquisition subsequent original agreements shionogi could also requested remeasurements reflected within operating income gsk acquire shareholding viiv healthcare six month within adjusting items income statement windows commencing gsk cash payments made shionogi viiv healthcare unconditional right long made subsequent distribution quarter reduce balance sheet liability contingent shareholders withhold consent exercise consideration result recorded income shionogi put option result gsk recognise liability statement total cash payments made shionogi put option balance sheet q gsk notified respect contingent consideration amounted million shionogi irrevocably given right accordingly payments calculated based sales performance recognised liability put option groups balance relevant products previous quarter reflected sheet initial value million q shionogi cash flow statement partly operating cash flows partly irrevocably agreed waive put option result gsk within investing activities tax relief payments derecognised liability put option groups balance reflected groups adjusting items part tax charge sheet directly equity value liability million part payment relating original estimate derecognised fair value contingent consideration acquisition gsk also call option shionogis shareholding viiv shionogiviiv healthcare joint venture million healthcare original agreements exercisable reported within investing activities cash flow statement six month windows commencing gsk part payment relating increase liability since irrevocably agreed waive first two exercise windows acquisition reported within operating cash flows last six month window remains call option movements contingent consideration payable shionogi fair value value accounting purposes follows contingent consideration beginning year additions remeasurement income statement cash payments operating cash flows cash payments investing activities movements contingent consideration end year additions represented recognition preferential dividends payable shionogi gsk annual report group financial review continued group turnover group turnover geographic region turnover bn aer growth cer growth revised growth growth bn cer us europe international us sales growth aer cer driven continued strong performances triumeq tivicay growth respiratory portfolio together strong performances us hepatitis meningitis vaccines europe sales grew aer flat cer growth triumeq tivicay meningitis vaccines offset decline established pharmaceuticals including impact disposal group turnover romanian distribution business q respiratory sales aer flat cer decline seretide offset growth growth cer growth new respiratory products pharmaceuticals international sales growth aer cer reflected vaccines strong growth triumeq tivicay respiratory portfolio consumer healthcare established pharmaceuticals flat including impact group turnover divestments growth emerging markets aer cer also impacted divestments group turnover year increased aer cer sales new pharmaceutical vaccine products million growth delivered three businesses pharmaceuticals sales aer cer reflecting growth growth cer continued strong growth new respiratory hiv products respiratory partly offset declines older respiratory products including seretideadvair established pharmaceuticals including anoro ellipta impact recent divestments arnuity ellipta incruse ellipta vaccines sales aer cer reflecting strong nucala performance meningitis influenza vaccines higher demand established vaccines well benefit relvarbreo ellipta favourable yearonyear us cdc stockpile movements cvmu eperzantanzeum consumer healthcare sales grew aer cer reflecting strong performance power brands pain oral health hiv categories partly offset impact continued competitive tivicay pressures us allergy category broader market slowdown triumeq key categories addition reported growth impacted pharmaceuticals nigerian beverages business divestment q bexsero implementation goods service tax gst india menveo july shingrix vaccines gsk identified series new pharmaceutical vaccine products expected deliver least billion revenues per annum cer basis products set include trelegy ellipta juluca initial sales million million respectively group previously announced plans withdraw tanzeum exchange rates equivalent value sales billion sales new pharmaceutical vaccine products million grew million sterling terms aer cer represented approximately pharmaceuticals vaccines turnover year gsk annual report strategic report governance remuneration financial statements investor information respiratory total respiratory portfolio sales aer cer pharmaceuticals us aer cer europe aer flat cer international aer cer growth new respiratory products offset decline seretideadvair turnover bn aer growth cer growth new respiratory products recorded combined sales bn million sales ellipta products aer cer driven continued strong growth us ongoing rollout across europe international sales nucala million group turnover sterling increase million included sales million us aggregate growth ellipta products driven primarily contribution us sales aer cer back market share gains total relvarbreo ellipta sales grew aer cer million us aer cer million anoro ellipta sales grew aer cer million also reflecting market share gains us ellipta products breo anoro incruse arnuity continued grow market share us year seretideadvair sales declined aer cer pharmaceuticals turnover million sales us declined aer cer volume decline negative impact price payer rebate growth growth cer adjustments related prior periods favourably impacting sales respiratory year europe seretide sales aer cer million volume decline negative impact hiv price reflecting continued competition generics immunoinflammation transition respiratory portfolio newer products established pharmaceuticals international sales seretide declined aer cer million volume decline negative impact price also reflecting increased generic competition transition pharmaceuticals turnover million aer newer respiratory products cer respiratory sales grew aer cer million driven ellipta portfolio nucala hiv sales pricing pressures also affected older products ventolin aer cer million driven increases sales declining aer cer million including market share triumeq tivicay sales established negative impact payer rebate adjustments related prior periods pharmaceuticals declined aer cer reflecting three us flixotideflovent sales aer cer percentage point impact recent divestments divestments million us aer cer reduced overall pharmaceuticals cer growth one percentage net impact adjustments payer rebates prior periods point significantly impacting contribution europe across us respiratory portfolio broadly neutral reported emerging markets us respiratory sales us sales growth aer cer driven hiv portfolio new respiratory products europe sales grew aer declined cer reflecting continued transition respiratory portfolio generic competition kivexa well disposal romanian distribution business q reduced growth three percentage points reported international sales growth impacted benefit q accelerated sale inventory supply agreements novartis well disposal thrombosis anaesthesia businesses aspen q reduced reported growth international one percentage point emerging markets two percentage points aer cer sales japan grew aer cer gsk annual report group financial review continued hiv established pharmaceuticals hiv sales increased aer cer million sales established pharmaceuticals million year us aer cer europe aer declining aer cer impacted comparison cer international aer cer growth accelerated sale inventory supply agreements novartis three regions driven continued increases market share q well disposal thrombosis anaesthesia triumeq tivicay partly offset impact generic businesses aspen q disposal romanian competition epzicomkivexa particularly affecting european distribution business q impact disposals market ongoing increase patient numbers triumeq growth established pharmaceuticals portfolio tivicay resulted sales million million approximately three percentage points respectively year juluca approved us avodart franchise declined aer cer million november recorded initial sales million primarily due loss exclusivity us europe epzicomkivexa sales declined aer cer impact favourable rar adjustments million reflecting ongoing generic competition since q dermatology sales grew aer cer million immunoinflammation reflecting improved supply emerging markets growth japan sales grew aer cer year negative impact augmentin sales grew aer cer million divestment raxibacumab recorded strong sales q offset growth benlysta aer cer million driven strong us performance gsk annual report strategic report governance remuneration financial statements investor information established vaccines sales dtpacontaining vaccines infanrix pediarix vaccines boostrix aer flat cer boostrix sales grew aer cer benefiting higher demand across regions infanrix pediarix sales aer cer turnover bn mainly driven increased competitive pressures us aer growth cer growth bn europe together new market entrant europe partly offset favourable yearonyear cdc stockpile movements us hepatitis vaccines grew aer cer million group turnover benefiting competitor supply shortage higher demand us partly offset unfavourable impact cdc stockpile movements us supply constraints europe international rotarix aer cer million reflecting higher demand europe international synflorix sales aer cer million due lower pricing emerging markets partly offset higher demand elsewhere international priorixpriorix tetravarilrix sales flat aer cer million mainly due supply constraints international vaccines turnover cervarix sales increased aer cer million growth growth driven recent launch china cer meningitis influenza shingles established vaccines vaccines turnover grew aer cer million primarily driven meningitis vaccines bexsero growing across regions menveo growing us europe higher sales influenza products primarily us europe established vaccines growth driven hepatitis vaccines mainly due competitor supply shortage us higher demand boostrix rotarix launch cervarix china favourable yearonyear cdc stockpile movements infanrix pediarix menveo us also contributed growth partly offset increasing competitive pressures infanrix pediarix us europe lower synflorix sales driven primarily lower pricing developing countries meningitis meningitis sales grew aer cer million bexsero sales growth aer cer driven new national immunisation programmes private market sales regional tenders europe well growing demand share gains us together strong private market sales international menveo sales grew aer cer primarily driven impact favourable yearonyear cdc stockpile movements partly offset supply constraints international influenza fluarixflulaval sales aer cer million reflecting strong sales execution primarily us higher demand europe shingles shingrix recorded initial sales channel million us fda approval favourable acip recommendations gsk annual report group financial review continued wellness wellness sales grew aer cer million consumer healthcare reflected strong performance voltaren cold flu seasonal products partly offset weaker performance us allergy products turnover bn aer growth cer growth respiratory sales aer cer strong broadly bn based growth theraflu otrivin particularly europe international partly offset competitive pressures us flonase otc private label products group turnover pain relief sales aer cer driven significantly voltaren growth across regions benefiting momentum hour variant strong instore marketing activation expansion expert detailing strong performances international markets panadol also grew strongly europe benefiting new advertising campaigns international low single digits oral health oral health sales grew aer cer million sensodyne continued drive performance reporting growth aer cer strong delivery regions following consumer healthcare turnover roll next generation sensodyne rapid relief launch pronamel strong bright sales parodontax continued growth growth cer grow strongly reflecting doubledigit performances europe international driven brand reset increases dentist wellness recommendations well us launch first quarter oral health denture care grew midsingle digits doubledigit growth nutrition emerging markets partly offset slower consumption growth skin health us germany nutrition nutrition sales grew aer declined cer million adversely impacted sale nigeria beverages business revised growth growth cer q implementation gst july well us continued competitive pressures horlicks india net impact divestment nigeria beverages business implementation europe gst offset favourable comparison impact international demonetisation prior year reduced nutrition cer growth approximately six percentage points consumer healthcare turnover aer cer skin health million impacted slower global growth key categories skin health sales grew aer flat cer strong performance power brands across wellness oral million low singledigit growth us slight decline health partly offset competitive pressures us allergy within europe international flat fenistil sales grew strongly category impacting flonase otc well lower sales tail good performances central eastern europe germany brands across nutrition skin health categories broader middle east following digital activation new media market slowdown key categories addition reported growth campaigns physiogel lamisil continued impacted impacted disposal nigeria beverages business competitor activity whilst lip care sales grew midsingle digits q implementation goods service tax gst india july net effects partly offset benefit comparison impact demonetisation india q divestment gst demonetisation combined reduce overall consumer healthcare cer growth approximately one percentage point sales new gsk innovations product introductions within last three years rolling basis represented approximately sales period notable launches year included parodontax flonase sensimist us continued global roll flonase otc several line extensions sensodyne including next generation sensodyne rapid relief sensodyne deep clean gsk annual report strategic report governance remuneration financial statements investor information total results cost sales cost sales percentage turnover turnover bn aer growth cer growth percentage points sterling terms percentage points bn cer terms compared primarily reflected phasing costs manufacturing restructuring programmes including noncash write downs result plant closures write assets related progressive withdrawal tanzeum well continued adverse pricing pressure pharmaceuticals primarily respiratory additional supply chain investments partly offset favourable product mix across three businesses particularly pharmaceuticals reflecting impact higher hiv sales vaccines reflecting benefit settlement lost third party supply volume favourable yearonyear comparison inventory adjustments also continued contribution integration restructuring savings three businesses total operating profit bn aer growth cer growth selling general administration bn sga costs turnover percentage points lower sterling cer terms primarily reflected lower restructuring costs tight control ongoing operating costs particularly consumer healthcare well continued cost reductions pharmaceuticals including benefits pharmaceuticals restructuring programme integration benefits vaccines consumer healthcare partly offset increased investment promotional product support particularly new launches respiratory hiv vaccines research development rd expenditure million turnover higher aer higher cer included charges million utilisation priority review total results group set voucher well increased investment progression number mid latestage programmes addition growth higher restructuring costs primarily result provision future clinical obligations result progressive turnover turnover cer withdrawal tanzeum decision terminate rights turnover sirukumab higher intangible asset impairments cost sales selling general royalty operating incomeexpense administration net operating expense million research million primarily reflected lower accounting charges arising development remeasurement contingent consideration liabilities related royalty income former shionogiviiv healthcare joint venture acquisition operating income former novartis vaccines business value attributable expense consumer healthcare joint venture put option liabilities operating profit pfizer put option pfizer shionogi preferential net finance costs dividends viiv healthcare remeasurement charges profit disposal million million reflected updated trading interest associates forecasts changes exchange rate assumptions well share tax unwinding discount applied future liabilities profits associates million also included charges million arising joint ventures positive impact us tax reform valuation profit taxation consumer healthcare hiv businesses charges taxation partly offset gain million disposal profit taxation anaesthesia business aspen royalty income million year million profit attributable shareholders earnings per share p earnings per ads us gsk annual report group financial review continued total results continued operating profit profit taxation total operating profit million compared taking account net finance costs profit disposal million increase primarily reflected reduced associates share profit associates profit impact accounting charges related remeasurement taxation million compared million liabilities contingent consideration put options preferential taxation dividends addition operating profit benefited improved operating margin driven sales growth across three businesses particularly vaccines favourable mix three uk current year charge businesses vaccines also favourable yearonyear rest world current year charge comparison inventory adjustments benefit oneoff settlement cost sales continued tight control charge respect prior periods ongoing costs benefits restructuring integration also total current taxation contributed improved margins vaccines consumer total deferred taxation healthcare pharmaceuticals benefits offset taxation total profits overall increase pharmaceuticals rd investment including tax charge million total profit represented effective impact priority review voucher together continuing price tax rate included charge pressure particularly respiratory supply chain investments million arising us tax reform described detail support new products partly offset million benefit swiss net finance costs tax reform arising revaluation deferred tax liabilities acquired consumer healthcare brands reflect reduction finance income headline tax rate interest income noncontrolling interests fair value movements allocation earnings noncontrolling interests amounted million million including noncontrolling interest allocations consumer healthcare profits million finance expense million allocation viiv healthcare profits interest expense increased million million loss including unwinding discounts liabilities impact changes proportions preferential dividends remeasurements fair value movements due shareholder increase allocation viiv finance expense healthcare profits primarily reflected impact lower remeasurement charges increase allocation consumer healthcare profits reflected improved operating profits together profit disposal associates benefit swiss tax reform profit disposal associates million nil earnings per share arose disposal entire shareholdings two total earnings per share p compared p associates river vision development co ltd jcr increase reflected reduced impact charges arising pharmaceuticals co ltd revaluations liabilities contingent consideration put options associated increases sterling value share tax profits associates joint ventures groups hiv consumer healthcare businesses benefit share profits associates joint ventures million swiss tax reform improved performances relevant million businesses partly offset charges arising us tax reform dividends board declared four interim dividends resulting total dividend year pence line dividend declared see note financial statements dividends gsk annual report strategic report governance remuneration financial statements investor information adjusting items divestments intangible intangible significant total asset asset major transaction legal us tax adjusted adjusted results reconciliation results amortisation impairment restructuring related items reform results december turnover cost sales gross profit selling general administration research development royalty income operating incomeexpense operating profit net finance costs profit disposal associates share tax profits associates joint ventures profit taxation taxation tax rate profit taxation profit attributable noncontrolling interests profit attributable shareholders earnings per share p p p p p p p p weighted average number shares millions divestments intangible intangible significant adjusted total asset asset major transaction legal results adjusted results reconciliation results amortisation impairment restructuring related items revised december turnover cost sales gross profit selling general administration research development royalty income operating incomeexpense operating profit net finance costs share tax profits associates joint ventures profit taxation taxation tax rate profit taxation profit attributable noncontrolling interests profit attributable shareholders earnings per share p p p p p p p weighted average number shares millions gsk annual report group financial review continued adjusting items continued intangible asset amortisation impairment aggregate impact unwinding discount future intangible asset amortisation million compared potential liabilities million million million intangible asset impairments million including million consumer healthcare joint venture million included impairments related progressive put option million contingent consideration related withdrawal tanzeum number commercial rd former shionogiviiv healthcare joint venture remaining assets following refocusing rd pipeline charge million driven adjustments trading amortisation impairment charges noncash forecasts impact updated exchange rate assumptions items forecasts relevant businesses well updated multiples used valuation consumer healthcare joint major restructuring integration venture put option major restructuring integration charges million incurred million noncash charges contingent consideration cash payments made million primarily reflecting write assets shionogi companies reduce balance sheet liability result decision withdraw tanzeum terminate rights hence recorded income statement total contingent sirukumab arising establishment groups new consideration cash payments amounted million business priorities well write assets related million included cash payments made viiv reductions site network cash charges million healthcare shionogi relation contingent consideration million including charges result decisions liability including preferential dividends amounted withdraw tanzeum terminate rights sirukumab cash million million payments made million million including explanation accounting noncontrolling interests settlement certain charges previously accrued also viiv healthcare set reflecting deferral payments cash payments approximately billion expected programme impact profit tax transactionrelated adjustments delivered incremental cost savings billion including includes accounting credit respect swiss tax reform billion currency benefits million arising revaluation deferred tax liabilities acquired consumer healthcare brands reflect reduction charges combined restructuring integration programme headline swiss tax rate date billion cash charges billion cash payments billion made date noncash charges divestments items billion divestments items included profit disposal anaesthesia business aspen million number extension existing combined programme agreed asset disposals equity investment impairments certain board july total cash charges combined adjusting items significant legal charges million programme expected approximately billion million included benefit settlement existing matters noncash charges billion programme well provisions ongoing litigation significant legal cash delivered approximately billion annual savings including payments million million currency benefit billion extended programme expected deliver total annual savings billion us tax reform constant currency basis together estimated billion enactment us tax cuts jobs act resulted currency benefits basis average exchange rates number additional charges reduced total earnings transactionrelated adjustments million transactionrelated adjustments resulted net charge firstly increased valuations hiv consumer healthcare million million primarily reflected businesses due lower us tax rates resulted increase accounting charges remeasurement liability related liabilities contingent consideration put options unwinding discounting effects contingent consideration million related acquisition former shionogiviiv healthcare joint secondly additional tax charge million comprised venture contingent consideration related acquisition reduction value us deferred tax assets held former novartis vaccines business value attributable future liabilities pensions current tax credit together consumer healthcare joint venture put option held novartis amounting million well charge million arising transactionrelated adjustments exclude impact reserves subsidiaries us entities group cash liabilities arising implementation us tax cuts impact latter charge spread eight years jobs act set separately approximately expected payable years six eight charges partly offset allocation noncontrolling chargecredit interests amounting million many adjustments consumer healthcare joint venture put option related viiv healthcare consumer healthcare joint contingent consideration former shionogiviiv venture healthcare joint venture including shionogi preferential dividends charges represent managements estimates impact us tax reform group based information currently viiv healthcare put options pfizer preferential dividends available guidance us treasury implementation act becomes available particularly regard contingent consideration former novartis vaccines business repatriation tax provisions assumptions underlying estimates adjustments could change could result adjustments charges taken could material impact results group total transactionrelated charges gsk annual report strategic report governance remuneration financial statements investor information adjusted results selling general administration turnover bn aer growth cer growth revised growth bn turnover turnover cer selling general administration sga costs turnover percentage points lower sterling terms percentage points lower cer basis primarily reflected tight control ongoing costs particularly consumer healthcare continued cost reductions pharmaceuticals including benefits pharmaceuticals restructuring programme integration benefits vaccines consumer healthcare partly offset increased investment promotional product support particularly new launches respiratory hiv vaccines adjusted operating profit bn aer growth cer growth research development bn growth turnover turnover cer research development rd expenditure million turnover higher aer higher cer included charge million utilisation priority review voucher q well increased investment progression number mid latestage programmes revised growth djusted results exclude significant legal charges per revised definition cer prior year figures revised discovery use adjusted results nonifrs measure among development metrics including total results cash flow generation facilities central support functions manage performance group nonifrs measures total pharmaceuticals may considered addition substitute vaccines rd superior information presented accordance ifrs consumer healthcare rd definition adjusted results set research development cost sales growth development expenditure driven growth progression number mid latestage programmes turnover turnover cer hiv respiratory anaemia together utilisation cost sales priority review voucher q continuing high growth discovery expenditure reflected investment early stage cost sales percentage turnover oncology portfolio percentage points sterling terms percentage points cer terms compared reflected royalty income favourable product mix across three businesses particularly royalty income million million pharmaceuticals including impact higher hiv sales well reduction primarily due patent expiry cialis q favourable product mix benefit settlement lost third catchup adjustment recorded q party supply volume favourable yearonyear comparison inventory adjustments vaccines also contribution integration restructuring savings three businesses offset continued adverse pricing pressure pharmaceuticals primarily respiratory additional supply chain investments gsk annual report group financial review continued adjusted results continued adjusted operating profit consumer healthcare adjusted operating profit million aer higher consumer healthcare operating profit million aer cer higher turnover increase cer higher cer higher turnover increase adjusted operating margin percentage points operating margin percentage points higher percentage points higher cer higher percentage points higher cer basis reflected improved operating leverage driven sales basis reflecting tight control costs integration synergies growth favourable mix three businesses together principally sga partly offset increased investment vaccines benefit settlement lost third party supply power brands volume favourable yearonyear comparison inventory adjustments also continued tight control net finance costs ongoing costs across three businesses well benefits restructuring integration partly offset charge finance income million utilisation priority review voucher interest income q well increases rd investment continuing fair value movements price pressure particularly respiratory supply chain investments finance expense adjusted operating profit business interest expense unwinding discounts liabilities revised growth remeasurements fair value movements margin margin finance expense cer pharmaceuticals pharmaceuticals rd share tax profits associates joint ventures pharmaceuticals share profits associates joint ventures million vaccines million consumer healthcare adjusted profit taxation corporate revised growth unallocated costs turnover turnover cer adjusted operating adjusted profit profit tax pharmaceuticals pharmaceuticals operating profit million aer higher taxation cer higher turnover increase cer tax adjusted profit amounted million represented operating margin percentage points higher effective adjusted tax rate sterling basis percentage points noncontrolling interests cer basis primarily reflected increased rd investment allocation adjusted earnings noncontrolling interests including impact utilisation priority review voucher amounted million million including q operating margin also reflected increased noncontrolling interest allocations consumer healthcare profits investment new product support well continued impact million million allocation viiv lower prices particularly respiratory broader transition healthcare profits increased million respiratory portfolio partly offset favourable million including impact changes proportions product mix primarily driven growth hiv sales preferential dividends due shareholder increase continued cost reduction benefit groups pharmaceuticals allocation also reflected comparison reduction restructuring programme allocation noncontrolling interests due higher net losses vaccines groups entities noncontrolling interests vaccines operating profit million aer higher cer higher turnover increase cer adjusted earnings per share operating margin percentage points higher adjusted eps p aer cer compared sterling basis percentage points higher cer cer increase adjusted operating profit basis primarily driven improved product mix benefit settlement lost third party supply volume favourable yearonyear comparison inventory adjustments together continued restructuring integration benefits partly offset increased sga resources support business growth new launches increased supply chain costs lower royalty income gsk annual report strategic report governance remuneration financial statements investor information cash generation conversion summary consolidated cash flow statement set reconciliation net cash inflow operating activities free cash flow reconciliation net cash inflow operating activities closest equivalent ifrs measure free cash flow shown net cash inflow operating activities net cash outflow investing activities net cash outflow financing activities revised decrease cash bank overdrafts net cash inflow operating activities cash bank overdrafts beginning year purchase property plant equipment decrease cash bank overdrafts purchase intangible assets exchange adjustments proceeds sale property plant equipment cash bank overdrafts end year interest paid cash bank overdrafts end year interest received comprise dividends associates joint ventures cash cash equivalents contingent consideration paid reported overdrafts investing activities contribution noncontrolling interests distributions noncontrolling interests net cash inflow operating activities year free cash flow million million increase primarily reflected improved operating profit performance well positive future cash flow currency benefit partly offset increased working capital reflecting long term expect future cash generated building inventory advance new product launches operations sufficient fund operating debt servicing increased contingent consideration payments legal settlements costs normal levels capital expenditure obligations total cash payments shionogi relation viiv healthcare existing licensing agreements expenditure arising restructuring contingent consideration liability year million programmes routine outflows including tax pension million recognised cash flows operating contributions dividends subject principal risks activities million recognised contingent consideration uncertainties discussed pages may time paid within investing cash flows payments deductible time additional demands finance acquisitions tax purposes including potentially acquiring increased ownership interests viiv healthcare consumer healthcare businesses capital expenditure financial investment minority shareholders hold put options access multiple cash payments tangible intangible fixed assets amounted sources liquidity short longterm capital markets million million disposals realised financial institutions needs addition cash flow million million cash payments acquire equity operations investments million million made sales equity investments realised million million investment appraisal capital allocation strengthened framework capital allocation free cash flow including creation new board govern allocation free cash flow amount cash generated business capital businesses utilise consistent cash return meeting obligations interest tax dividends paid invested capital croic methodology prioritise investment noncontrolling interests capital expenditure property across group whole effectively plant equipment intangible assets compare returns businesses allocate capital also consider impact eps credit profile relevant free cash inflow discount rate used perform financial analyses decided internally allow determination extent investments free cash flow million year cover cost capital individual investments discount rate million increase primarily reflected improved operating profit may adjusted take account specific country business performance well positive currency benefit increases project risk returns rebates partly offset increased working capital working capital reflecting seasonal factors building inventory advance new product launches increased contingent consideration payments purchase priority review voucher increased working capital percentage turnover dividends noncontrolling interests including catch working capital conversion cycle days adjustment higher legal settlements free cash flow also impacted costs acquiring hiv clinical assets reduction two days compared bms million predominantly due beneficial impact exchange approximately seven days partly offset build inventory advance new product launches increase trade receivables higher sales gsk annual report group financial review continued financial position resources property plant equipment business sciencebased technologyintensive highly assets regulated governmental authorities allocate significant noncurrent assets financial resources renewal maintenance property plant equipment minimise risks interruption production property plant equipment ensure compliance regulatory standards number goodwill processes use hazardous materials intangible assets investments associates joint ventures total cost property plant equipment december million net book value million investments land buildings represented million plant deferred tax assets equipment million assets construction million derivative financial instruments invested million new property plant noncurrent assets equipment mainly related large number projects total noncurrent assets renewal improvement expansion facilities various worldwide sites property mainly held freehold new investment current assets financed liquid resources december inventories contractual commitments future capital expenditure current tax recoverable million operating lease commitments million trade receivables believe property plant facilities adequate derivative financial instruments current needs liquid investments observe stringent procedures use specialist skills cash cash equivalents manage environmental risks activities environmental issues assets held sale sometimes dating operations modified discontinued reported environmental sustainability total current assets note financial statements legal proceedings total assets goodwill liabilities goodwill decreased year million current liabilities december million decrease primarily shortterm borrowings reflected impact exchange movements contingent consideration liabilities trade payables intangible assets intangible assets include cost intangibles acquired derivative financial instruments third parties computer software net book value current tax payable intangible assets december million shortterm provisions million decrease reflected impact total current liabilities exchange movements amortisation impairment existing intangibles million million respectively noncurrent liabilities partly offset development costs capitalised year longterm borrowings million additions million corporation tax payable deferred tax liabilities investments associates joint ventures held investments associates joint ventures carrying pensions postemployment benefits value december million million provisions market value december million contingent consideration liabilities million largest investments innoviva inc noncurrent liabilities book value december million total noncurrent liabilities million market value december total liabilities million see note financial statements net assets investments associates joint ventures equity investments share capital held investments carrying value december million million decrease share premium account carrying value year primarily due impact retained earnings exchange movements significant investments held reserves december theravance biopharma inc shareholders equity book value december million noncontrolling interests million investments included equity stakes companies research collaborations total equity provide access biotechnology developments potential interest interests companies arise business divestments gsk annual report strategic report governance remuneration financial statements investor information financial position resources continued derivative financial instruments assets pensions postemployment benefits current derivative financial instruments held fair value account pension postemployment million million noncurrent derivative arrangements accordance ias deficits financial instruments held fair value million nil net surpluses allowing deferred taxation majority financial instruments related foreign million million pension arrangements exchange contracts designated designated million million unfunded post accounting hedges employment liabilities decreases deficits predominantly driven special funding contributions inventories uk us schemes significant uk asset gains partly inventory million increased million offset lower discount rates used discount increase primarily reflected inventory build advance new value liabilities product launches noncurrent liabilities trade receivables noncurrent liabilities amounted million trade receivables million decreased december million decrease million primarily reflecting exchange movements reflects reclassification consumer healthcare put partly offset impact higher sales option current liabilities year deferred tax assets contingent consideration liabilities deferred tax assets million decreased million contingent consideration liabilities amounted million primarily result revaluation existing deferred tax december million million assets reflect lower headline us tax rate following enactment million represented estimated present value us tax reform partly offset increase deferred tax assets amounts payable shionogi relating viiv healthcare related intragroup profit inventory million million represented estimated present value contingent consideration payable novartis related derivative financial instruments liabilities vaccines acquisition liability due shionogi included held current derivative financial instruments fair value million respect preferential dividends liability million million primarily related foreign preferential dividends due pfizer december exchange contracts designated designated million explanation accounting treatment accounting hedges interests viiv healthcare set trade payables net debt trade payables amounting million increased million reflecting reclassification consumer healthcare put option million noncurrent cash cash equivalents liquid investments liabilities relates present value estimated amount payable us event full exercise novartis right require borrowings repayable within one year us acquire shareholding consumer healthcare borrowings repayable one year joint venture option became exercisable march net debt payment likely due several months exercise december net debt billion compared classified within current liabilities group balance sheet billion december comprising gross debt details provided note key accounting judgements billion cash liquid investments billion estimates decrease net debt primarily reflected improved free cash provisions flow billion disposal proceeds billion together carried deferred tax provisions shortterm billion favourable exchange impact translation noncurrent provisions million december nonsterling denominated debt offset cost million decrease year primarily reflected dividends paid shareholders billion reduction deferred tax provision result swiss tax december cash liquid investments held reform provisions yearend include million follows million related legal disputes million million related major restructuring programme provision made legal disputes bank balances deposits indemnified disposal liabilities employee related liabilities us treasury treasury repo costs restructuring programme extent balance money market funds sheet date legal constructive obligation existed could reliably estimated liquidity funds cash cash equivalents liquid investments government securities cash liquid investments billion billion held centrally december gsk annual report group financial review continued financial position resources continued maturity profile gross debt maturity profile gross debt equivalent gbp bonds eur bonds usd bonds commercial paper bank borrowings leases analysis cash gross debt effects hedging total equity follows december total equity decreased million december million primarily reflected impact dividends paid exceeding total profit year offset favourable exchange translation impact cash liquid investments weaker sterling rates total profit year impacted gross debt fixed charge respect us tax reform floating noninterest bearing summary movements equity set net debt total equity beginning year movements net debt total comprehensive income year dividends shareholders ordinary shares issued net debt beginning year changes noncontrolling interests decreaseincrease cash bank overdrafts recognition liabilities noncontrolling interests increase liquid investments derecognition liabilities noncontrolling increase longterm loans interests net repayment ofincrease shortterm loans shares acquired esop trusts exchange movements sharebased incentive plans movements tax sharebased incentive plans net debt end year contributions noncontrolling interests distributions noncontrolling interests total equity end year gsk annual report strategic report governance remuneration financial statements investor information financial position resources continued share purchases entered number research collaborations develop employee share ownership plan esop trusts new compounds pharmaceutical companies terms acquired million shares glaxosmithkline plc arrangements include upfront fees equity investments million shares held trusts satisfy future exercises loans commitments fund specified levels research options awards group share option award addition often agree make payments future schemes proportion shares held trusts milestones achieved respect awards rules scheme require us agreements relate compounds early satisfy exercises market purchases rather issue stages development potential obligation make milestone new shares shares held trusts matched payments continue number years compounds move options awards granted successfully development process generally closer december esop trusts held million product marketing approval greater probability million gsk shares future exercise success amounts shown within intangible assets share options share awards carrying value million represent maximum would paid milestones million deducted reserves achieved include billion relates externalised market value shares million million projects discovery portfolio reduction commitments due amendments made existing shares repurchased december agreements obligations ceased held million shares treasury shares million shares cost million million reached agreement trustees uk deducted retained earnings pension schemes make additional contributions including assist eliminating pension deficit identified part ordinary shares purchased period january december actuarial funding valuation table march company expect make includes commitment excludes normal ongoing annual ordinary share repurchases remainder funding requirement uk approximately million commitments contingent liabilities information pension obligations see note financial commitments summarised note financial financial statements pensions postemployment benefits statements commitments contingent liabilities contingent liabilities obligations respect short longterm debt set following table sets contingent liabilities comprising note financial statements contingent liabilities discounted bills performance guarantees letters credit note financial statements net debt items arising normal course business amounts provided pensions postretirement benefits expected expire set note financial statements pensions postemployment benefits amounts provided restructuring total yr yrs yrs yrs programmes legal environmental disputes set note financial statements provisions guarantees contingent liabilities contractual obligations commitments total following table sets contractual obligations commitments december fall due payment normal course business provided various indemnification guarantees respect business disposals total yr yrs yrs yrs legal disputes subsequently arisen provision made outflow resources considered probable loans reliable estimate made likely outcome dispute interest loans included note financial statements finance lease obligations provisions finance lease charges provide outcome tax legal disputes operating lease outflow resources considered probable reliable estimate commitments outflow may made december intangible assets disputes provision made possible property plant equipment make reliable estimate potential outflow funds might investments required settle disputes possibility purchase commitments outflow remote pensions ultimate liability matters may vary significantly commitments amounts provided dependent upon outcome litigation total proceedings negotiations relevant tax authorities discussed principal risks uncertainties pages commitments respect loans future interest payable loans notes financial statements disclosed taking account effect derivatives taxation legal proceedings gsk annual report group financial review continued critical accounting policies consolidated financial statements prepared accordance reconciliation gross turnover net turnover us ifrs adopted use european union also pharmaceuticals business including puerto rico follows ifrs issued iasb following accounting policies approved board described note financial margin margin margin statements accounting principles policies gross turnover required make estimates assumptions affect amounts assets liabilities revenue expenses reported market driven financial statements actual amounts results could differ segments estimates government critical accounting policies relate following areas mandated state programs turnover cash discounts taxation note customer returns legal disputes notes prior year adjustments intangible asset impairments note items business combinations note total deductions net turnover pensions postemployment benefits note information judgements estimates made areas market driven segments consist primarily managed care given note financial statements key accounting medicare plans gsk negotiates contract pricing judgements estimates honoured via rebates chargebacks mandated segments consist primarily medicaid federal government programmes turnover receive government mandated pricing via rebates respect turnover accounting policy largest business chargebacks us pharmaceuticals us market complex arrangements rebates discounts allowances following increased deductions market driven segments briefly describes nature arrangements existence gross turnover net turnover reconciliation primarily reflected us pharmaceuticals business higher rebates chargebacks respiratory products advair particular advair accounted arrangements certain indirect customers whereby us pharmaceuticals turnover approximately total customer able buy products wholesalers reduced deduction rebates returns respiratory portfolio prices chargeback represents difference whole accounted approximately total deduction invoice price wholesaler indirect customers year advair continued suffer pricing pressures contractual discounted price accruals estimating chargebacks business sought transition respiratory portfolio calculated based terms agreement historical newer products experience product growth rates balance sheet accruals rebates discounts allowances customer rebates offered key managed care group returns us pharmaceuticals vaccines businesses purchasing organisations gpo direct indirect managed combined basis december customers arrangements require customer achieve total accrual amounted million million certain performance targets relating value product purchased formulary status predetermined market shares monthly process operated monitor inventory levels relative competitors accrual customer rebates wholesalers abnormal movements process uses estimated based specific terms agreement gross sales volumes prescription volumes based third party historical experience product growth rates data sources information received key wholesalers us medicaid programme stateadministered programme aim maintain inventories consistent level year providing assistance certain poor vulnerable patients year based pattern consumption medicaid drug rebate program established basis us pharmaceuticals vaccines inventory levels reduce state federal expenditure prescription drugs wholesalers distribution channels december patient protection affordable care act became law estimated amount approximately four weeks turnover participate providing rebates states accruals medicaid calculation uses third party information accuracy rebates calculated based specific terms relevant totally verified believed sufficiently reliable regulations patient protection affordable care act purpose cash discounts offered customers encourage prompt payment accrued time invoicing adjusted subsequently reflect actual experience record accrual estimated sales returns applying historical experience customer returns amounts invoiced together market related information stock levels wholesalers anticipated price increases competitor activity gsk annual report strategic report governance remuneration financial statements investor information critical accounting policies continued legal disputes like many pharmaceutical companies faced various respect accounting policy legal disputes complex product liability antitrust patent litigation well following briefly describes process determine investigations operations conducted various governmental level provision necessary regulatory agencies throughout year general counsel group head groups legal function senior accordance requirements ias provisions vice president head global litigation group contingent liabilities contingent assets provide responsible litigation government investigations routinely anticipated settlement costs outflow resources brief chief executive officer chief financial officer considered probable reliable estimate may made board directors significant litigation pending likely outcome dispute legal expenses arising group governmental investigations group claims group may become involved significant legal proceedings respect possible meetings appropriate detail status significant litigation make reliable estimate expected financial effect government investigations review matters number could result ultimate resolution proceedings claims notified us information potential claims yet notified cases appropriate disclosure cases would included assessment validity claims progress made settling claims annual report provision would made recent settlement levels potential reimbursement insurers position could change time therefore meetings also include assessment whether assurance losses result outcome legal sufficient information available us able make reliable proceedings exceed material amount amount estimate potential outcomes disputes often external provisions reported groups financial statements counsel assisting us various litigation matters investigations also assist briefing board senior management following discussions matters possible make reliable estimate amount provision may required level provision legal disputes reviewed adjusted appropriate matters discussed note financial statements legal proceedings treasury policies report sterling pay dividends sterling cash flows capital management role treasury monitor manage groups external financial strategy implemented groups financial internal funding requirements financial risks support architecture supports gsks strategic priorities regularly strategic objectives gsk operates global basis primarily reviewed board manage capital structure subsidiary companies manage capital ensure group appropriate mix debt equity subsidiaries able operate going concerns gsks longterm credit rating standard poors optimise returns shareholders appropriate balance stable outlook moodys investor services moodys debt equity treasury activities governed policies stable outlook shortterm credit ratings p approved annually board directors recently standard poors moodys respectively july treasury management group tmg meeting chaired chief financial officer takes place regular liquidity risk management basis review treasury activities members receive management policy borrow centrally order meet anticipated funding information relating activities requirements cash flow forecasts funding requirements monitored tmg regular basis strategy diversify treasury operations liquidity sources using range facilities maintain broad objective treasury activity minimise posttax net access financial markets cost financial operations reduce volatility order benefit earnings cash flows use variety financial instruments day sweep cash number global subsidiaries finance operations derivative financial instruments manage central treasury accounts liquidity management purposes market risks operations derivatives principally interest rate risk management comprising interest rate swaps foreign exchange forward contracts objective minimise effective net interest cost swaps used swap borrowings liquid assets balance mix debt fixed floating interest rates currencies required group purposes manage exposure time policy interest rate risk management limits amount financial risks changes foreign exchange rates floating interest payments prescribed percentage interest rates operating profit hold issue derivatives speculative purposes gsks treasury policies specifically prohibit activity transactions financial instruments undertaken manage risks arising underlying business activities gsk annual report group financial review continued treasury policies continued foreign exchange risk management borrowings denominated swapped foreign currencies foreign currency transaction exposures arising external trade match investments overseas group assets may treated flows normally hedged foreign currency transaction hedge relevant assets forward contracts major exposures arising internal trade flows selectively hedged currencies also used reduce exposure groups objective minimise exposure overseas operating investment overseas group assets tmg reviews subsidiaries transaction risk matching local currency income ratio borrowings assets major currencies regularly local currency costs possible gsks internal trading counterparty risk management transactions matched centrally manage intercompany payment terms reduce foreign currency risk foreign currency set global counterparty limits banking cash flows hedged selectively management investment counterparties based longterm credit ratings treasury tmg include hedges foreign moodys standard poors treasurys usage limits exchange risk arising acquisitions disposals assets monitored daily corporate compliance officer cco possible manage cash surpluses borrowing operates independently treasury breach limits would requirements subsidiary companies centrally using forward reported cfo immediately contracts hedge future repayments back originating cco also monitors credit rating counterparties currency changes ratings occur notifies treasury changes order reduce foreign currency translation exposure seek made investment levels authority limits appropriate denominate borrowings currencies principal assets addition relationship banks credit ratings reviewed cash flows primarily denominated us dollars regularly report presented annually tmg approval euros sterling borrowings swapped currencies required strategic report strategic report approved board directors march signed behalf simon dingemans chief financial officer march ggsskk aannnnuuaall rreeppoorrtt ssttrraatteeggiicc rreeppoorrtt ggoovveerrnnaannccee aanndd rreemmuunneerraattiioonn ffiinnaanncciiaall ssttaatteemmeennttss iinnvveessttoorr iinnffoorrmmaattiioonn corporate governance section chairmans governance statement board corporate executive team leadership effectiveness nominations committee report accountability audit risk committee report relations stakeholders engagement activities science committee report corporate responsibility committee report directors report gsk annual report chairmans governance statement dear shareholder ceo transition pleased present corporate period formally took governance report reins ceo april emma working would evolve governance strategy longterm companys strategy support value creation guidance board met board remains committed achieving board director solicit views highest standards corporate company well meeting governance integrity governance employees levels business structure operates board across external advisers commentators gain group believe critical emma walmsley underpinning ability deliver wide view shaped thinking board evolved nonexecutive strategy create longterm value cet plan ensure directors fully engaged process benefit shareholders emma utilised diverse expertise around companys culture stakeholders investors also boardroom table test shape telling us never values consistent detail proposals particular greater need companies combine board committees provided emma strategy obligations society delivery management team continuous financial performance performance objectives feedback challenge review following pages set details culminated discussion joint strategy composition board corporate meeting full corporate executive governance arrangements processes team cet june proposed activities together reports innovation performance trust priorities boards committees scrutinised ahead board approval including new science committee july last year reported boards emma cet laid work ceo executive management investor update july innovation succession boards focus performance trust would provide supporting emma walmsleys transition platform growth beyond new role conducting detailed also reaffirmed commitment review companys strategy threebusiness structure subject certain management conditions would continue reviewed periodically commitment tested board joint strategy session june terms continuing board oversight innovation performance trust priorities board papers reshaped align new business priorities addition ceos report includes innovation performance trust performance indicators annual strategy meetings enable board consider progress effectiveness business priorities delivering longterm value investors gsk annual report strategic report governance remuneration financial statements investor information aligning strategy culture board evaluation governments corporate governance healthy culture vital tool unlocking appropriate time boards reform legislation new code protecting value biggest evolution carry external board expected effective financial driver culture leadership evaluation ceo senior years look forward providing update company emma walmsley cet independent nonexecutive director arrangements measure plan ensure companys culture therefore chose appoint new external new requirements next years report values consistent strategy board evaluator review bring uk corporate governance code performance objectives fresh perspective details externally compliance board reviewed proposed strategy facilitated review conclusions pleased report full culture featured heavily discussions set pages compliance requirements board approved move high corporate governance reform frcs uk corporate governance code performance valuesbased culture board taken close interest code copy code available new expectations courage uk governments development package wwwfrcorguk accountability development teamwork legislative best practice measures guide employee behavior board commend report supports initiatives raise bar received report managements shareholders corporate governance practices commitments initiatives effectiveness modern employer part reform drive financial cet held leadership conference reporting council frc recently october companys top leaders consulted proposals revised nonexecutive directors uk corporate governance code philip hampton attended critical transfer submitted views pleased note chairman ownership strategy culture frc included new measures leaders company march encourage companies take steps measuring progress implementing align strategy culture promote priorities monitoring aspects effective engagement workforce culture twice year allemployee wider stakeholders issues survey survey measures engagement described earlier relation approach progress innovation performance board trust priorities values expectations emma reports progress board regularly culture details companys commitment modern employer driving high levels employee engagement part trust agenda set pages strategic report gsk annual report board board composition ccoommpopsiotiosnition tteenunrue rneo nneoxnecuetixveecutive philip hampton nonexecutive chairman esx eact ut iavepril usp tto yperairl n oenxeecxuetcivueti u py etoar years n nonexecutive ye ayersars nationality ver eyeaarsrs british years appointed january deputy chairman gender diversity april nonexecutive chairman may board date publication april skills experience prior joining gsk philip male male chaired major ftse companies including royal bank female female scotland group plc j sainsbury plc also served group finance director lloyds tsb group bt group plc bg group executive plc british gas plc british date publication april steel plc philip previously male male appointed executive director lazards nonexecutive director rmc group plc female female belgacom sa chairman uk financial investments limited manages uk governments nonexecutive shareholdings banks date publication april male male external appointments philip senior independent director anglo american plc female female chairman remuneration committee member audit committee philip also chair hamptonalexander review international experience ftse women leaders international experience independent review improving april gender balance ftse leadership global us europe emap gsk annual report strategic report governance remuneration financial statements investor information emma walmsley simon dingemans dr hal barron dr patrick vallance chief executive officer chief financial officer chief scientific officer outgoing president rd president rd nationality nationality nationality nationality british british american british appointed appointed appointed appointed january chief executive january chief financial january january officer april officer april skills experience skills experience skills experience skills experience hal president rd calico patrick joined gsk emma joined gsk prior joining gsk simon llc california life company head drug discovery responsibility consumer years experience alphabetfunded company uses subsequently appointed senior healthcare europe investment banking sg warburg advanced technologies increase vice president medicines discovery subsequently appointed president goldman sachs simon advised understanding lifespan biology development glaxosmithkline consumer gsk decade prior joining calico hal member gsks corporate healthcare october appointment closely executive vice president head executive team since member gsks involved number gsks global product development appointed president rd january corporate executive team since key strategic projects simon chief medical officer roche patrick joined gsk board appointed ceo previously chairman responsible products january gsk consumer healthcare joint group finance directors combined portfolio roche prior joining gsk patrick venture gsk novartis genentech genentech clinical academic professor creation march external appointments senior vice president medicine led division appointment gsk ceo none development chief medical medicine university college designate september officer hal nonexecutive london years emma joined gsk board director chair science experience research clinical january succeeded technology committee juno medicine general internal medicine sir andrew witty gsk ceo therapeutics inc cardiovascular medicine clinical april pharmacology elected external appointments prior joining gsk emma worked academy medical sciences hal associate adjunct professor loreal years patrick previously epidemiology biostatistics held variety marketing nonexecutive director uk university california san general management roles paris biobank limited genome francisco london new york research limited based shanghai general manager consumer external appointments products loreal china emma patrick stepped president nonexecutive director rd end diageo plc january step executive director september holds effect march classics modern languages become uk governments chief oxford university scientific adviser head governments office science external appointments none key committee chair n nominations audit risk r remuneration science c corporate responsibility gsk annual report board continued manvinder singh vindi banga professor sir roy anderson dr vivienne cox lynn elsenhans senior independent independent nonexecutive independent nonexecutive independent nonexecutive nonexecutive director director scientific director director medical expert n r n c r c c n nationality nationality nationality nationality indian british british american appointed appointed appointed appointed september senior october july july independent nonexecutive director may skills experience skills experience skills experience professor sir roy world vivienne wide experience lynn wealth experience skills experience renowned medical scientist business gained energy running global business prior joining gsk vindi spent advanced knowledge infectious natural resources publishing significant knowledge global years unilever plc disease epidemiology sectors also deep markets gsk operates last role amongst several senior currently professor infectious understanding regulatory served chair president positions president disease faculty medicine government relationships chief executive officer sunoco global foods home personal imperial college london worked bp plc years inc prior care businesses fellow royal society britain continental europe joining sunoco president member unilever executive academy medical sciences posts including executive vice chief executive officer lynn board vindi sat prime royal statistical society president chief executive worked royal dutch shell minister indias council trade honorary fellow institute bps gas power renewable joined industry actuaries foreign associate business alternative energy held number senior roles board governors member national academy unit vivienne previously including executive vice president indian institute management medicine us national nonexecutive director bg global manufacturing iim ahmedabad vindi also academy sciences french group plc rio tinto plc lynn previously recipient padma bhushan academy sciences professor sir lead independent director nonexecutive director flowserve one indias highest civilian roy brings scientific expertise uk governments department corporation first tee honours boards deliberations international development vivienne greater houston vindi nonexecutive director appointed commander thomson reuters corp external appointments order british empire external appointments member hr committee vindi professor sir roy member new year honours lynn nonexecutive director also previously chairman holdingham international services uk economy baker hughes ge company supervisory board mauser group advisory board member sustainability chair audit committee science advisory board director texas medical external appointments natural history museum london external appointments center also trustee vindi partner private equity also member vaccine vivienne senior independent united way greater houston investment firm clayton dubilier international advisory board director pearson plc non rice also chairman kalle vacciab aj pharma holding executive director stena ab gmbh senior independent director sdn bhd malaysia chairman supervisory marks spencer group plc international alzheimers consortium board vallourec supplier member nomination harvard university boston energy industry committee chairman chairman scientific advisory remuneration committee vindi board netherlands centre nonexecutive director one health ncoh chairman confederation british industry oriole global health ltd cbi director high ridge brands co member holdingham international advisory board chair board trustees marie curie also governing board indian school business isb hyderabad member indo uk ceo forum gsk annual report strategic report governance remuneration financial statements investor information dr laurie glimcher dr jesse goodman judy lewent urs rohner independent nonexecutive independent nonexecutive independent nonexecutive independent nonexecutive director scientific director scientific director director medical expert medical expert c n r r n nationality nationality nationality nationality american american american swiss appointed appointed appointed appointed september january april january skills experience skills experience skills experience skills experience laurie currently professor jesse previously served senior judy extensive knowledge urs broad range business medicine harvard medical school leadership positions global pharmaceutical industry legal experience served ceo president us food drug administration corporate finance joined chairman number boards attending physician dana fda including recently merck co served recently credit suisse farber cancer institute fdas chief scientist previously chief financial officer worldleading financial services deputy commissioner retired company prior joining credit addition number senior science public health judy previously served suisse urs served leadership positions held director center biologics nonexecutive director dell chairman executive board harvard medical school evaluation research cber inc quaker oats company ceo prosieben harvard school public health motorola inc prosiebensat media ag laurie also served stephen jesse played leadership role followed number years suzanne weiss dean developing fdas board determined private practice major law firms professor medicine weill regulatory science medical judy recent relevant switzerland us cornell medical college countermeasures initiatives financial experience agreed admitted bars canton attending physician new york worked collaboratively appropriate zurich switzerland presbyterian hospitalweill cornell industry academia government qualifications background state new york us medical center laurie stepped global public health regulatory audit committee financial expert board bristol partners prepare respond myers squibb co bms major public health threats external appointments external appointments serving years including emerging infectious judy nonexecutive director urs currently chairman board laurie brings scientific diseases disasters terrorism thermo fisher scientific inc board credit suisse group public health expertise boards led fdas response west motorola solutions inc ag chairmans deliberations nile virus hn also trustee rockefeller governance committee influenza pandemic served family trust life member also chairman member external appointments senior leadership team massachusetts institute board trustees credit suisse laurie member us white house medical technology corporation member research institute credit suisse national academy sciences countermeasure review jesse american academy arts foundation urs appointed national academy medicine brings scientific public health sciences member vicechairman governing member scientific expertise boards business advisory board board swiss bankers steering committee parker deliberations twoxar association institute cancer immunotherapy nonexecutive director external appointments waters corporation also jesse currently professor serves corporate governance medicine georgetown university committee addition laurie directs georgetown university cofounder chair center medical product access scientific advisory board quentis safety stewardship therapeutics inc scientific compass active advisory board member repare clinician serves attending therapeutics inc american physician infectious diseases asthma foundation also serves president member board united key states pharmacopeia usp member regulatory working committee chair n nominations group coalition epidemic preparedness innovations cepi audit risk r remuneration science c corporate responsibility gsk annual report corporate executive team roger connor luc debruyne president global manufacturing supply president global vaccines roger joined cet appointed luc joined cet president president global manufacturing supply global vaccines role held since working year president joined gsk commercial strategy designate prior vice president director rd leading european office ceo corporate strategy commercial centre excellence roger joined gsk astrazeneca luc became general manager netherlands senior vice president appointed board gsk consumer healthcare joint venture general manager italy appointed senior vice president pharma europe novartis april prior current role luc member roger holds degree mechanical international federation pharmaceutical manufacturing engineering queens manufacturers associations vaccines ceo university belfast masters manufacturing roundtable management committee leadership cambridge university belgian federation enterprises chartered accountant holds masters degree physical education university leuven emma walmsley chief executive officer simon dingemans nick hirons brian mcnamara chief financial officer senior vice president global ethics ceo gsk consumer healthcare dr hal barron compliance chief scientific officer president rd nick appointed cet senior brian joined cet vice president global ethics compliance appointed ceo gsk consumer healthcare dr patrick vallance responsible compliance risk management joined gsk head europe outgoing president rd corporate security investigations americas gsk consumer healthcare following creation joint venture nick joined gsk international gsk novartis previously head biographical details auditor later head audit assurance see combined five audit functions novartiss otc division brian began career procter gamble independent team common riskbased methodology nick relocated china chairman world selfmedication establish governance model china industry association business created consistent approach earned undergraduate degree compliance electrical engineering union college nick fellow chartered institute new york mba finance management accountants university cincinnati abbas hussain member cet leaving company july gsk annual report strategic report governance remuneration financial statements investor information luke miels david redfern karenann terrell president global pharmaceuticals chief strategy officer chief digital technology officer luke joined gsk cet september david joined cet chief strategy officer karenann joined gsk cet september president global pharmaceuticals responsible corporate chief digital technology officer responsible commercial portfolio development strategic planning previously responsible technology digital data medicines vaccines senior vice president northern europe analytics strategy responsibility gsks pharmaceutical previously worked astrazeneca previously worked walmart chief businesses region prior executive vice president european information officer prior senior vice president central eastern business prior executive vice baxter international chief europe david joined gsk president global product portfolio information officer daimler strategy global medical affairs corporate appointed chairman board chrysler corporation karenann began affairs held roles increasing viiv healthcare limited non career general motors seniority roche sanofiaventis executive director aspen pharmacare karenann member board trustees holdings limited board holds bachelor science degree new york hall science biology flinders university adelaide david bachelor science degree became nonexecutive director mba macquarie university sydney bristol university uk chartered pluralsight llc accountant earned graduate postgraduate degrees electrical engineering kettering purdue universities respectively claire thomas phil thomson dan troy senior vice president human resources president global affairs senior vice president general counsel claire appointed cet senior vice phil joined cet appointed dan joined gsk cet senior vice president human resources president global affairs april president general counsel specific responsibilities groups strategic claire joined company senior previously partner washington approach reputation corporate responsibility manager human resources sales marketing law firm sidley austin llp principally global health china britains withdrawal group uk pharmaceuticals becoming represented pharmaceutical companies trade european union responsible director human resources uk associations matters related us food engagement investors media government pharmaceuticals appointed drug administration fda government key global community partners employees senior vice president human resources regulations dan formerly chief counsel pharmaceuticals europe previously senior vice president fda senior vice president human resources communications government affairs dan holds bs industrial labor relations pharmaceuticals international joined gsk commercial trainee cornell university jd columbia prior gsk worked ford motor university school law chairs us company holding various positions phil chairman whitehall industry chamber commerce litigation center human resources group board member chinabritain member american law institute business council claire bachelor science degree announced january dan troy economics management industrial earned degree english history leave gsk later date relations university wales russian studies durham university role relocates uk gsk annual report corporate governance continued leadership effectiveness corporate governance framework board established corporate governance framework clearly defined responsibilities accountabilities framework designed safeguard enhance longterm shareholder value provide platform realise groups strategy gsks new innovation performance trust priorities internal control risk management arrangements described pages integral part gsks governance framework board operate effectively give full consideration key matters board committees established set board chief nominations audit risk remuneration science corporate executive committee committee committee committee responsibility officer committee corporate executive read read read read read team see wwwgskcom terms reference board committee scheduled board committee attendance corporate board nominations audit risk remuneration science responsibility total number scheduled meetings members attended attended attended attended attended attended philip hampton emma walmsley simon dingemans dr patrick vallance professor sir roy anderson vindi banga dr vivienne cox lynn elsenhans dr laurie glimcher appointed september dr jesse goodman judy lewent urs rohner sir andrew witty retired march dr moncef slaoui retired march total number adhoc meetings directors served part year numbers brackets denote number meetings directors eligible attend see committee reports attendees committee meetings chairman ceo executive directors work committees year reports included later corporate governance report gsk annual report strategic report governance remuneration financial statements investor information board programme board responsible longterm success company authority accountable shareholders ensuring group appropriately managed achieves strategic objectives sets performance duties regard interests key stakeholders cognisant potential impact decisions makes board discharges responsibilities annual programme meetings year focused number specific areas outlined table line new longterm priorities innovation performance trust addition year ceo met nonexecutive directors discuss various matters including evolution thinking companys strategy succession planning ongoing sfo investigation areas focus longterm priorities link strategy boards oversight execution strategy included receiving discussing reports principal three businesses pharma vaccines consumer briefings products particular board keen oversee launch plans shingrix vaccine trelegy ellipta nucala products also reviewed background withdrawal tanzeum joint board corporate executive committee strategy day held discuss new innovation performance trust priorities external landscape changes business performance competitors governance arrangements evolution approach changes medical engagement key external experts conducting deep dive groups business strategy china receiving discussing reports pensions insurance tax treasury strategies performance boards focus performance included setting new ceos objectives setting reviewing agreeing annual budget forward looking three year plan receiving reports ceo principal three businesses scrutinising groups financial performance reviewing brexit impacts planning arrangements reviewing progress pipeline governance boards approach discharging corporate governance duties included receiving reports board committees approving annual report reviewing agm preparation approving notice agm considering observations agreeing actions internal evaluation boards performance receiving reports corporate governance regulatory developments undertaking training gsks code conduct approving appointment new chief scientific officer president rd new nonexecutive director scientific medical expert cultural head hr briefed board transformation aligning gsks culture values support strategy longterm priorities link longterm priorities innovation performance trust gsk annual report corporate governance leadership effectiveness continued key board roles responsibilities leadership independent oversight rigorous challenge chairman nonexecutive directors philip hampton provide strong independent element board leads manages business board constructively support challenge management provides direction focus scrutinise performance meeting agreed ensures clear structure effective operation deliverables board committees shape proposals strategy management sets board agenda ensures sufficient time letter appointment setting terms allocated promote effective debate support sound conditions directorship decision making devote time necessary proper ensures board receives precise timely clear performance duties information expected attend meetings required meets nonexecutive director annual independence statement basis discuss individual contributions performance together training development needs board considers nonexecutive directors shares peer feedback provided part board identified pages independent evaluation process includes professor sir roy anderson tenure meets nonexecutive directors independently nine years demonstrate executive directors appropriate degree independence character leads discussions shareholders judgement free business responsible groups performance relationship could materially interfere exercise judgement independence chairmans role description available wwwgskcom commitment professor sir roy anderson judy lewent served board six years chief executive officer subjected rigorous review emma walmsley responsible management group senior independent nonexecutive director three businesses vindi banga develops groups strategic direction consideration approval board acts sounding board chairman trusted intermediary directors implements agreed strategy supported members corporate executive together nonexecutive directors leads team annual review chairmans performance taking account views executive directors chief executive officers role description available wwwgskcom discusses results chairmans effectiveness review chairman leads search appointment process recommendation board new chairman acts additional point contact shareholders maintains understanding issues concerns major shareholders briefings investor relations team company secretary senior independent nonexecutive directors role description available wwwgskcom company secretary secretary board board committees victoria whyte supports board committee chairs annual agenda plan setting ensures information made available board members timely fashion supports chairman designing delivering board inductions coordinates ongoing business awareness training requirements nonexecutive directors undertakes internal board committee evaluations request chairman advises directors board practice procedures corporate governance matters chairs groups disclosure committee point contact shareholders corporate governance matters gsk annual report strategic report governance remuneration financial statements investor information board induction development company secretary assists chairman designing new corporate executive team cet members meet board facilitating individual induction programmes new directors members part induction ensure board designed purpose orientating familiarising maintains connections cet new directors industry organisation governance dr laurie glimcher new usbased science strategy innovation performance trust priorities medical expert january dr hal barron highly new director receives general induction personalised experienced rd leader joined board customised induction devised individually tailored induction programmes summarised new directors background education experience role board induction general board induction executive nonexecutive directors role executive director role nonexecutive director directors duties responsibilities build relationship gsk strategy competitors gsks corporate governance chairman board external environment structure fill capability gaps meet cet members gsks code conduct training gsks financial structure personal executive director induction personal nonexecutive director induction dr hal barron dr laurie glimcher chief scientific officer president rd scientific medical expert maximise handover opportunity outgoing rd vaccines deep dives president rd briefings rds key therapy areas detailed review pipeline assets including site visits ware stevenage wavre rd governance processes team briefing us business commercial model business development landscape inform audit risk science committee inductions updated rd strategy board business key stakeholder awareness training ensure nonexecutive directors develop maintain chairman meets director annually onetoone greater insight understanding business key basis discuss ongoing training development stakeholders requirements board kept date legal regulatory governance matters regular papers briefings invited attend internal management meetings including company secretary presentations internal meetings cet external advisers meet employees informally visits groups operations board members undertook training gsks receptions held staff around board meetings code conduct receive monthly investor relations stakeholder reports maintain awareness investor stakeholder views measure progress implementing innovation performance trust business priorities evolving culture allemployee survey undertaken every six months reports regular conversations cet directly workforce lets talk programme gsk annual report corporate governance leadership effectiveness continued external evaluation board board carries evaluation performance committees every year evaluation facilitated externally every third year market review ms ffion hague independent board evaluation appointed independently facilitate board committee evaluation neither ms hague independent board evaluation connection company ms hague met chairman senior independent nonexecutive director sid ceo company secretary discuss agree scope evaluation exercise timetable activities secretary provided evaluation evaluation team attended board team access board committee committee meetings held december papers materials part observe directors preparatory work evaluation operation dynamics meetings see phase one phase two phase three phase four phase five preparation interviews observations review outcomes november december report containing output evaluation ms hague conducted detailed interviews set draft conclusions compiled board member ms hague discussed initially based clear agenda sent chairman ceo sid report containing participant advance findings recommendations company secretary head presented ms hague whole board hr also interviewed gain main meeting january broader perspective separate reports compiled board committees presented individual committee chairs first discussed respective committee meetings january individual board member presented discussed chairman chairman initially discussed sid sid ms hague discussed nonexecutive directors sid discussed chairman gsk annual report strategic report governance remuneration financial statements investor information external evaluation board continued board review feedback outcomes response report board members highly engaged ms hagues report noted context board committed best interests company feel evaluation conducted recently boards work underpinned mechanisms established significant change composition board still support operations board takes governance seriously settling including chosen work following areas new chairman appointed may review rd strategy following appointment new chief scientific officer president rd new ceo starting role april enhancing boards focus decision making agreeing five members joining board within past three years clear priorities focus year though experienced field previous uk listed company experience succession planning senior executive board level welcoming dr barron board january building board relationships culture line ceos culture work across group due timing review occasion review team took input board members context board members expressed broad range views board settles issues identified focus action plan coming year board strongly supportive new ceo pleased ongoing work strengthen focus science new chief scientific officer president rd non executive scientific medical experts creation science committee formative stages board performance progress conclusions board evaluation review internally facilitated company secretary set areas focus progressachievements create opportunities deeper year board considered detailed review companys strategy management strategic discussions particularly context operating environment companys culture industry dynamics global healthcare evolution pharmaceuticals industry competitive landscape therapy areas gsk culture performance identify ways improve papers submitted board streamlined reshaped align new innovation boards decision making performance trust longterm business priorities allow continuing oversight focused decisionmaking increase board oversight good progress made establishing science committee details found science innovation collaboration science committee report new science committee consider data new reporting board enhanced area within new innovation performance trust systems contribute greater longterm business priorities framework dashboards aiding boards oversight companys key understanding hence help evolve performance indicators business strategy gsk annual report corporate governance leadership effectiveness continued nominations committee report dear shareholder philip hampton committee worked last years refresh nominations committee board replace retiring directors following ceo transition chair emma walmsley established innovation performance trust longterm priorities business committees focus turned supporting ceo establishing team needs lead company opportunities challenges ahead executive management succession dr patrick vallance president rd informed board intention become uk governments chief scientific adviser head governments office science committee role engaged korn ferry previously conducted proactive committee reviews recommends board desktop talent mapping exercise rd executives committee full participation nonexecutive directors compiled profile next leader rd profile contained brief structure size composition board requirements desired skill set potential successor appointment directors members patrick would need brief drafted emphasise board committees cet importance ceo committee placed identifying succession board cet recruiting worldrenowned rd leader strong track record developing rd organisational capabilities significant new medicines reviewing profile committee decided membership needed look externally talent committee members committee member since korn ferry initiated global searches agreed profile philip hampton chair january january across pharmaceuticals industry given importance professor sir roy anderson october search committee sought second opinion egon zehnder vindi banga january also experts field executive search yielded lynn elsenhans january pool candidates reduced shortlist several judy lewent may potential candidates shortlisted candidates met urs rohner january subsequently interviewed companys designated scientific medical experts sme audit risk committee chair details committee members skills experience chairman feedback candidate compiled given biographies board pages committee received ceos analysis candidates see committee member separate analysis head hr attendance levels process culminated committee meeting agree company secretary secretary committee recommendation board proposed appointment attends meetings attendees committee dr hal barron chief scientific officer president rd meetings may include recommendation received unanimous board approval november announced hal would join board regular attends executive director effect january patrick attendees attendee required stepped president rd end resign chief executive officer executive director cet member march head human resources board pleased hals appointment demonstrated appropriate external advisers companys continued ability attract world class talent organisation one worlds foremost rd leaders hal advisory services possesses exceptional track record developing significant year korn ferry egon zehnder provided new medicines roche genentech recently calico recruitment consultancy services committee building research organisation uses cuttingedge technologies addition recruitment hr services provide drug discovery development company signatories voluntary committee report last year reported mr luke miels code conduct executive search firms gender recruited astrazeneca executive vice diversity best practice president european business succeed abbas hussain president global pharmaceuticals luke subsequently joined gsk cet september luke hal previously worked together roche appointments complete top team global pharmaceuticals business gsk annual report strategic report governance remuneration financial statements investor information nominations committee report continued finally terms senior executive appointments ms karenann currently meeting parker reports recommendation terrell appointed support korn ferry cet least one board director colour september gsks first chief digital technology officer point wish personally acknowledge much companywide remit transform new technologies everyone involved work hamptonalexander review used improve performance across group karenanns miss dame helen sadly passed away august last year previous role chief information officer walmart outstanding leader believed women could led multiyear effort transform walmart use data able contribute far business ever analytics digital engagement customers acknowledged review team continue work senior executive appointments underscore immediate memory areas focus new ceo since taking appointment committee pleased progress made towards continues build senior leadership team drive female board representation combined corporate executive innovation performance trust agenda team cet direct reports targets least new nonexecutive director appointment gsk ranked th ftse summary standing year korn ferry also assisted committee hamptonalexander reviews ftse women leaders report search additional sme nonexecutive director reproduced enhance boards scientific capabilities strengthen boards female representation june scientific perspective join new science committee interviewing suitable sme candidates committee recommended combined executive report female committee direct dr laurie glimcher board potential nonexecutive representation metrics board reports director sme board subsequently approved dr glimchers ftse target appointment board effect september laurie gsk ranked th brings wealth expertise scientific medical innovation ftse public health invaluable assisting boards focus ftse average delivering longterm innovation performance trust priorities also appointed member science ftse highest audit risk committees currently board composition diversity women board rise sought balance composition board april dr patrick vallance stepped committees time board left company longer serving directors maintain understanding group women cet sector whilst newer appointees bring fresh external perspectives insights going forward closing gap board cet gender representation increasing pipeline female direct nonexecutive directors experience wide range reports cet achieve target area focus industries backgrounds including pharmaceuticals industry support approach gsk various actions enhance rd vaccines consumer products healthcare medical development pipeline including accelerating difference research academia insurance financial services well programme womens leadership initiative accelerating complex organisations global reach importantly majority transitions coaching programme joining rejoining board scientific mathematical background company extended time absence means attuned fundamentals industry operate representation women management positions illustrated part gender diversity gsks global workforce gsk committed equal opportunities employees alongside initiatives promote diversity inclusion levels organisation board committed encouraging throughout organisation diverse inclusive culture led cet committee evaluation key requirement effective board comprises committees annual evaluation exercise externally facilitated range balance skills experience knowledge gender ms ffion hague independent board evaluation concluded independence individuals prepared challenge committee continued operate effectively agreed work team needs backed diversity committees effectiveness could improved personal attributes including character intellect sound judgement honesty courage refining approach longterm succession planning around key additional skills capability needs board committee responsible developing measurable objectives support implementation boards diversity policy improving dialogue full board evolving areas meet measurable targets set focus committee parker review commissions report beyond one published october increase ethnic diversity appointments boards ftse companies philip hampton hamptonalexander reviews report worked nominations committee chair late dame helen alexander published increase number women senior leadership positions ftse march companies gsk annual report accountability audit risk committee report dear shareholder judy lewent following pages report aim share insights audit risk committee activities undertaken overseen audit risk committee chair committee year committee worked largely recurring structured programme activities devise programme company secretary agree content management external auditors start year adapted appropriate year progresses overseeing smooth audit transition process important focus committee year exercise together details committees continued scrutiny role enhancements simplifications internal controls risk management financial reporting systems processes committee reviews responsible covered external auditors financial internal reporting processes last year advised shareholders conclusion integrity financial statements including competitive audit contract tender board appointed annual report quarterly results announcements committees preferred choice deloitte llp deloitte system internal controls companys new auditors gsks financial year onwards identification management risks external committee overseen significant activity necessary internal audit processes transition pricewaterhousecoopers llp pwc deloitte initiating audit tenders selection appointment initially required deloitte achieve independence first half external auditors setting remuneration year could observe pwcs work statutory auditors exercising oversight work yearend audit committee received regular reports audit transition met regularly lead audit membership partners pwc deloitte discuss progress committee members committee member since pleased hear new perspectives deloitte judy lewent chair january april bring audit presented audit scoping end vindi banga january included significant opportunities data analytics bring full report audit transition arrangements given lynn elsenhans january pages dr laurie glimcher september would like thank pwc team professionalism details committee members financial accounting continuing deliver highquality audit particularly scientific experience expertise given backdrop transition audit firms cooperated make biographies board pages transition smooth one minimal disruption business see committee member attendance levels look forward reporting shareholders deloittes first audit company secretary secretary committee gsks annual report attends meetings entire board invited attend internal framework control risk management committee meetings attendees include developments regular attends core focus committee following attendee attendee required developments business units across enterprise helped general counsel strengthen culture compliance risk management financial controller gsk values expectations high priority head audit assurance committee year oversaw progress driven head global ethics compliance global ethics compliance gec embed measure chief medical officer effectiveness values integrate values chief product quality officer existing control processes example thirdparty oversight external auditors framework updated require third parties confirm adherence values thirdparty code conduct accordance financial reporting councils uk gsks values speak programme elements also corporate governance code board determined included general manager gm certification process judy lewent recent relevant financial companys gms confirm adherence internal experience board also agreed control framework gec continued deploy appropriate qualifications background audit leader led discussion programme gsks values right committee financial expert defined sarbanes first time culture ethical decision making workshops oxley act determined independent within meaning securities exchange act amended committee whole competence relevant sector company operates gsk annual report strategic report governance remuneration financial statements investor information audit risk committee report continued values maturity assessments values assessment reviews monitoring committee learned outcomes values maturity monitoring key element internal control framework assessments vmas performed used target serves continuous source insights inform improvements assessments specific areas implementation control environment significant focus business unit specific action plans address areas businesses area improvement identified vmas overseen local compliance activities risk management compliance boards vma insights sec settlement committee continues review consider highlighted overall patient focus integrity values updates us securities exchange commission sec employees feel affinity well agreed settlement made sec embedded positive shift perception relating compliance terms settlement track final values transparency respect people noted report due submission sec summer result audit assurance teams values assessment reviews assess well values embedded cia committee also oversight companys organisation responsibilities cia entered office inspector general oig us department health revised gsk employee survey human services last year group reported people took part gsks employee engagement survey oig commercial practices within global pharmaceuticals whose purpose outcomes discussed affirmative obligations cia expired strategic report group waiting official closure oig completes written standards controls work continued review groups final cia annual report cia required harmonise simplify written standards across several parts group ensure sufficient internal controls mitigate risks enterprise recognising improved accessibility clarity associated commercial practices involving us pharmaceutical around written standards enabler improved risk products interactions us healthcare professionals management informed decision making group received positive feedback oig consequently received release months earlier original training communication gec function continued year term cia although commitments certain focus personal development including us states regarding salesforce compensation extend ethics compliance academy gec ran faceto committee continued receive quarterly cia face ethics compliance academy launched virtual assurance updates head gec academy enable flexible participation first virtual responding issues integrated investigations academy held end held process developed gec hr legal clarify quarter currently certified ethics accountabilities safeguard reporters using speak compliance professionals since inception academy channels deliver improved outcomes decisions improvements helped accelerate steps taken living values april part enterprisewide substantiate allegation investigate resolution well living values training issued population delivering enhancements engagement key stakeholders employees complementary workers training individuals raise issues details reporting included scenarios explored values investigating concerns gsk set application companys ways working including strategic report awareness enterprise risks speak arrangements enterprise risk framework strategies year part focused several critical risks including privacy committee considered gsks enterprise risks strategies antibribery corruption abac mandatory training abac address reviews undertaken us corporate integrity agreement cia also completed targeted areas workforce depending annual unit risk assurance update reports role performed enterprise risk strategy papers significant risks annual risk reviews contained risk management internal control report presented head gec gsk annual report corporate governance accountability continued audit risk committee report continued part review committee assesses whether key financial reporting framework enhancements enterprise risks affecting unit managed mitigated committee continued improve clarity gsks external proportionate way committee examines whether financial reporting reviewing companys financial reporting satisfied control environment operation effectiveness framework committee made recommendations board whether refinements management propose ensure approved adoption early changes environment remains fit purpose appropriate also assesses improved way gsk reports explains adjusted results commitment units leadership maintaining strong adjusting items line european securities markets controls culture authority sec requirements addition two changes made companys use adjusted performance measures committee noted progress made delivering improve clarity financial reporting finally free enablers drive even stronger top risk management cash flow calculation adjusted include contingent approach gsks enterprise risks provide greater consistency consideration payments risk management drive efficiencies included common list enterprise risks subrisks assessed unit global reporting system platforms single list business activities risks committee pleased oversee continued progress mapped made moving towards standardised global systems support endtoend processes last significant third party oversight programme committee pleased deployments multiyear programme note end december assessments completed early focus moving capturing across countries completed since thirdparty benefits new standardised systems processes oversight tpo programme commenced generate gsk assessments currently progress assessments resulted issue approximately role corrective preventative actions designed improve finally role chair committee continues busy thirdparty engagements tpo framework continues evolve varied year significant interactions key senior efficient easier use currently executives auditors attended range management embedded gsks making easier buying goods services meetings programme details working third parties set committee worked closely emma walmsley strategic report gsks new ceo set new business priorities enhanced privacy compliance capability privacy centre innovation performance trust committee monitored excellence coe delivering change programme improve continue monitor evolution gsks culture sustainably manage gsks data privacy compliance whilst company sharpens business performance ensure performance also complying eu general data protection regulations delivered appropriately gdpr come effect may coe vindi banga also members remuneration committee made good progress defining privacy risk framework enable allows us provide input committees review gsk design proportionate controls prioritise deployment groups performance oversight risk factors relevant make effective decisions risk whilst programmes remuneration matters purpose increase privacy maturity globally coes remediation efforts focused initially european committee evaluation operations mitigate highest nearterm risk created committees annual evaluation exercise externally facilitated gdpr however remediation expected delivered ms ffion hague independent board evaluation report december point gsks enhanced privacy largely positive confirmed committee covered operating model deployed globally ground detail consideration report committee concluded continued operate effectively agreed implement performance improvements reviewing format papers terms accessibility considering increase focus committees time meetings allowing opportunity review discussion nominations committee succession planning board committee members financial experience judy lewent audit risk committee chair march gsk annual report strategic report governance remuneration financial statements investor information committee areas committee focus items discussed frequency financial reviewed integrity draft financial statements appropriateness accounting policies going concern reporting assumptions considered approval process confirming recommending board annual report fair balanced understandable reviewed recommended board approval annual report form f reviewed approved directors expenses reviewed recommended approval quarterly preliminary results announcements dividends q reviewed significant issues relation quarterly preliminary results q considered evolving market practice viability statement requirements reviewed recommended inclusion viability statement annual report reviewed accounting developments impacts key accounting issues p external received external auditors transition updates management auditors reviewed approved auditnonaudit expenditure incurred considered auditors report annual results performed evidencebased assessment external auditors effectiveness external audit considered qualifications expertise independence external auditors recommended board reappointment external auditors committee agree auditors remuneration approved audit plan audit fee proposal set performance expectations auditors considered initial results external audit p global internal reviewed assurance reports global pharmaceuticals vaccines consumer healthcare rd gms control viiv healthcare compliance reviewed gsks internal control framework confirmed compliance sarbanesoxley act reviewed audit assurance work approved planned work undertook corporate integrity agreement cia training received reviewed cia compliance assurance reports q reviewed reports operational excellence programme q reviewed implementation new systems group support functions p received litigation reports updates received reports ongoing investigations abac issues risk reviewed risk management framework compliance reviewed risk elements group treasury pensions risk insurance tax policies received status reports following enterprise risks abac ehss information protection patient safety p privacy product quality research practices third party oversight received terrorism cyber security risk assessment update p received updates implications brexit p received risk oversight compliance council meeting updates considered emerging risks governance confirmed compliance uk corporate governance code matters reviewed committees terms reference confirmed adhered received corporate governance updates p reviewed committees performance effectiveness reviewed approved groups approach modern slavery act p met privately separately heads global ethics compliance audit assurance p met privately external auditors end meeting required approved publication groups tax strategy committee activity key annually q quarterly p periodically standing gsk annual report corporate governance accountability continued significant issues relating financial statements considering quarterly financial results announcements financial results contained annual report committee reviewed significant issues judgements made management determining results committee reviewed papers prepared management setting key areas risk actions undertaken quantify effects relevant issues judgements made management appropriate accounting required address issues financial statements significant issues considered relation financial statements year ended december set following table together summary financial outcomes appropriate addition committee external auditors discussed significant issues addressed committee year areas particular audit focus described independent auditors report pages significant issues considered committee relation financial statements issue addressed committee going concern basis preparation committee considered outcome managements halfyearly reviews current forecast net financial statements debt positions various financing facilities options available group following review risk potential impact unforeseen events committee confirmed application going concern basis preparation financial statements continued appropriate revenue recognition including returns committee reviewed managements approach timing recognition revenue accruals rebates rar accruals customer returns rebates us pharmaceuticals vaccines accrual returns rebates billion december committee reviewed basis accrual made concurred managements judgements amounts involved fuller description process operated us pharmaceuticals vaccines business determining level accrual necessary set critical accounting policies provisions legal matters including committee received detailed reports actual potential litigation internal external investigations groups legal counsel together number detailed updates investigations groups commercial commercial practices practices management outlined levels provision corresponding disclosure considered necessary respect potential adverse litigation outcomes also areas yet possible determine provision necessary amount december provision legal matters billion set note financial statements provisions provisions uncertain tax positions committee considered current tax disputes areas potential risk concurred managements judgement levels tax contingencies required december tax payable liability billion including provisions uncertain tax positions recognised groups balance sheet impairments intangible assets committee reviewed managements process reviewing testing goodwill intangible assets potential impairment committee accepted managements judgements intangible assets required writing resulting impairment charge million see note financial statements intangible assets details valuation contingent consideration committee considered managements judgement following improved sales relation viiv healthcare performance tivicay triumeq necessary increase liability pay contingent consideration acquisition former shionogiviiv healthcare joint venture december groups balance sheet included contingent consideration liability billion relation viiv healthcare see note financial statements contingent consideration liabilities details consumer healthcare put option committee considered managements judgement valuation liability billion recognised respect novartis put option shareholding consumer healthcare joint venture included review impact unwinding discounting liability decrease liability caused significant strengthening sterling latter part year viiv healthcare put option committee reviewed agreed accounting pfizer put option concurred managements judgement valuation put option billion december gsk annual report strategic report governance remuneration financial statements investor information auditors appointment external auditors pricewaterhousecoopers llp pwc auditor company group since inception performance reviewed annually audit partner rotation requirements observed gsk conducted external audit tender view replacing pwc financial year onwards disclosed last years report pwc invited participate audit tender process comply audit firm rotation requirements audit tender process completed december board announced appointed deloitte llp deloitte gsks new external auditors effect january effectiveness quality external audit process committee committed ensuring ongoing basis gsk receives high quality effective audit external auditors effectiveness pwcs performance quality external audit process formally evaluated committee early criteria agreed conjunction management early committee undertaken number activities year satisfy pwcs continuous external audit quality effectiveness particularly year audit firm transition pwc deloitte activities timelines set recommend pwcs pwcs formal appointment review pwcs performance accept appointment performance approved audit resignation recommend expectations set process planning deloittes appointment matters addressed matters addressed matters addressed effectiveness pwc expectations shareholders approved resolutions appoint effectiveness pwc expectations set reviewed pwc authorise committee set march reviewed appropriate level challengescepticism determine remuneration appropriate level challengescepticism exhibited pwc work considered audit plan reviewed agreed exhibited pwc work considered pwcs independence appropriate level pwcs quality control procedures pwcs letter resignation received qualifications expertise resources considered deloittes independence appropriate level reviewed statutory audit fee agreed set qualifications expertise resources report pwcs audit gsks reviewed management feedback audit process annual report financial reporting survey received covering appointment deloitte fill vacancy councils audit quality team reviewed robustness audit process recommended board approve satisfied matters quality delivery people service audit plan reviewed agreed reappointment pwc next agm performance expectations deloitte may perform audit auditors audit agreed recommended board appointment deloitte next performance expectations pwc agm may perform audit auditors audit agreed recommended board budget nonaudit services audit fee agreed march may march gsk annual report corporate governance accountability continued auditors appointment continued detailed criteria committee used judging effectiveness pwc external auditors overriding responsibility deliver smoothrunning thorough efficiently executed audit set performance expectations gsks external auditors specific auditor discuss audit approach areas focus advance early engagement understanding implications new operating model responsibilities ensure sarbanesoxley act scope additional procedures discussed endorsed management communicated timely basis within gsk pwc avoid surprises timely reporting issues levels within company ensure clarity roles responsibilities local pwc gsk finance services respond issues raised management timely basis meet agreed deadlines provide continuity succession planning key staff members pwc provide sufficient time management consider draft auditors reports respond requests queries ensure consistent communication local central audit teams wider auditor provide timely uptodate knowledge technical governance issues including evolving market practice viability statement responsibilities requirements european securities markets authority securities exchange commission sec guidelines new ifrs standards ifrs ifrs serve industry resource communicating best practice trends reporting integrated reporting adhere independence policies gsks financial reporting councils revised ethical standard applicable sec standards deliver focused consistent audit approach globally reflects local risks materiality liaise audit assurance avoid duplication work global ethics compliance ensure common understanding audit outcomes provide consistency advice levels ultimately provide high quality service board scrupulous scrutiny group act utmost integrity specific audit contribute seamless effective efficient auditor transition deloitte includes following actions firm transition provide access relevant information respect audit glaxosmithkline plc subsidiaries relation audit responsibilities groups consolidated accounts provide information concerning gsk obtained course providing nonaudit services constitutes relevant information audit groups consolidated accounts provide factualevidenced based oral written explanation timely manner aid deloittes understanding audit working papers agree practical terms interaction establish appropriate environmentforum arrangements providing access information including format mechanism response time liaise deloitte enable observation audit activities independent provide sufficient analysis hours spent provision relevant information complete additional adhoc handover expectations agreed year competition markets authority compliance statement committee considers company complied mandatory audit processes audit committee responsibility provisions competition markets authority statutory audit services order pages report describes work committee discharging responsibilities nonaudit services sarbanesoxley act prohibits engagement ensuring adequate safeguards place objectivity external auditor provision certain services legal independence group audit threatened actuarial internal audit outsourcing financial information systems compromised design external auditor permitted provide nonaudit ensuring total fee levels exceed annual services auditrelated tax services audit fee except special circumstances would committee ensures auditor objectivity independence clear advantage companys auditor undertaking safeguarded policy requiring preapproval committee additional work services contractual similar obligations restricting groups choice external auditor existing policy reviewed revised committee december ensure compliance financial following core policy guidelines engaging external auditor reporting councils frc revised ethical standard provide nonaudit services observed eu audit regulation new regulations new policy ensuring nonaudit services put implemented across group beginning competitive tender financial service providers contains following three policy guidelines external auditor line groups procurement process fee cap gsks existing policy cap annual audit fee unless skills experience external auditor make cap retained new policy stringent suitable supplier nonaudit service frcs new fees cap set average fees preceding consideration three year period gsk annual report strategic report governance remuneration financial statements investor information nonaudit services continued prohibitions gsks new policy includes black list prohibited nonaudit services new regulations auditnonaudit services three year comparison graph preapproval categorywide preapproval process updated reflect restrictions frcs guidance audit committees nonaudit services preapproved committee chairman cfo delegated committee preapproved group financial controller approved designate group financial controller part external audit firm transition arrangements described deloitte subject restrictions policy since started required period independence july advance taking statutory audit groups audit assurance services financial statements january fee audit assurance services included million arising fees paid companys auditors associates set novartis transaction subsequent increase complexity group approximately half expected recurring details given note financial statements services including tax regulatory compliance treasuryrelated operating profit services possible accounting firms engaged undertake nonaudit services auditors transition significant activity committee throughout year enhance understanding gsk year committee exercised oversight responsibilities deloitte audit team engaged extensively various gsk manage transition period pwc deloitte business stakeholders primary focus finance committee satisfy smooth handover communities also begun engage priority local audit responsibilities one committees specific market entities identified representing higher audit transition performance expectations pwc set transition complexity given local regulatory requirements entities covered group audit local introductions progress throughout committee received detailed transition papers scheduled meeting begin primary focus oversee deloitte held series regional academies onboard steps needed deloitte achieve independence july local teams communicate audit vision approach firm could commence audit planning activities local partners deloitte also centrally coordinated introductory meetings senior finance managers deloitte involved scrutinising deloittes plan achieve partners every location statutory audit required independence together progress made overseeing termination nonaudit services would prohibited deloitte continue take part key pwc clearance deloitte takes role auditor example included meetings targeted pwc walkthroughs leverage work deloitte stepping role remuneration existing pwc procedures deloitte team performed committees advisers end june initial audit scoping risk assessment designed detailed audit plan compiled initial insights report presented since independence achieved committee december deloitte formally observing pwcs work pwc resign firm concluded external audit audit process committee recommend board prospective lead audit partner support deloitte appointed fill casual vacancy shareholders invited attend committee meetings invited appoint deloitte gsks new statutory auditors committee chair held number meetings agm pwcs audit partner make available lead partner agm answer shareholder questions annual report transition process thorough minimal disruption gsks business gsk annual report corporate governance accountability continued auditors transition continued external audit firm transition process key phases preindependence readiness postindependence transition january june july december key steps relationship building detailed audit knowledge transfer design audit planning january june july september october december key tasks achieving independence completing full risk assessment scoping building understanding gsk organisation structure business implementing audit analytics tools units deepening understanding business processes undertaking appropriate audit team selection onboarding walking processes assessing design controls agreeing process data extraction tools onboarding global teams communicating audit approach agreeing collaboration terms pwc incountry market introductions assessing concluding key historic accounting judgements observing pwc interim review process agreeing terms engagement fair balanced understandable assessment one key compliance requirements groups financial code conduct reporting lines statements annual report fair balanced also number wellestablished policies including understandable coordination review groupwide code conduct available governance section contributions annual report follows wellestablished website confidential speak reporting lines documented process performed parallel reporting investigation unlawful conduct updated formal process undertaken external auditors version code conduct last published april committee received summary approach taken management preparation gsks annual report ensure met requirements financial reporting councils uk corporate governance code enabled committee board confirm gsks annual report taken whole fair balanced understandable provides information necessary shareholders assess companys position performance business model strategy gsk annual report strategic report governance remuneration financial statements investor information internal control framework board recognises obligation present fair balanced fit purpose framework conjunction corporate understandable assessment gsks current position values behaviours speak processes ensures risks prospects board accountable evaluating approving associated gsks business activities actively effectively effectiveness internal controls including financial controlled line agreed risk appetite framework operational compliance controls risk management provides reasonable absolute assurance material processes operated gsk misstatement loss internal control framework framework comprehensive gsks risk oversight compliance council rocc enterprisewide risk management model means team senior leaders mandated board assist gsk ensures reliability financial reporting compliance committee overseeing risk management internal control laws regulations framework supports continuous activities also provides business units framework process boards identification evaluation management risk management upward escalation significant risks gsks principal risks required financial reporting business unit governed risk management compliance councils frcs uk corporate governance code uk code board rmcb reports rocc business unit designed enable gsk achieve business objectives rmcbs responsible promoting local tone top risk culture well ensuring effective oversight internal controls risk management processes risk owners members senior management assigned framework principal risk risk owner accountable management respective principal risk reporting risk management strategy rocc committee enterprise oversight least every two years rocc rmcbs assisted independent assurance b foy r g adlo vb anal c e int gh rc iss k mnd nc ao gm empl eia nn c ae c rg ose sc th e w eh ni tc eh r pis r isre es ap dn foib r l te h e independent business monitoring soe uve nl p gm ee cnt ao cf tw ivo elr yk pn rg mpr oa tc et sic ee ts h ch aa lt ba ere h ari vs iok ub ra ss wed ith inn th e et hically organisation seeks establish framework disc ep nl fi rce ea mn ed nt b r ui ss ssk e nsm een st w cori ntt te ron ls standards e c p tom h la sem np e apl l u g iy oe rw ree mt eis dh ac nbaa ap yn g p tso ehl uip mec ecr ba n nolt tcee e li nm n dw iia vs ttc e h sac eein oo bd nr pd orra oae vg rc diu dae l e oa w nt oi n tt n hnh dl es ng e ee ps f ew fek ni c dv h te va nl eu n n e aa es ss sa sun u ord r aa f n n ricc se ke p ro ble mer ssp n ding activities training funa lfidn l la inhg gee b goe san krt c sor rm tes e eg gt cs sk b vt jeeh cri ss tii vga ehs ss au nr na ddn bc ude v lh dise inolp grys r rs e ue sn p ti wor n itm hi ba pn il aia tig ie ee nm ti sne nt mom na toa rg ine gment communication fn ind cth iae lr st fa fik ce eh r al nd de r ts h e c oa h mas ta e ed ual reporting line chief committee receives regular reports business units principal risk owners gec aa areas significant risk gsk related internal controls reports provide assessment internal control environment within principal risk area including enhancements strengthen gsk values expectations control environment following consideration reports committee concludes effectiveness internal control environment reports board annually accordance uk code provisions committee boards behalf conducted robust assessment groups principal risks includes consideration nature extent risk willing take achieving groups strategic objectives gsk annual report internal control framework continued board committee maintained oversight information gsks risk management approach provided ensure effectiveness internal control environment risk manage risk section strategic report pages management processes operation across gsk whole year management principal risk explained date approval annual report principal risks uncertainties pages groups viability discussed group financial review section boards review focuses company subsidiaries strategic report extend material associated undertakings joint ventures investments although considers risk companys participation activities established procedures controls place identify entities whose results must consolidated groups results believe process followed board committee reviewing regularly system internal controls risk management processes accordance guidance risk management internal control related financial business reporting issued frc governance structure risk management gnirotinom rof ytilibatnuocca responsibility implementing corporate governance accountability continued board directors responsible system corporate governance strategy risk management financial performance responsible reviewing approving audit risk committee adequacy effectiveness risk management internal controls corporate executive team supports ceo managing business activities authorised board assist audit risk oversight compliance council risk committee overseeing risk management internal control activities group responsible system corporate business units governance strategy risk management financial performance ensure appropriate internal controls risk management compliance boards effective risk management implemented complemented country executive risk boards ensure consistent approach risk management across local geography level gsk annual report strategic report governance remuneration financial statements investor information relations stakeholders engagement activities performance duties company seeks major shareholders build trust priority board listens views year publication quarterly results shareholders key stakeholders including patients emma walmsley simon dingemans gave presentations consumers customers employees cognisant institutional investors analysts media webcast potential impacts decisions makes teleconference july emma walmsley senior team held investor update event audience principal board committees delegated powers shared innovation performance trust longterm priorities enables indepth assessment impacts concluded indepth qa session companys engagement stakeholders also provides means identifying emerging stakeholderrelated issues emma simon maintain continual active dialogue brought attention board turn enables institutional shareholders performance plans objectives us invest activities build trust programme regular meetings year held total individual meetings major shareholders shareholders hosted total group meetings major try engage shareholders several ways includes shareholders potential major shareholders regular communications agm investor relations activities announce results quarterly basis philip hampton also meets major shareholders hear annual results included annual report shareholders views discuss issues mutual importance receive annual summary advises annual communicates views rest board year report notice annual general meeting available held individual meetings major shareholders range issues senior independent nonexecutive director sid nonexecutive directors available meet major shareholders ongoing basis investor relations department offices london philadelphia acts focal point communication investors company secretary acts focal point communications corporate governance matters annual governance event cornerstone investor calendar annual governance aligning culture strategy event hold institutional shareholders key investment board stewardship stakeholder relationships industry bodies influential proxy advisory firms years event held december francis crick institute brexit london hosted chairman sid lynn elsenhans dr jesse goodman judy lewent committee chairs urs rohner provided overview work respective valued prior engagement input investor board committees undertaken year finally vindi forum members helping shape agenda banga sid provided insights perspectives board event chairman shared updates key areas focus dynamics role contribution nonexecutive board including directors challenging shaping groups strategy business model overview business performance listening views shareholders receiving board cet succession skills capabilities feedback event held run corporate diversity reporting agm season helps board understand new ceo shareholders views oversight new business priorities innovation performance trust capital allocation gsk annual report corporate governance relations stakeholders continued engagement activities continued annual general meeting retail shareholders company secretary acts focal point retail investors shareholders invited attend annual general manages key relationships companys registrars meeting year held may qeii equiniti uk bank new york mellon london agm good level attendance administer adr programme us engagement shareholders proposed resolutions approved shareholders level people support ranged provides opportunity board fully supportive groups commitment put questions board chairs progressive modern employer attract retain best talent board committees formal agm proceedings drive high levels employee engagement key providing shareholders chance meet informally transformation priority emma walmsley cet board directors make available evolve culture company enhance business performance meeting strategic success relies ability engage employees behind delivery companys innovation performance trust longterm priorities discussed length board well threeday conference october attended senior leaders employee engagement enhancements help enhance existing employee consultation activities board supported managements introduction roll following engagement activities lets talk programme employees encouraged cet regular input views conversations directly lets talk channels workforce feedback employee performance system engagement sessions shared advance new performance board employees system linked innovation performance trust priorities business performance trust new allemployee survey undertaken every six months regular allemployee whose engagement levels newsletter video details trust increased significantly since ceo rounds priority including employee previous survey news interest engagement companys provided valuable insights employees encourages approach developing employee sentiment feedback workforce safe diverse ethical environment found pages gsk annual report strategic report governance remuneration financial statements investor information science committee report dear shareholder dr jesse goodman pleased present first report science committee science committee committee established main board chair consider science pipeline rd capital allocation priorities committees core role throughout first year operation provide assurance board quality competitiveness integrity rd discharge role effectively requires committee composed members strong scientific capabilities therefore pleased joined committee fellow scientific medical experts professor sir roy anderson dr laurie glimcher together judy lewent background life sciences either role specialist commercial perspective committee committee committee focused establishing role undertakes periodic reviews rd strategy remit considered following matters progress rds pharmaceutical strategy performance assesses overall performance including relevant transformation programme financial metrics effectiveness competitiveness review vaccines strategy science rd medical healthcare trends helps identify critical emerging trends science medicine potential impact company antimicrobial resistance undertakes periodic reviews companys overarching focus committees work appraisal scientific capability talent rd transformation proposals associated funding reviews scientific opportunity specific large requirements prepared new ceo emma walmsley scale investments business transactions president rd dr patrick vallance committee shared reviews output groups science advisory feedback management incorporation proposals boards pleased note key milestones date driving focus prioritisation core therapy areas membership refocused committee members committee member since enhancing pipeline governance committee noted effect dr jesse goodman chair january january changes strengthen portfolio governance creating professor sir roy anderson january greater robustness financial commercial strategic review following introduction new portfolio strategy committee dr laurie glimcher september guide challenge work judy lewent january improving development significant progress made details committee members skills experience creating roadmap improving companys overall given biographies board capability development quick wins included talent pages see committee member development team optimisation acceleration planning attendance levels partnership commercial organisation company secretary secretary committee committee evaluation attends meetings attendees committee first annual evaluation committee externally facilitated meetings may include ms ffion hague independent board evaluation concluded committee establishing formalising structure regular attends ways working including continue oversight rd attendee attendee required next steps company chairman committee looking forward working hal chief scientific officer president rd oversee development plans reinvigorate rd president global vaccines accelerate discovery development transformational independent senior external scientific new medicines advisers finally would like thank dr patrick vallance steps chief financial officer board end march significant contribution company executives helping establish committee devising remit helping develop programme activities basis committees deliberations wish well future dr jesse goodman science committee chair march gsk annual report corporate governance continued corporate responsibility committee report dear shareholder lynn elsenhans corporate responsibility committee committee acts corporate responsibility custodian policies practices define safeguard committee chair reputation company chair committee continue together fellow committee members challenge shape companys responsible business agenda committee members bring wide range sector experience insight stakeholder perspectives help provide oversight topics helps board monitor companys work engage effectively key stakeholders assess company operating way seeks meet high expectations gsk global healthcare company delivers longterm value role shareholders society committee reviews work committee focused topics material companys mission strategy values e xternal issues potential serious much committees focus reviewing impact upon gsks business reputation companys proposals future responsible business activity support companys new longterm priority trust oversight stakeholder views engagement committee also provided oversight managements work nnual governance oversight progress review refocus gsks activity support global health gsks responsible business commitments moving forward committee pays close attention evolving views membership expectations companys broad range key stakeholders membership committee appointment dates regular report stakeholder developments reviewed set discussed meeting year committee also committee members committee member since received external report held discussion trends lynn elsenhans chair may october stakeholder expectations likely influence trust professor sir roy anderson may company longterm committee remuneration committee interested review preparation dr vivienne cox july companys gender pay gap disclosures set dr jesse goodman may since committees membership refreshed mid details committee members skills experience impressed way roy jesse vivienne given biographies board exercised knowledge understanding issues pages see committee member discussion brought new challenge oversight attendance levels committee stand us good stead company secretary secretary committee company evolves responsible business agenda also attends meetings attendees committee pleased invite roger connor president gms company meetings may include responsibility product quality well environment health regular attends safety sustainability attend committee regular basis attendee attendee required committee continues increase focus vital areas chief executive officer companys operations company chairman year continued enjoy positive engagement general counsel investors responsible business approach performance president global affairs particular opportunities enhance investment chief scientific officer president rd value create business opportunities mitigate risk alongside creating social value president gms president global pharmaceuticals company well positioned evolve responsible president global vaccines business commitments new set focused activity support delivery trust one gsks longterm ceo gsk consumer healthcare business priorities head human resources svp corporate affairs head global corporate responsibility lynn elsenhans executives corporate responsibility committee chair independent external corporate march responsibility adviser gsk annual report strategic report governance remuneration financial statements investor information corporate responsibility committee report continued main responsibilities work committee main responsibilities committee set committee continue seek understand management responding expectations external committee rolling agenda receives reports stakeholders seek align agendas activities members cet senior managers ensure progress support companys longterm priority trust meeting responsible business commitments within four areas focus reviewed annual basis follows independent external corporate responsibility adviser health innovating address currently unmet health needs support committee ensuring give sufficient improving access products irrespective people consideration views key stakeholders meeting live ability pay controlling eliminating diseases may sophia tickell appointed independent external affecting worlds vulnerable people adviser committee position previously held july ms tickell extensive experience pharmaceuticals behaviour putting interests patients consumers industry improving health systems productivity sustainability first driven values everything backed energy supply distribution climate change policy short robust policies strong compliance processes termism financial markets people enabling people thrive develop cofounder director meteos individuals deliver mission directs pharma futures series aims align better societal planet growing business reducing shareholder value holds number board environmental impact across value chain advisory roles addition meeting committee considers analysis ms tickell attended meetings committee provided management engagement expectations independent advice guidance corporate responsibility companys key stakeholders may bearing matters committee chair ceo companys reputation delivery responsible business committee evaluation agenda committee also reviews approves responsible committees annual evaluation exercise externally facilitated business supplement available reference ms ffion hague independent board evaluation concluded wwwgskcomresponsibility committee continued operate effectively gsk annual report corporate governance continued directors directors powers determined uk legislation change control essential contracts articles association contain rules appointment contracts arrangements individually replacement directors provide directors may fundamental ability business operate effectively appointed ordinary resolution members company party material agreements would take resolution directors provided appointed board effect altered terminate upon change control following director retires agm following appointment takeover bid agreements director would provide compensation loss office employment articles also provide directors normally subject resulting takeover except provisions companys reelection agm intervals three years annually share plans may cause options awards granted held office continuous period nine years plans vest takeover details termination provisions board agreed directors wish continue executive directors service contracts given full version members board seek reelection annually companys remuneration policy report available accordance uk corporate governance code wwwgskcom investors section director may cease director directors report becomes bankrupt purposes uk companies act directors ceases director virtue companies act report glaxosmithkline plc year ended december articles comprises pages corporate governance suffers mental physical ill health board resolves report directors statements responsibilities pages shall cease director pages investor information missed directors meetings continuous period six strategic report sets matters required disclosed months without permission board resolves directors report considered strategic shall cease director importance prohibited director law resigns offers resign board accepts offer risk management objectives policies pages required resign board likely future developments company strategic report directors conflicts interest research development activities pages directors duty companies act avoid diversity inclusion situation could direct indirect conflict provision information consultation employees interest possible conflict company articles provide general power board authorise conflicts carbon emissions nominations committee authorised board following information also incorporated directors report grant regularly review potential actual conflict location annual report authorisations recorded company secretary noted board directors counted quorum interest capitalised financial statements notes authorisation actual potential conflicts publication unaudited financial information group financial review ongoing basis directors responsible informing details longterm incentive schemes remuneration report company secretary new actual potential conflicts waiver emoluments director applicable may arise changes circumstances may affect authorisation previously given even provided waiver future emoluments director applicable authorisation director absolved statutory duty non preemptive issues equity cash applicable promote success company actual conflict arises non preemptive issues equity cash applicable postauthorisation board may choose exclude director unlisted major subsidiary undertaking receipt relevant information participation parent company participation placing applicable debate suspend director board last resort listed subsidiary require director resign provision services controlling applicable shareholder nominations committee reviewed register potential shareholder waiver dividends financial statements conflict authorisations january reported board notes conflicts appropriately authorised process authorisation continues operate effectively except shareholder waiver future dividends financial statements notes described note financial statements related party transactions end financial year director agreements controlling shareholders applicable person closely associated material interest directors report drawn presented contract significance group company accordance reliance upon english company law independent advice liabilities directors connection report shall company agreed procedure directors take subject limitations restrictions provided law independent legal andor financial advice companys expense directors report approved board directors deem necessary march signed behalf indemnification directors qualifying third party indemnity provisions defined companies act force benefit directors philip hampton former directors held office signing chairman annual report march ggsskk aannnnuuaall rreeppoorrtt ssttrraatteeggiicc rreeppoorrtt ggoovveerrnnaannccee aanndd rreemmuunneerraattiioonn ffiinnaanncciiaall ssttaatteemmeennttss iinnvveessttoorr iinnffoorrmmaattiioonn remuneration section chairmans annual statement annual report remuneration remuneration policy summary gsk annual report remuneration report chairmans annual statement dear shareholder remuneration outcomes behalf board pleased awards relation made present remuneration report accordance approved includes annual statement remuneration policy key decisions annual report remuneration made remuneration committee summary remuneration policy committee follows approved agm bonus outcomes executive shareholders voting favour directors determined reference annual report remuneration performance preagreed annual statement subject financial measure well decisions advisory vote agm may committees assessment individual levels performance gsk context executive remuneration gsk remuneration committee achieved performance excess seen gsk perform well sales relevant financial target year taken year grew across three businesses conjunction assessment individual pharmaceuticals vaccines consumer aligned performance resulted bonus healthcare continued good payments made target remuneration policy momentum new products driven maximum opportunities strong performances tivicay received overwhelming triumeq hiv inhaled ellipta portfolio details bonus outcomes year provided nucala respiratory meningitis shareholder support vaccines also seen three key vesting performance share agm approvals shingrix vaccine shingles plan psp awards matching trelegy ellipta oncedaily single inhaler awards deferred annual triple therapy copd juluca bonus plan dabp based dolutegravir rilpivirine first drug preagreed measures rd new regimen oncedaily single pill hiv gsk product performance adjusted free cash demonstrated continued cost controls flow relative tsr equal throughout year improved free cash weighting performance measured flow also achieved earnings growth three years december delivered adjusted eps growth line threshold levels tsr guidance total eps also increased cash flow measures exceeded finally returns shareholders maximum level achieved dividend line expectations rd new products measure resulting overall vesting level details vesting outcome psp dabp matching awards provided remuneration committee reviewed executive director salaries emma walmsleys simon dingemans salaries increased january line increases broader employee population remains committees intention keep ms walmsleys package review coming years subject development performance role gsk annual report strategic report governance remuneration financial statements investor information board changes looking ahead financial reporting council frc november dr patrick vallance rd new products measure lti recently consulted broadening announced would leave plans implemented recognise role remuneration committees company become uk governments importance rd future business proposed measures pay part chief scientific adviser head growth continue relevant wideranging review uk corporate governments office science lti performance rewards governance code revised code dr vallance voluntary leaver performance rd committee included views therefore receive severance organisation also successful matters companys response payment leaves company commercialisation launch excellence consultation revised code end march dr vallance continue remains important committee considers committee reviewed current receive base salary set means incentivise practices government leaves gsk also eligible commercial success across group frcs measures wellplaced receive bonus based committee therefore working comply look forward providing combination business individual design new lti measure based update issues next years performance receive bonus rd pipeline replace rd report portion new products measure lti employed psp dabp matching awards look forward sharing agm awards already vested prior details new innovation measure finally would like thank shareholders departure lapse leaves year progresses ongoing input engagement eligible receive lti award welcome shareholders feedback governance developments report look forward receiving committee taken close interest support annual report november announced legislative best practice developments remuneration agm may appointment dr hal barron role around director pay policy supports chief scientific officer president initiatives raise bar area rd january dr barron modern employer company takes one worlds foremost rd leaders responsibilities new gender pay spent career working regulations seriously committee usa dr barrons package fully corporate responsibility committee urs rohner line remuneration policy approved interested review preparation remuneration committee chairman shareholders base salary companys gender pay disclosures set march million incentive opportunities line approved remuneration policy aggregate total compensation uk government announced within competitive range seen among package measures executive pay global pharmaceutical peer group including secondary legislation requiring buyout awards made publication pay ratios companies ceos average sir andrew witty stepped ceo uk employees committee retired gsk mutual agreement supports enhancements march dr moncef slaoui transparency shareholders stepped board march interested stakeholders include retired gsk mutual agreement information report june agreed termination methodology calculating ratio arrangements cases set finalised new regulations last years report cases arrangements executed line approach described last year accordingly years remuneration report provides details final amounts paid gsk annual report annual report remuneration glance highlights summary following shows breakdown total remuneration paid executive directors office december respect emma walmsley ceo simon dingemans cfo dr patrick vallance outgoing president rd fixed pay salary benefits pension performance pay annual bonus ltis earned respect three years end emma walmsley dr patrick vallance appointed board january pay performance annual bonus financial performance lti outcome performance period ended december overall vesting maximum relative rd new target tsr products rd rd target threshold target core group pbit maximum performance target performance achieved adjusted lapsed free cash flow vested called adjusted group pbit rd executive directors shareholdings audited align interests executive directors share ownership vs sor multiples base salary shareholders required build maintain significant emma walmsley x x holdings shares gsk time executive directors required continue satisfy share ownership requirements sor minimum months simon dingemans x x leaving gsk dr patrick vallance x x executive directors cet multiple base salary x x x ceo sor december shareholding executive directors corporate executive team members gsk annual report strategic report governance remuneration financial statements investor information total remuneration audited value earned annual total salary benefits pension lti bonus remuneration awards fixed pay b pay performance total remuneration executive director set table dr patrick vallance dr moncef slaoui emma walmsley sir andrew witty simon dingemans outgoing president former chairman ceo former ceo cfo rd global vaccines janmar janmar fixed pay salary see benefits see pension see total fixed pay b pay performance annual bonus see pages vesting lti awards dabp matching awards psp see total pay performance ab total remuneration notes emma walmsley appointed board effect january succeeded sir andrew witty ceo april sir andrew stepped ceo retired board march emma walmsleys salary ceo designate january march ms walmsleys salary increased april succeeded sir andrew witty ceo details deferred annual bonus plan dabp bonus deferrals set matching awards made dabp details respect vesting dabp matching awards performance share plan psp awards threeyear period december provided psp dabp awards sir andrew witty dr moncef slaoui granted yet vested awards vest following oneyear anniversary termination accordance terms executive financial recoupment policy sir andrew awards vest march dr slaoui june addition delayed vesting psp awards twoyear holding period point normal vesting disclosed annual report sir andrew witty dr moncef slaoui left gsk mutual agreement neither received termination payments outstanding incentive awards treated accordance remuneration policy approved shareholders terms sir andrew dr slaoui received payments prorated proportion financial year worked lieu performance related bonus payments prorated amounts paid three months march respectively simon dingemans vested psp shares subject twoyear holding period committee may specific circumstances line stated principles apply clawbackmalus determines appropriate following due consideration committee recovery sums paid clawback reduction outstanding awards vesting levels malus applied respect executive directors gsk annual report annual report remuneration continued total remuneration audited continued following sections provide details element total remuneration including committee implemented approved remuneration policy comparator groups pay tsr committee used two pay comparator groups roles considering executive pay primary group used executive director follows uk crossindustry comparator group global pharmaceutical comparator group emma walmsley astrazeneca reckitt benckiser dr patrick vallance france us simon dingemans bhp billiton rio tinto sanofi abbvie bp royal dutch shell switzerland amgen british american tobacco unilever novartis bristolmyers squibb diageo vodafone roche holdings eli lilly johnson johnson uk merck co astrazeneca pfizer abbvie amgen included remuneration benchmarking included tsr comparator group reviewing ceos remuneration committee also references pay group leading european companies whose selection based size complexity fixed pay audited salary benefits benefits table sets base salaries executive directors last two years disclosed last year salary increases emma walmsley made aligned provided wider employee benefits workforce details salary levels provided travel benefits base salary total change emma walmsley sir andrew witty january march na employee benefits emma walmsley travel april december na benefits sir andrew witty total simon dingemans simon dingemans dr patrick vallance na employee benefits dr moncef slaoui travel benefits benefits table opposite shows breakdown grossed cash value total benefits received executive directors dr patrick vallance included employee benefits employee benefits employee share plans healthcare travel car allowance personal financial advice life assurancedeath benefits service cover total travel expenses car travel spousepartner costs associated dr moncef slaoui accompanying executive director gsk business deemed taxable benefits individual employee benefits travel benefits expenses incurred ordinary course business deemed taxable benefits benefits individual included table total dr moncef slaoui benefits include uk accommodation gsk annual report strategic report governance remuneration financial statements investor information fixed pay audited continued pensions executive director pension plan type member since emma walmsley base salary matching contributions first salary base salary lieu pension salary excess sir andrew witty uk defined benefit simon dingemans base salary lieu pension dr patrick vallance base salary lieu pension dr moncef slaoui us belgian plans member defined contribution plan emma walmsley eligible receive matching award first salary accordance terms plan emma walmsley receives cash payment lieu pension base salary excess line gsks defined contribution pension plan rates simon dingemans dr patrick vallance receive cash payment lieu pension base salary line gsks defined contribution pension plan rates since becoming member plans dr moncef slaoui built pensionable service belgian plan us cash balance supplemental pension plans annual employer cash contributions made k plan executive supplemental savings plan essp current pension entitlement product service progression within gsk following table shows breakdown pension values set emma walmsley sir andrew witty simon dingemans dr patrick vallance dr moncef slaoui janmar janmar pension remuneration values uk defined benefit us defined benefit uk defined contribution belgian defined benefit employer cash contributions total pension remuneration value pension remuneration figures calculated accordance methodology set large mediumsized companies group accounts reports amendment regulations remuneration regulations calculating defined benefit pension values sir andrew witty dr slaoui difference accrued pension march accrued pension december increased inflation uk defined benefit us defined benefit belgian defined benefit multiplied amounts translated euros us dollars using exchange rate details regarding pension values defined benefit plan participants set table accrued pension march dec pension remuneration sir andrew witty pa pa value uk funded uk unfunded total accrued pension march dec pension remuneration dr moncef slaoui pa pa value us funded us unfunded belgium funded total pensions figures disclosed sir andrew witty dr moncef slaoui members defined benefit plans table shows accrued benefit ie annual pension accrued date pension remuneration calculated increase accrued benefit adjusted inflation multiplier reflect fact benefit received number years movement negative year value shown amounts translated euros us dollars using exchange rate gsk annual report annual report remuneration continued pay performance audited annual bonus core group pbit individual annual bonus objectives renamed adjusted group pbit performance targets financial measures weightings follows weighting performance positioning performance measure executive directors target outcome target core group pbit called adjusted group pbit individual objectives threshold maximum performance targets set target respectively core group pbit target outcome purposes annual bonus calculation differs core group pbit disclosed elsewhere annual report primarily target outcome numbers calculated applying gsk budget exchange rates actual exchange rates following table shows actual bonuses earned compared opportunity bonus opportunity bonus outcome financial individual total total base salary target maximum performance objectives bonus bonus bonus salary salary salary salary salary emma walmsley simon dingemans dr patrick vallance sir andrew witty dr moncef slaoui ceased executive directors year accordance remuneration policy received prorata payment lieu variable bonus opportunity committee set role specific objectives period two individuals ceased executive directors remuneration policy approved target bonus opportunities set policy approved shareholders ie salary sir andrew salary dr slaoui contractual payments shown table table provides detail delivery core group pbit target called adjusted group pbit financial performance core group pbit group turnover billion increase aer cer adjusted group adjusted operating profit million higher cer basis higher aer pbit adjusted operating margin percentage points higher percentage points higher cer basis reflected improved operating leverage driven sales growth favourable mix three businesses margin also benefited continued tight control ongoing costs across three businesses well restructuring integration benefits vaccines consumer healthcare businesses partly offset continued pricing pressures particularly respiratory investments rd supply chain gsk annual report strategic report governance remuneration financial statements investor information pay performance audited continued following table summarises performance scorecard individual objectives agreed committee executive director individual objectives emma walmsley successful induction transition sir andrew witty delivered strong overall financial performance group strong performance new product sales billion aer cer track deliver billion new product sales cer basis sales billion cer building top corporate executive team outstanding new hires new chief scientific officer president rd president global pharmaceuticals chief digital technology officer top roles new hires internal promotions successfully completed strategic review pharmaceuticals business key areas portfolio footprint operating model implementation ongoing significant pipeline reprioritisation new rd portfolio governance process across rd commercial new year pharmaceuticals supply chainstrategy reduce complexity improve productivity whilst maintaining compliance innovation performance trust priorities kpis defined communicated used basis employee objectives business performance management improving cash cost discipline newly established capital allocation process integrated business pl cash flow management new employee expectations incentive system launched key enablers culture change significant improvements reliability quality supply pharmaceuticals consumer health businesses gsk ranked access vaccines index antimicrobial resistance benchmark per cent improvement comparable employee engagement score since simon dingemans delivered strong financial leadership group improved cash flow generation improved cash cost discipline newly established capital allocation process integrated business pl cash flow management restructuring synergy programmes delivered combined benefits billion billion cer developed capital allocation framework support strategy including business development requirements strong support new ceo appointment new chief digital technology officer dr patrick vallance strong performance new product sales billion aer cer including strong performances tivicay triumeq hiv inhaled ellipta portfolio nucala respiratory two key approvals pharmaceuticals pipeline included trelegy ellipta daily single inhaler triple therapy copd juluca first drug regimen oncedaily single pill hiv continued strong delivery rd organisation across rd pipeline completed rd performance review leading significant pipeline reprioritisation operational changes areas diagnosis early implementation strengthened rd partnership commercial pharmaceuticals particular attention paid pipeline prioritisation malus clawback policy details policy malusclawback please refer remuneration policy report annual report available wwwgskcom investors section january respect financial year committee decided disclose whether recoupment committee exercised malus clawback disclosure made matter subject public reports misconduct fully resolved legally permissible disclose made without unduly prejudicing company therefore shareholders line disclosure guidelines neither committee recoupment committee exercised malus clawback policies details policies recruitment remuneration loss office termination payments please refer remuneration policy report pages annual report available wwwgskcom investors section gsk annual report annual report remuneration continued pay performance audited continued value earned longterm incentives ltis following tables set performance achieved management targets set companys lti plans also includes update performance outstanding awards line committees agreed principles measure applicable lti awards actual performance targets reviewed adjustments made appropriate reflect impact novartis transaction business ensure vesting outcome reflects genuine underlying business performance details adjustments made provided time vesting awards performance period ended december committee reviewed performance psp dabp matching awards granted executive directors targets set performance achieved three years december vesting levels set table outcome vesting level performance measures relative weighting performance targets outcome maximum award rd new product rd new product sales performance measures aggregate threeyear sales new bn performance products launched threeyear performance period preceding two years rd ie original target adjusted target vesting maximum bn bn bn bn bn bn threshold bn bn adjusted free line companys agreed principles afcf figures included adjustments bn cash flow afcf number material distorting items including legal settlements exchange rate performance movements special pension contributions rd target vesting maximum bn bn bn threshold bn afcf target set announced following close novartis transaction target adjusted relative tsr ranked th tsr ranking within comparator group vesting performance maximum st nd rd rd th th threshold median th th sr comparator group astrazeneca bristolmyers squibb eli lilly gsk johnson johnson merck co novartis pfizer roche holdings sanofi vesting schedule based delivering vesting median performance comparator group ten companies median falls two companies total vesting respect awards gsk annual report strategic report governance remuneration financial statements investor information pay performance audited continued historical vesting gsks ltis year grant performance measures total vesting level lapsed r dabp matching awards made r onwards dabp matching awards wholly subject tsr performance total vesting level r b awards subject measures psp r b vested line figures shown chart r b performance measures key r rd new product adjusted free cash flow tsr b business diversification lapsed update performance ongoing lti awards committee also reviewed performance psp dabp matching awards granted executive directors following charts provide estimate vesting levels taking account performance december actual vesting levels determined based performance full threeyear performance periods indications therefore regarded predictions final vesting levels award performance update award performance update ranked rd ranked rd bn threshold bn threshold maximum maximum commercially commercially median bn sensitive median bn sensitive threshold threshold tsr adjusted free rd new tsr adjusted free rd new rd cash flow product rd cash flow product estimated vesting level rd rd estimated vesting level rd rd threshold performance award vest respect rd new product afcf measures tsr element tsr comparator group remains unchanged shown respect awards adjusted free cash flow target award revised reflect additional investments key rd projects priority review voucher juluca launch us please refer pages annual report committee intends disclose targets full following end performance period annual report remuneration lti awards levels participation dabp respect bonus deferrals shown table table details last matching award showing maximum vesting potential respect bonuses table also shows psp award details dabp matching awards psp awards total bonus number face value award level number face value deferred shares award base salary shares award emma walmsley shares shares sir andrew witty simon dingemans shares shares dr patrick vallance shares shares dr moncef slaoui face value dabp awards calculated based share price closing price february face value psp awards calculated based share price closing price july performance period awards january december gsk annual report annual report remuneration continued ceo pay comparison ceo total remuneration positioning historic ceo remuneration uk single figure crossindustry remuneration group annual bonus award global pharmaceutical maximum group vesting lti awards european maximum crossindustry group bonus include amounts paid operational efficiency bonus place years overall maximum bonus receivable still subject limit base salary lower quartile median upper emma walmsleys percentage change remuneration ceo median quartile current position uk remuneration includes salary expected value incentives based gsk ceo employees committees agreed benchmarking methodology change change performance graph ceo emma walmsley sir andrew witty following graph sets performance company relative salary ftse index pharmaceutical performance benefits comparator group nineyear period december annual bonus indices selected comparison purposes reflect primary index gsk constituent industry wider uk employee population salary increase includes operates annual salary review well additional changes year eg promotion uk employee benefits unchanged previous year changes benefit policies levels reflect changes level benefits individual may received result change role eg promotion uk population considered relevant comparison closely reflects economic environment encountered ceo ceo ratio committee intends disclose pay ratios gsks ceo average uk employees annual report methodology calculating ratio finalised legislation gsk total return gsk pharma peers ftse total return index total return index index comprises astrazeneca bristolmyers squibb eli lilly johnson johnson merck co novartis pfizer roche holdings sanofi gsk annual report strategic report governance remuneration financial statements investor information additional remuneration disclosures relative importance spend pay shareholder votes remuneration matters table shows total employee pay groups dividends paid table provides details shareholder votes shareholders recent resolutions respect annual remuneration remuneration policy reports votes total employee pay total votes total votes total votes withheld agm cast billion million dividends remuneration report figures table reflect payments made remuneration policy year impact movements exchange rates set pages however dividends declared external appointments executive directors respect million million executive directors held remunerated external appointments increase excluding special dividend million dr hal barron director juno therapeutics inc declared paid company expect retained fees received role make ordinary share repurchases payments past directors audited total employee pay based employees average none number people employed payments loss office audited service contracts none table sets relevant dates executive directors service contracts available review companys registered office office hours gskcom executive directors service contract contains month notice period set remuneration policy date contract effective date expiry date emma walmsley simon dingemans dr patrick vallance dr hal barron remuneration governance role committee membership role committee set companys remuneration members committee together appointment policy gsk able recruit retain motivate dates set executives committee members committee member since remuneration policy regularly reviewed ensure consistent companys scale scope operations urs rohner january chair chair since may supports business strategy growth plans helps drive creation shareholder value vindi banga january terms reference dr vivienne cox january committees full terms reference available judy lewent january companys website terms reference reviewed least annually last revised january reflect best committee meetings usually include closed session practice corporate governance developments members committee present individuals may also invited attend committee meetings year governance executives committee attendees involved board considers members committee decisions present discussions regarding independent nonexecutive directors accordance remuneration uk corporate governance code details committee members skills experience given biographies board pages see committee member attendance levels gsk annual report annual report remuneration continued remuneration governance continued company secretary secretary committee attends willis towers watson member remuneration consultants meetings attendees committee include group voluntarily operates code conduct relation executive remuneration consulting uk code committee attendees conduct found wwwremunerationconsultantsgroupcom regular attends attendee attendee required deloitte provided independent commentary matters ceo consideration committee updates market practice cfo legislative requirements part prior willis towers watsons appointment fees advice period head human resources fees charged time materials basis head reward deloitte also provided consulting tax assurance services committee adviser deloittewillis towers watson gsk year however committee satisfied judy lewent vindi banga members audit risk compromise deloittes independence remuneration committees provide input audit risk willis towers watsons fees advice provided committees review groups performance oversight willis towers watson provided additional market data risk factors relevant remuneration decisions committee adviser committee committee evaluation company undertook tender process appointed committees annual evaluation externally facilitated willis towers watson independent adviser committee ffion hague independent board evaluation concluded effect july committee chairman agrees committee continued operate effectively terms protocols willis towers watson provides advice enhancements committees work agreed board committee satisfied advice objective members would provided detailed updates matters independent considered committee committee areas committee focus items discussed remuneration policy proposed remuneration policy committee sets broad structure remuneration policy engagement shareholders determines remuneration executive directors chairman shareholder feedback proposed remuneration policy corporate officers board approval salary review remuneration environment including wider employee trends committee periodically reviews considers remuneration executive director cet benchmarking competitiveness gsk environment executive directors cet approving annual amendments comparator groups necessary executive director cet salary recommendations increases setting remuneration dr hal barron annual bonus ceo executive director cet bonus recommendations committee responsible setting specific performance measures bonus objectives annual bonus rd annual bonus target metric lti plans review deferred annual bonus plan performance share plan rules committee responsible approving lti plan rule changes grants lti performance outcomes vesting lti awards cet assessments performance vesting lti awards executive lti grants cet directors cet governance areas focus committee evaluation process committee adheres robust remuneration governance framework remuneration report ensuring alignment internal actions external reporting remuneration considerations compliance requirements agm remuneration report feedback external remuneration environment performance target disclosure incentives plans chairmans fees remuneration report disclosures remuneration committee external adviser tender process gender pay group reporting gsk annual report strategic report governance remuneration financial statements investor information nonexecutive directors fees chairman nonexecutive directors nonexecutive directors fees applied set company aims provide chairman nonexecutive table directors fees competitive paid per annum companies equivalent size complexity subject limits standard annual fee contained gsks articles association supplemental fees chairmans fees chair audit risk committee chairman philip hampton paid fee per annum senior independent director elected take gsk shares chairmans scientificmedical experts fees reviewed year changed chairs remuneration corporate responsibility science committees nonexecutive directors fees nonexecutive director fees reviewed year nonexecutive director undertaking intercontinental per meeting travel meetings following last increase january agreed increase supplemental fees chairs remuneration corporate responsibility committees january chair new science committee also receives supplementary fee fees remain unchanged minimum fees continue delivered shares ads deferred nonexecutive director steps board audited table sets value fees benefits received nonexecutive directors form cash shares ads details nonexecutive directors share allocation plan set nonexecutive directors fees paid currency gbp converted using average exchange rate reviewed time time nonexecutive directors fixed fees fixed fees emoluments audited cash sharesads benefits total pay cash sharesads benefits total pay professor sir roy anderson vindi banga dr vivienne cox lynn elsenhans dr laurie glimcher dr jesse goodman philip hampton judy lewent urs rohner former directors dr stephanie burns stacey cartwright sir deryck maughan dr daniel podolsky jing ulrich hans wijers dr laurie glimcher appointed board effect september dr stephanie burns sir deryck maughan dr daniel podolsky hans wijers retired board may stacey cartwright retired board december jing ulrich retired board may figures restated remove tax gross flights non ukdomiciled directors travel uk board meetings reflecting fact tax due flights income tax year time publishing annual report believed income tax would due gsk annual report annual report remuneration continued directors interests shares audited interests directors company office persons closely associated pca shown tables total share plan interests december date retirement total directors interests sharesads options december aunvested unvested aunvested unvested march date january subject subject subject subject vested exercised retirement performance performance performance performance exercised year executive directors shares emma walmsleyabcdh sir andrew wittyabcfh simon dingemansabcdfh dr patrick vallanceabcdfh dr moncef slaoui ads dr hal barroni dr moncef slaouiacegh share allocation plan nonexecutive directors total directors interests number shares ads december january dividends dividends reinvested reinvested march date date year december allocated december retirement appointment end paid year elected nonexecutive directors sharesj professor sir roy anderson vindi banga dr vivienne cox philip hampton urs rohner stacey cartwright adsj lynn elsenhans dr laurie glimcher dr jesse goodman judy lewent dr daniel podolsky unvested options subject performance emma walmsley represent bonus deferrals unvested shares subject performance sir andrew witty represent shares awarded end threeyear performance periods psp grants together subsequent reinvested dividends shares subject twoyear holding periods sir andrews unvested options subject performance represent bonus deferrals share save options unvested options subject performance simon dingemans represent bonus deferrals share save options unvested options subject performance dr patrick vallance represent bonus deferrals share save options unvested ads subject performance dr moncef slaoui represent bonus deferrals deferrals psp plan share value plan awards pca b total directors interests includes shares purchased glaxosmithkline share reward plan emma walmsley simon dingemans dr patrick vallance awarded shares plan total number shares held within plan follows share reward plan shares march december january emma walmsley sir andrew witty simon dingemans dr patrick vallance dr hal barron dr moncef slaoui eligible participate share reward plan open uk employees gsk annual report strategic report governance remuneration financial statements investor information directors interests shares audited continued c total directors interests includes options shares ads resulting deferral bonus subsequent reinvestment dividends dabp totals shown table include bonus deferrals exclude unvested matching awards subject ongoing performance criteria amounts represent gross share ads balances prior sale shares ads satisfy tax liabilities december deferred annual bonus plan bonus deferrals march date retirement january emma walmsley shares sir andrew witty shares simon dingemans shares dr patrick vallance shares dr moncef slaoui ads total directors interests march includes shares ads vested due performance met elements dabp psp awards less sold satisfy tax liabilities vested amounts see pages details e dr moncef slaoui total directors interests includes ads purchased within k plan us executive supplemental savings plan essp ads awarded dr slaouis pca share value plan svp relevant balances follows dr moncef slaoui ads march march january us retirement savings plans share value plan executive director dr slaoui eligible receive awards svp svp awards shown reflect holdings dr slaouis pca also employee gsk awards subject threeyear vesting periods vesting contingent continued employment within gsk gains arose vesting included dr slaouis total remuneration figures dr slaouis total share plan interests also include psp awards held pca awards subject performance criteria relevant employees cet f share save plan sir andrew witty simon dingemans dr patrick vallance unvested options subject performance include holdings respectively share save plan sir andrew participated mr dingemans dr vallance participate terms employees mr dingemans granted options plan november g ads vested unexercised options totalling dr moncef slaoui represent ads options held pca gsk annual report annual report remuneration continued directors interests shares audited continued h following table sets details options including nilcost options dabp exercised executive directors dr moncef slaoui exercise options year number shares market gain exercise type award date grant option date exercise grant price price exercise emma walmsley dabp deferral dabp matching sir andrew witty share save dabp deferral dabp matching simon dingemans share save dabp deferral dabp matching dr patrick vallance dabp deferral dabp matching respect options share save plan remuneration receivable executive director calculated date options first vest remuneration difference amount executive director required pay buy shares total value shares vesting date executive director chooses exercise options vesting date subsequent increase decrease amount realised due movements share price vesting date date exercise increase decrease value result investment decision executive director recorded remuneration respect nilcost options dabp bonus deferred director recorded remuneration annual bonus year relates gain recorded exercise nilcost option comprises remuneration total amounts received reinvested dividends prior vesting gains losses resulting movements share price dates grant exercise initial bonus amount deferred dates dividend reinvestment exercise reinvested dividends matching element dabp remuneration executive director recorded year performance period ends represents number vested shares multiplied price vesting gain recorded exercise nilcost option comprises total remuneration gain loss resulting movement share price vesting exercise emma walmsley gain recorded following exercise nilcost options relating deferral bonus earned respect comprises remuneration recorded annual bonus net gain relating reinvestment dividends prior vesting movements share price grant dividend reinvestment dates exercise date gain recorded following exercise nilcost options relating dabp matching award comprises remuneration recorded relation dabp see investment gain relating movement share price vesting exercise dates sir andrew witty gain resulted exercise options granted share save plan number shares reduced sir andrew retired march part way share save contract gain recorded following exercise nilcost options relating deferral bonus earned respect comprises remuneration recorded annual bonus net gain relating reinvestment dividends prior vesting movements share price grant dividend reinvestment dates exercise date gain recorded following exercise nilcost options relating dabp matching award comprises remuneration recorded relation dabp see investment gain relating movement share price vesting exercise dates gsk annual report strategic report governance remuneration financial statements investor information directors interests shares audited continued simon dingemans gain resulted exercise options granted share save plan gain recorded following exercise nilcost options relating deferral bonus earned respect comprises remuneration recorded annual bonus net gain relating reinvestment dividends prior vesting movements share price grant dividend reinvestment dates exercise date gain recorded following exercise nilcost options relating dabp matching award comprises remuneration recorded relation dabp see investment gain relating movement share price vesting exercise dates dr patrick vallance gain recorded following exercise nilcost options relating deferral bonus earned respect comprises remuneration recorded annual bonus net gain relating reinvestment dividends prior vesting movements share price grant dividend reinvestment dates exercise date gain recorded following exercise nilcost options relating dabp matching award comprises remuneration recorded relation dabp see investment gain relating movement share price vesting exercise dates dr hal barron appointed board january j nonexecutive directors total interests include shares ads received part fees nonexecutive directors share allocation plan note dividends received shares ads plan january converted shares ads february gsk annual report annual report remuneration continued directors interests shares audited continued deferred annual bonus plan matching awards following tables provide details executive director office respect dabp matching awards market price grant vesting represent closing share prices business day prior dates performance period emma walmsley shares market price grant unvested december granted face value grant dividends reinvested vested lapsed unvested december dividends reinvested vested lapsed unvested march vested shares number shares market price vesting gain remuneration remuneration performance period sir andrew witty shares market price grant unvested december dividends reinvested vested lapsed unvested december dividends reinvested unvested march vested shares number shares market price vesting gain remuneration gsk annual report strategic report governance remuneration financial statements investor information directors interests shares audited continued deferred annual bonus plan matching awards continued performance period simon dingemans shares market price grant unvested december granted face value grant dividends reinvested vested lapsed unvested december dividends reinvested vested lapsed unvested march vested shares number shares market price vesting gain remuneration remuneration performance period dr patrick vallance shares market price grant unvested december granted face value grant dividends reinvested vested lapsed unvested december dividends reinvested vested lapsed unvested march vested shares number shares market price vesting gain remuneration remuneration gsk annual report annual report remuneration continued directors interests shares audited continued deferred annual bonus plan matching awards continued performance period dr moncef slaoui ads market price grant unvested december dividends reinvested vested lapsed unvested december dividends reinvested unvested march vested ads number ads market price vesting gain remuneration gsk annual report strategic report governance remuneration financial statements investor information directors interests shares audited continued performance share plan awards following tables provide details executive director office respect psp awards market price grant vesting represent closing share prices dates performance period emma walmsley shares market price grant unvested december granted face value grant dividends reinvested vested lapsed unvested december granted face value grant dividends reinvested vested lapsed unvested march vested shares number shares market price vesting total gain remuneration remuneration performance period sir andrew witty shares market price grant unvested december dividends reinvested vested lapsed unvested december dividends reinvested unvested march vested shares number shares market price vesting gain remuneration gsk annual report annual report remuneration continued directors interests shares audited continued performance share plan awards continued performance period simon dingemans shares market price grant unvested december granted face value grant dividends reinvested vested lapsed unvested december granted face value grant dividends reinvested vested lapsed unvested march vested shares number shares market price vesting gain remuneration remuneration performance period dr patrick vallance shares market price grant unvested december granted face value grant dividends reinvested vested lapsed unvested december dividends reinvested vested lapsed unvested march vested shares number shares market price vesting gain remuneration remuneration gsk annual report strategic report governance remuneration financial statements investor information directors interests shares audited continued performance share plan awards continued performance period dr moncef slaoui ads market price grant unvested december dividends reinvested vested lapsed unvested december dividends reinvested unvested march vested ads number ads market price vesting gain remuneration remuneration dr hal barron appointed board january following table provides details psp awards granted february performance period dr hal barron granted ads number ads market price grant face value grant unvested march gsk annual report annual report remuneration continued directors senior management information provided compensation interests directors senior management group group purpose group defined nonexecutive executive directors members cet company secretary financial year following table sets aggregate remuneration group periods served capacity remuneration total compensation paid aggregate increase accrued pension benefits net inflation aggregate payments defined contribution schemes members group one pca also employee gsk awarded shares ads companys various executive share plans set table awards dividend reinvestment awards awarded shares ads shares ads deferred annual bonus plan performance share plan deferred investment awardsa b share value planb march group pcas following interests shares ads company interests awarded various executive share plans described note financial statements employee share schemes interests march shares ads owned unexercised options deferred annual bonus plan performance share plan deferred investment awardsa b share value planb notional shares ads b executive directors eligible receive deferred investment awards participate share value plan gsk annual report strategic report governance remuneration financial statements investor information share plans dilution limits allemployee share plans dilution limits executive directors participate various allemployee share awards made plans incorporate dilution plans including share save share reward hm revenue limits consistent guidelines published investment customs approved plans association limits rolling tenyear period plans rolling tenyear period executive share participants share save plan may save month plans estimated dilution existing awards made last net salaries fixed term three years end ten years december follows savings period option buy gsk shares discount market price set launch savings contract gsk employee share plans participants share reward plan contribute month gross salaries purchase gsk shares company matches number gsk shares bought month monthly saving share save share reward emma walmsley executive share plans simon dingemans dr patrick vallance actual limit gsk annual report annual report remuneration continued implementation remuneration policy salary long term incentive plans committee determined following salary increases taking deferred annual bonus plan dabp awards account average increase wider workforce table provides details mandatory deferral dabp respect annual bonus payments associated change awards granted wider workforce emma walmsley total bonus dabp award deferred shares number shares simon dingemans emma walmsley dr patrick vallance simon dingemans dr hal barron na dr patrick vallance based average increased budget employees level cet uk performance share plan psp awards benefits table provides details awards granted psp significant changes provision benefits proposed full details policy relation benefits please psp award psp award refer details remuneration policy report pages salary number shares annual report available wwwgskcom emma walmsley investors section simon dingemans dr hal barron pension table provides overview pension arrangements ward form ads ongoing executive director details dr hal barrons pension arrangements set performance measures metrics psp awards remain unchanged pension contribution awards continue based three equally weighted emma walmsley base salary matching contributions measures simon dingemans base salary lieu pension rd new product performance member defined contribution plan eligible receive matching adjusted free cash flow contributions first salary accordance terms plan ie relative tsr annual bonus tsr continue measured global pharmaceutical significant changes operation annual bonus plan peers prior years targets rd new products accordance shareholder approved remuneration commercially sensitive time grant however policy proposed committee intends disclose targets full following end performance period target maximum emma walmsley addition committee continue provide shareholders simon dingemans interim performance updates element course performance period dr hal barron adjusted free cash flow targets disclosed shareholders financial measure adjusted group pbit previously core prospective basis time grant thereafter group pbit inevitably targets linked directly financial reported annual report remuneration strategic plan commercially sensitive committee consider appropriate disclose annual bonus targets year may result competitive harm however details performance targets disclosed retrospective basis annual report gsk annual report strategic report governance remuneration financial statements investor information implementation remuneration policy continued termination arrangements dr patrick vallance remuneration arrangements new executive director announced dr patrick vallance leave board dr hal barron joined gsk chief scientific officer president march rd january executive director summary remuneration set dr vallance voluntary leaver receive severance payment leaves company salary bonus outstanding us notes incentive awards treated accordance shareholder base salary comparator group pay top approved remuneration policy rd position global pharmaceutical comparator group full disclosure payments made upon cessation included annual bonus ontarget bonus would annual report remuneration maximum outgoing president rd remuneration element summary treatment award ltis assumes expected value annual bonus receive bonus award performance shares psp dabp granted psp awards companys performance share plan defer bonus dabp x multiple base salary outstanding psp awards vested prior dr vallances outgoing president rd dabp matching awards departure lapse leaves gsk share ownership line gsks dabp deferred bonus awards respect bonuses deferred requirement base salary remuneration policy awards respect prior years vest sor normal vesting dates pension pension line gsks remuneration policy arrangements addition dr vallance required maintain executives based us shareholding equal respective share ownership requirement benefits benefits line gsks least months leaving company remuneration policy gsk annual report remuneration policy summary executive director remuneration policy companys remuneration policy approved may gsks annual general meeting full policy available wwwgskcom investors section following summary policy value earned annual total salary benefits pension lti bonus remuneration awards fixed pay b pay performance salary provide core reward role set level appropriate secure retain high calibre individuals needed deliver groups strategic priorities operation opportunity performance measures individuals role experience performance formal maximum limit ordinarily salary overall performance independently sourced data relevant comparator groups increases broadly line average increases individual key consideration considered determining salary levels wider gsk workforce determining salary increases however increases may higher reflect change scope individuals role responsibilities experience salary adjustments may also reflect wider market conditions geography individual operates details current salary levels set annual report remuneration pages benefits levels set recruit retain high calibre individuals execute business strategy operation opportunity performance measures executive directors generally eligible receive formal maximum limit benefits costs none benefits line policy employees fluctuate depending changes provider cost may vary location include travel allowances individual circumstances including spousepartner travel healthcare life details current benefits costs set annual assurancedeath service provided part report remuneration individuals pension arrangements personal financial advice contractual postretirement benefits pension pension arrangements provide competitive level retirement income operation opportunity performance measures pension arrangements structured accordance policy current executive directors new external none plans operated country recruits individual likely retire individual chooses uk salary contribution defined become member pension plan cash lieu contribution plan matched relevant pension contribution paid instead contributions subject relevant cap line implementation principles new executive directors uk entitled either members plan join defined contribution pension plan receive salary cash payment lieu pension cash payment lieu pension contribution contribution individual member gsk legacy defined benefit us eligible benefits us senior plan defined contribution plan alternative executives pension plan arrangement subsequently c ash balance pension plan supplemental appointed board may remain cash balance pension plan including executive member plan pension credit provide maximum contribution base salary across pension plans gsk k plan formerly us retirement savings plan executive supplemental savings plan core contributions salary bonus matched contributions salary bonus gsk annual report strategic report governance remuneration financial statements investor information executive director remuneration policy summary continued annual incentivise recognise execution business strategy annual basis rewards achievement stretching annual bonus financial strategic business targets delivery personal objectives operation opportunity performance measures financial operational business targets set maximum bonus opportunity executive directors based combination start year committee bonus salary threshold performance bonus financial targets individual levels determined committee based payout nil strategic performance performance targets objectives majority target performance bonus payout bonus assessed individual objectives set start year maximum opportunity financial measures committee performance objectives weighting different assessed committee measures determined executive directors required defer year according bonus earned shares ads appropriate business priorities three years deferred shares vest end three years lti awards incentivise recognise delivery longer term business priorities financial growth increases shareholder value compared pharmaceutical companies provide alignment shareholder interests retention element encourage longterm shareholding discourage excessive risk taking psp operation opportunity performance measures conditional awards made annually vesting normal maximum award limits may granted based combination dependent achievement performance psp individual one year set financial share price related conditions three years subject table strategic performance additional twoyear holding period conditions aligned salary companys strategic committee may adjust formulaic vesting ceo plan awards outcome either ensure cfo vest threshold overall outcome reflects underlying business executive directors performance performance vesting period dabp current operation bonus payments onwards executive directors required defer bonus earned shares three years dabp legacy pre operation opportunity performance measures bonus payments executive directors deferred shares matched maximum outstanding matching required defer bonus earned shares subject achievement performance awards subject three years could also voluntarily defer conditions three years matching awards measures awards additional bonus earned conditional shares nilcost options eligible made psp dividend equivalents given year share ownership requirements sor align interests executive directors shareholders executive directors required continue satisfy requirements required build maintain significant holdings shares minimum months following retirement gsk gsk time sor requirement ceo salary sor requirement executive directors salary details policy clawbackmalus recruitment remuneration loss office termination payments please refer full remuneration policy report pages annual report available wwwgskcom investors section gsk annual report remuneration policy summary continued scenarios future total remuneration charts opposite provide illustrations future total remuneration executive directors respect emma walmsley ceo remuneration opportunity granted policy range potential outcomes provided executive director underlying assumptions set scenarios base salary used benefits pension figures used ceo cfo outgoing president rd ie based actual amounts received respect ongoing policy new chief scientific officer president rd role benefits value role based value benefits excluding benefits travel including pension contribution based policy fixed expected maximum amounts shown value psp awards based relevant multiples include amounts simon dingemans cfo respect dividends reinvested factor changes share price vesting period fixed none pay performance annual bonus psp would payable expected annual bonus assumed target performance achieved psp awards threshold levels vesting assumed fixed expected maximum maximum dr hal barron chief scientific officer president rd assumed annual bonus would payable maximum level awards psp would vest full fixed expected maximum dr patrick vallance outgoing president rd fixed fixed fixed fixed pay annual bonus psp outgoing president rd leave gsk march eligible bonus psp award figures represent actual remuneration january march gsk annual report strategic report governance remuneration financial statements investor information nonexecutive director remuneration policy companys remuneration policy nonexecutive directors set approved may gsks annual general meeting chairmans provide inclusive flat rate fee competitive paid companies equivalent size complexity subject fees limits contained gsks articles association operation opportunity performance measures committee responsible evaluating making formal maximum however fees reviewed none recommendations board fees payable annually set reference review chairmans chairman chairman participate discussions performance independently sourced market data respect fees details current fees set annual report fees paid combination cash andor gsk remuneration shares ads via nonexecutive directors share allocation plan basic fees operation opportunity performance measures chairman ceo responsible evaluating chairman fees reviewed annually set none making recommendations board fees payable reference independently sourced data companys nonexecutive directors details current fees set annual report minimum delivered form gsk shares remuneration ads using nonexecutive directors share allocation plan delivers shares ads nonexecutive director following retirement board supplemental compensate nonexecutive directors chairman taking additional board responsibilities undertaking fees intercontinental travel operation opportunity performance measures additional fees committee chairmen senior details supplemental fees set annual report none independent nonexecutive director science medical remuneration experts intercontinental travel benefits facilitate execution responsibilities duties required role operation opportunity performance measures travel subsistence costs nonexecutive directors formal maximum limit benefit costs none incurred normal course business relation fluctuate depending changes provider costs meetings board committee matters individual circumstances gskhosted events overseasbased nonexecutive details current benefits costs set directors includes travel meetings uk annual report remuneration event necessary business purposes whilst normal practice nonexecutive directors may accompanied spouse partner meetings events costs associated met company instances deemed taxable therefore treated benefits nonexecutive director gsk annual report remuneration policy summary continued operation scope remuneration policy remuneration policy policy set pages performance share plan deferred annual bonus plan awards annual report intended policy gsks subject terms relevant plan rules executive nonexecutive directors operate period award granted committee may adjust amend three years date approval companys annual awards accordance provisions plan rules general meeting may includes making adjustments reflect oneoff corporate events change companys capital structure committee wrote policy principally relation remuneration arrangements executive directors whilst committee may also make minor amendments policy taking account possible recruitment replacement regulatory exchange control tax administrative purposes additional executive director operation policy take account change legislation without obtaining shareholder committee intends policy operate period set approval amendments entirety however may due consideration seek statement consideration shareholder views change policy period believes committee engages regular dialogue shareholders appropriate longterm success company holds annual meetings gsks largest investors discuss consultation shareholders sought shareholder take feedback remuneration policy governance matters approval general meeting annual meeting held december urs committee reserves right make remuneration rohner committee chairman shared updates remuneration payments andor payments loss office including exercising matters last months proposals onwards discretions available connection payments notwithstanding line policy terms payment agreed agm may date companys first shareholderapproved directors remuneration policy came effect ii policy came effect provided terms payment consistent shareholderapproved remuneration policy force time agreed iii time relevant individual director company opinion committee payment consideration individual becoming director company purposes payments includes committee satisfying awards variable remuneration relation award shares ads terms payment agreed time award granted basis preparation annual report remuneration prepared annual report remuneration approved board accordance companies act large directors signed behalf mediumsized companies groups accounts reports amendment regulations regulations accordance regulations following parts annual report urs rohner remuneration subject audit total remuneration figures remuneration committee chairman executive directors including details element remuneration salary benefits pension annual bonus longterm march incentive awards nonexecutive directors fees emoluments received year directors interests shares including interests gsk share plans payments past directors payments loss office share ownership requirements holdings opinion thereon expressed remaining sections annual report remuneration subject audit pages referred within audited sections ggsskk aannnnuuaall rreeppoorrtt ssttrraatteeggiicc rreeppoorrtt ggoovveerrnnaannccee aanndd rreemmuunneerraattiioonn ffiinnaanncciiaall ssttaatteemmeennttss iinnvveessttoorr iinnffoorrmmaattiioonn financial statements section directors statement responsibilities independent auditors report financial statements notes financial statements financial statements glaxosmithkline plc prepared uk gaap gsk annual report directors statement responsibilities directors responsible preparing annual report strategic report risk sections annual report remuneration report group financial statements represent management report include fair review accordance applicable law regulations development performance business position group together description principal risks uk company law requires directors prepare financial uncertainties faces statements financial year law directors required prepare group financial statements accordance disclosure information auditors international financial reporting standards ifrs adopted directors office date annual report european union preparing group financial statements confirmed directors also elected comply ifrs issued far aware relevant audit information international accounting standards board iasb company companys auditors unaware law directors must approve group financial statements unless satisfied give true fair view state taken steps ought taken affairs group profit loss period director make aware relevant audit information establish companys auditors aware preparing financial statements directors information required confirmation given interpreted accordance select suitable accounting policies apply provisions section companies act consistently going concern basis make judgements accounting estimates pages contain information performance reasonable prudent group financial position cash flows net debt position state group financial statements comply ifrs borrowing facilities information including treasury risk adopted european union ifrs issued iasb management policies exposures market credit risk subject material departures disclosed explained hedging activities given note financial statements group financial statements financial instruments related disclosures assessed principal risks matters considered connection prepare financial statements going concern basis unless viability statement directors considered appropriate adopt inappropriate presume group continue going concern basis accounting preparing financial business statements directors responsible keeping adequate accounting internal control records sufficient show explain companys board audit risk committee reviewed transactions disclose reasonable accuracy time assessment risks internal control framework operates financial position group enable ensure gsk considered effectiveness system group financial statements remuneration report comply internal control operation group year covered companies act article ias regulation annual report date approval board also responsible safeguarding assets group directors hence taking reasonable steps prevention detection fraud irregularities uk corporate governance code board considers glaxosmithkline plc applies principles group financial statements year ended december complies provisions uk corporate governance comprising principal statements supporting notes code maintained financial reporting council described set financial statements pages corporate governance section pages board report responsibilities auditors relation group considers annual report taken whole fair financial statements set independent auditors report balanced understandable provides information pages necessary shareholders assess groups position group financial statements year ended december performance business model strategy included annual report published required financial conduct authoritys listing rules printed form made available website directors auditors considered directors statement compliance responsible maintenance integrity annual report relation points uk corporate governance code website accordance uk legislation governing specified review preparation dissemination financial statements access website available outside uk comparable annual report legislation may different annual report year ended december comprising report directors remuneration report current directors whose names functions listed financial statements additional information investors corporate governance section annual report approved board directors signed behalf confirms best knowledge group financial statements prepared philip hampton accordance ifrs adopted eu ifrs chairman issued iasb give true fair view assets liabilities financial position profit group march gsk annual report strategic report governance remuneration financial statements independent auditors report investor information members glaxosmithkline plc report group financial statements opinion taken together components audit work opinion glaxosmithkline plcs group financial statements performed accounted consolidated revenue financial statements consolidated profit tax profit tax adjusted certain items used determine materiality give true fair view state groups affairs covered components individually contributed december profit cash flows year revenue profit tax profit tax adjusted ended certain items used determine materiality properly prepared accordance international areas focus financial reporting standards ifrss adopted european union rebates discounts allowances returns us pharmaceuticals vaccines business prepared accordance requirements companies act article ias regulation carrying value goodwill intangible assets acquisitionrelated liabilities audited financial statements included within annual report comprise consolidated balance sheet uncertain tax positions transfer pricing impact december consolidated income statement us tax reform consolidated statement comprehensive income year litigation ended consolidated cash flow statement year ended finance transformation consolidated statement changes equity year ended notes financial statements include investigations groups commercial operations description significant accounting policies scope audit opinion consistent reporting audit risk part designing audit determined materiality committee assessed risks material misstatement financial statements particular looked directors made separate opinion relation ifrss issued iasb subjective judgements example respect significant explained note financial statements group accounting estimates involved making assumptions addition applying ifrss adopted european union considering future events inherently uncertain also applied ifrss issued international accounting standards board iasb gained understanding legal regulatory framework applicable group industry operates opinion group financial statements properly considered risk acts group contrary prepared accordance ifrss issued iasb applicable laws regulations including fraud designed audit basis opinion procedures group significant component levels respond conducted audit accordance international risk recognising risk detecting material standards auditing uk isas uk applicable law misstatement due fraud higher risk detecting one responsibilities isas uk described resulting error fraud may involve deliberate concealment auditors responsibilities audit financial statements example forgery intentional misrepresentations section report believe audit evidence collusion designed audit procedures focused laws obtained sufficient appropriate provide basis regulations could give rise material misstatement event opinion noncompliance particularly relating limited defence products pricing practices legislation taxation anti independence bribery corruption legislation tests included remained independent group accordance limited enquiries management review related work ethical requirements relevant audit financial performed component audit teams review relevant internal statements uk includes frcs ethical standard audit reports discussions inhouse legal counsel applicable listed public interest entities fulfilled supplemented review external legal counsel correspondence ethical responsibilities accordance requirements certain cases discussions external legal counsel best knowledge belief declare nonaudit also inspected underlying support calculations services prohibited frcs ethical standard provided assessed tested design operating effectiveness group related controls inherent limitations audit procedures described removed noncompliance laws disclosed note financial statements regulations events transactions reflected provided nonaudit services group period financial statements less likely would become aware january december audits also addressed risk management audit approach override internal controls including evaluating whether overview evidence bias directors represented risk material materiality misstatement due fraud risk fraud revenue overall group materiality million million recognition procedures designed executed address based profit tax adding back certain items risks included use data enabled auditing techniques test journal entries postclose adjustments testing evaluating audit scope managements key accounting estimates reasonableness audit included full scope audits reporting components consistency undertaking cutoff procedures verify proper cutoff specific audit procedures performed reporting revenue expenses testing existence accuracy components revenue transactions addition incorporate element unpredictability audit work year gsk annual report independent auditors report continued report group financial statements continued key audit matters key audit matters matters auditors professional judgement significance audit financial statements current period include significant assessed risks material misstatement whether due fraud identified auditors including greatest effect overall audit strategy allocation resources audit directing efforts engagement team matters comments make results procedures thereon addressed context audit financial statements whole forming opinion thereon provide separate opinion matters complete list risks identified audit key audit matter audit addressed key audit matter rebates discounts allowances returns us obtained managements calculations accruals applicable pharmaceuticals vaccines business schemes validated assumptions used reference refer notes group financial statements groups stated commercial policies terms applicable contracts third party data related patient enrolment us group makes sales various customers us fall government funded benefit schemes historical levels certain commercial government mandated contracts product returns reimbursement arrangements significant medicaid medicare group also provides right compared assumptions contracted prices historical rebates return customers certain products discounts allowances returns levels relevant current payment trends also considered historical accuracy arrangements result deductions gross sales arriving groups estimates previous years impact competitive turnover give rise obligations group provide pricing pressures greater discounting us market customers rebates discounts allowances right generally formed independent expectation largest return unsettled amounts recognised accrual elements accrual december using third party data focused area rebates discounts allowances compared expectation actual accrual recognised returns arrangements complex establishing group appropriate accrual requires significant judgement based procedures performed identify material estimation directors judgement particularly complex differences independent expectations accrual us healthcare environment competitive pricing pressure product discounting increasingly prevalent directors determined accrual million necessary december million carrying value goodwill intangible assets deploying valuations specialists obtained groups refer notes group financial impairment analyses tested reasonableness key statements assumptions including profit cash flow growth decline terminal values impact expiry patents potential product group billion intangible assets december obsolescence selection discount rates challenged billion comprising significant licences patents management substantiate assumptions including comparing acquired trademarks excluding computer software addition relevant assumptions industry economic forecasts group billion goodwill december billion verified integrity supporting calculations corroborated certain information third party sources including carrying values goodwill intangible assets expectations performance certain assets components recovered future cash flows risk business obtained evaluated managements sensitivity assets impaired cash flows meet analyses ascertain impact changes key assumptions groups expectations impairment reviews performed performed independent sensitivity calculations quantify group contained number significant judgements downside changes managements models required result estimates including revenue growth success new product impairment launches genericisation existing products following patent expiry profit margins cash conversion terminal values result work determined carrying values discount rate changes assumptions could lead goodwill intangible assets appropriate context impairment carrying value intangible assets goodwill group financial statements taken whole focused intangible assets acquired historical acquisitions significant individually aggregate number indefinite lives including significant intangible assets acquired novartis group also recognised goodwill number acquisitions including threepart transaction novartis gsk annual report strategic report governance remuneration financial statements investor information report group financial statements continued key audit matter audit addressed key audit matter acquisitionrelated liabilities deployed valuations specialists evaluate certain key refer notes group financial assumptions including growth projections discount rates well statements integrity mechanical accuracy managements valuation models evaluation included lookback tests assess recent years group completed number significant historical accuracy groups forecasts assumptions transactions including performing sensitivity analysis key assumptions determine threepart transaction novartis could significant impact value recorded certain establishment viiv healthcare procedures specific individual liabilities included acquisition viiv healthcare remaining following interest shionogiviiv healthcare joint venture consumer healthcare put option redemption value transactions resulted recognition agreed gsk novartis estimated gsk based measurement material acquisitionrelated liabilities multiple consumer healthcares profit verified integrity necessitate significant management judgement balance model compared certain key assumptions including sheet date exchange rates multiples third party sources gsk obtained valuations third party banks support estimate significant acquisitionrelated liabilities obtained considered part work compared outlined earnings forecast approved consumer healthcare board consumer healthcare put option group recorded directors used management model actual earnings liability present value expected redemption price understood reasons changes also considered written put option novartis noncontrolling interest appropriateness assumed exercise date considered consumer healthcare december liability impact different exercise dates discounted redemption carrying value million million value option viiv healthcare contingent consideration acquisition viiv healthcare contingent consideration compared remaining interest shionogiviiv healthcare projections groups dolutegravir products third party joint venture million recorded expectations growth considered potential upside contingent consideration represented fair value downside impact products launched expected launched expected payments made shionogi contingent groups competitors future sales dolutegravir products liability required viiv healthcare put option certain assumptions related forecast remeasured fair value reporting date since revenue dolutegravir products used valuation initial recognition increased response actual liability consistent viiv healthcare contingent future sales significantly exceeding original expectations consideration valuation components valuation december liability million considered appropriateness assumptions made million forecast growth rates margins reference historical viiv healthcare put option pfizer granted performance board approved budgets third party written put option group enables put forecast data noncontrolling interest back group future three acquisitionrelated liabilities subject significant december liability respect pfizers estimation uncertainty range possible outcomes written put option carrying value million broad however based procedures performed million comfortable value liability december addition liabilities group recorded certain reasonable context group financial statements taken acquisitionrelated liabilities december whole reflects managements best estimates time including million relation contingent consideration payable acquisition novartis vaccines business reviewed disclosures acquisitionrelated liability including managements commentary estimation uncertainty range alternative outcomes satisfied focused area carrying value disclosures appropriate financial liabilities material determined management judgements estimates including projections future sales products potential impact competitor products delivery anticipated synergies addition valuation sensitive changes assumptions including discount rates tax rates us tax reform therefore significant impact valuations gsk annual report independent auditors report continued report group financial statements continued key audit matter audit addressed key audit matter uncertain tax positions transfer pricing impact conjunction uk us international tax transfer pricing us tax reform specialists evaluated challenged managements judgements refer notes group financial statements respect estimates tax exposures contingencies order assess adequacy groups tax provisions included group operates complex multinational tax environment obtaining evaluating certain third party tax advice group open tax transfer pricing matters uk obtained assess appropriateness assumptions used overseas tax authorities addition time time group enters commercial transactions complicated accounting understanding evaluating managements judgements tax consequences considered status recent current tax authority audits enquiries outturn previous claims judgemental positions taken judgement required assessing level provisions required tax returns current year estimates developments tax respect uncertain tax positions december environment noted assumptions judgements group recorded provisions million respect required formulate provisions mean range possible uncertain tax positions million outcomes broad however based evidence obtained also number changes tax law us considered level provisioning related disclosure switzerland resulted material impact acceptable context group financial statements taken groups current deferred tax balances december whole significant impact respect us tax deploying us tax specialists evaluated key judgements cuts jobs act substantively enacted assumptions interpretations used management assess yearend aggregate total adjusting item account impact us tax reform undertaken procedures validate impact amounts million tax line main material corporate tax rate change adjustments current changes include reduction corporate tax rate deferred tax balances applied deferred taxation balances introduction toll tax deemed repatriation certain deferred foreign respect million toll tax charge deemed earnings changes complex repatriation foreign earnings subsidiaries us entities number areas uncertainty relating manner group evaluated documentation prepared management law apply accounting certain areas assessed underlying calculations together advice third party advisors undertaken procedures validate key inputs underpinning estimated charge confirmed liability appropriately presented groups balance sheet given complexity uncertainty relating us tax reform expect trueups updates estimates guidance issued however satisfied accounting positions taken group december represent managements best estimate impact us tax reform time litigation discussed status significant known actual potential refer notes group financial litigation inhouse legal counsel obtained substantively statements tested evidence support decisions rationale provisions held decisions record provisions including correspondence pharmaceuticals industry heavily regulated increases external legal counsel also monitored considered external inherent litigation risk group engaged number legal information sources identify potential legal actions actions including product liability antitrust related private litigation significant disclosed notes developed independent expectation litigation provisions based product litigation history available evidence challenge valuation completeness provisions recognised focused area eventual outcome claims group included obtaining confirmations external legal uncertain positions taken directors based counsel confirm understanding settled outstanding application material judgement estimation accordingly litigation asserted claims also evaluated significant adjustments unexpected adverse outcomes could significantly impact legal provisions recorded year groups reported profit balance sheet position disclosed notes group financial statements december group held provisions million eventual outcome legal proceedings dependent respect legal actions million outcome future events position taken group significant reduction provision result group inherently judgemental found context group financial settling largest individual cases relating paxil nevertheless statements taken whole judgements made management continued focus area given possibility reasonable disclosures made respect adverse outcomes provisions contingent liabilities appropriate gsk annual report strategic report governance remuneration financial statements investor information report group financial statements continued key audit matter audit addressed key audit matter finance transformation centrally managed work performed component audit teams group continues rationalise simplify finance bpos bscs consisted controls substantive testing processes including rollout enterprisewide resource conducted oversight visits key bsc bpo sites group planning system erp migrations accounting services audit scope namely india malaysia romania us uk inhouse business service centres bscs third party direct work performed business process outsourcing locations bpos number evaluated design tested operating effectiveness key market migrations onto central erp system lower automated manual controls migration however number markets migrating centralised processing environment including general controls pose particular complexity due position groups controls respect data migration erp systems supply chain continued focus area also substantively tested accuracy completeness data changes represent financial reporting risk migrations migration new erp along controls process happening controls processes established embedded number years updated migrated new environment increased risk breakdown internal financial controls transition increased risk inaccurate incomplete migration financial data would turn increase risk material misstatements group financial statements investigations groups commercial operations met directors management inhouse legal counsel refer notes group financial spoke groups external advisors assess risk statements occurrence inappropriate activities status ongoing investigations potential fines penalties group remains subject ongoing investigation included understanding evaluating groups internal commercial operations sfo uk december investigations processes assess risks allegations reported group concluded sufficient clarity various channels including whistleblowing hotlines also likely timing completion investigation evaluated ongoing enhancements changes able make sufficiently reliable estimate fine penalty made control processes business practices recent years sfo might impose group completion investigation result group stated note deploying forensic specialists assessed scope findings unable recognise provision estimate investigative work performed group well risk eventual outcome assessment exercise management performed third party addition group continues carry investigations interaction engagement broadly used output number markets ascertain whether inappropriate assessment instruct component teams including certain markets commercial operations may taken place otherwise included group audit scope undertake riskfocused audit procedures address audit risk group financial focused following risks might material statements might materially misstated due potential financial impact groups financial statements implications alleged illegal acts fine penalty might forthcoming respect respect sfo investigation independently circularised ongoing investigation groups commercial operations spoke external legal counsel engaged group obtain sfo could give rise need material views status investigation ascertain provision reasonableness managements assertions respect likely inappropriate activities occurred could outcome related disclosures group financial statements also give rise material fines penalties result asset impairments satisfied groups provisioning decisions december context group financial statements taken whole adequacy disclosures given status investigations gsk annual report independent auditors report continued report group financial statements continued tailored audit scope specific audit procedures central functions group tailored scope audit ensure performed consolidation areas significant judgement including taxation enough work able give opinion financial statements goodwill intangible assets treasury postretirement benefits whole taking account structure group elimination unrealised intercompany profit inventory accounting processes controls industry directly led group audit team operates taken together territories functions performed group financial statements consolidation audit work accounted consolidated revenue reporting components identified reporting components consolidated profit tax profit tax adjusted view required audit complete financial information certain items used determine materiality due size risk characteristics excludes central considering contribution audit evidence performing adjustment entities audited group level specific audit audit work divisional group levels including testing procedures significant balances transactions monitoring controls disaggregated analytical review procedures performed reporting components give appropriate covers significant portion groups smaller lower coverage material balances reporting risk components directly included group audit components supported shared financial service centres scope addition obtained indirect audit evidence certain centres also included group audit scope none outofscope components procedures undertook reporting components included group audit scope groups shared service centres encompassing bpos individually contributed consolidated revenue bscs centralised infrastructure processes profit tax profit tax adjusted certain items used standardised determine materiality work performed component auditors determined level involvement needed audit work reporting component units result overseas components visited senior members group audit team including groups financially significant components us visited least annually well japan india switzerland italy brazil korea germany belgium addition visited six overseas shared service centres supporting reporting components group audit scope components group audit scope site visit undertaken involvement included regular dialogue component teams review component auditor work papers gsk annual report strategic report governance remuneration financial statements investor information report group financial statements continued materiality scope audit influenced application materiality set certain quantitative thresholds materiality together qualitative considerations helped us determine scope audit nature timing extent audit procedures individual financial statement line items disclosures evaluating effect misstatements individually aggregate financial statements whole based professional judgement determined materiality financial statements whole follows overall group materiality million million determined profit tax adding back certain items including remeasurement charges shionogiviiv healthcare contingent consideration million vaccines contingent consideration million remeasurement charges consumer healthcare put option liability million viiv put option remeasurement credit million remeasurement acquisition related liabilities result us tax reform million major restructuring costs million significant legal costs million impairment intangible assets million deducting net income relating gain disposal assets million rationale benchmark applied groups principal measure earnings comprises adjusted results adds back statutory results number items income expenditure including detailed management uses measure believes eliminates material unusual nonoperational items may obscure key trends factors determining groups operational performance took measure account determining materiality except adjust profit tax add back amortisation intangible assets certain smaller adjusting items view recurring items introduce volatility groups earnings component scope group audit allocated materiality less overall group materiality range materiality allocated across components million million certain components audited local statutory audit materiality also less overall group materiality agreed audit risk committee would report misstatements identified audit million million well misstatements amount view warranted reporting qualitative reasons going concern accordance isas uk report follows reporting obligation outcome required report anything material add nothing material add draw attention however draw attention respect directors statement future events conditions predicted financial statements whether directors considered statement guarantee groups ability continue appropriate adopt going concern basis accounting going concern preparing financial statements directors identification material uncertainties groups ability continue going concern period least twelve months date approval financial statements required report directors statement relating nothing report going concern accordance listing rule r materially inconsistent knowledge obtained audit gsk annual report independent auditors report continued reporting information reporting information directors assessment prospects group information comprises information annual principal risks would threaten solvency report financial statements auditors report liquidity group thereon directors responsible information nothing material add draw attention regarding opinion financial statements cover directors confirmation annual report information accordingly express audit opinion carried robust assessment principal risks except extent otherwise explicitly stated report facing group including would threaten business form assurance thereon model future performance solvency liquidity connection audit financial statements disclosures annual report describe risks responsibility read information explain managed mitigated consider whether information materially inconsistent financial statements knowledge obtained audit directors explanation annual report otherwise appears materially misstated identify assessed prospects group apparent material inconsistency material misstatement period done consider period required perform procedures conclude whether appropriate statement whether material misstatement financial statements material reasonable expectation group able continue misstatement information based work operation meet liabilities fall due period performed conclude material misstatement assessment including related disclosures drawing information required report fact attention necessary qualifications assumptions nothing report based responsibilities nothing report performed review respect strategic report directors report also directors statement carried robust assessment considered whether disclosures required uk companies principal risks facing group statement relation act included longerterm viability group review substantially less scope audit consisted making inquiries based responsibilities described work considering directors process supporting statements undertaken course audit companies act checking statements alignment relevant ca isas uk listing rules financial conduct provisions uk corporate governance code code authority fca require us also report certain opinions matters considering whether statements consistent described required isas uk unless otherwise stated knowledge understanding group environment obtained strategic report directors report course audit listing rules opinion based work undertaken course code provisions audit information given strategic report directors nothing report respect responsibility report report year ended december consistent financial statements prepared accordance applicable legal requirements ca statement given directors consider annual report taken whole fair balanced light knowledge understanding group understandable provides information necessary environment obtained course audit identify members assess groups position performance material misstatements strategic report directors business model strategy materially inconsistent report ca knowledge group obtained course performing audit section annual report pages describing work audit risk committee appropriately address matters communicated us audit risk committee directors statement relating parent companys compliance code properly disclose departure relevant provision code specified listing rules review auditors gsk annual report strategic report governance remuneration financial statements investor information responsibilities financial statements audit responsibilities directors financial statements use report explained fully directors statement responsibilities report including opinions prepared set directors responsible preparation parent companys members body accordance financial statements accordance applicable chapter part companies act framework satisfied give true fair view purpose giving opinions accept assume directors also responsible internal control responsibility purpose person determine necessary enable preparation financial report shown whose hands may come save statements free material misstatement whether due expressly agreed prior consent writing fraud error companies act exception reporting preparing financial statements directors responsible companies act required report assessing groups ability continue going concern opinion disclosing applicable matters related going concern using received information explanations going concern basis accounting unless directors either require audit intend liquidate group cease operations realistic alternative certain disclosures directors remuneration specified law made auditors responsibilities audit financial statements objectives obtain reasonable assurance whether exceptions report arising responsibility financial statements whole free material appointment misstatement whether due fraud error issue auditors audited group since inception report includes opinion reasonable assurance high legacy firms previously auditors certain groups legacy level assurance guarantee audit conducted components since least far back records accordance isas uk always detect material obtained period total uninterrupted engagement least misstatement exists misstatements arise fraud years covering minimum years ended december error considered material individually aggregate december year ended december could reasonably expected influence economic final year engagement following groups decision rotate decisions users taken basis financial statements external audit description responsibilities audit financial statements located frcs website wwwfrcorg ukauditorsresponsibilities description forms part auditors report matters reported separately parent company financial statements glaxosmithkline plc year ended december parent company passed resolution accordance section companies act senior statutory auditors name stated pricewaterhousecoopers llp chartered accountants statutory auditors london march gsk annual report consolidated income statement year ended december notes turnover cost sales gross profit selling general administration research development royalty income operating incomeexpense operating profit finance income finance expense profit disposal interest associates share tax profits associates joint ventures profit taxation taxation profit taxation year profitloss attributable noncontrolling interests profit attributable shareholders basic earnings per share pence p p p diluted earnings per share pence p p p consolidated statement comprehensive income year ended december profit year items may subsequently reclassified income statement exchange movements overseas net assets net investment hedges reclassification exchange liquidation disposal overseas subsidiaries fair value movements availableforsale investments deferred tax fair value movements availableforsale investments reclassification fair value movements availableforsale investments deferred tax reversed reclassification availableforsale investments fair value movements cash flow hedges deferred tax fair value movements cash flow hedges reclassification cash flow hedges income statement share comprehensive expense associates joint ventures items reclassified income statement exchange movements overseas net assets noncontrolling interests remeasurement gainslosses defined benefit plans tax remeasurement defined benefit plans comprehensive incomeexpense year total comprehensive income year total comprehensive income year attributable shareholders noncontrolling interests total comprehensive income year gsk annual report strategic report governance remuneration financial statements consolidated balance sheet investor information december notes noncurrent assets property plant equipment goodwill intangible assets investments associates joint ventures investments deferred tax assets derivative financial instruments noncurrent assets total noncurrent assets current assets inventories current tax recoverable trade receivables derivative financial instruments liquid investments cash cash equivalents assets held sale total current assets total assets current liabilities shortterm borrowings contingent consideration liabilities trade payables derivative financial instruments current tax payable shortterm provisions total current liabilities noncurrent liabilities longterm borrowings corporation tax payable deferred tax liabilities pensions postemployment benefits provisions contingent consideration liabilities noncurrent liabilities total noncurrent liabilities total liabilities net assets equity share capital share premium account retained earnings reserves shareholders equity noncontrolling interests total equity financial statements pages approved board march signed behalf philip hampton chairman gsk annual report consolidated statement changes equity year ended december shareholders equity share share retained noncontrolling total capital premium earnings reserves total interests equity january profitloss year comprehensive expenseincome year total comprehensive incomeexpense year distributions noncontrolling interests dividends shareholders gains transfer net assets consumer healthcare joint venture consumer healthcare joint venture put option changes noncontrolling interests loss transfer equity investment investment associate ordinary shares issued ordinary shares acquired esop trusts writedown shares held esop trusts sharebased incentive plans tax sharebased incentive plans december profit year comprehensive income year total comprehensive income year distributions noncontrolling interests dividends shareholders recognition liabilities noncontrolling interests derecognition liabilities noncontrolling interests changes noncontrolling interests ordinary shares issued ordinary shares acquired esop trusts writedown shares held esop trusts sharebased incentive plans tax sharebased incentive plans december profit year comprehensive income year total comprehensive income year distributions noncontrolling interests contribution noncontrolling interests dividends shareholders changes noncontrolling interests ordinary shares issued ordinary shares acquired esop trusts writedown shares held esop trusts sharebased incentive plans tax sharebased incentive plans december gsk annual report strategic report governance remuneration financial statements consolidated cash flow statement investor information year ended december notes cash flow operating activities profit taxation year adjustments reconciling profit tax operating cash flows cash generated operations taxation paid net cash inflow operating activities cash flow investing activities purchase property plant equipment proceeds sale property plant equipment purchase intangible assets proceeds sale intangible assets purchase equity investments proceeds sale equity investments contingent consideration paid purchase businesses net cash acquired disposal businesses investments associates joint ventures proceeds disposal subsidiary interest associate decreaseincrease liquid investments interest received dividends associates joint ventures equity investments net cash outflowinflow investing activities cash flow financing activities shares acquired esop trusts issue share capital purchase noncontrolling interests increase longterm loans repayment ofincrease shortterm loans net repayment obligations finance leases interest paid dividends paid shareholders distributions noncontrolling interests contributions noncontrolling interests financing cash flows net cash outflow financing activities decreaseincrease cash bank overdrafts cash bank overdrafts beginning year exchange adjustments decreaseincrease cash bank overdrafts cash bank overdrafts end year cash bank overdrafts end year comprise cash cash equivalents overdrafts gsk annual report notes financial statements presentation financial statements description business financial statements prepared accordance gsk major global healthcare group engaged groups accounting policies approved board creation discovery development manufacture marketing described note accounting principles policies pharmaceutical products vaccines overthecounter otc information application accounting policies medicines healthrelated consumer products gsks principal including areas estimation judgement given note pharmaceutical products include medicines following key accounting judgements estimates therapeutic areas respiratory hiv immunoinflammation antivirals preparation financial statements conformity central nervous system cardiovascular urogenital metabolic generally accepted accounting principles requires management antibacterials dermatology rare diseases make estimates assumptions affect reported compliance applicable law ifrs amounts assets liabilities disclosure contingent financial statements prepared accordance assets liabilities date financial statements companies act article ias regulation reported amounts revenues expenses reporting international financial reporting standards ifrs related period actual results could differ estimates interpretations adopted european union implementation new accounting standards interpretations financial statements also compliance ifrs issued agenda decision ifrs interpretations committee international accounting standards board september clarified charges interest tax reported within finance expense certain penalties tax composition financial statements settlements reported within administrative expenses consolidated financial statements drawn sterling previously gsk reported charges within overall tax functional currency glaxosmithkline plc accordance charge income statement comprehensive income ifrs accounting presentation financial statements appropriate comprise gsk adopted revised basis reporting consolidated income statement result number settlements year recorded consolidated statement comprehensive income credits interest tax million finance expense consolidated balance sheet material charges penalties settlements required adjustment consolidated statement changes equity accrued interest payable tax december consolidated cash flow statement million included within trade payables notes financial statements group balance sheet impact prior years material prior year amounts restated composition group list subsidiaries associates opinion financial period directors principally affected amount profit net assets financial statements cover financial year january group given note principal group companies december comparative figures financial years january december appropriate accounting principles policies january december financial statements prepared using historical cost convention modified revaluation certain items parent company financial statements stated accounting policies going concern basis financial statements parent company glaxosmithkline plc prepared accordance uk gaap uk accounting presentation company balance sheet presented accounting policies given accounting principles policies consolidation group ability exercise joint control consolidated financial statements include rights net assets entities entities accounted joint ventures group ability exercise joint assets liabilities results cash flows control arrangement rights specified assets company subsidiaries including esop trusts obligations specified liabilities arrangement groups share results net assets associates arrangement accounted joint operation group joint ventures ability exercise significant influence entities groups share assets liabilities revenue expenses accounted associates results assets liabilities joint operations associates joint ventures incorporated consolidated financial statements using equity method accounting financial statements entities consolidated made groups rights assets liabilities revenue expenses joint december year operations included consolidated financial statements entities group power direct relevant accordance rights obligations activities affect returns group generally interests acquired entities consolidated date control financial operating policies accounted group acquires control interests sold deconsolidated subsidiaries date control ceases gsk annual report strategic report governance remuneration financial statements investor information accounting principles policies continued transactions balances subsidiaries eliminated revenue profit tax taken sales subsidiaries revenue recognised income statement goods products sold customers outside group relevant services supplied made available external customers proportion profits transactions joint ventures joint orders received title risk loss passed customer operations associates also deferred products reliable estimates made relevant deductions relevant sold third parties transactions noncontrolling interests obligations fulfilled earnings process recorded directly equity deferred tax relief unrealised intra regarded complete group profit accounted extent considered turnover represents net invoice value deduction recoverable discounts allowances given accruals estimated future business combinations rebates returns methodology assumptions used business combinations accounted using acquisition estimate rebates returns monitored adjusted regularly accounting method identifiable assets liabilities contingent light contractual legal obligations historical trends past liabilities acquired measured fair value acquisition date experience projected market conditions market conditions consideration transferred measured fair value evaluated using wholesaler thirdparty analyses market includes fair value contingent consideration research data internally generated information value added tax consideration transferred together noncontrolling interest sales taxes excluded revenue exceeds fair value net assets liabilities contingent group copromotes product counterparty liabilities acquired excess recorded goodwill costs records sale group records share revenue co acquisition charged income statement period promotion income within turnover nature copromotion incurred activities group records costs sales goodwill capitalised separate item case subsidiaries pharmaceutical turnover includes copromotion revenue part cost investment case joint ventures million million million addition initial associates goodwill denominated currency operation eventbased milestone income excluding royalty income arising acquired development marketing collaborations groups compounds products parties recognised turnover cost acquisition fair value net assets income included turnover periods presented acquired difference recognised directly income statement royalty income recognised accruals basis accordance terms relevant licensing agreements equity subsidiary acquired non controlling interest recognised either fair value non expenditure controlling interests share net assets subsidiary expenditure recognised respect goods services received casebycase basis changes groups ownership percentage supplied accordance contractual terms provision subsidiaries accounted within equity made obligation exists future liability respect past event amount obligation reliably foreign currency translation estimated manufacturing startup costs validation foreign currency transactions booked functional currency achievement normal production expensed incurred group company exchange rate ruling date advertising promotion expenditure charged income transaction foreign currency monetary assets liabilities statement incurred shipment costs intercompany transfers retranslated functional currency rates exchange ruling charged cost sales distribution costs sales customers balance sheet date exchange differences included included selling general administrative expenditure income statement restructuring costs recognised provided consolidation assets liabilities including related goodwill appropriate respect direct expenditure business overseas subsidiaries associates joint ventures translated reorganisation plans sufficiently detailed well sterling rates exchange ruling balance sheet date advanced appropriate communication affected results cash flows overseas subsidiaries associates undertaken joint ventures translated sterling using average rates exchange exchange adjustments arising opening net assets profits year retained overseas subsidiaries associates joint ventures translated sterling less exchange differences arising related foreign currency borrowings hedge groups net investment operations taken separate component equity translating sterling assets liabilities results cash flows overseas subsidiaries associates joint ventures reported currencies hyperinflationary economies adjustments made material reflect current price levels loss net monetary assets charged consolidated income statement gsk annual report notes financial statements continued accounting principles policies continued research development employee share plans research development expenditure charged income incentives form shares provided employees statement period incurred development share option share award schemes expenditure capitalised criteria recognising asset fair values options awards calculated met usually regulatory filing made major grant dates using blackscholes option pricing model charged market approval considered highly probable property plant income statement relevant vesting periods equipment used research development capitalised depreciated accordance groups policy group provides finance esop trusts purchase company shares meet obligation provide shares employees environmental expenditure exercise options awards costs running esop trusts environmental expenditure related existing conditions resulting charged income statement shares held esop past current operations current future trusts deducted reserves transfer made benefit discernible charged income statement group reserves retained earnings vesting periods recognises liability sitebysite basis reliably related share options awards reflect ultimate proceeds estimated liability includes groups portion total costs receivable employees exercise also portion potentially responsible parties costs probable able satisfy respective property plant equipment shares cleanup obligation recoveries reimbursements property plant equipment ppe stated cost recorded assets virtually certain purchase construction less provisions depreciation impairment financing costs capitalised within cost legal disputes qualifying assets construction provision made anticipated settlement costs legal disputes group outflow resources depreciation calculated write cost less residual value considered probable reliable estimate made likely ppe excluding freehold land using straightline basis outcome addition provision made legal expenses expected useful life residual values lives reviewed arising claims received disputes respect product appropriate adjusted annually normal expected useful liability claims related certain products sufficient history lives major categories ppe claims made settlements enable management make reliable estimate provision required cover unasserted claims freehold buildings years certain cases incurred reported ibnr actuarial leasehold land buildings lease term years technique used determine estimate plant machinery years group may become involved legal proceedings respect equipment vehicles years possible make reliable estimate expected financial effect could result ultimate resolution disposal ppe cost related accumulated depreciation proceedings cases appropriate disclosure impairments removed financial statements cases would included provision would made costs net amount less proceeds taken income statement associated claims made group third parties leases charged income statement incurred leasing agreements transfer group substantially pensions postemployment benefits benefits risks ownership asset treated finance costs providing pensions defined benefit schemes leases asset purchased outright assets calculated using projected unit credit method spread included ppe computer software capital elements period benefit expected derived leasing commitments shown obligations finance employees services consistent advice qualified actuaries leases assets held finance leases depreciated basis pension obligations measured present value estimated consistent similar owned assets lease term shorter future cash flows discounted rates reflecting yields high interest element lease rental included income quality corporate bonds pension scheme assets measured statement leases operating leases rental costs fair value balance sheet date charged income statement straightline basis lease term costs postemployment liabilities calculated similar way defined benefit pension schemes spread goodwill period benefit expected derived goodwill stated cost less impairments goodwill deemed employees services accordance advice qualified indefinite useful life tested impairment least actuaries annually actuarial gains losses effect changes actuarial fair value interest acquired entitys assets assumptions recognised statement comprehensive liabilities contingent liabilities exceeds consideration paid income year arise excess recognised immediately gain income statement groups contributions defined contribution plans charged income statement incurred gsk annual report strategic report governance remuneration financial statements investor information accounting principles policies continued intangible assets availableforsale investments intangible assets stated cost less provisions amortisation liquid investments investments classified available impairments forsale investments initially recorded fair value plus transaction costs remeasured subsequent reporting licences patents knowhow marketing rights separately dates fair value unrealised gains losses availableforsale acquired acquired part business combination investments recognised directly comprehensive income amortised estimated useful lives generally exceeding impairments arising significant prolonged decline fair years using straightline basis time available value equity investment reduce carrying amount asset use estimated useful lives determining amortisation directly charged income statement charge take account patent lives applicable well value obtained periods nonexclusivity asset lives disposal impairment investments gains reviewed appropriate adjusted annually contingent losses deferred comprehensive income milestone payments recognised point contingent reclassified income statement dividends equity event becomes probable development costs incurred investments recognised income statement group associated acquired licences patents knowhow groups right receive payment established equity investments marketing rights written income statement recorded noncurrent assets unless expected incurred unless criteria recognition internally generated sold within one year intangible asset met usually regulatory filing purchases sales equity investments accounted made major market approval considered highly probable trade date purchases sales availableforsale acquired brands valued independently part fair value investments accounted settlement date businesses acquired third parties brand value inventories substantial long term brands either inventories included financial statements lower contractual legal nature sold separately rest cost including raw materials direct labour direct costs businesses acquired brands amortised related production overheads net realisable value cost estimated useful lives years except considered generally determined first first basis prelaunch inventory useful economic life indefinite held asset high probability regulatory costs acquiring developing computer software internal approval product point provision made use internet sites external use capitalised intangible carrying value recoverable amount provision fixed assets software site supports significant reversed point high probability regulatory business system expenditure leads creation approval determined durable asset erp systems software amortised seven trade receivables ten years computer software three five years trade receivables carried original invoice amount less impairment noncurrent assets provisions doubtful debts provisions made carrying values noncurrent assets reviewed evidence risk nonpayment taking account ageing impairment either standalone basis part larger cash previous experience general economic conditions trade generating unit indication assets might receivable determined uncollectable written firstly impaired additionally goodwill intangible assets indefinite provision available income statement useful lives intangible assets yet available use subsequent recoveries amounts previously provided tested impairment annually provision impairment credited income statement longterm receivables charged income statement year concerned discounted effect material impairments goodwill reversed impairment losses borrowings noncurrent assets reversed change borrowings initially recorded amount proceeds estimates used determine recoverable amounts received net transaction costs borrowings subsequently extent revised recoverable amounts exceed carried amortised cost difference proceeds carrying values would existed net depreciation net transaction costs amount due redemption amortisation impairments recognised recognised charge income statement period investments associates joint ventures joint operations relevant borrowing investments associates joint ventures carried consolidated balance sheet groups share net assets date acquisition postacquisition retained profits losses together goodwill arising acquisition group recognises rights assets liabilities revenue expenses joint operations gsk annual report notes financial statements continued accounting principles policies continued taxation derivative financial instruments classified heldfortrading current tax provided amounts expected paid applying carried balance sheet fair value derivatives tax rates enacted substantively enacted designated hedging instruments classified inception balance sheet date cash flow hedges net investment hedges fair value hedges deferred tax provided full temporary differences arising changes fair value derivatives designated cash flow tax bases assets liabilities carrying hedges recognised comprehensive income amounts financial statements deferred tax assets extent hedges effective ineffective portions recognised extent probable future taxable profits recognised profit loss immediately amounts deferred available temporary differences comprehensive income reclassified income utilised deferred tax provided temporary differences arising statement hedged item affects profit loss investments subsidiaries associates joint ventures except net investment hedges accounted similar way cash timing reversal temporary difference flow hedges controlled probable temporary difference reverse foreseeable future deferred tax provided using rates changes fair value derivatives designated fair value tax enacted substantively enacted hedges recorded income statement together balance sheet date changes fair value hedged asset liability derivative financial instruments hedging changes fair value derivative instruments derivative financial instruments used manage exposure qualify hedge accounting recognised immediately market risks principal derivative instruments used gsk income statement foreign currency swaps interest rate swaps foreign exchange discounting forward contracts options group hold issue time value money material balances derivative financial instruments trading speculative discounted current values using appropriate discount rates purposes unwinding discounts recorded finance income finance expense key accounting judgements estimates preparing financial statements management required taxation make judgements items tax charge year million million recognised financial statements estimates december current tax payable million assumptions affect amounts assets liabilities revenue million noncurrent corporation tax payable expenses reported financial statements actual million nil current tax recoverable million amounts results could differ estimates million deferred tax liabilities million following considered key accounting judgements million deferred tax assets million estimates made million turnover deferred tax assets recognised judgement made reported group turnover million probable future taxable profits available million temporary differences utilised based managements assumptions relating amounts timing future taxable gross turnover reduced rebates discounts allowances profits factors affecting tax charge future years particular product returns given expected given vary product us tax reform set note taxation change arrangements buying groups arrangements groups effective tax rate would changed total tax purchasing organisations dependent upon submission charge year approximately million claims time initial recognition sale accruals made time sale estimated rebates discounts group open tax issues number revenue authorities allowances payable returns made based available market management makes judgement outflow funds information historical experience probable reliable estimate outcome dispute made provision made best estimate liability amounts estimated may fully reflect estimating liability gsk applies riskbased approach final outcome amounts subject change dependent takes account appropriate probability upon amongst things types buying group product group would able obtain compensatory adjustments sales mix international tax treaties estimates take account level accrual rebates returns reviewed adjusted specific circumstances dispute relevant external advice regularly light contractual legal obligations historical inherently judgemental could change substantially time trends past experience projected market conditions market dispute progresses new facts emerge conditions evaluated using wholesaler thirdparty analyses market research data internally generated information future events could cause assumptions accruals based change could affect future results group gsk annual report strategic report governance remuneration financial statements investor information key accounting judgements estimates continued gsk continues believe made adequate provision contingent consideration put option liabilities liabilities likely arise open assessments december income statement charge contingent consideration group recognised provisions million put option liabilities million million respect uncertain tax positions million december liability contingent consideration open issues exist ultimate liability matters may vary amounted million million amount amounts provided dependent upon outcome million million related acquisition negotiations relevant tax authorities necessary litigation former shionogiviiv healthcare joint venture proceedings million million related acquisition legal disputes vaccines business novartis legal costs year million million contingent consideration included consideration payable december provisions legal disputes business combination recorded fair value date amounted million million acquisition fair values generally based riskadjusted group provides anticipated settlement costs future cash flows discounted using appropriate posttax discount management makes judgement outflow resources rates fair values reviewed regular basis least probable reliable estimate made likely outcome annually changes reflected income statement dispute legal expenses arising claims see note contingent consideration liabilities group estimated provisions take account specific group granted put option novartis respect circumstances dispute relevant external advice novartis shareholding consumer healthcare joint venture inherently judgemental could change substantially time certain circumstances novartis right require gsk dispute progresses new facts emerge details status acquire shareholding consumer healthcare joint various uncertainties involved significant unresolved venture marketbased valuation right exercisable disputes set note legal proceedings certain windows may exercised either companys directors taken legal advice respect novartis entire shareholding four instalments established provisions taking account relevant facts gsk recognised financial liability million circumstances matter accordance accounting december million represents requirements respect product liability claims related certain present value redemption value estimated gsk event products sufficient history claims made settlements full exercise right novartis calculated applying enable management make reliable estimate provision relevant public company multiples premium discount required cover unasserted claims group may become involved forecast future profits accordance shareholder legal proceedings respect possible make agreements sensitivity analysis given note trade reliable estimate expected financial effect could payables result ultimate resolution proceedings cases pfizer may request ipo viiv healthcare time either appropriate disclosure cases would provided gsk consent ipo offering completed provision would made contingent liability quantified within nine months pfizer could require gsk acquire ultimate liability legal claims may vary amounts shareholding liability put option recognised provided dependent upon outcome litigation groups balance sheet initial value proceedings investigations possible settlement negotiations million gsk also recognised liabilities future preferential position could change time therefore dividends anticipated become payable pfizer shionogi assurance losses result outcome legal groups balance sheet liability pfizer put proceedings exceed amount provisions reported option derived internal valuation viiv groups financial statements material amount healthcare business utilising discounted forecast future cash flow multiplesbased methodologies amounted million intangible asset impairments december million sensitivity analysis december intangible assets million also given note trade payables million impairment tests intangible assets undertaken events occur call question carrying values assets addition intangible assets indefinite useful lives yet available use subject annual impairment tests valuations impairment tests based established market multiples riskadjusted future cash flows estimated useful life asset limited discounted using appropriate discount rates set note intangible assets assumptions relating future cash flows estimated useful lives discount rates based business forecasts therefore inherently judgemental future events could cause assumptions used impairment tests change consequent adverse effect future results group gsk annual report notes financial statements continued key accounting judgements estimates continued pensions postemployment benefits discount rates derived aa rated corporate bond yields costs providing pensions postemployment benefits except countries deep market corporate assessed basis assumptions selected management bonds government bond yields used sensitivity analysis assumptions include future earnings pension increases provided note pensions postemployment discount rates expected longterm rates return assets benefits reduction discount rate would lead mortality rates disclosed note pensions increase net pension deficit approximately million postemployment benefits surplus defined benefit increase annual pension cost approximately million scheme arises potential surplus arise selection different assumptions could affect future results committed future contributions rights trustees prevent group group obtaining refund surplus future considered determining whether necessary restrict amount surplus recognised new accounting requirements following new amended accounting standards new standard expected material impact issued iasb likely affect future annual reports reported results financial statements gsk adopt ifrs retrospectively certain permitted exceptions ifrs revenue contracts customers issued may result prior year results restated implemented group january cumulative adjustment decrease equity january standard provides single principlesbased approach approximately million recognition revenue contracts customers focuses identification performance obligations contract ifrs leases issued january requires revenue recognised performance implemented group january standard obligations satisfied replace ias leases require lease liabilities right use assets recognised balance sheet new standard expected material impact almost leases expected result significant increase amount timing recognition reported revenue financial assets liabilities recognised costs operating statements gsk adopt ifrs applying modified leases currently included within operating costs split retrospective approach cumulative adjustment decrease financing element charge reported within finance equity january approximately million accordance expense finance lease obligations december requirements standard modified set note net debt undiscounted commitments retrospective approach adopted prior year results noncancellable operating leases set note restated commitments ifrs financial instruments issued final form july group assessing potential impact ifrs implemented group january standard replaces majority ias covers ifric uncertainty income tax treatments issued june classification measurement derecognition financial assets implemented group january financial liabilities introduces new impairment model interpretation clarifies considered probable tax financial assets based expected losses rather incurred authority accept uncertain tax treatment tax charge losses provides new hedge accounting model calculated basis considered probable effect uncertainty estimated reflected tax charge assessing uncertainty assumed tax authority full knowledge information related matter group continuing assess potential impact new interpretation exchange rates group uses average exchange rates prevailing period translate results cash flows overseas average rates subsidiaries joint ventures associates sterling period us end rates translate net assets entities currencies euro influence translations relevant exchange rates follows yen period end rates us euro yen gsk annual report strategic report governance remuneration financial statements investor information segment information operating segments reported based financial information provided chief executive officer responsibilities corporate executive team cet gsk reports results four segments pharmaceuticals pharmaceuticals rd vaccines consumer healthcare individual members cet responsible segment groups management reporting process allocates intragroup profit product sale market sale recorded profit analyses presented basis explained january significant legal charges excluded segment profit reported within reconciling items segment profit operating profit segment profits revised onto comparable basis corporate unallocated turnover costs included results several vaccines consumer healthcare products held sale number markets order meet antitrust approval requirements together costs corporate functions turnover segment pharmaceuticals vaccines consumer healthcare segment turnover corporate unallocated turnover pharmaceuticals turnover therapeutic area respiratory hiv immunoinflammation established pharmaceuticals us operations pharmaceuticals vaccines businesses made sales three wholesalers approximately million million million million million million million million million respectively allocating finalcustomer discounts wholesalers vaccines turnover category meningitis influenza shingles established vaccines consumer healthcare turnover category wellness oral care nutrition skin health gsk annual report notes financial statements continued segment information continued revised revised segment profit pharmaceuticals pharmaceuticals rd pharmaceuticals including rd vaccines consumer healthcare segment profit corporate unallocated costs reconciling items segment profit operating profit operating profit finance income finance costs profit disposal interest associates share tax profits associates joint ventures profit taxation taxation profit taxation year reconciling items segment profit operating profit comprise items specifically allocated segment profit include impairment amortisation intangible assets major restructuring charges significant legal charges expenses settlement litigation government investigations disposals businesses products associates certain items related major acquisition disposal activity pretax impact enactment us tax cuts jobs act depreciation amortisation segment pharmaceuticals pharmaceuticals rd pharmaceuticals including rd vaccines consumer healthcare segment depreciation amortisation corporate unallocated depreciation amortisation reconciling items segment depreciation amortisation total depreciation amortisation total depreciation amortisation gsk annual report strategic report governance remuneration financial statements investor information segment information continued ppe intangible asset goodwill impairment segment pharmaceuticals pharmaceuticals rd pharmaceuticals including rd vaccines consumer healthcare segment impairment corporate unallocated impairment reconciling items segment impairment total impairment total impairment reconciling items segment impairment total impairment included million related progressive withdrawal tanzeum ppe intangible asset impairment reversals segment pharmaceuticals pharmaceuticals rd pharmaceuticals including rd vaccines consumer healthcare segment impairment reversals corporate unallocated impairment reversals reconciling items segment impairment reversals total impairment reversals total impairment reversals net assets segment pharmaceuticals pharmaceuticals rd pharmaceuticals including rd vaccines consumer healthcare segment net operating assets corporate unallocated net operating assets net operating assets net debt investments associates joint ventures derivative financial instruments current deferred taxation assets held sale net assets pharmaceuticals segment includes shionogiviiv healthcare contingent consideration liability million million pfizer put option million million consumer healthcare segment includes put option liability million million gsk annual report notes financial statements continued segment information continued geographical information uk regarded groups country domicile turnover location customer uk us international external turnover noncurrent assets location subsidiary uk us international noncurrent assets noncurrent assets location excludes amounts relating investments deferred tax assets derivative financial instruments pension assets amounts receivable insurance contracts certain noncurrent receivables operating incomeexpense impairment equity investments disposal equity investments disposal businesses assets fair value remeasurements contingent consideration recognised business combinations remeasurement viiv healthcare put option liabilities preferential dividends remeasurement consumer healthcare put option liability fair value adjustments derivative financial instruments incomeexpense disposal businesses assets included profit million disposal anaesthesia business aspen disposals included milestone income million relation divestment ofatumumab number smaller divestments included disposal oncology business novartis million initial million divestment ofatumumab fair value remeasurements contingent consideration recognised business combinations included million related acquisition former shionogiviiv healthcare joint venture million payable novartis related vaccines acquisition fair value remeasurements contingent consideration remeasurement viiv healthcare put option liabilities preferential dividends remeasurement consumer healthcare put option liability include additional charge arising us tax reform million gsk annual report strategic report governance remuneration financial statements investor information operating profit following items included operating profit employee costs note advertising distribution costs depreciation property plant equipment impairment property plant equipment net reversals amortisation intangible assets impairment intangible assets net reversals net foreign exchange losses inventories cost inventories included cost sales writedown inventories reversal prior year writedown inventories operating lease rentals minimum lease payments contingent rents sublease payments fees payable companys auditor associates relation group see reversals prior year writedowns inventories principally arise reassessment usage demand expectations prior inventory expiration net foreign exchange losses include net loss million nil nil exchange arising reclassification exchange liquidation disposal overseas subsidiaries included within operating profit major restructuring charges million million million see note major restructuring costs fees payable companys auditor associates audit parent company consolidated financial statements audit companys subsidiaries attestation sarbanesoxley act audit auditrelated services taxation compliance taxation advice assurance services services assurance services provided auditor relate agreed upon procedures assurance services outside statutory audit requirements services provided auditor primarily related advisory services year ended december addition fees paid respect gsk pension schemes audit services gsk annual report notes financial statements continued employee costs wages salaries social security costs pension postemployment costs including augmentations note cost sharebased incentive plans severance costs integration restructuring activities increase wages salaries included impact movements exchange rates group provides benefits employees commensurate local practice individual countries including markets healthcare insurance subsidised car schemes personal life assurance cost sharebased incentive plans analysed follows share value plan performance share plan share option plans cash settled plans average monthly number persons employed group including directors year number number number manufacturing selling general administration research development average monthly number group employees excludes temporary contract staff numbers group employees end financial year given financial record monthly average number persons employed glaxosmithkline plc nil nil compensation directors senior management members cet aggregate follows wages salaries social security costs pension postemployment costs cost sharebased incentive plans gsk annual report strategic report governance remuneration financial statements investor information major restructuring costs major restructuring costs charged arriving operating profit include restructuring costs arising major change programme initiated pharmaceuticals restructuring programme announced october following novartis transaction completed ceo strategic initiatives programme announced july total restructuring costs million incurred following areas restructuring rd organisation predominantly united kingdom north america projects simplify eliminate processes leading staff reductions support functions restructuring pharmaceuticals commercial operating model supply chain leading staff reductions sales force administration transformation manufacturing vaccines businesses deliver step change quality cost productivity costs charged operating profit programmes follows increase provision major restructuring programmes see note amount provision reversed unused see note impairment losses recognised noncash charges cash costs provision reversals million million million reflected release legacy support function novartis integration provisions asset impairments million million million noncash charges totalling million million million noncash items principally fixed asset write downs across support functions manufacturing research facilities accelerated depreciation asset lives rd manufacturing shortened result major restructuring programme charges settled cash include termination leases site closure costs consultancy project management fees finance income interest income arising cash cash equivalents availableforsale investments derivatives fair value profit loss loans receivables fair value adjustments derivatives fair value profit loss derivatives accounted fair value profit loss designated effective hedging instruments see note financial instruments related disclosures classified heldfortrading financial instruments ias gsk annual report notes financial statements continued finance expense interest expense arising financial liabilities amortised cost derivatives fair value profit loss fair value movements derivatives fair value profit loss reclassification cash flow hedge comprehensive income unwinding discounts provisions finance expense derivatives accounted fair value profit loss designated effective hedging instruments see note financial instruments related disclosures classified heldfortrading financial instruments ias interest expense arising derivatives fair value profit loss relates swap interest expense finance expense includes million credit interest relating income taxes see note presentation financial statements amounts material comparatives restated associates joint ventures groups share tax profits losses associates joint ventures set share tax profits associates share tax losses joint ventures december group held one significant associate innoviva inc summarised income statement information respect innoviva set periods group accounted investment innoviva associate groups share tax profits associates comprehensive income includes profit million comprehensive income nil respect innoviva since september turnover profit taxation comprehensive income total comprehensive income results innoviva included summarised income statement information represent estimated earnings innoviva relevant periods innovivas turnover royalty income gsk relation relvarbreo ellipta anoro ellipta trelegy ellipta sales aggregated financial information respect gsks share associated undertakings joint ventures set share turnover share tax lossesprofits share comprehensive income share total comprehensive expenseincome groups sales associates joint ventures million million million gsk annual report strategic report governance remuneration financial statements investor information taxation groups tax charge sum total current deferred tax expense taxation charge based profits year uk current year charge rest world current year charge credit respect prior periods total current taxation total deferred taxation total tax gsk made payments million uk corporation tax hmrc amounts uk corporation tax include various business taxes borne uk gsk year deferred tax credit reflected revaluation existing deferred tax liabilities reflect lower swiss tax rate applicable following swiss tax reform increase deferred tax assets related intragroup profit inventory impact items partly offset revaluation existing deferred tax assets reflect lower headline us tax rate following enactment us tax reform comparison net deferred tax credits impacted greater extent remeasurements contingent consideration relation former shionogiviiv healthcare joint venture credit also included unwind deferred tax liabilities disposal groups oncology business novartis following table reconciles tax charge calculated uk statutory rate group profit tax actual tax charge year reconciliation taxation group profits profit tax uk statutory rate taxation differences overseas taxation rates benefit intellectual property incentives rd credits remeasurement nontaxable put option liabilities losses recognisedpreviously unrecognised losses permanent differences disposals acquisitions permanent differences reassessment prior year estimates respect current deferred taxes us swiss tax reform tax unremitted earnings tax chargetax rate gsk substantial business presence many countries around globe impact differences overseas taxation rates arose profits earned countries tax rates higher uk statutory rate significant us belgium india adverse impact partly offset increased benefit intellectual property incentives uk patent box belgian patent income deduction regimes regimes provide reduced rate corporate income tax profits earned qualifying patents groups tax rate influenced impact us swiss tax reforms together transactionrelated charges arising groups put option liabilities relation viiv healthcare consumer healthcare joint venture reassessment estimates uncertain tax positions following settlement number open issues tax authorities various jurisdictions included within permanent differences million charge arises following enactment belgium tax reform future tax charges therefore groups effective tax rate may affected factors acquisitions disposals restructurings location research development activity tax regime reforms resolution open matters continue bring tax affairs date around world gsk annual report notes financial statements continued taxation continued tax items charged equity statement comprehensive income current taxation sharebased payments defined benefit plans deferred taxation sharebased payments defined benefit plans exchange movements fair value movements cash flow hedges fair value movements availableforsale investments total chargecredit equity statement comprehensive income items charged statement comprehensive income except tax share based payments following enactment us belgian tax reform group recognised deferred tax charges million million respectively equity statement comprehensive income amounts included within million net deferred tax charge presented international tax reform groups tax charge influenced impact international tax reform enacted year us tax cuts jobs act act expected positive impact future tax earnings gsks us businesses however enactment new law resulted number nonrecurring charges addition enactment swiss tax reform resulted nonrecurring tax credit arising revaluation deferred tax liabilities relating certain consumer healthcare brands acquired novartis reflect reduction headline swiss tax rate charges associated us tax reform based information currently available guidance us treasury implementation act becomes available particularly regard repatriation tax provisions assumptions underlying estimates could change could result adjustments charges taken could material impact results group impact tax reform profits attributable shareholders set swiss tax us tax reform reform operating expenses current tax deferred tax impact profit taxation year profit attributable noncontrolling interests profit attributable shareholders valuations hiv consumer healthcare businesses increased due lower us tax rates resulted increase related liabilities contingent consideration put options hence additional operating cost million current tax charge respect us tax reform relates primarily introduction repatriation tax accumulated reserves nonus subsidiaries us entities group cash impact spread eight years onwards deferred tax charge relates primarily revaluation existing balance sheet tax assets held future liabilities pensions tax charge associated us tax reform partly offset allocation noncontrolling interests amounting million many adjustments related viiv healthcare consumer healthcare joint venture tax credit associated swiss tax reform similarly offset million charge due allocation noncontrolling interests related consumer healthcare joint venture impact tax charge arising us tax reform follows current tax deferred tax total revaluation assets liabilities repatriation tax group also incurred charge million following enactment belgian tax reform predominantly relating revaluation existing deferred tax assets continued focus tax reform expected future years driven oecds base erosion profit shifting beps project european commission initiatives including fiscal state aid investigations together domestic initiatives around world may result significant changes established tax principles increase tax authority disputes turn could adversely affect gsks effective tax rate could result higher cash tax liabilities gsk annual report strategic report governance remuneration financial statements investor information taxation continued issues relating taxation integrated nature groups worldwide operations involves significant investment research strategic manufacture limited number locations consequential crossborder supply routes numerous endmarkets line current oecd guidelines group base transfer pricing policy arms length principle however different tax authorities may seek attribute profit activities undertaken jurisdiction potentially resulting double taxation group also open items several jurisdictions concerning matters deductibility particular expenses tax treatment certain business transactions gsk applies riskbased approach determine transactions likely subject challenge probability group would able obtain compensatory adjustments international tax treaties calculation groups total tax charge therefore necessarily involves degree estimation judgment respect certain items whose tax treatment finally determined resolution reached relevant tax authority appropriate formal legal process december group recognised provisions million respect uncertain tax positions million decrease recognised provisions driven reassessment estimates utilisation provisions uncertain tax positions following settlement number open issues tax authorities various jurisdictions transfer accrued interest payable tax balances payables foreign exchange impact revaluing overseas exposures also contributed reduction recognised provisions whilst ultimate liability matters may vary amounts provided dependent upon outcome agreements relevant tax authorities litigation appropriate group continues believe made appropriate provision periods open yet agreed tax authorities currently anticipate material changes amounts provided transfer pricing tax contingencies next months provision deferred tax liabilities million million made respect withholding taxation would arise distribution profits certain overseas subsidiaries whilst aggregate amount unremitted profits balance sheet date approximately billion billion majority unremitted profits would subject tax including withholding tax repatriation uk legislation relating company distributions provides exemption tax overseas profits subject certain exceptions prior years temporary difference arose accumulated reserves nonus subsidiaries us entities group timing reversal temporary difference could controlled considered probable foreseeable future deferred tax provided however result us tax cuts jobs act temporary difference reversed group recorded oneoff repatriation tax charge million accordingly unremitted profits deferred tax provided nil billion movement deferred tax assets liabilities pensions share accelerated post option net capital intangible contingent intragroup employment tax award temporary allowances assets consideration profit benefits losses schemes differences total january exchange adjustments creditcharge income statement creditcharge income statement associated us tax reform credit income statement associated swiss tax reform chargecredit statement comprehensive income equity december net deferred tax credit million income statement included million credit associated swiss tax reform million credit relation origination reversal temporary differences credits partly offset million charge relation us tax reform net credit income statement million included million charge related rd incentives recognised within operating profit taxation charge income statement deferred tax liabilities provided relation intangible assets predominately relate temporary differences arising assets liabilities acquired part historic business combinations group continues recognise deferred tax assets future obligations respect contingent consideration amounts payable minority shareholders payments tax deductible point time payment made deferred tax asset recognised intragroup profits arising intercompany inventory eliminated within consolidated financial statements intragroup profits eliminated individual entities tax returns temporary difference arises reverse point time inventory sold externally deferred tax asset recognised tax losses million related trading losses million related trading losses million related capital losses net temporary differences included accrued expenses tax deduction available paid basis rebates deferred tax assets liabilities recognised balance sheet follows deferred tax assets deferred tax liabilities gsk annual report notes financial statements continued taxation continued deferred tax assets recognised us foreign tax credits possible future taxable profits available gross amount foreign tax credits deferred tax recognised million december deferred tax assets recognised probable future taxable profit available utilise losses unrecognised tax losses follows unrecognised unrecognised deferred tax deferred tax tax losses asset tax losses asset unrecognised tax losses trading losses expiring within years years available indefinitely december capital losses december earnings per share pence pence pence basic earnings per share diluted earnings per share basic earnings per share calculated dividing profit attributable shareholders weighted average number shares issue period deducting shares held esop trusts treasury shares trustees waived rights dividends shares held esop trusts diluted earnings per share calculated adjusting weighted average number shares used basic calculation assume conversion potentially dilutive shares potentially dilutive share forms part employee share schemes exercise price average market price gsk shares period performance conditions attaching scheme met balance sheet date numbers shares used calculating basic diluted earnings per share reconciled weighted average number shares issue millions millions millions basic dilution share options awards diluted dividends dividend total dividend total dividend total per share dividend per share dividend per share dividend paidpayable pence paid pence paid pence first interim july july july second interim october october october third interim january january january fourth interim april april april total special dividend april ifrs interim dividends recognised financial statements paid declared gsk normally pays dividend two quarters quarter relates one quarter declared financial statements recognise dividends paid namely third fourth interim dividends first second interim dividends amounts recognised year follows dividends shareholders gsk annual report strategic report governance remuneration financial statements investor information property plant equipment plant land equipment assets buildings vehicles construction total cost january exchange adjustments additions capitalised borrowing costs disposals writeoffs reclassifications transfer assets held sale cost december exchange adjustments additions capitalised borrowing costs disposals writeoffs reclassifications transfer assets held sale cost december depreciation january exchange adjustments charge year disposals writeoffs transfer assets held sale depreciation december exchange adjustments charge year disposals writeoffs transfer assets held sale depreciation december impairment january exchange adjustments disposals writeoffs impairment losses reversal impairments transfer assets held sale impairment december exchange adjustments disposals writeoffs impairment losses reversal impairments transfer assets held sale impairment december total depreciation impairment december total depreciation impairment december net book value january net book value december net book value december weighted average interest rate capitalised borrowing costs year disposals writeoffs year include number assets nil net book value longer use business gsk annual report notes financial statements continued property plant equipment continued net book value december groups land buildings comprised freehold properties million million properties leases years million million properties leases less years million million included land buildings december leased assets cost million million accumulated depreciation million million impairment nil million net book value million million included plant equipment vehicles december leased assets cost million million accumulated depreciation million million impairment million nil net book value million million lease agreements include renewal purchase options escalation clauses impairment losses principally arose decisions rationalise facilities calculated based either fair value less costs disposal value use fair value less costs disposal valuation methodology uses significant inputs based observable market data therefore valuation technique classified level fair value hierarchy calculations determine net present value projected riskadjusted posttax cash flows relevant asset cash generating unit applying discount rate group posttax weighted average cost capital wacc adjusted appropriate relevant specific risks value use calculations impairment indicated pretax cash flow calculation expected give materially different result test would reperformed using pretax cash flows pretax discount rate group wacc equivalent pretax discount rate approximately net impairment losses charged cost sales million million rd million million sga million million included million million arising major restructuring programmes reversals impairment arose subsequent reviews impaired assets conditions gave rise original impairments deemed longer apply reversals credited cost sales carrying value december assets impairments charged reversed year million million million million computer software reclassified assets construction intangible assets becoming ready use goodwill cost january exchange adjustments additions business combinations note transfer assets held sale cost december net book value january net book value december goodwill allocated groups segments follows pharmaceuticals vaccines consumer healthcare net book value december gsk annual report strategic report governance remuneration financial statements investor information goodwill continued recoverable amounts cash generating units assessed using fair value less costs disposal model fair value less costs disposal calculated using discounted cash flow approach posttax discount rate applied projected riskadjusted posttax cash flows terminal value discount rate used based group wacc cash generating units integrated operations across large parts group discount rate adjusted appropriate specific country currency risks valuation methodology uses significant inputs based observable market data therefore valuation technique classified level fair value hierarchy details relating discounted cash flow models used impairment tests pharmaceuticals vaccines consumer healthcare cash generating units follows valuation basis fair value less costs disposal key assumptions sales growth rates profit margins terminal growth rate discount rate taxation rate determination assumptions growth rates internal forecasts based internal external market information margins reflect past experience adjusted expected changes terminal growth rates based managements estimate future longterm average growth rates discount rates based group wacc adjusted appropriate taxation rates based appropriate rates region period specific projected cash flows five years terminal growth rate discount rate terminal growth rate discount rate pharmaceuticals pa vaccines pa consumer healthcare pa terminal growth rates exceed longterm projected growth rates relevant markets reflect impact future generic competition take account new product launches case valuations indicated sufficient headroom reasonably possible change key assumptions unlikely result impairment related goodwill goodwill monitored segmental level pharmaceuticals cash generating unit comprises collection smaller cash generating units including assets indefinite lives carrying value million million consumer healthcare cash generating unit also comprises collection smaller cash generating units including brands indefinite lives carrying value billion billion details indefinite life brands given note intangible assets gsk annual report notes financial statements continued intangible assets computer licences amortised indefinite life software patents etc brands brands total cost january exchange adjustments capitalised development costs capitalised borrowing costs additions business combinations additions disposals asset writeoffs transfer assets held sale reclassifications cost december exchange adjustments capitalised development costs capitalised borrowing costs additions disposals asset writeoffs transfer assets held sale reclassifications cost december amortisation january exchange adjustments charge year disposals asset writeoffs transfer assets held sale amortisation december exchange adjustments charge year disposals asset writeoffs transfer assets held sale amortisation december impairment january exchange adjustments impairment losses disposals asset writeoffs transfer assets held sale impairment december exchange adjustments impairment losses disposals asset writeoffs transfer assets held sale impairment december total amortisation impairment december total amortisation impairment december net book value january net book value december net book value december weighted average interest rate capitalised borrowing costs year net book value computer software included million million internally generated costs charge impairments year included million related progressive withdrawal pharmaceutical product tanzeum fully impaired carrying value december intangible assets impairments charged reversed year following impairments reversals million million patent expiry dates groups significant assets relevant set pages gsk annual report strategic report governance remuneration financial statements investor information intangible assets continued amortisation impairment losses net reversals charged income statement follows amortisation net impairment losses cost sales selling general administration research development licences patents etc includes large number acquired licences patents knowhow agreements marketing rights either marketed use still development note acquisitions disposals gives details additions business combinations year book values largest individual items follows meningitis portfolio dolutegravir benlysta fluarixflulaval hiv assets acquired bms selzentry okairos technology platform others meningitis portfolio includes menveo bexsero men abcwy indefinite life brands comprise portfolio consumer healthcare products primarily acquired acquisitions sterling winthrop inc block drug company inc cns inc novartis consumer healthcare business together number pharmaceutical brands acquisition stiefel laboratories inc book values major brands follows voltaren otrivin fenistil theraflu panadol sensodyne lamisil breathe right stiefel trade name excedrin physiogel polident others brands considered indefinite life given strength durability brand level marketing support brands relatively similar stable profitable market sectors similar risk profiles size diversification market shares mean risk marketrelated factors causing reduction lives brands considered relatively low group aware material legal regulatory contractual competitive economic factors could limit useful lives accordingly amortised brand tested annually impairment amortised intangible assets tested indicators impairment arise testing applies fair value less costs disposal methodology generally using posttax cash flow forecasts terminal value calculation discount rate equal group posttax wacc adjusted appropriate specific country currency risks valuation methodology uses significant inputs based observable market data therefore valuation technique classified level fair value hierarchy main assumptions include future sales price volume growth product contribution future expenditure required maintain products marketability registration relevant jurisdictions exchange rates assumptions based past experience reviewed part managements budgeting strategic planning cycle changes market conditions sales erosion competition terminal growth rates applied nil managements estimates future longterm average growth rates relevant markets case valuations indicate sufficient headroom reasonably possible change key assumptions unlikely result impairment intangible assets gsk annual report notes financial statements continued investments associates joint ventures joint joint ventures associates total ventures associates total january exchange adjustments additions disposals distributions received movements lossprofit tax recognised consolidated income statement december group held one significant associate december innoviva inc december group owned million shares innoviva biopharmaceutical company listed nasdaq innoviva partnered gsk development long acting beta agonist vilanterol currently receives royalty income sales products contain component namely relvarbreo ellipta anoro ellipta trelegy ellipta remaining economic interest royalties due theravance biopharma inc company spun innoviva group holds common stock investment innoviva market value million december million group divested shareholdings two associates see note acquisitions disposals summarised balance sheet information based results information respect innoviva set december december noncurrent assets current assets current liabilities noncurrent liabilities net liabilities interest associated undertaking goodwill fair value adjustments carrying value december gsk annual report strategic report governance remuneration financial statements investor information investments january exchange adjustments additions net fair value movements impairment losses disposals december investments comprise noncurrent equity investments availableforsale investments recorded fair value balance sheet date investments traded active market fair value determined reference relevant stock exchange quoted bid price investments fair value estimated management reference relevant available information including current market value similar instruments discounted cash flows underlying net assets investments include listed investments million million significant investments held december theravance biopharma inc group holds common stock investment fair value december million million investments include equity stakes companies gsk research collaborations companies provide access biotechnology developments potential interest disposal investments fair value movements reclassified equity income statement based average cost shares acquired different times impairment losses recorded recognised income statement year within operating income together amounts reclassified fair value reserve recognition impairments impairments initially result prolonged significant declines fair value equity investments acquisition cost subsequent declines fair value immediately taken income statement carrying value december investments impaired follows original cost cumulative impairments recognised income statement subsequent fair value increases carrying value december noncurrent assets amounts receivable insurance contracts pension schemes surplus receivables inventories raw materials consumables work progress finished goods gsk annual report notes financial statements continued trade receivables trade receivables net provision bad doubtful debts accrued income prepayments interest receivable employee loans advances receivables trade receivables included million million due associates joint ventures receivables included million million due associates joint ventures bad doubtful debt provision january exchange adjustments charge year subsequent recoveries amounts provided utilised december cash cash equivalents cash bank hand shortterm deposits assets held sale property plant equipment goodwill intangibles inventory included within assets held sale million intangible impairments million ppe impairments million intangible impairment reversals million ppe impairment reversals noncurrent assets disposal groups transferred assets held sale expected carrying amounts recovered principally disposal sale considered highly probable held lower carrying amount fair value less costs sell included within assets held sale assets written fair value less costs sell million million valuation methodology uses significant inputs based observable market data therefore valuation classified level fair value hierarchy gsk annual report strategic report governance remuneration financial statements investor information trade payables trade payables wages salaries social security consumer healthcare put option viiv healthcare put option payables deferred income customer return rebate accruals accruals trade payables included million million due associates joint ventures customer return rebate accruals provided group point sale respect estimated rebates discounts allowances payable customers included million million respect us pharmaceuticals vaccines fully described group financial review accruals made time sale actual amounts paid based claims made time initial recognition sale amounts estimated may fully reflect final outcome subject change dependent upon amongst things types buying group product sales mix level accrual reviewed adjusted quarterly light historical experience actual rebates discounts allowances given returns made changes arrangements future events could cause assumptions accruals based change could affect future results group consumer healthcare put option liability relates ability novartis put shares consumer healthcare joint venture gsk certain points future option became exercisable march payment likely due several months exercise classified within current liabilities liability recorded present value estimated redemption value applying discount rate calculated applying average relevant public company multiples approach premium discount based forecast profits earnings consumer healthcare joint venture forms part gsks consumer healthcare segment remeasurement charge year million including impact us tax reform million see note operating incomeexpense table shows indicative basis income statement balance sheet sensitivity reasonably possible changes key assumptions increasedecrease financial liability lossgain income statement increase sales forecasts sales multiple applied decrease sales forecasts sales multiple applied cent appreciation us dollar cent depreciation us dollar cent appreciation euro cent depreciation euro pfizers put option shareholding viiv healthcare recognised currently exercisable table shows indicative basis income statement balance sheet sensitivity pfizer put option reasonably possible changes key assumptions increasedecrease financial liability lossgain income statement increase sales forecasts decrease sales forecasts cent appreciation us dollar cent depreciation us dollar cent appreciation euro cent depreciation euro explanation accounting viiv healthcare set gsk annual report notes financial statements continued pensions postemployment benefits pension postemployment costs uk pension schemes us pension schemes overseas pension schemes unfunded postretirement healthcare schemes analysed funded defined benefithybrid pension schemes unfunded defined benefit pension schemes unfunded postretirement healthcare schemes defined benefit schemes defined contribution pension schemes costs defined benefit pension postretirement healthcare schemes charged income statement follows cost sales selling general administration research development gsk entities operate pension arrangements cover groups material obligations provide pensions retired employees arrangements developed accordance local practices countries concerned pension benefits provided state schemes defined contribution schemes whereby retirement benefits determined value funds arising contributions paid respect employee defined benefit schemes whereby retirement benefits based employee pensionable remuneration length service pension costs defined benefit schemes accounting purposes calculated using projected unit method certain countries pension benefits provided unfunded basis administered trustee companies formal independent actuarial valuations groups main plans undertaken regularly normally least every three years actuarial movements year recognised statement comprehensive income discount rates derived aa rated corporate bond yields except countries deep market corporate bonds government bond yields used discount rates selected reflect term expected benefit payments projected inflation rate pension increases longterm predictions based yield gap longterm indexlinked fixed interest gilts uk mortality rates determined adjusting saps standard mortality tables reflect recent scheme experience rates projected reflect improvements life expectancy line cmi projections longterm rate improvement per year males females us mortality rates calculated using rp white collar table adjusted reflect recent experience rates projected using mp allow future improvements life expectancy gsk annual report strategic report governance remuneration financial statements investor information pensions postemployment benefits continued average life expectancy assumed individual age projected apply individual age follows uk us male female male female years years years years current projected assets funded schemes generally held separately administered trusts either specific assets proportion general fund insurance contracts assets invested different classes order maintain balance risk return investments diversified limit financial effect failure individual investment group reviewed investment strategy uk plans asset allocation uk plans adjusted approximately return seeking assets liability matching assets target asset allocation us plans also updated return seeking assets liability matching assets pension plans exposed risk arises estimated market value plans assets might decline investment returns might reduce estimated value plans liabilities might increase line agreed mix return seeking assets generate future returns liability matching assets better match future pension obligations group defined overall longterm investment strategy plans investments across broad range assets main market risks within asset hedging portfolio credit risk interest rates longterm inflation equities property bank counterparty risk plan liabilities series future cash flows relatively long duration ias r basis cash flows sensitive changes expected longterm inflation rate discount rate aa corporate bond yield curve increase longterm inflation corresponds increase liabilities increase discount rate corresponds decrease liabilities uk defined benefit pension schemes operated benefit former glaxo wellcome employees former smithkline beecham employees remain separate schemes closed new entrants subsequent uk employees entitled join defined contribution scheme us former glaxo wellcome smithkline beecham defined benefit schemes merged addition group operates number postretirement healthcare schemes principal one us group applied following financial assumptions assessing defined benefit liabilities uk us rest world pa pa pa pa pa pa pa pa pa rate increase future earnings discount rate expected pension increases na na na cash balance creditconversion rate na na na inflation rate gsk annual report notes financial statements continued pensions postemployment benefits continued amounts recorded income statement statement comprehensive income three years ended december relation defined benefit pension postretirement healthcare schemes follows postretirement pensions benefits uk us rest world group group amounts charged operating profit current service cost past service cost net interest cost expenses remeasurement gainslosses recorded statement comprehensive income postretirement pensions benefits uk us rest world group group amounts charged operating profit current service cost past service cost net interest cost gains settlements expenses remeasurement losses recorded statement comprehensive income postretirement pensions benefits uk us rest world group group amounts charged operating profit current service cost past service costcredit net interest cost lossesgains settlements expenses remeasurement gainslosses recorded statement comprehensive income amounts included within past service costs include million million million augmentation costs million arising major restructuring programmes see note provisions gsk annual report strategic report governance remuneration financial statements investor information pensions postemployment benefits continued summarised balance sheet presentation group defined benefit pension schemes postretirement benefits set table recognised noncurrent assets pension schemes surplus recognised pensions postemployment benefits pension schemes deficit postretirement benefits fair values assets liabilities uk us defined benefit pension schemes together aggregated data defined benefit pension schemes group follows uk us rest world group december equities listed unlisted multiasset funds property unlisted corporate bonds listed unlisted government bonds listed insurance contracts assets fair value assets present value scheme obligations net surplusobligation included noncurrent assets included pensions postemployment benefits actual return plan assets multiasset funds comprise investments pooled investment vehicles invested across range asset classes increasing diversification within growth portfolio indexlinked gilts held part uk repo programme included government bonds related loan included within assets value million million million uk us rest world group december equities listed unlisted multiasset funds property unlisted corporate bonds listed unlisted government bonds listed insurance contracts assets fair value assets present value scheme obligations net obligation included noncurrent assets included pensions postemployment benefits actual return plan assets gsk annual report notes financial statements continued pensions postemployment benefits continued uk us rest world group december equities listed unlisted multiasset funds property unlisted corporate bonds listed unlisted government bonds listed insurance contracts assets fair value assets present value scheme obligations net obligation included noncurrent assets included pensions postemployment benefits actual return plan assets postretirement pensions benefits uk us rest world group group movements fair values assets assets january exchange adjustments additions business combinations interest income expenses settlements curtailments remeasurement employer contributions scheme participants contributions benefits paid assets december exchange adjustments interest income expenses settlements curtailments remeasurement employer contributions scheme participants contributions benefits paid assets december exchange adjustments interest income expenses settlements curtailments remeasurement employer contributions scheme participants contributions benefits paid assets december group made special funding contributions uk pension schemes totalling million million million million nil million us scheme gsk reached agreement trustees uk pension schemes make additional contributions eliminate pension deficit identified december actuarial funding valuation based funding agreements following valuation additional contributions eliminate pension deficit expected million contributions based government bond yield curve approach selecting discount rate rate chosen included allowance expected investment returns reflected asset mix schemes employer contributions including special funding contributions estimated approximately million respect defined benefit pension schemes million respect postretirement benefits gsk annual report strategic report governance remuneration financial statements investor information pensions postemployment benefits continued postretirement pensions benefits uk us rest world group group movements defined benefit obligations obligations january exchange adjustments additions business combinations service cost past service cost interest cost settlements curtailments remeasurement scheme participants contributions benefits paid obligations december exchange adjustments service cost past service cost interest cost settlements curtailments remeasurement scheme participants contributions benefits paid obligations december exchange adjustments service cost past service cost interest cost settlements curtailments remeasurement scheme participants contributions benefits paid obligations december defined benefit pension obligation analysed follows funded unfunded liability us postretirement healthcare scheme assessed using assumptions us pension scheme together assumption future medical inflation grading thereafter december us postretirement healthcare scheme obligation million million million postretirement benefits unfunded gsk annual report notes financial statements continued pensions postemployment benefits continued movement net defined benefit liability follows january exchange adjustments additions business combinations service cost past service cost interest cost settlements curtailments remeasurements return plan assets excluding amounts included interest gain change demographic assumptions lossgain change financial assumptions experience lossesgains employer contributions expensesother movements december remeasurements included within postretirement benefits detailed gain change demographic assumptions lossgain change financial assumptions experience gainslosses gsk annual report strategic report governance remuneration financial statements investor information pensions postemployment benefits continued defined benefit pension obligation analysed membership category follows active retired deferred postretirement benefit obligation analysed membership category follows active retired deferred weighted average duration defined benefit obligation follows years years years pension benefits postretirement benefits sensitivity analysis effect changes assumptions used benefit obligations annual defined benefit pension post retirement costs decrease discount rate would following approximate effect increase annual pension cost decrease annual postretirement benefits cost increase pension obligation increase postretirement benefits obligation one year increase life expectancy would following approximate effect increase annual pension cost increase annual postretirement benefits cost increase pension obligation increase postretirement benefits obligation increase rate future healthcare inflation would following approximate effect increase annual postretirement benefits cost increase postretirement benefits obligation increase inflation would following approximate effect increase annual pension cost increase pension obligation gsk annual report notes financial statements continued provisions legal major employee restructuring related disputes programmes provisions provisions total january exchange adjustments charge year reversed unused unwinding discount utilised reclassifications movements transfer pension obligations december settled within one year settled one year december legal disputes pharmaceuticals restructuring programme announced group involved substantial number legal october focused rescaling commercial disputes including notification possible claims set operations global support functions certain rdmanufacturing note legal proceedings provisions legal disputes operations across pharmaceuticals addition integration include amounts relating product liability antitrust government restructuring programme initiated following investigations contract terminations self insurance completion novartis transaction ceo strategic environmental cleanup initiatives programme announced july restructuring integration programmes reported together charge year million net reversals one combined major restructuring programme estimated insurance recoveries primarily related provisions product liability cases regarding paxil products provisions staff severance payments made management commercial disputes various government investigations made formal decision eliminate certain positions communicated groups employees affected discount provisions increased million appropriate consultation procedures completed appropriate increased million discount calculated provision made staff severance payments made using riskadjusted projected cash flows riskfree rates return immediately respect product liability claims related certain products pension augmentations arising staff redundancies sufficient history claims made settlements enable million million charged management make reliable estimate provision required year transferred pension obligations provision cover unasserted claims ultimate liability matters may shown note pensions postemployment benefits vary amounts provided dependent upon outcome asset writedowns recognised impairments litigation proceedings investigations possible settlement property plant equipment note property plant negotiations equipment majority amounts provided expected nature groups business number utilised next two years matters may subject negotiation litigation employee related provisions many years litigation proceedings including various appeal employee related provisions include obligations certain medical procedures often take many years reach resolution benefits disabled employees spouses us outofcourt settlement discussions also often protracted december provision benefits amounted group potential settlement discussions number million million employee benefits reflect disputes amounts provided based variety provisions severance costs jubilee awards current assessment progress disputes longservice benefits estimates million amount provided december provisions settled within one year december included provisions insurance provisions million expected nil million nil provision made legal million onerous property lease provisions disputes reimbursed third party insurers million million number provisions discussion legal issues see note legal proceedings including vehicle insurance regulatory matters major restructuring programmes group initiated major change restructuring programme focused opportunities simplify supply chain processes build groups capabilities manufacturing rd restructure european pharmaceuticals business gsk annual report strategic report governance remuneration financial statements investor information noncurrent liabilities accruals deferred income consumer healthcare put option liability payables net debt listing exchange current assets liquid investments cash cash equivalents shortterm borrowings commercial paper bank loans overdrafts obligations finance leases us us medium term note new york stock exchange european medium term note london stock exchange us us medium term note new york stock exchange longterm borrowings us us medium term note new york stock exchange european medium term note london stock exchange european medium term note london stock exchange us us medium term note new york stock exchange us us medium term note new york stock exchange european medium term note london stock exchange european medium term note london stock exchange european medium term note london stock exchange european medium term note london stock exchange european medium term note london stock exchange european medium term note london stock exchange us us medium term note london stock exchange us us medium term note new york stock exchange european medium term note london stock exchange european medium term note london stock exchange us us medium term note new york stock exchange european medium term note london stock exchange obligations finance leases long term borrowings net debt gsk annual report notes financial statements continued net debt continued current assets liquid investments classified availableforsale investments december included us treasury notes government bonds effective interest rate liquid investments december approximately approximately liquid investment balances december earning interest floating rates amount million million liquid investment balances december earning interest fixed rates amount nil million nil effective interest rate cash cash equivalents december approximately approximately cash cash equivalents december earning interest floating fixed rates amount million million respectively million million gsks policy regarding credit quality cash cash equivalents referred note financial instruments related disclosures shortterm borrowings gsk billion billion us commercial paper programme billion billion issue december billion billion gsk also billion five year committed facilities billion billion day committed facilities fiveyear committed facilities agreed september extended one year september day committed facilities agreed august liquid investments cash cash equivalents shown table weighted average interest rate commercial paper borrowings december weighted average interest rate current bank loans overdrafts december average effective preswap interest rate notes classified short term december longterm borrowings yearend gsk longterm borrowings billion billion billion billion falls due five years average effective preswap interest rate notes issue december approximately approximately longterm borrowings repayable five years carry interest effective rates repayment dates ranging pledged assets group held pledged investments us treasury notes par value million million million million security irrevocable letters credit issued groups behalf respect groups selfinsurance activity provisions respect selfinsurance included within provisions legal disputes discussed note provisions addition million million assets included note noncurrent assets form part net debt pledged collateral future rental payments operating lease arrangements entered human genome sciences inc prior acquisition group finance lease obligations rental payments due within one year rental payments due one two years rental payments due two three years rental payments due three four years rental payments due four five years rental payments due five years total future rental payments future finance charges total finance lease obligations contingent liabilities december contingent liabilities comprising guarantees discounted bills items arising normal course business amounted million million december million million financial assets pledged collateral contingent liabilities provision made outcome tax legal disputes probable group suffer outflow funds possible make reliable estimate outflow december disputes provision made possible make reliable estimate potential outflow funds might required settle disputes possibility outflow remote descriptions significant tax legal disputes group party set note taxation note legal proceedings gsk annual report strategic report governance remuneration financial statements investor information share capital share premium account share ordinary shares p premium number share capital authorised december december december share capital issued fully paid january issued employee share schemes december issued employee share schemes ordinary shares acquired esop trusts december issued employee share schemes ordinary shares acquired esop trusts december december december number shares issuable employee share schemes number unissued shares option december issued share capital shares held esop trusts shares held treasury shares shares free issue issued shares fully paid nominal carrying market values shares held esop trusts disclosed note employee share schemes gsk annual report notes financial statements continued movements equity retained earnings reserves amounted million december million million million million million relates joint ventures associated undertakings cumulative translation exchange equity follows net translation exchange included non total retained fair value controlling translation earnings reserve interests exchange january exchange movements overseas net assets december exchange movements overseas net assets december exchange movements overseas net assets reclassification exchange liquidation disposal overseas subsidiaries december analysis comprehensive income equity category follows non retained controlling earnings reserves interests total items may subsequently reclassified income statement exchange movements overseas net assets net investment hedges reclassification exchange liquidation disposal overseas subsidiaries fair value movements availableforsale investments reclassification fair value movements availableforsale investments deferred tax fair value movements availableforsale investments deferred tax reversed reclassification available sale investments fair value movements cash flow hedges items reclassified income statement exchange movements overseas net assets noncontrolling interests remeasurement gains defined benefit plans tax remeasurement gains defined benefit plans comprehensive incomeexpense year non retained controlling earnings reserves interests total items may subsequently reclassified income statement exchange movements overseas net assets net investment hedges fair value movements availableforsale investments reclassification fair value movements availableforsale investments deferred tax reversed reclassification availableforsale investments reclassification cash flow hedges income statement fair value movements cash flow hedges deferred tax fair value movements cash flow hedges items reclassified income statement exchange movements overseas net assets noncontrolling interests remeasurement losses defined benefit plans tax remeasurement losses defined benefit plans comprehensive income year gsk annual report strategic report governance remuneration financial statements investor information movements equity continued non retained controlling earnings reserves interests total items may subsequently reclassified income statement exchange movements overseas net assets net investment hedges fair value movements availableforsale investments deferred tax fair value movements availableforsale investments reclassification fair value movements availableforsale investments deferred tax reversed reclassification availableforsale investments reclassification cash flow hedges income statement fair value movements cash flow hedges share comprehensive expense associates joint ventures items reclassified income statement exchange movements overseas net assets noncontrolling interests remeasurement gains defined benefit plans tax remeasurement gains defined benefit plans comprehensive expenseincome year analysis reserves follows esop trust fair value cash flow shares reserve hedge reserve reserves total january transferred income expense year disposals transferred income expense year impairments net fair value movement year ordinary shares acquired esop trusts writedown shares held esop trusts december transferred income expense year disposals transferred income expense year impairments net fair value movement year ordinary shares acquired esop trusts writedown shares held esop trusts december transferred income expense year disposals transferred income expense year impairments net fair value movement year ordinary shares acquired esop trusts writedown shares held esop trusts december reserves include various nondistributable merger premerger reserves amounting million december million million reserves also include capital redemption reserve created result share buyback programme amounting million december million million gsk annual report notes financial statements continued related party transactions december gsk owned million shares innoviva inc biopharmaceutical company listed nasdaq gsk began recognising innoviva associate september royalties due gsk innoviva year million million december balance payable gsk innoviva million million december gsk held interest japan vaccine co ltd jvc subsidiary glaxosmithkline kk joint venture daiichi sankyo co ltd primarily responsible development marketing certain prophylactic vaccines japan gsk sold million million vaccine products joint venture december trading balance due gsk jvc million million balance payable gsk jvc nil million nil loans million jvc million medicxi ventures lp million index ventures life vi jersey lp remained due gsk december aggregate compensation directors cet given note employee costs adjustments reconciling profit tax operating cash flows profit tax tax profits share tax profits associates joint ventures finance expense net finance income depreciation amortisation intangible assets impairment assets written profit sale businesses profit sale intangible assets profit sale investments associates profit sale equity investments changes working capital increasedecrease inventories increasedecrease trade receivables increase trade payables decreaseincrease receivables contingent consideration paid see note noncash increase contingent consideration liabilities increase payables decreaseincrease pension provisions sharebased incentive plans fair value adjustments cash generated operations gsk annual report strategic report governance remuneration financial statements investor information reconciliation net cash flow movement net debt net debt beginning year decreaseincrease cash bank overdrafts decreaseincrease liquid investments net increase longterm loans net repayment ofincrease shortterm loans net repayment obligations finance leases exchange adjustments noncash movements movement net debt net debt end year january profit reclass december exchange loss ifications disposals cash flow analysis changes net debt liquid investments cash cash equivalents overdrafts debt due within one year commercial paper european us medium term notes debt due one year european us medium term notes net debt analysis changes liabilities financing activities debt due within one year debt due one year hedge borrowings derivative financial instruments financing items interest payable total liabilities financing activities information significant changes net debt see note net debt gsk annual report notes financial statements continued acquisitions disposals details acquisition disposal significant subsidiaries associates joint ventures businesses given business acquisitions business acquisitions business disposals gsk made number small business disposals year net cash consideration million including contingent consideration receivable million profit disposal determined follows total consideration including currency forwards purchase adjustments net assets sold goodwill intangible assets property plant equipment inventory cash cash equivalents net assets transaction costs reclassification exchange comprehensive income profit disposal investment associates joint ventures year gsk made cash investments million associates joint ventures addition gsk sold holdings two associates million cash total cash consideration net book value shares reclassification exchange comprehensive income transaction costs profit disposal cash flows associates associates business jv jv disposals investments disposals cash consideration net deferred consideration received cash cash equivalents divested transaction costs paid cash inflow business acquisitions gsk completed two small business acquisitions cash consideration million paid year acquire hiv rd preclinical discovery stage portfolio bristol myers squibb consideration contingent commercial milestones future sales performance may due initial estimate million recognised contingent consideration intangible assets acquired valued million goodwill million recognised gsk formed galvani bioelectronics limited year acquired intangible assets million cash cash equivalents million verily life sciences llc return shareholding galvani bioelectronics fair value shareholding million gsk also recognised credit million noncontrolling interests representing verilys share net assets contributed business disposals gsk also made number small business disposals year net cash consideration million addition deferred consideration receivable million recognised gsk annual report strategic report governance remuneration financial statements investor information acquisitions disposals continued cash flows business business acquisitions disposals cash consideration paidreceived purchase adjustments cash cash equivalents acquired cash inflow addition gsk made cash investments million associates joint ventures business acquisitions novartis consumer healthcare vaccines businesses threepart interconditional transaction novartis ag involving consumer healthcare vaccines oncology businesses completed march gsk novartis contributed respective consumer healthcare businesses consumer healthcare joint venture noncash transaction gsk equity interest majority control joint venture addition gsk acquired novartis global vaccines business excluding influenza vaccines initial cash consideration billion billion contingent consideration representing subsequent potential milestone payments billion billion arising achievement specified development targets ongoing royalties based future sales performance certain products total amount payable unlimited first milestone million million paid march business acquisitions addition gsk completed one smaller vaccines business acquisition cash consideration million net cash acquired fair value existing investments million represented goodwill million intangible assets million less net liabilities million fair values assets acquired business combinations including goodwill set table novartis consumer novartis healthcare vaccines business business net assets acquired intangible assets property plant equipment inventory trade receivables assets including cash cash equivalents trade payables deferred tax liabilities liabilities noncontrolling interest goodwill consideration settled shares gsk consumer healthcare holdings cash consideration paid purchase adjustments fair value equity investment disposal contingent consideration deferred tax contingent consideration loss settlement preexisting relationships total consideration gsk annual report notes financial statements continued acquisitions disposals continued noncontrolling interest consumer healthcare joint venture calculated applying full goodwill method represents novartis share net assets contributed joint venture together attributable goodwill goodwill businesses acquired represents potential synergies arising combining acquired businesses gsks existing businesses together value workforce acquired majority goodwill recognised expected deductible tax purposes total transaction costs recognised acquisitions novartis amounted million march december turnover million arising novartis consumer healthcare vaccines businesses included group turnover businesses acquired beginning year estimated group turnover would approximately million higher businesses integrated groups existing activities practical identify impact group profit period business disposals oncology gsk divested marketed oncology business related rd activities rights akt inhibitor also granted commercialisation partner rights future oncology products novartis consideration billion million purchase adjustments business disposals gsk also made number small business disposals period net cash consideration million profit disposal businesses determined follows oncology cash consideration including currency forwards purchase adjustments net assets sold goodwill intangible assets property plant equipment inventory cash net assets loss currency forwards booked disposal costs profit disposal associates joint ventures year gsk made cash investments million associates joint ventures addition march gsk sold half shareholding aspen representing issued share capital company million cash result sale group longer considered ability exert significant influence aspen groups remaining investment transferred investments associates investments cash consideration net book value shares reclassification exchange comprehensive income transaction fees items profit disposal business business associates acquisitions disposals jv disposals total cash flows cash consideration paidreceived purchase adjustments cash cash equivalents acquireddivested deferred cash proceeds contingent consideration paid transaction costs cash outflowinflow gsk annual report strategic report governance remuneration financial statements investor information contingent consideration liabilities consideration certain acquisitions includes amounts contingent future events development milestones sales performance group provided fair value contingent consideration follows shionogi viiv novartis healthcare vaccines total january additions business combinations remeasurement income statement cash payments operating cash flows cash payments investing activities movements december additions business combinations remeasurement income statement cash payments operating cash flows cash payments investing activities movements december remeasurement income statement cash payments operating cash flows cash payments investing activities december contingent consideration payable december million million expected paid within one year contingent consideration payable respect novartis vaccines business included sales milestone million settled january consideration payable acquisition shionogiviiv healthcare joint venture novartis vaccines business expected paid number years result total estimated liabilities discounted present values shown shionogi viiv healthcare contingent consideration liability discounted novartis vaccines contingent consideration liability discounted partly partly shionogiviiv healthcare contingent consideration liability calculated based forecast sales performance specified products principally dolutegravir life products table shows indicative basis income statement balance sheet sensitivity reasonably possible changes key inputs valuations contingent consideration liabilities shionogi novartis viiv healthcare vaccines increasedecrease financial liability lossgain income statement increase sales forecasts decrease sales forecasts increase discount rate decrease discount rate increase probability milestone success decrease probability milestone success cent appreciation us dollar cent depreciation us dollar cent appreciation euro cent depreciation euro explanation accounting viiv healthcare set gsk annual report notes financial statements continued noncontrolling interests group two subgroups material noncontrolling interests viiv healthcare limited subsidiaries gsk consumer healthcare holdings limited subsidiaries summarised financial information respect viiv healthcare group gsk consumer healthcare joint venture set viiv healthcare turnover profitloss taxation comprehensive income total comprehensive incomeexpense noncurrent assets current assets total assets current liabilities noncurrent liabilities total liabilities net liabilities net cash inflow operating activities net cash outflow investing activities net cash outflow financing activities increase cash bank overdrafts year financial information relates viiv healthcare group standalone basis impact grouprelated adjustments primarily related recognition preferential dividends profit taxation million loss taxation million loss taxation million stated charging preferential dividends payable gsk shionogi pfizer charge million million million remeasurement contingent consideration payable acquisition former shionogiviiv healthcare joint venture consideration expected paid number years following amounts attributable viiv healthcare group included gsks consolidated statement comprehensive income consolidated statement changes equity consolidated balance sheet total comprehensive incomeexpense year attributable noncontrolling interests dividends paid noncontrolling interests noncontrolling interests consolidated balance sheet gsk annual report strategic report governance remuneration financial statements investor information noncontrolling interests continued consumer healthcare joint venture turnover profitloss taxation comprehensive income total comprehensive income noncurrent assets current assets total assets current liabilities noncurrent liabilities total liabilities net assets net cash inflow operating activities net cash inflowoutflow investing activities net cash outflow financing activities decrease cash bank overdrafts year financial information relates consumer healthcare joint venture standalone basis impact grouprelated adjustments major restructuring charges following amounts attributable consumer healthcare joint venture included gsks consolidated statement comprehensive income consolidated statement changes equity consolidated balance sheet total comprehensive income year attributable noncontrolling interests dividends paid noncontrolling interests noncontrolling interests consolidated balance sheet gsk annual report notes financial statements continued commitments contractual obligations commitments contracted provided financial statements intangible assets property plant equipment investments purchase commitments pensions commitments interest loans finance lease charges commitments related intangible assets include milestone payments dependent successful clinical development meeting specified sales targets represent maximum would paid milestones however unlikely achieved amounts riskadjusted discounted decrease intangible commitments attributable amendments made agreement adaptimmune therapeutics plc reduction commitments third parties ionis pharmaceuticals inc gsk reached agreement trustees uk pension schemes make additional contributions eliminate pension deficit identified december actuarial funding valuation payment million due subsequent year including table includes commitment excludes normal ongoing annual funding requirement uk approximately million group also commitments principally relate revenue payments made licences alliances commitments respect future interest payable loans disclosed taking account effect interest rate swaps commitments noncancellable operating leases disclosed million million provided commitments groups balance sheet commitments noncancellable operating leases rental payments due within one year rental payments due one two years rental payments due two three years rental payments due three four years rental payments due four five years rental payments due five years total commitments noncancellable operating leases gsk annual report strategic report governance remuneration financial statements investor information financial instruments related disclosures gsk uses variety financial instruments finance operations market risk derivative financial instruments manage market risks interest rate risk management operations derivatives principally comprising interest gsks objective minimise effective net interest cost rate swaps foreign exchange forward contracts swaps used balance mix debt fixed floating interest rates swap borrowings liquid assets currencies required time policy interest rate risk management limits amount group purposes manage exposure financial risks floating interest payments prescribed percentage changes foreign exchange rates interest rates operating profit gsk hold issue derivatives speculative purposes foreign exchange risk management gsks treasury policies specifically prohibit activity foreign currency transaction exposures arising external trade transactions financial instruments undertaken manage flows normally hedged foreign currency transaction risks arising underlying business activities exposures arising internal trade flows selectively hedged groups objective minimise exposure overseas operating capital management subsidiaries transaction risk matching local currency income gsks financial strategy supports groups strategic priorities local currency costs possible gsks internal trading regularly reviewed board gsk manages capital transactions matched centrally intercompany payment terms structure group appropriate mix debt equity managed reduce foreign currency risk foreign currency cash capital structure group consists net debt flows hedged selectively including hedges foreign billion see note net debt total equity including exchange risk arising acquisitions disposals assets provided noncontrolling interests billion see possible gsk manages cash surpluses borrowing consolidated statement changes equity requirements subsidiary companies centrally using forward total capital including provided noncontrolling interests contracts hedge future repayments back originating billion currency longterm credit rating standard poors stable order reduce foreign currency translation exposure group outlook moodys investor services moodys seeks denominate borrowings currencies principal stable outlook groups shortterm credit ratings assets cash flows primarily denominated us p standard poors moodys respectively dollars euros sterling borrowings swapped currencies required liquidity risk management gsks policy borrow centrally order meet anticipated borrowings denominated swapped foreign currencies funding requirements strategy diversify liquidity sources match investments overseas group assets may treated using range facilities maintain broad access financial hedge relevant assets forward contracts major markets currencies also used reduce exposure groups investment overseas assets see net investment hedges december gsk billion borrowings section note details repayable within one year held billion cash cash equivalents liquid investments billion held centrally gsk access shortterm finance billion billion us commercial paper programme billion billion issue december billion gsk also billion five year committed facilities billion billion day committed facilities fiveyear committed facilities agreed september extended one year september day committed facilities agreed august facilities undrawn december gsk considers level committed facilities adequate given current liquidity requirements gsk billion european medium term note programme december billion notes issue programme group also billion billion notes issue december us shelf registration gsks borrowings mature dates put options owned minority interest partners viiv healthcare consumer healthcare jv business exercisable reviewing liquidity requirements gsk considers sufficient financing options available put options exercised gsk annual report notes financial statements continued financial instruments related disclosures continued credit risk december million cash categorised held group considers maximum credit risk december unrated subinvestment grade rated counterparties lower million december million bbbbaa million cash transit total groups financial assets exception remaining exposure concentrated overseas banks used local investments comprising equity investments bear cash management investment purposes including million equity risk rather credit risk see details nigeria held united bank africa zenith bank stanbic groups total financial assets december gsks greatest ibtc bank first bank nigeria million btv concentrations credit risk billion citibank aa austria million bank balances deposits held billion one us wholesaler bbbbaa bbbbaa rated counterparties million held bbb billion citibank aa baa rated counterparties including balances deposits million hdfc bank india million state treasuryrelated credit risk bank india banks used local investment purposes gsk sets global counterparty limits gsks banking investment counterparties based longterm credit ratings moodys standard poors usage limits monitored daily gsk actively manages exposure credit risk reducing surplus cash balances wherever possible part gsks strategy regionalise cash management concentrate cash centrally much possible table sets credit exposure counterparties rating liquid investments cash cash equivalents derivatives gross asset position derivative contract considered purpose table although isda agreements amount risk net position counterparty table e sets groups financial assets liabilities offset basis bbba aaaaaa aaaa aa bbbbaa unrated total bank balances deposits us treasury treasury repo money market funds liquidity funds government securities rd party financial derivatives total bbba aaaaaa aaaa aa bbbbaa unrated total bank balances deposits us treasury treasury repo money market funds liquidity funds government securities rd party financial derivatives total credit ratings assigned standard poors moodys respectively opinions two rating agencies differ gsk assigns lower rating two counterparty local rating agency fitch data source available ratings converted global ratings equivalent standard poors moodys using published conversion tables gsk annual report strategic report governance remuneration financial statements investor information financial instruments related disclosures continued gsks centrally managed cash reserves amounted billion following methods assumptions used estimate december available within three months includes fair values billion centrally managed cash held viiv healthcare cash cash equivalents approximates carrying amount owned subsidiary group invested centrally managed liquid assets bank deposits aaaaaa rated us treasury treasury liquid investments based quoted market prices calculated repo money market funds aaaaaa rated liquidity funds based observable inputs case marketable securities based principal amounts case nonmarketable wholesale retail credit risk securities short repricing periods outside us customer accounts groups trade receivables balance investments equity investments traded active market determined reference relevant stock exchange quoted bid us line pharmaceutical companies group price equity investments determined reference sells products small number wholesalers addition current market value similar instruments reference hospitals pharmacies physicians groups sales discounted cash flows underlying net assets three largest wholesalers amounted approximately sales us pharmaceuticals vaccines businesses shortterm loans overdrafts commercial paper december group trade receivables due approximates carrying amount short maturity three wholesalers totalling million instruments million group exposed concentration credit risk longterm loans based quoted market prices case respect wholesalers one european us medium term notes fixed rate encounters financial difficulty could materially adversely borrowings level fair value measurement approximates affect groups financial results carrying amount case floating rate bank loans groups credit risk monitoring activities relating loans wholesalers include review quarterly financial information contingent consideration business acquisitions based standard poors credit ratings development gsk internal present values expected future cash flows risk ratings establishment periodic review credit limits however group believes credit risk provision interest rate swaps foreign exchange forward contracts swaps required excess normal provision bad doubtful debts options based present value contractual cash see note trade receivables flows option valuation models using market sourced data exchange rates interest rates balance sheet date fair value financial assets liabilities table presents carrying amounts fair receivables payables including put options approximates values groups financial assets liabilities december carrying amount december companyowned life insurance policies based cash fair values financial assets liabilities included surrender value price would received sell asset paid transfer lease obligations approximates carrying amount liability orderly transaction market participants fair value investments gsk shares measurement date december employee share ownership plan esop trusts held gsk shares carrying value million million fair value million million based quoted market price shares held esop trusts satisfy future exercises options awards employee incentive schemes carrying value lower cost expected proceeds shares recognised deduction reserves december gsk held treasury shares cost million million deducted retained earnings gsk annual report notes financial statements continued financial instruments related disclosures continued carrying fair carrying fair value value value value notes availableforsale investments liquid investments government bonds investments loans receivables cash cash equivalents trade receivables noncurrent assets scope ias b financial assets fair value profit loss trade receivables noncurrent assets scope ias ab derivatives designated fair value profit loss ade derivatives classified held trading ias ade total financial assets financial liabilities measured amortised cost borrowings excluding obligations finance leases bonds designated hedging relationship bonds bank loans overdrafts commercial paper borrowings total borrowings excluding obligations finance leases f obligations finance leases total borrowings trade payables provisions certain noncurrent liabilities scope ias c financial liabilities fair value profit loss contingent consideration liabilities ac derivatives designated fair value profit loss ade derivatives classified held trading ias ade total financial liabilities net financial assets financial liabilities valuation methodology used measure fair value table described categorised trade receivables noncurrent assets trade payables provisions noncurrent liabilities contingent consideration liabilities reconciled relevant notes gsk annual report strategic report governance remuneration financial statements investor information financial instruments related disclosures continued financial instruments held fair value following tables categorise groups financial assets liabilities held fair value valuation methodology applied determining fair value possible quoted prices active markets used level prices available asset liability classified level provided significant inputs valuation model used based observable market data one significant inputs valuation model based observable market data instrument classified level investments classified level tables comprise equity investments unlisted entities group entered research collaborations also investments emerging life science companies level level level total december financial assets fair value availableforsale financial assets liquid investments investments noncurrent assets financial assets fair value profit loss noncurrent assets trade receivables derivatives designated fair value profit loss derivatives classified held trading ias financial liabilities fair value financial liabilities fair value profit loss contingent consideration liabilities derivatives designated fair value profit loss derivatives classified held trading ias level level level total december financial assets fair value availableforsale financial assets liquid investments investments noncurrent assets financial assets fair value profit loss noncurrent assets derivatives designated fair value profit loss derivatives classified held trading ias financial liabilities fair value financial liabilities fair value profit loss contingent consideration liabilities derivatives designated fair value profit loss derivatives classified held trading ias movements year financial instruments measured using level valuation methods presented january net losses recognised income statement net gains recognised comprehensive income contingent consideration businesses divestedacquired year payment contingent consideration liabilities additions disposals transfers level exchange december gsk annual report notes financial statements continued financial instruments related disclosures continued net losses million million attributable level financial instruments recognised income statement attributable financial instruments held end year losses million million reported operating income income million nil recorded finance income million million arose remeasurement contingent consideration payable acquisition former shionogiviiv healthcare joint venture million million arose remeasurement contingent consideration payable acquisition novartis vaccines business net gains million million attributable level financial instruments reported comprehensive income fair value movements availableforsale investments included net losses million net gains million respect financial instruments held end year financial liabilities measured using level valuation methods december included million million respect contingent consideration payable acquisition former shionogiviiv healthcare joint venture consideration expected paid number years vary line future performance specified products movements certain foreign currencies also included million million respect contingent consideration acquisition novartis vaccines business consideration expected paid number years vary line future performance specified products achievement certain milestone targets movements certain foreign currencies sensitivity analysis balances provided note contingent consideration liabilities b trade receivables noncurrent assets scope ias following table reconciles financial instruments within trade receivables noncurrent assets fall within scope ias relevant balance sheet amounts financial assets predominantly noninterest earning financial instruments within noncurrent assets balance include companyowned life insurance policies nonfinancial instruments include tax receivables pension surplus balances prepayments outside scope ias fair value non fair value non loans financial financial loans financial financial profit loss receivables instruments instruments total profit loss receivables instruments instruments total trade receivables note noncurrent assets note following table shows ageing financial assets past due provision bad doubtful debts made past due days past due days past due days past due days past due days c trade payables provisions noncurrent liabilities contingent consideration liabilities scope ias following table reconciles financial instruments within trade payables provisions noncurrent liabilities contingent consideration liabilities fall within scope ias relevant balance sheet amounts financial liabilities predominantly noninterest bearing accrued wages salaries included within financial liabilities nonfinancial instruments includes payments account tax social security payables provisions arise contractual obligations deliver cash another financial asset outside scope ias fair value fair value financial nonfinancial financial nonfinancial profit loss liabilities instruments instruments total profit loss liabilities instruments instruments total trade payables note provisions note noncurrent liabilities note contingent consideration liabilities note gsk annual report strategic report governance remuneration financial statements investor information financial instruments related disclosures continued derivative financial instruments hedging programmes following table sets fair values derivatives held gsk derivative liabilities million million derivative assets maturity less one year fair value fair value assets liabilities assets liabilities net investment hedges foreign exchange contracts principal amount million million cash flow hedges foreign exchange contracts principal amount million million derivatives designated fair value profit loss foreign exchange contracts principal amount million million embedded derivatives derivatives classified held trading ias total derivative instruments foreign exchange contracts classified held trading ias principal amount foreign exchange contracts absolute total outstanding positions balance sheet date groups foreign exchange contracts periods months less december group held outstanding foreign exchange contracts net asset fair value million million asset less million liability december fair value million net asset million asset less million liability overall decrease net asset fair value due weakening sterling euro strengthening sterling us dollar impacted portion hedging portfolio designated accounting hedge fair value movements taken income statement period offset exchange gains losses related underlying balances fair value hedges december group designated fair value hedges net investment hedges year certain foreign exchange contracts designated net investment hedges respect foreign currency translation risk arising consolidation groups net investment european euro foreign operations shown table carrying value bonds includes million million designated hedging instruments net investment hedges cash flow hedges group entered forward foreign exchange contracts designated cash flow hedges hedging foreign exchange exposure arising euro denominated coupon payments relating notes issued groups european medium term note programme number highly probable forecast transactions denominated us dollars addition group carries balance reserves arose prehedging fluctuations longterm interest rates pricing bonds issued prior years balance reclassified finance costs life bonds gsk annual report notes financial statements continued financial instruments related disclosures continued e offsetting financial assets liabilities financial assets liabilities offset net amount reported balance sheet legally enforceable right offset recognised amounts intention settle net basis realise asset settle liability simultaneously also arrangements meet criteria offsetting still allow related amounts offset certain circumstances bankruptcy termination contract following tables set financial assets liabilities offset subject enforceable master netting arrangements similar agreements offset december december column net amount shows impact groups balance sheet offset rights exercised gross financial financial liabilities net financial related assets assets assets amounts net liabilities offset liabilities offset amount december financial assets trade receivables derivative financial instruments financial liabilities trade payables derivative financial instruments gross financial financial liabilities net financial related assets assets assets amounts net liabilities offset liabilities offset balance december financial assets trade receivables derivative financial instruments financial liabilities trade payables derivative financial instruments amounts meet criteria offsetting balance sheet could settled net certain circumstances principally relate derivative transactions isda international swaps derivatives association agreements party option settle amounts net basis event default party presently legally enforceable right offset amounts offset balance sheet presented separately table gsk annual report strategic report governance remuneration financial statements investor information financial instruments related disclosures continued f debt interest rate repricing table following table sets exposure group interest rates debt including commercial paper maturity analysis fixed rate debt stated contractual maturity floating rate debt interest rate repricing dates purpose table debt defined classes borrowings obligations finance leases total debt total floating fixed rate debt less one year one two years two three years three four years four five years five ten years greater ten years total original issuance profile fixed rate interest floating rate interest total interest bearing noninterest bearing g sensitivity analysis tables illustrate estimated impact income statement equity result hypothetical market movements foreign exchange interest rates relation groups financial instruments range variables chosen sensitivity analysis reflects managements view changes reasonably possible oneyear period foreign exchange sensitivity group operates internationally primarily exposed foreign exchange risk relation sterling movements us dollar euro japanese yen foreign exchange risk arises translation financial assets liabilities functional currency entity holds based groups net financial assets liabilities december weakening strengthening sterling currencies variables held constant illustrated tables tables exclude financial instruments expose group foreign exchange risk risk fully hedged another financial instrument increasedecrease increasedecrease income income income statement impact nonfunctional currency foreign exchange exposures cent appreciation us dollar cent appreciation euro yen appreciation yen increasedecrease increasedecrease income income income statement impact nonfunctional currency foreign exchange exposures cent depreciation us dollar cent depreciation euro yen depreciation yen gsk annual report notes financial statements continued financial instruments related disclosures continued equity impact shown foreign exchange sensitivity relates derivative nonderivative financial instruments hedging groups net investments european euro foreign operations cash flow hedges foreign exchange exposure arising euro denominated coupon payments relating notes issued groups european medium term note programme number highly probable forecast transactions denominated us dollar increasedecrease increasedecrease equity equity equity impact nonfunctional currency foreign exchange exposures cent appreciation us dollar cent appreciation euro increasedecrease increasedecrease equity equity equity impact nonfunctional currency foreign exchange exposures cent depreciation us dollar cent depreciation euro tables present groups sensitivity weakening strengthening sterling relevant currency based composition net debt shown note adjusted effects foreign exchange derivatives part net debt affect future foreign currency cash flows increasedecrease increasedecrease net debt net debt impact foreign exchange movements net debt cent appreciation us dollar cent appreciation euro yen appreciation yen increasedecrease increasedecrease net debt net debt impact foreign exchange movements net debt cent depreciation us dollar cent depreciation euro yen depreciation yen interest rate sensitivity group exposed interest rate risk outstanding borrowings investments changes interest rates affect future cash flows fair values financial instruments majority debt issued fixed interest rates changes floating rates interest significantly affect groups net interest charge although majority cash liquid investments earn floating rates interest table hypothetically shows groups sensitivity changes interest rates relation sterling us dollar euro floating rate financial assets liabilities interest rates applicable floating rate financial assets liabilities increased basis points assuming variables remained constant estimated groups finance income would increased approximately million million increase basis points movement interest rates deemed material effect equity increasedecrease increasedecrease income income income statement impact interest rate movements basis points increase sterling interest rates basis points increase us dollar interest rates basis points increase euro interest rates gsk annual report strategic report governance remuneration financial statements investor information financial instruments related disclosures continued h contractual cash flows nonderivative financial liabilities derivative instruments following tables provides analysis anticipated contractual cash flows including interest payable groups nonderivative financial liabilities undiscounted basis group use interest rate swaps manage interest rate risk purpose table debt defined classes borrowings except obligations finance leases interest calculated based debt held december without taking account future issuance floating rate interest estimated using prevailing interest rate balance sheet date cash flows foreign currencies translated using spot rates december contractual cash flows respect operating lease vacant space provisions excluded table included commitments noncancellable operating leases table note commitments obligations finance charge trade payables interest finance obligations liabilities debt debt leases finance leases net debt total december due less one year one two years two three years three four years four five years five ten years greater ten years gross contractual cash flows finance charge trade payables obligations obligations interest finance finance liabilities debt debt leases leases net debt total december due less one year one two years two three years three four years four five years five ten years greater ten years gross contractual cash flows increase contractual cash flows nonderivative financial liabilities due less one year billion decrease cash flows due one two years billion principally reflect move consumer healthcare put option amounts due less one year option relates ability novartis put shares consumer healthcare joint venture gsk certain points commencing march payment likely due several months exercise see note trade payables information consumer healthcare put option anticipated contractual cash flows repayment debt debt interest decreased billion year due reduction issuance commercial paper favourable exchange rate movements us dollar denominated debt table provides analysis anticipated contractual cash flows groups derivative instruments excluding embedded derivatives equity options material using undiscounted cash flows cash flows foreign currencies translated using spot rates december gross cash flows foreign exchange contracts presented purpose table although practice group uses standard settlement arrangements reduce liquidity requirements instruments amounts receivable payable less one year decreased compared december result reduced hedging us commercial paper programme receivables payables receivables payables due less one year one two years gross contractual cash flows gsk annual report notes financial statements continued employee share schemes gsk operates several employee share schemes including share value plan whereby awards granted employees acquire shares ads glaxosmithkline plc cost three year vesting period performance share plan whereby awards granted employees acquire shares ads glaxosmithkline plc cost subject achievement group specified performance targets granting restricted share awards replaced granting options employees cost schemes readily equates potential gain made employee group also operates savings related share option schemes whereby options granted employees acquire shares glaxosmithkline plc discounted price grants restricted share awards normally exercisable end three year vesting performance period awards normally granted employees acquire shares ads glaxosmithkline plc circumstances may settled cash grants savingsrelated share option schemes normally exercisable three years saving accordance uk practice majority options savingsrelated share option schemes granted price market price ruling date grant options historical share option schemes granted market price ruling date grant total charge sharebased incentive plans million million million amount million million million arose share value plan see note employee costs details glaxosmithkline share award schemes share value plan share value plan share awards granted certain employees cost awards vest two half three years performance criteria attached fair value awards determined based closing share price day grant deducting expected future dividend yield duration award shares weighted ads weighted number shares ads issuable number fair value number fair value january awards granted awards exercised awards cancelled december awards granted awards exercised awards cancelled december awards granted awards exercised awards cancelled december performance share plan performance share plan share awards granted directors senior executives cost percentage award vests based upon performance group defined measurement period dividends reinvested period awards granted performance conditions based three equally weighted measures three year performance period adjusted free cash flow tsr rd new product performance fair value awards determined based closing share price day grant tsr performance elements adjusted likelihood condition met assessed time grant awards made million shares weighted fair value million ads weighted fair value december outstanding awards million shares million ads gsk annual report strategic report governance remuneration financial statements investor information employee share schemes continued share options savingsrelated options purposes valuing savingsrelated options arrive share based payment charge blackscholes option pricing model used assumptions used model follows grant grant grant riskfree interest rate dividend yield volatility expected life years years years savingsrelated options grant price including discount share option share option savingsrelated options outstanding schemes shares schemes ads share option schemes weighted weighted weighted number exercise number exercise number exercise price price price december range exercise prices options outstanding year end weighted average market price exercise year weighted average remaining contractual life years years years options million shares granted year savingsrelated share option scheme weighted average fair value december million savingsrelated share options exercisable share options ads options currently exercisable expire exercised july change effective exercise price outstanding options year employee share ownership plan trusts group sponsors employee share ownership plan esop trusts acquire hold shares glaxosmithkline plc satisfy awards made employee incentive plans options granted employee share option schemes trustees esop trusts purchase shares finance provided group way loans contributions treasury shares carrying value million purchased us esop trust satisfy future awards costs running esop trusts charged income statement shares held esop trusts deducted reserves amortised value proceeds receivable employees exercise transfer retained earnings trustees waived rights dividends shares held esop trusts shares held share award schemes number shares nominal value carrying value market value shares held share option schemes number shares nominal value carrying value market value gsk annual report notes financial statements continued principal group companies following represent principal subsidiaries countries incorporation group december equity share capital entities wholly owned group except percentage interest shown otherwise companies incorporated principal country operation except stated england us glaxo group limited block drug company inc glaxo operations uk limited corixa corporation glaxosmithkline capital plc glaxosmithkline capital inc glaxosmithkline consumer healthcare holdings limited glaxosmithkline consumer healthcare lp glaxosmithkline consumer healthcare uk trading limited glaxosmithkline holdings americas inc glaxosmithkline export limited glaxosmithkline llc glaxosmithkline finance plc human genome sciences inc glaxosmithkline holdings limited gsk consumer health inc formerly novartis consumer health inc glaxosmithkline research development limited sr one limited glaxosmithkline services unlimited stiefel laboratories inc glaxosmithkline uk limited viiv healthcare company setfirst limited smithkline beecham limited viiv healthcare limited viiv healthcare uk limited europe others glaxosmithkline biologicals sa belgium glaxosmithkline argentina sa argentina glaxosmithkline pharmaceuticals sa belgium glaxosmithkline australia pty ltd australia glaxosmithkline biologicals sas france glaxosmithkline consumer healthcare australia pty ltd australia glaxosmithkline sante grand public sas france glaxosmithkline brasil limitada brazil laboratoire glaxosmithkline france glaxosmithkline consumer healthcare inc canada viiv healthcare sas france glaxosmithkline inc canada glaxosmithkline consumer healthcare gmbh co kg id biomedical corporation quebec canada germany glaxosmithkline limited china hong kong glaxosmithkline gmbh co kg germany sinoamerican tianjin smith kline french laboratories ltd china gsk vaccines gmbh germany glaxosmithkline consumer healthcare limited india glaxosmithkline consumer healthcare spa italy glaxosmithkline pharmaceuticals limited india glaxosmithkline spa italy glaxosmithkline consumer healthcare japan kk japan gsk vaccines srl italy glaxosmithkline kk japan glaxosmithkline bv netherlands viiv healthcare kabushiki kaisha japan glaxosmithkline consumer healthcare spzoo poland glaxosmithkline pakistan limited pakistan glaxosmithkline pharmaceuticals sa poland glaxo wellcome manufacturing pte ltd singapore gsk services sp z oo poland glaxosmithkline korea limited republic korea glaxosmithkline trading services limited republic ireland glaxosmithkline llaclari sanayi ticaret turkey glaxosmithkline healthcare ao russia glaxosmithkline sa spain laboratorios viiv healthcare sl spain novartis consumer health sa switzerland e xempt provisions section companies act ireland accordance exemptions noted section act subsidiaries disclosed pages exempt provisions also consolidated group financial statements directly held wholly owned subsidiary glaxosmithkline plc subsidiaries associates listed principally affect figures groups financial statements glaxosmithkline capital inc glaxosmithkline capital plc glaxosmithkline llc whollyowned finance subsidiary company company fully unconditionally guaranteed securities issued glaxosmithkline capital inc glaxosmithkline capital plc glaxosmithkline llc see pages complete list subsidiary undertakings associates joint ventures form part financial statements gsk annual report strategic report governance remuneration financial statements investor information legal proceedings group involved significant legal administrative intellectual property proceedings principally product liability intellectual property tax intellectual property claims include challenges validity antitrust governmental investigations well related private enforceability groups patents various products litigation significant matters tax processes well assertions noninfringement matters described group makes provision patents loss cases could result loss patent proceedings regular basis summarised note protection product issue consequences accounting principles policies note provisions loss could significant decrease sales product could materially affect future results operations group group may become involved significant legal proceedings respect possible make reliable estimate flovent hfa expected financial effect could result ultimate february group received paragraph iv resolution proceedings cases appropriate certification teva flovent hfa first paragraph disclosures cases would included note iv certification group received generic provision would made cases pharmaceutical company seeking make ab rated version respect legal proceedings described flovent hfa three patents issue teva alleged generic provision made group version flovent infringe two patents directed actuation unable make reliable estimate expected financial effect indicators metered dose listed orange book teva also stage group believe information alleged us patent patent claims amount sought plaintiffs known would meaningful method treatment formulation containing active respect legal proceedings due number medication propellant known substantially free factors including limited stage proceedings surfactant use hydrofluoroalkane hfa metered dose entitlement parties appeal decision clarity theories inhalers flovent valid reviewing teva complaint liability damages governing law group sue teva patent asked fda remove patent orange book teva produced legal expenses incurred provisions related legal claims evidence showing infringe dose counter patents charged selling general administration costs provisions june group withdrew case teva made taking appropriate legal specialist advice outflow resources considered probable reliable bexseromen b vaccines estimate made likely outcome dispute certain following acquisition novartis vaccines business product liability claims group make provision group took patent litigation originally filed novartis sufficient history claims made settlements enable pfizer inc pfizer uk italy united states related management make reliable estimate provision required meningococcal b men b vaccines various cases novartis cover unasserted claims december groups alleged european patents owned pfizer infringed aggregate provision legal disputes including tax groups vaccine bexsero invalid novartis also matters described note taxation million filed suit pfizer patent infringement alleging pfizers ultimate liability legal claims may vary amounts provided sale vaccine trumenba infringes novartis patents related dependent upon outcome litigation proceedings men b vaccines pfizer filed suit group uk investigations possible settlement negotiations seeking invalidate six uk patents owned group groups position could change time therefore relevance trumenba canada infringement patent assurance losses result outcome covering trumenba april group pfizer entered legal proceedings exceed material amount confidential global settlement resolving matters permits amount provisions reported groups financial company manufacture sell respective men b statements happen could material adverse vaccines impact results operations group reporting period judgements incurred settlements entered gsk annual report notes financial statements continued legal proceedings continued dolutegravirtivicaytriumeq doc generici filed action september court september october viiv healthcare received patent rome seeking declaration italian spc covering kivexa challenge letters hatchwaxman act lupin mylan invalid based upon invalid lamivudine cipla dr reddys labs triumeq cipla dr reddys abacavir combination patent viiv healthcare counterclaimed apotex sandoz tivicay triumeq viiv healthcare lists two infringement italian spc trial action heard patents dolutegravir active ingredient tivicay one q active ingredients triumeq fda orange book one patent june biogaran commenced proceedings france seeking covering molecule dolutegravir expires october revocation french spc covering kivexa trial date second patent claiming certain crystal form dolutegravir expires set action december letters challenged patent crystal form generic companies alleged crystal portugal viiv healthcare initiated arbitration proceedings form patent valid others challenged validity asserted farmoz spc covering kivexa farmoz filed proposed product would infringe crystal form patent marketing approval generic version kivexa arbitration february viiv healthcare filed patent infringement suits date yet scheduled action generic companies us district court february kyowa pharmaceuticals filed nullity action district delaware additionally viiv healthcare also filed suit relating kivexa japan oral hearing trial held certain generic companies us district court japan patent office january decision japan district new jersey us district court district patent office expected west virginia trial date yet set lexiva february viiv healthcare filed patent infringement us patent covering lexiva expired december litigation gilead sciences inc gilead bictegravir product paediatric exclusivity june pursuant us district court district delaware us patent settlement litigation confidential licence agreement mylan canadian federal court canadian patent presently selling generic version lexiva us viiv healthcare alleges gileads triple combination hiv drug containing hiv integrase inhibitor bictegravir infringes product liability viiv healthcares patent covering dolutegravir compounds preclinical clinical trials conducted development include dolutegravirs unique chemical scaffold us potential products determine safety efficacy products canada viiv healthcare seeks financial redress rather use humans following approval regulatory bodies injunctive relief trial date yet set notwithstanding efforts drugs vaccines kivexa introduced marketplace unanticipated safety issues may q q viiv healthcare reached become claimed evident group confidential agreements vale pharmaceuticals lupin currently defendant number product liability lawsuits related sandoz stada zentiva settle various challenges groups pharmaceutical vaccine consumer healthcare validity supplementary protection certificate spc products group able make reliable estimate patent covering combination lamivudine abacavir expected financial effect matters discussed category kivexa certain counterclaims brought viiv healthcare included provision appropriate matters infringement spc settlements brought end provision legal disputes matters litigation arbitration proceedings viiv healthcare group made provision also noted note lupin germany portugal viiv healthcare provisions stada germany italy viiv healthcare sandoz austria germany portugal spain sweden viiv healthcare vale pharmaceuticals portugal viiv healthcare zentiva portugal gsk annual report strategic report governance remuneration financial statements investor information legal proceedings continued avandia seroxatpaxil paxil cr group named product liability lawsuits behalf group received numerous lawsuits claims alleging individuals asserting personal injury claims arising use use paxil paroxetine caused variety injuries avandia economic loss actions also filed seeking lawsuits contain one following allegations restitution penalties consumer protection laws use paxil pregnancy caused congenital malformations federal cases filed group part multidistrict persistent pulmonary hypertension autism ii paxil treatment litigation proceeding pending us district court eastern caused patients commit suicidal violent acts iii district pennsylvania mdl court cases also group failed warn patients could experience certain filed number state courts addition county santa symptoms discontinuing paxil treatment clara california brought action behalf california pregnancy residents pending mdl court alleging violations group reached agreements settle majority us californias false advertising act seeking restitution damages claims relating use paxil pregnancy february civil penalties number claims related use pregnancy february five remaining personal injury cases still pending various courts us remaining lawsuits appeal summary judgement decisions favour group three cases still pending state court california one one federal court pennsylvania four california state federal court california one case state court court kentucky one state court oklahoma one lawsuit joining claims eight plaintiffs state court illinois matters four purported class actions us seeking economic dismissed without payment damages behalf third party payers asserting claims racketeer influenced corrupt organizations act rico singh action alberta canada proposed national class consumer protection laws two plaintiffs voluntarily dismissed action seeks certify class relating birth defects generally actions december mdl court granted groups group awaiting hearing motion singh certify motion summary judgement two remaining plaintiffs case class action another canadian class action jensen claims plaintiffs filed appeal decision us alleging claims paxil ssri use autism filed court appeals third circuit briefing schedule saskatchewan january march court approval set received settlement bartram third class action suit british columbia santa clara county action group filed motion summary judgement basis preemption also acts violence seeking partial summary judgement countys restitution february six pending claims cases claim december mdl court granted groups concerning allegations patients took paroxetine paxil motion countys claims civil penalties remain pending committed attempted commit suicide acts violence five mdl court claims cases us one case canada one us cases dolin involving suicide man allegedly purported class actions canada two took generic paroxetine manufactured mylan resulted active two active cases class certification hearings million verdict plaintiff group appealed held ontario action proceedings adjourned verdict us court appeals seventh circuit december nova scotia court issued order certifying nationwide class users avandia group filed appeal class certification decision gsk annual report notes financial statements continued legal proceedings continued discontinuation secdoj sfo anticorruption enquiries uk longpending group action alleges seroxat caused may uk serious fraud office sfo began formal severe discontinuation symptoms legal services criminal investigation groups commercial operations commission lsc withdrew public funding hundreds number countries including china group cooperating claimants causing termination claims legal responding requests sfo inquiry followed aid agency formerly lsc discharged public funding investigations initiated chinas ministry public security june certificate following recommendation special cases china investigations resulted ruling review panel cases poor prospects success according chinese law gsk china investment co ltd however recently fortitude law engaged gskci offered money property nongovernment purpose resurrecting seroxat group action obtained personnel order obtain improper commercial gains gskci thirdparty funding experts remaining claimants found guilty bribing nongovernment personnel group asked court require thirdparty funder september group reached global resolution provide security litigation costs event plaintiffs lose us securities exchange commission sec regarding december high court ruled favour group secs investigation us foreign corrupt practices act application order claimants litigation funder fcpa groups commercial practices countries outside give security costs sum excess total funding us including china part resolution group agreed committed case trial action scheduled pay civil penalty million us government us commence may department justice doj confirmed concluded zofran investigation groups commercial practices would take plaintiffs allege children suffered birth defects result action group part resolution sec mothers ingestion zofran andor generic ondansetron group agreed certain undertakings including period pregnancyrelated nausea vomiting plaintiffs assert selfmonitoring reporting groups obligations group sold zofran knowing unsafe pregnant women failed resolution continue september warn risks illegally marketed zofran offlabel use course current inquiry sfo requested additional pregnant women february group defendant information group regarding third party advisers engaged personal injury lawsuits us cases part company course china investigations sec multidistrict litigation proceeding mdl district doj also investigating matters following groups massachusetts reporting sfos inquiries group cooperating mdl cases discovery mdl continues monthly responding requests status conferences issues sufficiency group unable make reliable estimate expected pleadings scope discovery addressed group financial effect investigations provision continues seek dismissal individual cases appropriate made brown case pending oregon discovery scheduled us vaccines subpoena trial october remaining nine state court cases february group received subpoena us us eight california still early days attorneys office southern district new york requesting group also defendant four proposed class actions documents relating groups vaccines business group canada significant activity responding subpoena group unable make reliable canadian class actions estimate expected financial effect matter sales marketing regulation provision made groups marketing promotion pharmaceutical vaccine products subject certain governmental us subpoena relating imitrex amerge investigations private lawsuits brought litigants various march group received subpoena us theories law group able make reliable estimate attorneys office southern district new york requesting expected financial effect matters discussed documents relating groups us contracts imitrex category included provision matters amerge group completed response subpoena provision legal disputes except noted group unable make reliable estimate expected financial effect matter provision made matters group made provision also noted note provisions gsk annual report strategic report governance remuneration financial statements investor information legal proceedings continued average wholesale price lamictal attorney general illinois filed suit group purported classes direct indirect purchasers filed suit number pharmaceutical companies claiming damages us district court district new jersey alleging restitution due average wholesale price awp andor wholesale group teva pharmaceuticals unlawfully conspired delay acquisition cost wac price reporting pharmaceutical products generic competition lamictal resulting overcharges covered states medicaid programmes case alleges purchasers entering allegedly anticompetitive reverse group reported caused reported false awp wac payment settlement resolve patent infringement litigation prices turn allegedly caused state medicaid agency separate count accuses group monopolising market reimburse providers money covered medicines june court appeals reversed trial courts agency intended state sought recovery behalf decision dismiss case remanded action back payer behalf instate patients consumers case trial court may trial court denied indirect ongoing trial date yet set group purchaser class plaintiffs motion reconsideration result cidra thirdparty payer litigation indirect purchaser class representatives agreed settlement july number major us healthcare insurers filed suit exit case resolve remaining claims terms group philadelphia pennsylvania county court settlement confidential case continue move forward common pleas seeking compensation reimbursements document production witness depositions regard made medicines manufactured groups former cidra plant claims direct purchasers puerto rico insurers claim group knowingly wellbutrin xl illegally marketed sold adulterated drugs manufactured plaintiffs claimed antitrust injury related allegedly sham patent conditions noncompliant cgmp current good manufacturing litigation filed biovail generic companies pursuing andas practices thirdparty insurers unlawfully generic wellbutrin xl plaintiffs alleged conspiracy delay induced pay suit alleges us federal various generic approval existed biovail group us state law causes action court denied groups motion district court granted summary judgement favour group dismiss discovery scheduled completed claims sole remaining claims matter relate case scheduled trial sometime late plaintiffs allegations group entered anticompetitive antitrustcompetition reverse payment settlement resolve patent infringement certain governmental actions private lawsuits brought litigation district court granted summary judgement favour group alleging violation competition antitrust laws group claims august us court appeals group able make reliable estimate expected third circuit court affirmed trial courts dismissal financial effect matters discussed category plaintiffs case summary judgement august plaintiffs included provision matters provision legal filed motion rehearing en banc third circuit disputes except noted matters group denied september plaintiffs file petition made provision also noted note provisions certiorari asking united states supreme court review decision dismissal action final uk competition markets authority investigation commercial corporate february uk competition markets authority cma issued decision fining group two group defendant certain cases allege violation pharmaceutical companies infringement competition us federal securities erisa laws group able act cma imposed fine million group make reliable estimate expected financial effect well fines totaling million companies matters discussed category included provision relates agreements settle patent disputes group matters provision legal disputes matters potential suppliers generic paroxetine formulations entered group made provision also noted note group terminated agreements provisions issue group believes strong grounds appeal cmas finding competition appeal tribunal cat order overturn fine substantially reduce appeal concluded april cat delivered initial judgement appeal march referring principle points issue court justice eu preliminary ruling matter return cat final judgement provision made matter gsk annual report notes financial statements continued legal proceedings continued securitieserisa class actions stiefel environmental matters december us securities exchange group notified potential responsibility relating commission sec filed formal complaint stiefel past operations past waste disposal practices certain laboratories inc charles stiefel us district court sites primarily us matters subject district florida alleging stiefel principals violated litigation including proceedings initiated us federal state federal securities laws inducing stiefel employees sell governments waste disposal site remediation costs tort shares employee stock plan back company greatly actions brought private parties undervalued price without disclosing employees group advised may responsible party company sold group case stayed approximately sites appear national priority several private actions brought former stiefel employees list created comprehensive environmental response proceeded courts returned active status compensation liability act superfund proceedings early summer unclear case ultimately seek require operators hazardous waste facilities scheduled trial transporters waste sites generators hazardous waste addition sec case one private matter martinolich disposed sites clean sites reimburse us case remains also pending federal district court florida government cleanup costs instances group stayed pending trial sec matter involved alleged generator hazardous waste allegations martinolich case largely track sec although superfund provides defendants jointly matter plaintiff former stiefel employee alleges stiefel severally liable cleanup costs proceedings frequently officers directors violated us employee retirement resolved basis nature quantity waste disposed income security act erisa federal state securities generator site groups proportionate liability laws inducing stiefel employees sell shares cleanup costs substantially determined sites employee stock plan back stiefel greatly undervalued price referred without disclosing employees stiefel sold group groups potential liability varies greatly site site cost investigation study remediation sites could time significant group made provision matters noted note provisions gsk annual report strategic report governance remuneration financial statements investor information financial statements glaxosmithkline plc prepared uk gaap including frs reduced disclosure framework directors statements responsibilities relation companys financial statements directors responsible preparing parent company disclosure information auditors glaxosmithkline plc financial statements remuneration directors office date annual report report accordance applicable law regulations confirmed uk company law requires directors prepare financial far aware relevant audit information statements financial year law directors companys auditors unaware elected prepare parent company financial statements taken steps ought taken accordance united kingdom accounting standards director make aware relevant audit applicable law united kingdom generally accepted accounting information establish companys auditors aware practice company law directors must approve information parent company financial statements unless satisfied give true fair view state affairs parent confirmation given interpreted accordance company profit loss period provisions section companies act preparing financial statements directors required going concern basis assessed principal risks matters considered select suitable accounting policies apply connection viability statement directors considered consistently appropriate adopt going concern basis accounting make judgements accounting estimates reasonable preparing financial statements prudent uk corporate governance code state regard parent company financial statements board considers glaxosmithkline plc applies principles applicable uk accounting standards followed subject complies provisions uk corporate governance material departures disclosed explained parent code maintained financial reporting council described company financial statements corporate governance section pages board considers annual report taken whole fair prepare financial statements going concern basis unless balanced understandable provides information inappropriate presume parent company necessary shareholders assess groups position continue business performance business model strategy directors responsible keeping adequate accounting required financial conduct authoritys listing rules records sufficient show explain companys auditors considered directors statement compliance transactions disclose reasonable accuracy time relation points uk corporate governance code financial position company enable ensure specified review parent company financial statements remuneration report pages comply companies act also responsible safeguarding assets company hence taking reasonable steps prevention detection fraud irregularities philip hampton parent company financial statements year ended chairman december comprising balance sheet year march ended december supporting notes set pages report responsibilities auditors relation parent company financial statements set independent auditors report pages financial statements year ended december included annual report published printed form made available website directors responsible maintenance integrity annual report website accordance uk legislation governing preparation dissemination financial statements access website available outside uk comparable legislation may different strategic report risk sections annual report represent management report include fair review development performance business position company group taken whole together description principal risks uncertainties faces gsk annual report independent auditors report members glaxosmithkline plc report parent company financial statements opinion audit approach opinion glaxosmithkline plcs parent company financial overview statements financial statements materiality give true fair view state parent companys overall materiality million million based affairs december total assets capped allocation group materiality properly prepared accordance united kingdom scope generally accepted accounting practice united kingdom parent company single entity operates one location accounting standards comprising frs reduced areas focus disclosure framework applicable law carrying value investments subsidiaries prepared accordance requirements vaccines contingent consideration liability companies act audited financial statements included within scope audit annual report comprise company balance sheet part designing audit determined materiality december company statement changes equity assessed risks material misstatement financial year ended notes financial statements statements particular looked directors made include description significant accounting policies subjective judgements example respect significant accounting estimates involved making assumptions opinion consistent reporting audit risk considering future events inherently uncertain committee gained understanding legal regulatory framework basis opinion applicable company pharmaceutical industry conducted audit accordance international standards operates considered risk acts company auditing uk isas uk applicable law contrary applicable laws regulations including fraud responsibilities isas uk described auditors designed audit procedures respond risk recognising responsibilities audit financial statements section risk detecting material misstatement due fraud report believe audit evidence obtained higher risk detecting one resulting error fraud sufficient appropriate provide basis opinion may involve deliberate concealment example forgery independence intentional misrepresentations collusion focused remained independent group accordance laws regulations could give rise material misstatement ethical requirements relevant audit financial company financial statements event noncompliance statements uk includes frcs ethical standard including limited companies act uk listing applicable listed public interest entities fulfilled rules uk taxation legalisation tests included ethical responsibilities accordance requirements limited review financial statement disclosures underlying supporting documentation review correspondence best knowledge belief declare nonaudit legal advisors enquiries management review internal services prohibited frcs ethical standard provided audit reports far related financial statements group parent company inherent limitations audit procedures described disclosed note group financial removed noncompliance laws statements provided nonaudit services group regulations events transactions reflected subsidiaries period january financial statements less likely would become aware december identify key audit matters relating irregularities including fraud audits also addressed risk management override internal controls including testing journals evaluating whether evidence bias directors represented risk material misstatement due fraud gsk annual report strategic report governance remuneration financial statements investor information report parent company financial statements continued key audit matters key audit matters matters auditors professional judgement significance audit financial statements current period include significant assessed risks material misstatement whether due fraud identified auditors including greatest effect overall audit strategy allocation resources audit directing efforts engagement team matters comments make results procedures thereon addressed context audit financial statements whole forming opinion thereon provide separate opinion matters complete list risks identified audit key audit matter audit addressed key audit matter carrying value investments subsidiaries evaluated managements assumption whether indicators refer note f parent company financial statements impairment existed comparing net assets subsidiaries december parent companys investment carrying parent company holds fixed asset investments comprising values investments subsidiaries million december million investments net assets lower carrying values considered recoverable value reference investments subsidiaries accounted cost less groups market capitalisation december impairment company balance sheet december valuations implied models including valuation models prepared investments tested impairment impairment indicators acquisitionrelated liabilities goodwill impairment review exist indicators exist recoverable amounts purposes subject audit procedures part investments subsidiaries estimated order determine group audit extent impairment loss impairment loss recognised income statement result work agreed management carrying values investments held parent company supportable management judgement required area impairment context parent company financial statements taken testing particularly determining whether impairment triggers whole arisen trigger need impairment review assessing whether carrying value asset supported recoverable amount determined reference groups market capitalisation valuations implied acquisitionrelated liabilities vaccines contingent consideration liability deployed valuation specialists consider reasonableness refer note h j parent company financial managements assumptions including growth projections statements probability success well integrity accuracy managements model compared sales forecasts independent acquisition vaccines business novartis market analysis board approved long range forecasts also parent company recognised contingent consideration liability verified projections consistent used represents certain future milestone royalty payments estimates including intangible asset impairment models liability includes milestone payments acquired products reaching set revenue development targets considered appropriateness managements judgements probability achieving milestones relation liability required remeasured fair value development progress quantified sensitive liability reporting date based latest forecast expectations different assumptions around probability success probability successful product launches value liability probability success changed verified driven december million million comparative change stage development vaccine carrying value liability based assumptions liability subject significant estimation uncertainty however forecast cash flows discount rates taxation rates based procedures performed comfortable value probability certain vaccines achieving development milestones liability december reasonable context parent company financial statements taken whole reflects managements best estimate time reviewed disclosures liability included group financial statements satisfied disclosures appropriate gsk annual report independent auditors report members glaxosmithkline plc continued report parent company financial statements continued tailored audit scope tailored scope audit ensure performed enough work able give opinion financial statements whole taking account structure parent company accounting processes controls industry operates materiality scope audit influenced application materiality set certain quantitative thresholds materiality together qualitative considerations helped us determine scope audit nature timing extent audit procedures individual financial statement line items disclosures evaluating effect misstatements individually aggregate financial statements whole based professional judgement determined materiality financial statements whole follows overall group materiality million million determined total assets capped allocation group materiality rationale benchmark applied parent company holds groups investments profitoriented strength balance sheet key measure financial health important shareholders since primary concern parent company payment dividends using benchmark total assets therefore appropriate capped million following allocation group audit materiality since parent company component group audit agreed audit risk committee would report misstatements identified audit million million well misstatements amount view warranted reporting qualitative reasons going concern accordance isas uk report follows reporting obligation outcome required report anything material add nothing material add draw attention however draw attention respect directors statement future events conditions predicted financial statements whether directors considered statement guarantee parent companys ability appropriate adopt going concern basis accounting continue going concern preparing financial statements directors identification material uncertainties parent companys ability continue going concern period least twelve months date approval financial statements required report directors statement relating nothing report going concern accordance listing rule r materially inconsistent knowledge obtained audit gsk annual report strategic report governance remuneration financial statements investor information reporting information information comprises information annual nothing report performed review report financial statements auditors report directors statement carried robust assessment thereon directors responsible information principal risks facing parent company statement opinion financial statements cover relation longerterm viability parent company review information accordingly express audit opinion substantially less scope audit consisted except extent otherwise explicitly stated report form making inquiries considering directors process supporting assurance thereon statements checking statements alignment relevant provisions uk corporate governance code connection audit financial statements code considering whether statements consistent responsibility read information knowledge understanding parent company consider whether information materially inconsistent environment obtained course audit listing rules financial statements knowledge obtained audit otherwise appears materially misstated identify code provisions apparent material inconsistency material misstatement nothing report respect responsibility report required perform procedures conclude whether material misstatement financial statements material statement given directors misstatement information based work consider annual report taken whole fair balanced performed conclude material misstatement understandable provides information necessary information required report fact members assess parent companys position nothing report based responsibilities performance business model strategy materially respect strategic report directors report also inconsistent knowledge parent company obtained considered whether disclosures required uk companies course performing audit act included section annual report pages describing based responsibilities described work work audit risk committee appropriately undertaken course audit companies act address matters communicated us audit risk ca isas uk listing rules financial conduct committee authority fca require us also report certain opinions matters directors statement relating parent companys described required isas uk unless otherwise stated compliance code properly disclose departure strategic report directors report relevant provision code specified listing opinion based work undertaken course rules review auditors audit information given strategic report directors directors remuneration report year ended december consistent opinion part directors remuneration report financial statements prepared accordance audited properly prepared accordance applicable legal requirements ca companies act ca light knowledge understanding parent company environment obtained course audit identify material misstatements strategic report directors report ca directors assessment prospects parent company principal risks would threaten solvency liquidity parent company nothing material add draw attention regarding directors confirmation annual report carried robust assessment principal risks facing parent company including would threaten business model future performance solvency liquidity disclosures annual report describe risks explain managed mitigated directors explanation annual report assessed prospects parent company period done consider period appropriate statement whether reasonable expectation parent company able continue operation meet liabilities fall due period assessment including related disclosures drawing attention necessary qualifications assumptions gsk annual report independent auditors report members glaxosmithkline plc continued responsibilities financial statements audit responsibilities directors financial statements use report explained fully directors statement responsibilities report including opinions prepared set directors responsible preparation parent companys members body accordance chapter financial statements accordance applicable part companies act purpose framework satisfied give true fair view giving opinions accept assume responsibility directors also responsible internal control purpose person report determine necessary enable preparation financial shown whose hands may come save expressly agreed statements free material misstatement whether due prior consent writing fraud error companies act exception reporting preparing financial statements directors responsible companies act required report assessing parent companys ability continue going concern opinion disclosing applicable matters related going concern using received information explanations going concern basis accounting unless directors either require audit intend liquidate parent company cease operations realistic alternative adequate accounting records kept parent company returns adequate audit received auditors responsibilities audit financial statements branches visited us objectives obtain reasonable assurance whether financial statements whole free material misstatement certain disclosures directors remuneration specified law whether due fraud error issue auditors report made includes opinion reasonable assurance high level financial statements part directors assurance guarantee audit conducted remuneration report audited agreement accordance isas uk always detect material misstatement accounting records returns exists misstatements arise fraud error considered material individually aggregate could exceptions report arising responsibility reasonably expected influence economic decisions users appointment taken basis financial statements audited financial statements parent company since year ended december following parent companys description responsibilities audit financial inception period total uninterrupted engagement years statements located frcs website wwwfrcorguk covering years ended december december auditorsresponsibilities description forms part auditors year ended december final year engagement report following companys decision rotate external audit matters reported separately group financial statements glaxosmithkline plc year ended december parent company passed resolution accordance section companies act senior statutory auditors name stated pricewaterhousecoopers llp chartered accountants statutory auditors london march gsk annual report strategic report governance remuneration financial statements company balance sheet investor information uk gaap including frs reduced disclosure framework december notes fixed assets investments f current assets trade receivables g cash bank total current assets bank overdrafts trade payables h total current liabilities net current assets total assets less current liabilities provisions liabilities noncurrent liabilities j net assets capital reserves share capital k share premium account k reserves retained earnings january profitloss year changes retained earnings l equity shareholders funds financial statements pages approved board march signed behalf philip hampton chairman glaxosmithkline plc registered number company statement changes equity year ended december share share premium retained total capital account reserves earnings equity january loss attributable shareholders dividends shareholders shares issued employee share schemes treasury shares transferred esop trust december profit attributable shareholders dividends shareholders shares issued employee share schemes treasury shares transferred esop trust december gsk annual report notes company balance sheet uk gaap including frs reduced disclosure framework presentation financial statements b accounting policies description business foreign currency transactions glaxosmithkline plc parent company gsk major global foreign currency transactions recorded exchange rate healthcare group engaged creation discovery ruling date transaction foreign currency assets development manufacture marketing pharmaceutical liabilities translated rates exchange ruling balance products including vaccines overthecounter otc medicines sheet date healthrelated consumer products dividends paid received preparation financial statements dividends paid received included financial statements financial statements prepared using historical period related dividends actually paid cost convention modified include revaluation certain received financial instruments going concern basis prepared accordance financial reporting standard reduced expenditure disclosure framework uk accounting presentation expenditure recognised respect goods services received companies act december comparative supplied accordance contractual terms provision figures december made obligation exists future liability respect past event amount obligation reliably permitted section companies act estimated income statement company presented annual report investments subsidiary companies investments subsidiary companies held cost less company included group financial statements provision impairment also adjusted movements glaxosmithkline plc publicly available contingent consideration following exemptions requirements ifrs applied preparation financial statements impairment investments accordance frs carrying value investments reviewed impairment indication investment might impaired paragraphs b ifrs sharebased payment provision resulting impairment review charged ifrs financial instruments disclosures income statement year concerned paragraphs ifrs fair value measurement share based payments paragraph ias presentation financial statements issuance company subsidiaries grant comparative information requirements respect companys shares represents additional capital contributions paragraph iv ias company subsidiaries additional investment paragraphs f b subsidiaries results corresponding increase shareholders ias presentation financial statements equity additional capital contribution based fair value ias statement cash flows grant issued allocated underlying grants vesting period paragraph ias accounting policies changes accounting estimates errors taxation current tax provided amounts expected paid applying paragraph ias related party disclosures tax rates enacted substantively enacted requirement ias disclose related party transactions balance sheet date entered two members group deferred tax provided full using liability method temporary differences arising tax bases assets accounting convention standards liabilities carrying amounts financial statements balance sheet prepared using historical deferred tax assets recognised extent cost convention complies applicable uk accounting considered recoverable future taxable profits standards deferred tax measured average tax rates expected accounting principles policies apply periods temporary differences preparation balance sheet conformity generally expected realised settled deferred tax liabilities assets accepted accounting principles requires management make discounted estimates assumptions affect reported amounts assets liabilities disclosure contingent assets financial guarantees liabilities date balance sheet actual amounts could liabilities relating guarantees issued company behalf differ estimates subsidiaries initially recognised fair value amortised life guarantee balance sheet prepared accordance companys accounting policies approved board legal disputes described note b policies consistently applied company provides anticipated settlement costs unless otherwise stated outflow resources considered probable reliable estimate may made likely outcome dispute legal expenses arising claims company december provisions legal disputes amounted million million gsk annual report strategic report governance remuneration financial statements investor information c key accounting judgements estimates ultimate liability legal claims may vary amounts legal disputes provided dependent upon outcome litigation company provides anticipated settlement costs proceedings investigations possible settlement negotiations management makes judgement outflow resources position could change time therefore probable reliable estimate made likely outcome assurance losses result outcome legal dispute legal expenses arising claims proceedings exceed amount provisions reported company estimated provisions take account companys financial statements material amount specific circumstances dispute relevant external advice operating profit inherently judgemental could change substantially time fee relating audit dispute progresses new facts emerge company charged operating profit companys directors taken legal advice e dividends established provisions taking account relevant facts circumstances matter accordance accounting directors declared four interim dividends resulting dividend requirements december provisions legal year pence line dividend disputes amounted million million details see note group financial statements dividends f fixed assets investments shares glaxosmithkline services unlimited shares glaxosmithkline holdings one limited shares glaxosmithkline holdings limited shares glaxosmithkline mercury limited capital contribution relating share based payments contribution relating contingent consideration g trade receivables amounts due within one year uk corporation tax recoverable receivables amounts owed group undertakings amounts due one year amounts owed group undertakings h trade payables amounts due within one year creditors contingent consideration payable amounts owed group undertakings company guaranteed debt issued subsidiary companies two receives fees aggregate company outstanding guarantees billion debt instruments billion amounts due subsidiary company relation guarantee fees recovered life bonds disclosed within trade receivables see note g gsk annual report notes company balance sheet uk gaap including frs reduced disclosure framework continued provisions liabilities january exchange adjustments charge year utilised december provisions relate number legal disputes company currently involved j noncurrent liabilities contingent consideration payable contingent consideration relates amount payable acquisition novartis vaccines portfolio current year liability included within trade payables k share capital share premium account share premium ordinary shares p account number share capital authorised december december share capital issued fully paid january issued employee share schemes treasury shares transferred esop trust december issued employee share schemes treasury shares transferred esop trust december december december number shares issuable employee share schemes number unissued shares option december issued share capital shares held esop trusts shares held treasury shares shares free issue issued shares fully paid nominal carrying market values shares held esop trusts disclosed note employee share schemes l retained earnings profit glaxosmithkline plc year million million loss dividends million million gave retained profit million million loss treasury shares purchased year nil effect million treasury shares transferred subsidiary company million retained earnings december stood million million million unrealised million addition billion dividend received company distributable annual report filed april group companies see pages complete list subsidiaries associates joint ventures forms part financial statements ggsskk aannnnuuaall rreeppoorrtt ssttrraatteeggiicc rreeppoorrtt ggoovveerrnnaannccee aanndd rreemmuunneerraattiioonn ffiinnaanncciiaall ssttaatteemmeennttss iinnvveessttoorr iinnffoorrmmaattiioonn investor information section quarterly trend pharmaceuticals vaccines turnover five year record product development pipeline products competition intellectual property principal risks uncertainties share capital share price dividends financial calendar annual general meeting tax information shareholders shareholder services contacts us law regulation group companies glossary terms gsk annual report financial record quarterly trend unaudited analysis group results provided quarter sterling financial year income statement total months q q q q reported reported reported reported reported cer cer cer cer cer turnover pharmaceuticals vaccines consumer healthcare total turnover cost sales selling general administration research development royalty income operating incomeexpense operating profitloss net finance costs profit disposal associates share tax profitslosses associates joint ventures profitloss taxation taxation tax rate profitloss taxation period profit attributable noncontrolling interests profitloss attributable shareholders basic earningsloss per share pence p p p p p diluted earningsloss per share pence p p p p p income statement adjusted total turnover cost sales selling general administration research development royalty income operating profit net finance costs share tax profitslosses associates joint ventures profit taxation taxation tax rate profit taxation period profit attributable noncontrolling interests profit attributable shareholders adjusted earnings per share pence p p p p p calculation adjusted results described gsk annual report strategic report governance remuneration financial statements investor information quarterly trend quarterly trend continued unaudited analysis group results provided quarter sterling financial year income statement total months q q q q reported reported reported reported reported cer cer cer cer cer turnover pharmaceuticals vaccines consumer healthcare total turnover cost sales selling general administration research development royalty income operating incomeexpense operating profitloss net finance costs profit disposal associates share tax profitslosses associates joint ventures profitloss taxation taxation tax rate profitloss taxation period profit attributable noncontrolling interests profitloss attributable shareholders basic earningsloss per share pence p p p p p diluted earningsloss per share pence p p p p p income statement adjusted total turnover cost sales selling general administration research development royalty income operating profit net finance costs share tax profitslosses associates joint ventures profit taxation taxation tax rate profit taxation period profit attributable noncontrolling interests profit attributable shareholders adjusted earnings per share pence p p p p p calculation adjusted results described gsk annual report financial record continued pharmaceutical turnover therapeutic area total us europe international revised growth growth growth growth therapeutic areamajor products cer cer cer cer respiratory anoro ellipta arnuity ellipta avamysveramyst flixotideflovent incruse ellipta nucala relvarbreo ellipta seretideadvair trelegy ellipta ventolin hiv epzicomkivexa juluca selzentry tivicay triumeq immunoinflammation benlysta established pharmaceuticals dermatology augmentin avodart coreg eperzantanzeum imigranimitrex lamictal requip serevent seroxatpaxil valtrex zeffix pharmaceuticals vaccines turnover total us europe international revised growth growth growth growth major products cer cer cer cer meningitis bexsero menveo influenza fluarix flulaval shingles shingrix established vaccines infanrix pediarix boostrix hepatitis rotarix synflorix priorix priorix tetra varilrix cervarix vaccines represents growth actual exchange rates cer represents growth constant exchange rates gsk annual report strategic report governance remuneration financial statements investor information pharmaceutical turnover therapeutic area total us europe international revised growth growth growth growth therapeutic areamajor products cer cer cer cer respiratory anoro ellipta arnuity ellipta avamysveramyst flixotideflovent incruse ellipta nucala relvarbreo ellipta seretideadvair ventolin hiv epzicomkivexa selzentry tivicay triumeq immunoinflammation benlysta established pharmaceuticals dermatology augmentin avodart coreg eperzantanzeum imigranimitrex lamictal requip serevent seroxatpaxil valtrex zeffix pharmaceuticals vaccines turnover total us europe international revised growth growth growth growth major products cer cer cer cer meningitis bexsero menveo influenza fluarix flulaval established vaccines infanrix pediarix boostrix hepatitis rotarix synflorix priorix priorix tetra varilrix cervarix vaccines represents growth actual exchange rates cer represents growth constant exchange rates gsk annual report financial record continued five year record record financial performance provided analysed accordance current reporting practice information included five year record prepared accordance ifrs adopted european union also ifrs issued international accounting standards board comparative information also reported including effect divestments completed revised revised revised revised group turnover geographic region us europe international divestments total turnover including divestments group turnover segment pharmaceuticals vaccines consumer healthcare segment turnover corporate unallocated turnover divestments completed pharmaceuticals turnover respiratory hiv immunoinflammation established pharmaceuticals vaccines turnover meningitis influenza shingles established vaccines consumer healthcare turnover wellness oral care nutrition skin health gsk annual report strategic report governance remuneration financial statements investor information five year record continued financial results total turnover operating profit profit taxation profit taxation pence pence pence pence pence basic earnings per share diluted earnings per share millions millions millions millions millions weighted average number shares issue basic diluted revised revised revised revised financial results adjusted turnover operating profit profit taxation profit taxation pence pence pence pence pence adjusted earnings per share return capital employed return capital employed calculated total profit taxation percentage average net assets year gsk annual report financial record continued five year record continued balance sheet noncurrent assets current assets total assets current liabilities noncurrent liabilities total liabilities net assets shareholders equity noncontrolling interests total equity number employees us europe international manufacturing selling administration research development geographic distribution employees table based location gsks subsidiary companies number employees number permanent employed staff end financial period excludes employees employed managed gsk contract basis exchange rates guide holders ads following tables set periods indicated information exchange rate us dollars sterling reported bank england pm buying rate average rate year calculated average pm buying rates day year average mar feb jan dec nov oct sep high low pm buying rate march us gsk annual report strategic report governance remuneration financial statements investor information pipeline products competition pharmaceuticals vaccines product development pipeline key inlicence alliance relationship third party maa marketing authorisation application europe v iiv healthcare global specialist hiv company nda new drug application us gsk pfizer inc shionogi limited shareholders phase e valuation clinical pharmacology usually conducted responsible developing delivering hiv medicines volunteers optionbased alliance ionis pharmaceuticals inc phase ii etermination dose initial evaluation efficacy month first submission conducted small number patients onth first regulatory approval maa first phase iii l arge comparative study compound versus placebo eu approval letter andor established treatment patients establish bla biological licence application clinical benefit safety maa ndabla regulatory review milestones shown table achieved future filing dates included list achieved regulatory review milestones compound type indication phase maa ndabla hiv infectious diseases dolutegravir hiv integrase strand transfer inhibitor non hiv infection virologically suppressed patientsapproved may nov rilpivirine nucleoside reverse transcriptase inhibitor nnrti tafenoquine aminoquinoline plasmodium vivax malaria submitted nov dectova zanamivir ivneuraminidase inhibitor iv influenza submitted nov dolutegravir hiv integrase strand transfer inhibitor nucleoside hiv infection iii lamivudine reverse transcriptase inhibitor nrti fostemsavir hiv attachment inhibitor hiv infection iii cabotegravir hiv integrase strand transfer inhibitor longacting hiv preexposure prophylaxis iii cabotegravir hiv integrase strand transfer inhibitor non hiv infection iii rilpivirine nucleoside reverse transcriptase inhibitor nnrti longacting regimen gepotidacin type topoisomerase inhibitor bacterial infections ii hbv antisense oligonucleotide hepatitis b ii hbv lica antisense oligonucleotide hepatitis b ii cci viral replication inhibitor nucleoside viral exacerbations copd hiv maturation inhibitor hiv infection leucyl trna synthetase inhibitor tuberculosis respiratory mepolizumab interleukin il monoclonal antibody eosinophilic granulomatosis polyangiitis approved adec trelegy fluticasone glucocorticoid agonist longacting beta chronic obstructive pulmonary disease copd approved anov asep furoate vilanterol agonist muscarinic acetylcholine antagonist umeclidinium mepolizumab interleukin il monoclonal antibody copd submitted snov fluticasone furoate glucocorticoid agonist longacting beta asthma iii vilanterol agonist muscarinic acetylcholine antagonist umeclidinium mepolizumab interleukin il monoclonal antibody hypereosinophilic syndrome iii mepolizumab interleukin il monoclonal antibody nasal polyposis iii nemiralisib phosphatidylinositol kinase delta pik inhibitor copd acute chronic ii danirixin chemokine cxc motif receptor cxcr copd ii antagonist oral recombinant human angiotensin converting acute lung injury ii enzyme rhace tumour necrosis factor receptor tnfr acute lung injury ii domain antibody tolllike receptor tlr agonist asthma ii nemiralisib phosphatidylinositol kinase delta pik inhibitor activated pik delta syndrome ii interleukin r ilr monoclonal antibody severe asthma ii recombinant human angiotensin converting pulmonary arterial hypertension enzyme rhace gsk annual report pipeline products competition continued pharmaceuticals vaccines product development pipeline continued achieved regulatory review milestones compound type indication phase maa ndabla respiratory continued alpha v beta integrin antagonist idiopathic pulmonary fibrosis nemiralisib phosphatidylinositol kinase delta bronchiectasis pik inhibitor phosphatidylinositol kinase delta copd pik inhibitor interleukin il longacting asthma monoclonal antibody oncology nyeso autologous engineered sarcoma multiple myeloma nonsmall cell lung cancer ii tcrt cells engineered tcr melanoma ovarian cancer bcell maturation antigen antibody multiple myeloma ii drug conjugate bet family bromodomain inhibitor solid tumours haematological malignancies ox agonist monoclonal antibody solid tumours haematological malignancies protein arginine methyltransferase cancer prmt inhibitor induced tcell costimulator icos cancer agonist antibody tolllike receptor tlr agonist cancer phosphatidylinositol kinase pik beta castration resistant prostate cancer inhibitor immunoinflammation benlysta b lymphocyte stimulator monoclonal systemic lupus erythematosus approved nov jul antibody sc granulocyte macrophage colony osteoarthritis ii stimulating factor monoclonal antibody granulocyte macrophage colony rheumatoid arthritis ii stimulating factor monoclonal antibody benlysta rituxan b lymphocyte stimulator monoclonal sjogrens syndrome ii antibody sc cluster differentiation cd monoclonal antibody iv receptorinteracting protein rip psoriasis ii kinase inhibitor receptorinteracting protein rip rheumatoid arthritis ii kinase inhibitor oncostatin osm monoclonal antibodysystemic sclerosis ii receptorinteracting protein rip ulcerative colitis ii kinase inhibitor lymphocyte activation gene lag autoimmune disease protein monoclonal antibody receptorinteracting protein rip inflammatory bowel diseases kinase inhibitor kynurenine monooxygenase inhibitor acute pancreatitis future pipeline optionality daprodustat prolyl hydroxylase inhibitor oral anaemia associated chronic renal disease iii dezamizumab serum amyloid p component sap amyloidosis ii monoclonal antibody sap depleter cphpc oxytocin inhaled oxytocin postpartum hemorrhage ii tapinarof nonsteroidal antiinflammatory topical atopic dermatitis ii tapinarof nonsteroidal antiinflammatory topical psoriasis ii selective androgen receptor modulator muscle wasting following strategic review assets rare diseases unit longer included pipeline table future ownership assets consideration gsk annual report strategic report governance remuneration financial statements investor information pharmaceuticals vaccines product development pipeline continued achieved regulatory review milestones compound type indication phase maa ndabla vaccines shingrix recombinant herpes zoster prophylaxis approved nov oct zoster vaccine us submitted eu rotavirus live attenuated pcv rotavirus prophylaxis iii porcine circovirus free mmr live attenuated measles mumps rubella prophylaxis iii us ebola recombinant viral vector ebola haemorrhagic fever prophylaxis ii pneumoniae next recombinant conjugated streptococcus pneumoniae disease prophylaxis ii generation copd recombinant reduction frequency moderate severe ii acute exacerbations copd patients targeting nontypeable haemophilus influenzae moraxella catarrhalis hepatitis c heterologous recombinant viral vectors hepatitis c virus prophylaxis prevention ii establishment chronic infection malaria next generation recombinant malaria prophylaxis plasmodium falciparum ii men abcwy recombinant conjugated meningococcal abcw disease prophylaxis ii adolescents shigella conjugated outer membrane shigella diarrhea prophylaxis ii tuberculosis recombinant tuberculosis prophylaxis ii rsv replicationdefective recombinant respiratory syncytial virus prophylaxis paediatric ii viral vector population flu universal universal inactivated influenza vaccine flu infection prophylaxis broad protection iii multiple seasons hiv recombinant proteins hiv infection prophylaxis ii brand names appearing italics trade marks owned licensed gsk group companies exception rituxan owned biogen inc gsk annual report pipeline products competition continued pharmaceuticals products competition intellectual property major patent expiry dates products compounds indications competitor brands us eu respiratory anoro ellipta umeclidinium bromide copd respimat stiolto vilanterol trifenatate utibronultibro nce nce breezhaler duaklir genuair device device bevespi formulation formulation arnuity ellipta fluticasone furoate asthma qvar pulmicort na asmanex alvesco nce device formulation avamysveramyst fluticasone furoate rhinitis nasonex flixotideflovent fluticasone propionate asthmacopd qvar singulair expired expired diskus device diskus device expired hfadevice hfadevice incruse ellipta umeclidinium bromide copd spiriva handihaler respimat eklira genuair nce nce seebri breezhaler device device formulation formulation nucala mepolizumab severe eosinophilic asthma egpa xolair cinqair fasenra expired relvarbreo ellipta fluticasone furoate asthmacopd symbicort foster vilanterol trifenatate flutiform dulera nce nce device device formulation formulation seretideadvair salmeterol xinafoate asthmacopd symbicort foster expired expired fluticasone propionate flutiform dulera diskus device diskus device expired hfadevice hfadevice serevent salmeterol xinafoate asthmacopd foradil striverdi expired expired respimat onbrez diskus device diskus device breezhaler hfadevice trelegy ellipta fluticasone furoate copd trimbow vilanterol trifenatate nce nce umeclidinium bromide device device formulation formulation ventolin hfa albuterol sulphate asthmacopd generic companies expired hfadevice hfadevice antivirals valtrex valaciclovir genital herpes coldsores shingles famvir expired expired central nervous system lamictal lamotrigine epilepsy bipolar disorder keppra dilantin expired expired imigranimitrex sumatriptan migraine zomig maxalt relpax expired expired seroxatpaxil paroxetine depression various anxiety effexor cymbalta expired expired disorders lexapro cardiovascular urogenital avodart dutasteride benign prostatic hyperplasia proscar flomax expired expired finasteride coreg cr carvedilol phosphate mildtosevere heart failure toprol xl na hypertension left ventricular formulation dysfunction post mi antibacterials augmentin amoxicillinclavulanate common bacterial generic products na expired potassium infections see note financial statements legal proceedings generic competition commenced includes supplementary protection certificates granted multiple countries eu patent term extensions granted us data exclusivity expires eu us gsk annual report strategic report governance remuneration financial statements investor information pharmaceutical products competition intellectual property continued major patent expiry dates products compounds indications competitor brands us eu rare diseases volibris ambrisentan pulmonary hypertension tracleer revatio na immunoinflammation benlysta benlysta sc belimumab systemic lupus erythematosus hiv epzicomkivexa lamivudine abacavir hivaids truvada atripla expired descovy genvoya combination odefsey juluca dolutegravir rilpivitine hivaids genvoya odefsey descovy atripla nce nce lexivatelzir fosamprenavir hivaids prezista kaletra expired reyataz nce selzentrycelsentri maraviroc hivaids isentress intelence prezista nce nce tivicay dolutegravir hivaids isentress prezista reyataz kaletra nce nce biktarvy triumeq dolutegravir lamivudine hivaids atripla descovy abacavir odefsey genvoya nce nce biktarvy vaccines products competition intellectual property major patent expiry dates products compounds indications competitor brands us eu bexsero meningococcal groupb meningitis group b prevention trumenba vaccine boostrix diphtheria tetanus acellular diphtheria tetanus acellular adacel expired expired pertussis pertussis booster vaccination infanrix hexapediarix diphtheria tetanus pertussis prophylaxis diphtheria pentacel pediacel expired polio hepatitis b haemophilus tetanus pertussis polio pentaxim pentavac influenzae type b eu hepatitis b haemophilus hexaxim hexyon influenzae type b eu vaxelis cervarix hpv virus like human papilloma virus gardasil silgard particles vlps type adjuvant mpl aluminium hydroxide fluarix tetra split inactivated influenza seasonal influenza prophylaxis intenza flumist qiv antigens virus subtypes vaxigrip qiv subtype b fluzone qiv fluzone high dose flulaval split inactivated influenza seasonal influenza prophylaxis vaxigrip mutagrip antigens virus subtypes fluzone influvac subtype b aggripal fluad intenza flumist menveo meningococcal group c w meningitis group c w nimenrix menactra conjugate vaccine prophylaxis prepandrix derived split inactivated pandemic hn influenza aflunov vepacel influenza virus antigen prophylaxis adjuvant priorix priorix tetraab live attenuated measles mumps measles mumps rubella mmr ii mmrvaxpro expired varilrixb rubella varicella vaccine chickenpox prophylaxis proquad varivax rotarix human rotavirus rix strain rotavirus prophylaxis rotateq synflorix conjugated pneumococcal prophylaxis invasive prevenar prevnar na polysaccharide disease pneumonia acute otitis media shingrix zoster vaccine herpes zoster zostavax recombinant adjuvanted shingles see note financial statements legal proceedings refers priorix priorix tetra patents varilrix expired generic competition commenced many markets related compoundsindications measles mumps rubella vaccineprophylaxis includes supplementary protection certificates granted b related compound varicella vaccine multiple countries eu patent term extensions granted us gsk annual report pipeline products competition continued consumer healthcare products competition brand products application markets competition wellness respiratory otrivin nasal spray nasal decongestant germany poland afrin merck russia sweden ukraine nasivin merck theraflu tablets syrups cold flu relief russia poland ukraine tylenol cold flu us johnson johnson mucinex reckitt benckiser lemsip reckitt benckiser flonase nasal spray allergy relief us claritin bayer nasacort sanofi flixonase piriton nasal spray tablets allergy relief uk ireland benadryl johnson johnson nicorette us lozenges gum transdermal treatment nicotine withdrawal global nicorette johnson johnson nicoderm patches aid smoking reduction niquitin perrigo nicotinell cessation ex australia pain relief panadol tablets caplets infant paracetamolbased treatment global except us advil pfizer panadol cold syrup drops headache joint pain fever aspirin bayer flu cold symptoms tylenol johnson johnson voltaren topical gel nonsteroidal diclofenac based global except us advil pfizer antiinflammatory aspirin bayer tylenol johnson johnson eno effervescent immediate relief antacid global except us estomazil hypermarca gelusil pfizer tums chewable tablets immediate relief antacid us alkaseltzer bayer gaviscon reckitt benckiser rolaids sanofi oral health sensodyne toothpastes toothbrushes relief dentinal hypersensitivity global colgate sensitive prorelief pronamel mouth rinse pronamel additionally protects colgatepalmolive acid erosion elmex colgatepalmolive oral b procter gamble parodontax toothpaste medicated helps prevent bleeding gums germany ireland colgate total gum health corsodyl mouthwash gel spray treats prevents gingivitis italy united kingdom colgatepalmolive yunnan baiyao state enterprise china polident denture adhesive denture improve retention comfort global fixodent kukident poligrip cleanser dentures cleans dentures procter gamble corega steradent reckitt benckiser aquafresh toothpastes toothbrushes aids prevention dental cavities global colgate colgatepalmolive mouthwashes maintains healthy teeth gums crest procter gamble fresh breath oralb procter gamble skin health zovirax topical cream lip care treat prevent global compeed johnson johnson abreva nonmedicated patch onset cold sores carmex carma labs blistex blistex incorporated retail label nutrition horlicks malted drinks foods nutritional indian subcontinent bournvita mondelez beverages food united kingdom ireland complan heinz gsk annual report strategic report governance remuneration financial statements investor information principal risks uncertainties principal risks discussed risks uncertainties similarly global business exposes us litigation government relevant business financial condition results operations investigations including limited product liability litigation may affect performance ability achieve objectives patent antitrust litigation sales marketing litigation risks believe could cause actual litigation government investigations including related provisions results differ materially expected historical results may make unfavourable outcomes increases related costs insurance premiums could materially adversely must adapt comply broad range laws affect financial results regulations requirements apply research development manufacturing testing approval distribution sales marketing detail status various uncertainties involved pharmaceutical vaccine consumer healthcare products significant unresolved disputes potential litigation set affect cost product development also time note legal proceedings pages required reach market likelihood uk regulations require discussion mitigating activities successfully company takes address principal risks uncertainties moreover rules regulations change governmental summary activities group takes manage interpretation rules regulations evolves nature principal risks accompanies description principal particular risk may change changes certain regulatory regimes risk principal risks uncertainties listed may substantial change failure comply order significance applicable law regulations could materially adversely affect financial results patient safety risk definition individual medical officers within pharmaceutical vaccines failure appropriately collect review follow report adverse consumer healthcare businesses substantial safety events potential sources act relevant findings pharmacovigilance organisation keep track adverse issues timely manner reported products course clinical studies group product approved marketing extensive risk impact postmarketing surveillance signal detection system information risk impact potential compromise ability possible side effects products received several sources conduct robust safety signal detection interpretation including unsolicited reports healthcare professionals hcps ensure appropriate decisions taken respect risk patients regulatory authorities medical scientific literature benefit profile products including completeness traditional media social media policy employees accuracy product labels pursuit additional studies required report immediately issues relating safety analyses appropriate could lead potential harm quality products country managers responsible patients reputational damage product liability claims monitoring exception tracking training helps assure litigation governmental investigation regulatory action fines collection safety information reporting information penalties loss product authorisation relevant central safety department accordance policy context legal requirements preclinical clinical trials conducted development information changes riskbenefit profile one investigational pharmaceutical vaccine consumer healthcare products result certain actions characterise communicate products determine safety efficacy products use minimise risk proposed actions discussed humans notwithstanding efforts make determine regulatory authorities include modifying prescribing safety products appropriate preclinical clinical information communications physicians healthcare trials unanticipated side effects may become evident providers restrictions product prescribingavailability help products widely introduced marketplace questions assure safe use sometimes carrying clinical trials safety products may raised certain cases may appropriate stop clinical trials ongoing safety surveillance postmarketing studies also withdraw medicine market governmental agencies third parties may analyse publicly available clinical trial results global safety board gsb comprising senior physicians representatives supporting functions integral component group currently defendant number product liability system gsb including subsidiary boards dedicated lawsuits including class actions involve significant claims consumer healthcare products vaccines reviews safety damages related products litigation particularly us investigational marketed products authority inherently unpredictable class actions seek sweep together stop clinical trial continued conduct trial ethically persons take products increase potential liability scientifically justified light information emerged since claims pain suffering punitive damages frequently start trial asserted product liability actions allowed represent potentially openended exposure thus could materially addition medical governance framework described adversely affect groups financial results use several mechanisms foster early evaluation mitigation resolution disputes arise potential mitigating activities claims even occur goal programmes chief medical officer cmo also medical officer create culture early identification evaluation risks pharmaceuticals responsible medical governance claims actual potential order minimise liability litigation global policy policy safeguarding human subjects clinical trials patients take products paramount importance cmo authoritative role evaluating addressing matters human safety gsk annual report principal risks uncertainties continued product quality risk definition industry standard incorporates quality concepts failure comply current good manufacturing practices throughout product lifecycle gsk pqs augmented cgmp inadequate controls governance quality consolidation numerous regulatory requirements defined supply chain covering supplier standards manufacturing markets across world assures meets external distribution products expectations product quality markets supplied pqs routinely updated ensure keeps pace evolving risk impact external regulatory environment new scientific failure ensure product quality could far reaching understanding products processes part drive implications terms patient consumer safety resulting continually improve operational deployment pqs product launch delays supply interruptions product recalls making policies procedures simpler understand would potential damage reputation implement well adopting innovative tools give well result regulatory legal financial consequences userfriendly experience context extensive global network quality compliance professionals patients consumers hcps trust quality products aligned business unit provide oversight assist product quality may influenced many factors including delivery quality performance operational compliance product process understanding consistency manufacturing site level senior management level management oversight components compliance gmp accuracy labelling reliability activities accomplished hierarchy quality external supply chain embodiment overarching councils independent chief product quality officer quality culture internal external environment continues global product quality office provide corporate evolve new products new legislation introduced executive team risk oversight compliance council critically addressing impact brexit supply integrated assessment regulated quality gxp performance chain management quality oversight uk defined key performance indicators cover manufacturing practice eu developing deploying appropriate contingency clinical practice pharmacovigilance practice regulatory practice plans avoid interruption supply patients drug safety assessment animal welfare mitigating activities implemented riskbased approach assessing developed implemented single pharmaceutical managing third party suppliers provide materials used quality system pqs defines quality standards systems finished products contract manufacturers making products businesses associated pharmaceuticals vaccines expected comply gsk standards regularly consumer healthcare products clinical trial materials audited provide assurance standards met system broad scope applicable throughout product lifecycle rd mature commercial supply staff members regularly trained ensure cgmp standards behaviours based values followed single external quality standard system governs additionally advocacy communication programmes routinely detailed global regulatory expectations quality medicinal deployed ensure consistent messages conveyed across products requirements often complex fragmented across organisation whether originate changes regulation national regional boundaries consequently adopted learnings inspections regulatory submissions internationally recognised principles ich q continued emphasis value quality performance metrics pharmaceutical quality systems framework basis facilitate improvement foster culture right first time gsk pqs financial controls reporting risk definition changes substance application governing tax failure comply current tax laws incurring significant laws failure comply tax laws significant losses due losses due treasury activities failure report accurate financial treasury activities could materially adversely affect information compliance accounting standards applicable financial results legislation context risk impact group required laws various jurisdictions disclose noncompliance existing new financial reporting publicly financial results events could materially affect disclosure requirements changes recognition income financial results group regulators routinely review expenses could expose us litigation regulatory action financial statements listed companies compliance new could materially adversely affect financial results changes revised existing accounting regulatory requirements tax laws application respect matters group believes complies appropriate regulatory transfer pricing foreign dividends controlled companies rd tax requirements concerning financial statements disclosure credits taxation intellectual property restriction tax relief material information including transactions relating business allowed interest debt funding could impact effective restructuring acquisitions divestitures however tax rate significant losses may arise inconsistent application subject investigation potential noncompliance treasury policies transactional settlement errors counterparty accounting disclosure requirements may lead defaults restatements previously reported results significant penalties gsk annual report strategic report governance remuneration financial statements investor information financial controls reporting continued treasury group deals high value transactions mostly foreign shared accountability financial results across exchange cash management transactions daily basis businesses financial results reviewed approved regional transactions involve market volatility counterparty risk management reviewed financial controller groups effective tax rate reflects rates tax jurisdictions chief financial officer cfo allows financial controller group operates higher lower cfo assess evolution business time uk rate takes account regimes encourage innovation evaluate performance plan significant judgments reviewed investment science providing tax incentives confirmed senior management business reorganisations changed could affect groups tax rate addition worldwide newly acquired activities integrated risk assessments nature operations means intellectual property rd appropriate controls reviews applied manufacturing operations centred number key disclosure committee reporting board reviews locations consequence crossborder supply groups quarterly results annual report determines routes necessary ensure supplies medicines numerous throughout year consultation legal advisors whether end markets complex result conflicting claims tax necessary disclose publicly information group authorities profits taxed individual countries tax stock exchange announcements treasury management legislation also complex differs across countries group meets regular basis seek ensure liquidity operate tax risk also arise due differences interest rate counterparty foreign currency transaction foreign interpretation legislation tax charge included currency translation risks managed line conservative financial statements best estimate tax liability pending audits approach detailed associated risk strategies policies tax authorities adopted board expect continued focus tax reform counterparty exposure subject defined limits approved future years driven organisation economic cooperation board credit rating individual counterparties oversight developments base erosion profit shifting project treasurys role managing counterparty risk line agreed european commission initiatives including use fiscal state aid policy performed corporate compliance officer investigations together domestic initiatives around world operates independently treasury details mitigation may result significant changes established tax principles treasury risks found pages note increase tax authority disputes regardless financial instruments related disclosures tax risk managed merit outcomes costly divert management attention robust internal policies processes training compliance may adversely impact reputation relationship key programmes ensure alignment across business stakeholders meet tax obligations seek maintain open positive mitigating activities relationships governments tax authorities worldwide maintain control environment designed identify material welcome constructive debate taxation policy monitor errors financial reporting disclosure design operating government debate tax policy key jurisdictions deal effectiveness key financial reporting controls regularly tested proactively potential future changes tax law engage management via independent business monitoring advisors legal counsel confirm implications provides us assurance controls key financial business tax legislation recently enacted us tax cuts reporting disclosure processes operated effectively jobs act appropriate active providing relevant minimum standard control set implemented whereby business input tax policy makers significant decisions finance personnel irrespective size geographical location submitted consideration tax governance board required apply ensure monitored global finance meets quarterly comprises senior personnel across risk management controls centre excellence provides extra gsks finance division support large group organisations undergoing transformation tax affairs managed global basis coordinated system deployment significant business transformation team tax professionals led global head tax works also added operational resources ensure processes closely business suitably qualified roles controls maintained business transformation upgrade perform support training needs order financial systems processes additional risk mitigation continue able provide date technical advice submit introduced amending programme timelines tax returns according statutory time limits engage tax system upgrades authorities seek ensure tax affairs current entering keep uptodate latest developments financial arrangements continuous audit programmes advance reporting requirements working external auditors pricing agreements appropriate agreements provide legal advisors longterm certainty tax authorities us tax treatment business exceptional cases matters settled agreement tax authorities may resolve disputes formal appeals proceedings gsk annual report principal risks uncertainties continued antibribery corruption risk definition mitigating activities failure gsk employees consultants third parties comply code conduct values behaviours commitment antibribery corruption abac principles standards zero tolerance integral mitigate risk light well applicable legislation complexity geographic breadth risk constantly evolve oversight activities data reinforce workforce clear risk impact expectations regarding acceptable behaviours maintain regular failure mitigate risk could expose group associated communications centre local markets persons governmental investigation regulatory action civil criminal liability may compromise groups ability supply enterprisewide abac programme designed ensure products certain government contracts addition legal compliance abac policies mitigate risk bribery penalties failure prevent bribery complying abac corruption builds values business standards legislation regulations could substantial implications form comprehensive practical approach compliance reputation company credibility senior leaders flexible evolving nature business erosion investor confidence governance risk abac programme built best class principles management subject ongoing review development provides us context basis seek manage risk top exposed bribery corruption risk global bottom example programme comprises toplevel business operations markets government structure commitment board directors leadership global rule law less developed bearing risk assessment enable targeted intervention compliance bribery corruption risk exposure addition global nature monitoring activities programme underpinned global business healthcare sector nature maintains abac policy written standards address commercial relationships government bodies highly competitive practices give rise abac risk ongoing training subject regulation increases instances communications addition programme mandates enhanced exposed activities interactions bribery corruption risk controls interactions government officials business development transactions provide mandatory periodic group subject number abac inquiries abac training staff relevant third parties accordance reached resolution us authorities regarding roles responsibilities risks face abac inquiry following subject selfmonitoring arrangement september government investigations programme governance provided abac governance regarding china business operations ongoing board includes representation key functional areas investigations discussed note legal business units dedicated abac team responsible proceedings implementation evolution programme response developments internal external environment complemented independent oversight assurance undertaken audit assurance independent business monitoring teams continually benchmark abac programme large multinational companies use external expertise drive improvements programme gsk annual report strategic report governance remuneration financial statements investor information commercial practices risk definition mitigating activities failure engage commercial activities consistent strategic objectives designed ensure achieve letter spirit legal industry groups requirements relating mission helping people feel better live longer marketing communications medicines continue strive new product launches competitive associated therapeutic areas appropriate interactions hcps resourced effectively also strive healthy proportion patients legitimate transparent transfer value groups sales ratio attributable new product innovation sales risk impact failure manage risks related commercial practices could innovation helps us defray effect example downward materially adversely affect ability grow diversified global price pressure major markets declining emerging market growth business deliver products value patients negative foreign exchange impact establishing new products consumers failure comply applicable laws rules priced balance expectations patients consumers regulations may result governmental investigation regulatory action hcps payers shareholders community enables us legal proceedings brought group governmental maintain strong global business remain relevant needs private plaintiffs could result government sanctions patients consumers values behaviours provide guide criminal andor financial penalties failure provide accurate lead make decisions constantly strive complete information related products may result incomplete right thing deliver quality products ensure supply awareness riskbenefit profile products possibly sustained meet customer needs demand requirements suboptimal treatment patients consumers seeking ensure actions reflect values behaviours mission company practices found misaligned values could also result reputational harm dilute trust established taken action enhance improve standards external stakeholders procedures promotional interactions including increased focus digital marketing based values transparency respect context integrity patient focus policies standards operate global basis industry highly governing promotional activities undertaken us behalf competitive highly regulated competitors may make activities conduct worldwide must conform high significant product innovations technical advances may ethical regulatory industry standards local standards intensify price competition light competitive environment differ global standards stringent two applies continued development commercially viable new products harmonised policies procedures guide development additional uses existing products reflect country commercial practices processes well clarified insights help ensure products address needs applicable standards operations various markets patientsconsumers hcps payers critical achieve operate business unit adopted internal control strategic objectives framework support assessment management risks pharmaceutical vaccine consumer companies commercial practices activities appropriate monitoring face downward price pressure major markets declining emerging programmes oversight business unit risk market growth negative foreign exchange impact management compliance boards country executive developing new pharmaceutical vaccine consumer healthcare boards manage risks across incountry business activities products costly lengthy uncertain process product past fallen candidate may fail stage including significant economic regulatory industry standards sought improve human resources invested competitors framework culture compliance processes products pricing strategies failure part develop promotional materials activities must reviewed commercially successful products develop additional uses approved according policies standards conducted existing products could materially adversely affect ability accordance local laws regulations seek ensure achieve strategic objectives materials activities fairly represent products services committed ethical responsible commercialisation group necessary disciplined products support mission improve quality including termination employees engaged misconduct human life enabling people feel better live longer broadened ability claw back remuneration accomplish mission engage healthcare community senior management event misconduct various ways provide important information medicines evolved commercial operating model embedding promotion approved products seeks ensure hcps globally industry leading changes compensation model sales access information need patients consumers professionals managers interact hcps access information products need changes eliminated rewards based individual sales market products prescribed recommended used manner share prescription products individuals territories favour provides maximum healthcare benefit patients consumers rewards based quality individuals interactions committed communicating information related hcps allow fair market value payments made approved products responsible legal ethical manner gsk expert researchers practitioners speak science behind products disease clinical practice limited number gsk sponsored medicalled meetings gsk annual report principal risks uncertainties continued research practices risk definition scientific engagement se defined interaction failure adequately conduct ethical sound preclinical exchange information gsk external communities clinical research addition failure engage scientific activities advance scientific medical understanding including consistent letter spirit law industry appropriate development use products essential groups requirements failure secure adequate patent part scientific discourse nonpromotional engagement protection gsks products external stakeholder groups vital gsks mission necessary scientific medical advance se activities essential risk impact present legal regulatory reputational risk sharing data impacts risk include harm human subjects reputational invited media coverage payments hcps perceived damage failure obtain necessary regulatory approvals promotional intent products governmental investigation legal proceedings brought group governmental private plaintiffs product wide variety biological materials used gsk discovery liability suits claims damages loss revenue due research development phases convention inadequate patent protection inability supply gsk products biological diversity cbd nagoya protocol regulatory action fines penalties loss product international community established global framework authorisation consequences could materially regulating access use genetic resources nonhuman adversely affect financial results cause loss trust origin rd support principles access benefit customers patients sharing genetic resources outlined cbd nagoya protocol recognising importance appropriate effective context proportionate implementation measures national regional research relating animals raise ethical concerns levels attempt address proactively animal studies remain vital part research many cases method addition loss patent protection market gsks used investigate effects potential new medicine living products developed rd including reducing body tested humans generally mandated availability scope patent rights compulsory licensing regulators ethically imperative animal research provide government forces manufacturer license patents critical information causes diseases specific products competitor could materially adversely develop nonetheless continually seeking ways affect financial results market absence adequate minimise use animals research whilst complying patent data exclusivity protection could lead regulatory requirements example competition manufacturers generic pharmaceutical products could limit opportunity rely markets clinical trials healthy volunteers patients used assess future sales growth products could also materially demonstrate investigational products efficacy safety adversely impact financial results following expiration certain evaluate product approved intellectual property rights generic manufacturer may lawfully marketing also work human biological samples produce generic version product generic drug samples fundamental discovery development safety manufacturers also exhibited readiness market generic monitoring products versions many important products prior integrity data essential success stages expiration patents introduction generic products typically research data lifecycle design generation recording leads rapid dramatic loss sales reduces management analysis reporting storage retrieval revenues margins proprietary products moreover research data governed legislation regulatory us become common patent infringement actions requirements research data supporting documents core prompt claims antitrust laws violated components various stages pipeline progression decision prosecution patent litigation involving defence making form content regulatory submissions poor data patent integrity compromise research efforts negatively impact company reputation innate complexities interdependencies required regulatory filings particularly given global research development footprint continually changing increasingly stringent submission requirements continue increase complexity worldwide product registration gsk annual report strategic report governance remuneration financial statements investor information research practices continued mitigating activities established access benefit sharing centre established office animal welfare ethics excellence oversee applicable requirements enforcement strategy oawes led chief animal welfare ethics measures acquisition use genetic material non strategy ensures humane responsible care animals human origin scope nagoya protocol increases knowledge application nonanimal rd maintains controls prepublication procedures guard alternatives oawes provides framework animal welfare public disclosure advance filing patent applications governance promotes application rs replacement refinement addition loss patent protection occur due lack reduction animals research conducts quality assessments data integrity preparing patent application data information develops deploys strategies animal model reproducibility legal experts collaborate rd support review process translatability new patent applications chief medical officer oversees following enterprise medical research practices risk aligned new enterprise governance boards framework seeks ensure strengthened governance across human subject research board place provide rd businesses pharmaceuticals vaccines consumer oversight management clinical trials sponsored healthcare leadership chief research practices supported us ensure conform ethical medical officer management risk takes pragmatic approach scientific standards information sharing streamlining risk identification escalation ensuring ownership stays business unit level allows data disclosure board provides oversight disclosure proportional risk treatment sponsored supported clinical trials make information available clinical studies including summaries results whether positive negative first company publish clinical study reports form basis submissions regulatory agencies publicly posted clinical study reports addition study result summaries detailed appropriately protected patientlevel data approximately clinical studies requested accessed clinicalstudydatarequestcom specific accountability authorisation se overseen scientific engagement promotional practices board board responsible oversight applicable policies seeking ensure highest level integrity continuous development se global human biological samples management hbsm governance framework place oversee ethical lawful acquisition management human biological samples global hbsm network champions hbsm activities provides experienced group support internal sample custodians best practice remains important priority enhance data integrity controls data integrity committees place provide oversight data integrity quality assurance team conducts assessments provide independent business monitoring internal controls rd activities chief regulatory officer chairs regulatory governance board serves global regulatory risk management compliance board promoting compliance regulatory requirements procedures oversees groupwide written standards cross business regulatory processes gsk annual report principal risks uncertainties continued third party oversight risk risk definition mitigating activities failure maintain adequate governance oversight third business unit leadership team retains ultimate accountability party relationships failure third parties meet managing third party interactions risks working third contractual regulatory confidentiality obligations parties employees expected manage external interactions commitments responsibly expectation embedded risk impact values code conduct responsibility activities failure adequately manage third party relationships could result carried behalf performed safely compliance business disruption exposure risks ranging suboptimal applicable laws values standards code conduct contractual terms conditions severe business legal sanctions andor significant reputational damage guide enforce global principles interactions third consequences could materially adversely affect business parties place policy framework applicable buying operations financial results goods services managing external spend paying working third parties policy framework applies context employees complementary workers worldwide framework third parties critical business delivery integral complemented technical local standards designed ensure part solution meeting business objectives rely alignment nature third party interactions good third parties including suppliers advisors distributors individual manufacturing practice adherence local laws regulations contractors licensees pharmaceutical biotechnology independent business monitoring key financial operational collaboration partners discovery manufacture marketing controls place supplemented periodic checks products supporting important business processes companys independent audit assurance function business relationships present material risk example continuous monitoring performance third parties enhanced share critical sensitive information marketing plans clinical third party oversight programme managed data employee data specific third parties conducting global ethics compliance organisation programme takes relevant outsourced business activities inadequate protection enterprisewide view third party related risks strengthened misuse information third parties could significant risk assessment contractual terms due diligence efforts third business impact similarly use distributors agents range parties improved overall management third party risks activities promotion tendering inherent risks lifecycle third party engagement inappropriate promotion corruption insufficient internal compliance controls distributors could affect reputation risks increased complexities working large numbers third parties across diverse geographical spread environment health safety sustainability risk definition mitigating activities failure manage environment health safety sustainability corporate executive team cet responsible ehss ehss risks line objectives policies governance global policy policy cet seeks relevant laws regulations ensure control framework place manage risks impacts legal compliance issues relate ehss risk impact assigning responsibility senior managers providing failure manage ehss risks could lead significant harm maintaining controls individual managers seek ensure people environment communities operate fines ehss control framework effective well implemented failure meet stakeholder expectations regulatory requirements respective business area fully compliant litigation regulatory action damage groups reputation applicable laws regulations adequately resourced maintained could materially adversely affect financial results communicated monitored additionally employee context personally responsible ensuring applicable local standard subject health safety environmental laws various operating procedures followed expected take jurisdictions laws impose duties protect people responsibility ehss matters environment communities operate well riskbased proactive approach articulated refreshed potential obligations remediate contaminated sites also global ehss standard supports ehss policy identified potentially responsible party us objective discover develop manufacture supply sell comprehensive environmental response compensation products without harming people environment addition liability act number sites remediation costs relating design provision safe facilities plant equipment use ownership sites us failure manage operate rigorous procedures help us eliminate hazards environmental risks properly could result litigation regulatory practicable protect employees health wellbeing action additional remedial costs may materially continuing efforts improve environmental sustainability adversely affect financial results see note financial reduced value chain carbon intensity per pack water statements legal proceedings discussion consumption waste generation actively manage environmental related proceedings involved environmental remediation obligations seek ensure practices routinely accrue amounts related liabilities matters environmentally sustainable compliant ehss performance results shared externally year responsible business supplement gsk annual report strategic report governance remuneration financial statements investor information information protection risk definition aim apply industry best practices part information risk gsk business activities information becomes disclosed security policies processes technologies invest strategies authorised see information systems fail commensurate changing nature security threat available corrupted typically cybersecurity threats landscape include suitable levels cyberrisk insurance although accident malicious insider action may contributory cover future causes nevertheless cyber threats growing evolving also includes risk failure collect secure use increasingly involve highlyresourced threat actors nation personal information accordance data privacy laws states organised criminals combined size complexity systems supply chain partners risk impact including outsourced operations means systems failure adequately protect critical sensitive systems information expected continue information may result loss commercial strategic advantage subject cyberattacks various types could materially affect ongoing business operations scientific research clinical trials manufacturing supply enhancing approach data privacy compliance part chain activities failure comply data privacy laws could lead comply new eu general data protection regulation adverse impact individuals example financial loss distress gdpr deploying enterprisewide privacy programme prejudice cases damage reputation litigation launched scheduled deployment business disruption including regulatory sanction could occur involve greater standardisation additional expert could materially adversely affect financial results resources support business new standards controls context enable us better address data privacy outset rely critical sensitive systems data corporate business process changes also prepare us strategic plans intellectual property manufacturing systems introduction gdpr may trade secrets potential computer systems employees required complete training privacy information may exposed misuse unauthorised disclosure appropriate handling maintaining personal information believe cyber security incidents programme governance provided privacy governance experienced date resulted significant disruptions board includes representation key functional areas operations significant adverse effect dedicated privacy team responsible results operations third parties however threats implementation evolution programme response evolve provide assurance significant efforts developments internal external environment protecting monitoring systems information always successful preventing compromise disruption future parts business process personal information use information critical operations innovation including development sale products well management employees new evolving laws regulations european union general data protection regulation gdpr likely bring increased scrutiny data management mitigating activities global information protection policy accompanying information technology standards processes supported dedicated team programme activity information protection function provides strategy direction oversight including active monitoring cyber security enhancing global information security capabilities ongoing programme investment fifth year assess changes information protection risk environment briefings government agencies subscription commercial threat intelligence services knowledge sharing pharmaceutical businesses crossindustry bodies changes regularly reviewed executive team board suitable adjustments agreed gsk annual report principal risks uncertainties continued supply continuity crisis management risk definition mitigating activities failure deliver continuous supply compliant finished product supply chain model designed ensure supply quality inability respond effectively crisis incident timely manner security products globally far possible closely recover sustain critical operations including key supply chains monitor supply chain governance committees inventory status delivery products aim ensure risk impact customers pharmaceutical vaccines consumer recognise failure supply products adversely healthcare products need improved links commercial impact consumers patients rely material forecasting manufacturing made possible core interruption supply exclusion healthcare programmes commercial cycle time reduce risk associated could expose us litigation regulatory action financial demand fluctuations impact ability supply penalties could adversely affect groups financial results cost writeoffs products exceed expiry date groups international operations partners node supply chain periodically reviewed ensure adequate expose workforce facilities operations information safety stock balancing working capital endtoend technology potential disruption natural events eg storm supply chain particular attention placed mitigating supply risks earthquake manmade events eg civil unrest terrorism global associated medically critical highrevenue products emergencies eg ebola outbreak flu pandemic important robust crisis management recovery plans place routinely monitor compliance manufacturing external manage events suppliers identify manage risks supply base practical minimise dependence single sources supply context critical items alternative sourcing arrangements supply chain operations subject review approval possible inventory strategy aims protect supply chain various regulatory agencies effectively provide licence unanticipated disruption operate failure manufacturing distribution facilities suppliers key services materials could lead litigation continue implement anticounterfeit systems product regulatory action product recalls seizures interruption serialisation accordance emerging supply chain requirements supply delays approval new products suspension around world manufacturing operations pending resolution manufacturing corporate policy requires business unit functional area logistics issues head ensure effective crisis management business continuity rely materials services provided third party suppliers plans place include authorised response recovery make products including active pharmaceutical ingredients strategies key areas responsibility clear communication api antigens intermediates commodities components routes business disruption occurs manufacture packaging pharmaceutical vaccine corporate security supports business coordinating crisis consumer healthcare products third party services management business continuity training facilitating simulation procured services provided contract manufacturing exercises assessing preparedness recovery capability clinical research organisations support development key providing assurance oversight central repository plans products important ensure continuous operation supporting critical business processes business unit businesses governance board performs risk oversight monitoring although undertake risk mitigation recognise certain including identifying new emerging threats events could nevertheless still result delays service interruptions coordinated approach evaluate manage implications use effective crisis management business continuity business arising brexit approach brexit set planning provide health safety people minimise impact us maintaining functional operations following activities help ensure appropriate level readiness natural manmade disaster public health emergency response capability maintained also develop maintain partnerships external bodies like business continuity institute un international strategy disaster risk reduction helps improve business continuity initiatives disasterprone areas supports development community resilience disasters gsk annual report strategic report governance remuneration financial statements investor information shareholder information share capital control details issued share capital number shares held share buyback programme treasury december found note board authorised issue allot ordinary shares financial statements share capital share premium account article companys articles association power article authority company make purchases ordinary shares listed london stock exchange shares subject shareholder authorities also quoted new york stock exchange nyse sought annual basis annual general meeting agm form american depositary shares ads ads shares purchased company may cancelled held represents two ordinary shares details listed debt treasury shares used satisfying share options grants listed refer note financial statements group employee share plans net debt programme covers purchases shares cancellation holders ordinary shares ads entitled receive held treasury shares accordance authority dividends declared companys annual report attend renewed shareholders agm may speak general meetings company appoint proxies company authorised purchase maximum exercise voting rights million shares details shares purchased cancelled restrictions transfer limitations holding held treasury shares subsequently transferred ordinary shares ads requirements obtain approval treasury satisfy awards groups employee share prior transfers ordinary shares ads carry special plans disclosed note financial statements share rights regard control company capital share premium account restrictions voting rights major shareholders determining specific share repurchase levels company voting rights per share shareholders considers development free cash flow year given known arrangements financial rights held impact sustained strength sterling free cash flow person holder shares known company suspended share repurchase programme agreements restrictions share transfers voting rights shares purchased financial years ended shares acquired groups employee share plans rank equally shares issue special rights company confirms currently intend make trustees employee share ownership plan trusts market purchases company review waived rights dividends shares held trusts potential future share buybacks line exchange controls limitations affecting security holders usual annual cycle subject return ratings criteria certain economic sanctions may force market capitalisation time time currently applicable laws decrees market capitalisation based shares issue excluding regulations force uk restricting import export treasury shares gsk december billion capital affecting remittance dividends payments date gsk sixth largest company market holders companys shares nonresidents uk capitalisation ftse index similarly certain economic sanctions may force time time limitations relating share price nonresidents uk english law companys articles association right holder vote january respect companys shares december interests voting rights decreaseincrease stated far aware high year persons significant direct indirect holdings company low year information provided company pursuant financial conduct authoritys fca disclosure guidance transparency table sets middle market closing prices rules dtrs published regulatory information service companys share price decreased compares companys website wwwgskcom increase ftse index year company received notifications accordance share price march fcas dtrs following notifiable interests voting rights companys issued share capital uk us december march percentage percentage issued issued shares capital shares capital blackrock inc percentage ordinary shares issue excluding treasury shares acquired disposed interests shares period review exception transferred treasury satisfy awards groups employee share plans uk share price uk us ads price us gsk annual report shareholder information continued share capital control continued nature trading market following tables set periods indicated high low middle market closing quotations pence shares london stock exchange high low closing prices us dollars ads nyse ordinary shares ads pence per share us dollars per share high low high low march february january december november october september quarter ended december quarter ended september quarter ended june quarter ended march quarter ended december quarter ended september quarter ended june quarter ended march year ended december year ended december year ended december year ended december year ended december march analysis shareholdings december number total total number accounts accounts shares shares holding shares held nominee companies investment trust companies insurance companies individuals corporate bodies bny nominees limited held treasury shares glaxosmithkline bny mellon depositary companys ads listed nyse ordinary shares representing companys ads programme managed depositary registered name bny nominees limited march bny nominees limited held ordinary shares representing issued share capital excluding treasury shares date march number holders ordinary shares us holdings ordinary shares number registered holders ads holdings ads certain ordinary shares ads held brokers nominees result number holders record registered holders us representative number beneficial holders residence beneficial holders gsk annual report strategic report governance remuneration financial statements investor information dividends company pays dividends quarterly continues return cash shareholders dividend policy dividends remain essential component total shareholder return gsk recognises importance dividends shareholders company aims distribute regular dividend payments determined primarily reference free cash flow generated business funding investment necessary support groups future growth board intends maintain dividend current level p per share subject material change external environment performance expectations time free cash flow strengthens intends build free cash flow cover annual dividend target range x returning dividend growth details dividends declared amounts payment dates given note financial statements dividends dividends per share dividend calendar table sets dividend per share per ads exdividend last five years dividend per ads translated us dollars quarter date record date payment date applicable exchange rates q february february april q may may july year dividend pence us q august august october q november november january special q interim ordinary dividend receivable ads holders calculated based exchange rate april annual fee per ads per ads per quarter charged depository cumulative dividend receivable ads holders q q q special dividend related return part net cash proceeds novartis transaction completed march paid fourth quarter ordinary dividend financial calendar results announcements event date results announcements issued london stock exchange quarter results announcement april available news service also sent annual general meeting may us securities exchange commission nyse issued quarter results announcement july media made available website quarter results announcement october financial reports preliminaryquarter results announcement february company publishes annual report made available annual report publication februarymarch website date publication shareholders may annual report distribution march elect receive annual report contacting registrar alternatively shareholders may elect receive notification information company including share price available email publication financial reports registering website wwwgskcom information made available wwwshareviewcouk website constitute part annual report copies previous financial reports available website printed copies obtained registrar uk see contact details gsk annual report shareholder information continued annual general meeting pm uk time may ads holders wishing attend meeting contact bny queen elizabeth ii centre broad sanctuary westminster mellon depositary request proxy appointment london swp ee enable attend vote business transacted ads holders may instruct bny mellon way agm companys principal forum communication shares represented ads voted completing private shareholders addition formal business returning voting card provided depositary presentation ceo performance group future development opportunity documents display questions asked board chairmen boards articles association company directors service committees take questions relating committees contracts applicable letters appointment directors company subsidiaries side investors holding shares nominee service arrange letters relating severance terms pension arrangements nominee service appointed proxy respect available inspection companys registered office shareholding order attend vote meeting made available inspection agm tax information shareholders summary certain uk tax us federal income tax taxation capital gains consequences holders shares ads citizens uk resident shareholders may liable uk tax gains uk us set complete analysis disposal shares ads possible tax consequences purchase ownership sale disposals individuals uk tax year onwards securities intended general guide holders taxable capital gain accruing disposal shares ads advised consult advisers respect tax taxed basic rate taxpayers allowable consequences purchase ownership sale shares deductions individuals taxable income year exceeds ads consequences state local tax laws basic rate income tax limit note following use us implications current ukus tax conventions exceptions available individual taxpayer annual us holders ads generally treated owners exempt amount underlying shares purposes current usuk double corporation taxpayers may entitled indexation allowance taxation conventions relating income gains income tax applies reduce capital gains extent gains convention estate gift taxes estate gift tax convention arise due inflation indexation allowance may reduce chargeable purposes internal revenue code amended gain create allowable loss assets acquired code january legislation finance bill uk shareholders freezes level indexation allowance given calculating summary applies uk resident shareholder holds companys chargeable gains value would apply shares capital assets disposal asset december assets acquired january onwards legislation finance bill taxation dividends removes indexation allowance disposal uk tax years uk resident individuals entitled dividend tax allowance first inheritance tax dividends received tax year free tax allowance individual ukdomiciled otherwise shareholders may liable reduce uk tax year onwards dividends uk inheritance tax transfer shares ads tax may excess allowance taxed basic rate charged amount value shareholders taxpayers higher rate taxpayers additional estate reduced result transfer way lifetime gift rate taxpayers disposal less full market value case bequest death tax may charged value shares uk resident shareholders corporation taxpayers note date shareholders death gift disposal dividends payable ordinary shares generally entitled subject uk inheritance tax us estate gift tax exemption corporation tax estate gift tax convention would generally provide tax paid us credited tax payable uk gsk annual report strategic report governance remuneration financial statements investor information tax information shareholders continued stamp duty stamp duty reserve tax dividends qualified subject taxation us uk stamp duty andor stamp duty reserve tax sdrt subject federal graduated tax rates maximum rate certain exemptions payable transfer shares rate types dividends automatically excluded qualified rounded nearest case stamp duty dividends even meet requirements include consideration transfer notwithstanding provided limited instrument executed pursuance agreement gave rise capital gains distributions charge sdrt instrument stamped within six years agreement including stamped exempt dividends bank deposits sdrt charge cancelled sdrt already ividends held corporation employee stock paid repaid ownership plan esop us shareholders dividends paid taxexempt corporations summary applies shareholder citizen resident us domestic corporation person us state local tax rates qualified nonqualified dividends otherwise subject us federal income tax net income basis may vary would assessed addition federal tax rates respect shares ads holds shares ads capital communicated assets resident uk uk tax purposes taxation capital gains hold shares purposes trade profession vocation generally us holders subject uk capital gains tax carried uk branch agency subject us tax capital gains realised sale summary also address tax treatment holders disposal shares ads gains longterm capital subject special tax rules banks taxexempt gains subject reduced rates taxation individual holders entities insurance companies dealers securities currencies shares ads held one year date persons hold shares ads part integrated investment shares vestedreleased shortterm capital gains including straddle comprised share ads one subject taxation rates whereas longterm capital positions persons directly indirectly gains may subject rates state local tax voting stock company address tax rates capital gains may also apply treatment may applicable result international income information reporting backup withholding tax treaties dividends payments proceeds sale shares taxation dividends ads paid within us certain usrelated financial gross amount dividends received treated foreign source intermediaries subject information reporting may dividend income us tax purposes eligible dividend subject backup withholding unless us holder corporation received deduction allowed us corporations dividends ads exempt recipient provides taxpayer identification number payable us dollars dividends shares payable certifies loss exemption occurred nonus sterling dividends paid sterling included income holders generally subject information reporting backup us dollar amount calculated reference exchange rate withholding may required provide certification day dividends received holder subject certain nonus status connection payments received amounts exceptions shortterm hedged positions individual eligible withheld allowed refund credit holders us us holder subject us taxation maximum rate federal income tax liability provided required information respect qualified dividends qualified dividend defined furnished internal revenue service us internal revenue service irs dividend meets estate gift taxes following criteria estate gift tax convention us shareholder must issued us corporation corporation incorporated generally subject uk inheritance tax us possession corporation eligible stamp duty benefits comprehensive income tax treaty deemed uk stamp duty andor sdrt subject certain exemptions satisfactory published irs payable transfer shares ads custodian dividends listed irs dividends depository rate amount consideration qualify provided transferred sale value transferred consideration required dividend holding period met shares must owned days however stamp duty sdrt payable transfer holding period defined day period agreement transfer ads begins days exdividend date day stock trades without dividend priced example stocks exdividend date october shares must held days period august november year order count qualified dividend gsk annual report shareholder information continued shareholder services contacts registrar companys registrar equiniti limited aspect house spencer road lancing bn da wwwshareviewcouk tel uk tel outside uk equiniti provides range services shareholders service offers participate dividend reinvestment plan alternative receiving cash dividends may choose drip election form downloaded drip reinvest dividends buy gsk shares wwwshareviewcouk requested contacting equiniti dividend payment direct bank currently receive dividends cheque dividend bank mandate form account bank mandate post instead paid directly bank downloaded wwwshareviewcouk building society account quicker secure requested contacting equiniti avoids risk cheque going astray dividend payment direct bank instead waiting sterling cheque arrive post details service costs account overseas shareholders equiniti convert dividend local currency involved please contact equiniti send direct local bank account service available countries worldwide electronic communications shareholders may elect receive electronic notifications register wwwshareviewcouk company communications including annual report dividend payments paid way bank mandate access electronic tax vouchers availability online voting general meetings time gsk mails hard copy shareholder documents receive email containing link document relevant website shareview portfolio service enables create free online portfolio view register wwwshareviewcouk share balance movements update address dividend payment instructions register votes agm duplicate publications mailings receive duplicate copies report mailings please contact equiniti please contact equiniti arrange accounts merged one convenience avoid waste unnecessary costs share dealing service shareholders may trade shares either held certificated form internet transactions please log held corporate sponsored nominee internet wwwshareviewcoukdealing please note market trading hours pm uk time telephone postal dealing service provided equiniti telephone transactions please call monday friday excluding public financial services limited uk holidays england wales outside uk postal transactions please call request dealing form corporate sponsored nominee account convenient way manage shares without requiring application form requested share certificate service provides facility hold wwwshareviewcouk shares nominee account sponsored company contacting equiniti continue receive dividend payments annual reports attend vote companys general meetings shareholders names appear publicly available share register service free join individual savings accounts isas company arranged equiniti financial services details available wwwshareviewcouk limited provide gsk corporate isa hold gsk requested telephoning equiniti ordinary shares lines open pm dealing pm enquiries monday friday excluding public holidays england wales uk lines open pm monday friday excluding public holidays england wales provision share dealing details intended invitation inducement engage investment activity advice share dealing obtained stockbroker independent financial adviser gsk annual report strategic report governance remuneration financial statements investor information shareholders services contacts continued ads depositary contacts investor relations ads programme administered bank new york mellon investor relations may contacted follows uk bny mellon shareowner services great west road po box brentford middlesex tw gs louisville ky tel overnight correspondence sent us bny mellon shareowner services crescent drive south th street suite philadelphia pa louisville ky tel us toll free wwwmybnymdrcom tel outside us tel us toll free gsk response center tel outside us tel us toll free email shrrelationscpushareownerservicescom share scam alert depositary also provides global buydirect direct ads receive unsolicited telephone call offering sell buy purchasesale dividend reinvestment plan ads holders shares please take extra care caller may part details enrol please visit wwwmybnymdrcom highly organised financial scam call helpline number obtain enrolment pack uk shareholder please contact financial conduct glaxo wellcome smithkline beecham authority information similar activities corporate peps wwwfcaorgukconsumers consumer helpline share centre limited oxford house oxford road aylesbury bucks hp sz tel uk tel tel outside uk wwwsharecom lines open pm uk time monday friday except uk public donating shares save children holidays pm saturdays gsk embarked ambitious global partnership responsible business supplement save children share expertise resources publishing responsible business supplement aim helping save lives one million children online outline gsks approach performance shareholders small number shares value key responsible business areas health behaviour makes uneconomical sell may wish consider donating people planet save children donated shares aggregated sold save children use funds raised help reach goal obtain share donation form please contact registrar equiniti managing donation sale uk shares save children free charge provision share dealing details intended invitation inducement engage investment activity advice share dealing obtained stockbroker independent financial adviser gsk annual report statutory disclosures us law regulation number provisions us law regulation apply responsible establishing maintaining internal company shares quoted new york stock control financial reporting provides reasonable assurance exchange nyse form ads regarding reliability financial reporting preparation financial statements external purposes accordance nyse rules generally accepted accounting principles general nyse rules permit company follow uk corporate governance practices instead applied us disclosed annual report form f provided explain significant variations explanation changes internal controls financial reporting contained form f accessed period covered annual report form f securities exchange commissions sec edgar database materially affected reasonably likely affect materially via website nyse rules came effect require us companys internal control financial reporting file annual interim written affirmations concerning audit disclosed based recent evaluation internal control risk committee statement significant differences financial reporting external auditors arc corporate governance significant deficiencies material weaknesses design operation internal controls financial reporting sarbanesoxley act reasonably likely affect adversely companys ability record following number corporate accounting scandals us process summarise report financial information fraud congress passed sarbanesoxley act sarbanesoxley regardless materiality involving persons significant wideranging piece legislation concerned largely financial role companys internal control financial reporting reporting corporate governance group carried evaluation supervision recommended sec company established participation management including ceo disclosure committee committee reports ceo cfo effectiveness design operation groups cfo audit risk committee arc chaired disclosure controls procedures december company secretary members consist senior managers finance legal corporate communications investor relations inherent limitations effectiveness system disclosure controls procedures including possibility external legal counsel external auditors internal experts human error circumvention overriding controls invited attend meetings periodically responsibility procedures accordingly even effective disclosure controls considering materiality information timely basis procedures provide reasonable assurance achieving determining disclosure information responsibility control objectives timely filing reports sec formal review annual report form f committee met ceo cfo expect complete certifications times report conclusions effectiveness disclosure controls procedures march following certificates sarbanesoxley requires annual report form f filed sec part groups form f contain statement whether member arc audit committee financial expert defined sarbanesoxley section managements annual report internal control statement relevant member arc judy lewent financial reporting included audit risk committee report accordance requirements section sarbanes biography additional disclosure requirements arise oxley following report provided management respect section section sarbanesoxley respect companys internal control financial reporting defined disclosure controls procedures internal control rules af df us securities exchange financial reporting act amended exchange act section corporate responsibility financial reports management responsible establishing maintaining sarbanesoxley also introduced requirement ceo adequate internal control financial reporting group cfo complete formal certifications confirming internal control financial reporting designed provide reasonable assurance regarding reliability financial reporting reviewed annual report form f preparation financial statements external purposes based knowledge annual report form f accordance ifrs contains material misstatements omissions management conducted evaluation effectiveness based knowledge financial statements internal control financial reporting based framework financial information fairly present material respects internal control integrated framework issued financial condition results operations cash flows committee sponsoring organisations treadway dates periods presented annual report commission coso form f changes groups internal control responsible establishing maintaining disclosure financial reporting materially affected controls procedures ensure material information reasonably likely affect materially groups internal made known evaluated effectiveness control financial reporting controls procedures yearend results management assessed effectiveness internal control evaluation contained annual report financial reporting december form f conclusion filed part groups form f gsk annual report strategic report governance remuneration financial statements investor information us law regulation continued pricewaterhousecoopers llp audited group regularly receive information regarding consolidated financial statements group year identity distributors downstream customers ended december also assessed effectiveness establish proportion gross revenue sales potentially groups internal control financial reporting attributable entities affiliated iranian government parties auditing standard public company accounting sanctioned disclosable activities result group oversight board united states audit report filed reporting entire gross revenues million net profits groups form f million groups sales iran section r exchange act group also aware hospitals medical section r exchange act section r requires issuers facilities lebanon may affiliated controlled hezbollah make specific disclosure annual reports certain types designated united states terrorist organisation dealings iran including transactions dealings group deal directly facilities sells governmentowned entities well dealings entities distributors group also unable identify sanctioned activities related terrorism proliferation certainty degree nature affiliation end customers weapons mass destruction even activities hezbollah group unable establish proportion prohibited us law involve us persons group gross revenue sales potentially attributable reportable exports certain pharmaceutical vaccine consumer products entities result group reporting entire gross revenues iran via sales nonus entities two privately held iranian million net profits million groups sales distributors lebanon believe groups direct dealings addition section r us law also generally restricts dealings iran require specific disclosure requirements us persons persons subject us jurisdiction certain countries territories subject comprehensive group regularly receive information regarding sanctions group business via nonus entities identity distributors downstream customers iran jurisdictions targeted sanctions laws including syria cuba possible customers include entities north korea crimea believe group complies governmentowned hospitals pharmacies owned applicable us sanctions laws laws complex controlled directly indirectly iranian government continue evolve rapidly persons entities sanctioned connection terrorism proliferation activities donations political organisations political expenditure effect january ensure consistent approach notwithstanding policy companies act requires political contributions across group introduced global companies continue obtain shareholder approval policy stop voluntarily corporate political contributions make donations eu political organisations incur eu political expenditure therefore make intend period january december group make donations eu political parties organisations make political donations eu noneu organisations incur eu political expenditure definitions political notwithstanding introduction policy accordance donations political expenditure political organisations used federal election campaign act us continue legislation wide annually seek shareholder support employeeoperated political action committee pac authorisation inadvertent expenditure particular facilitates voluntary political donations eligible gsk definition eu political organisations may extend bodies employees concerned policy review law reform representation pac controlled gsk decisions amounts business community special interest groups recipients contributions made participating employees concerned environment company exercising legal right pool resources make political subsidiaries might wish support result definitions may contributions subject strict limitations total cover legitimate business activities ordinary sense us us donated political considered political donations political expenditure organisations gsk employee pac activities designed support political party independent election candidate authority board sought annually precautionary measure ensure company subsidiaries inadvertently breach legislation authorisation process expenditure year dates back agm held may following introduction political parties elections referendums act authority since renewed annually gsk annual report statutory disclosures continued group companies accordance section companies act full list subsidiaries associates joint ventures joint arrangements address registered office effective percentage equity owned december disclosed unless otherwise stated share capital disclosed comprises ordinary shares indirectly held glaxosmithkline plc percentage held class share stated less unless otherwise stated subsidiary companies registered office country incorporation subsidiary companies resident tax purposes country incorporation unless otherwise stated name security registered address wholly owned subsidiaries alberta ulc common nd street sw calgary ab tp j canada action potential venture capital limited ordinary great west road brentford middlesex tw gs england adechsa gmbh ordinary co prv provides treuhandgesellschaft ag dorfstrasse baar switzerland affymax research institute common corporation service company gateway oaks drive suite n sacramento california ca united states alenfarma especialidades farmaceuticas limitada iv ordinary quota rua dr antonio loureiro borges arquiparque miraflores alges portugal allen hanburys limited iv ordinary great west road brentford middlesex tw gs england allen hanburys pharmaceutical nigeria limited ordinary abimbola way ilasamaja isolo lagos nigeria allen farmaceutica sa ordinary severo ochoa parque tecnologico de madrid tres cantos madrid spain allen pharmazeutika gesellschaft mbh ordinary wagenseilgasse euro plaza gebude stock vienna austria barrier therapeutics inc common corporation service company little falls drive wilmington delaware united states beecham group plc p shares p shares b great west road brentford middlesex tw gs england beecham pharmaceuticals pte limited ordinary quality road jurong industrial estate jurong singapore beecham pharmaceuticals sa iv vi nominative av de agosto n naciones unidas edificio electroectuatoriana piso quito ecuador beecham portuguesaprodutos farmaceuticos e quimicos lda ordinary quota rua dr antonio loureiro borges arquiparque miraflores alges portugal beecham sa iv vi ordinary parc de la noire epine rue fleming wavre belgium biddle sawyer limited equity dr annie besant road mumbai india biovesta ilalari ltd sti iv nominative bykdere caddesi levent plaza b blok levent istanbul turkey burroughs wellcome co australia pty limited liquidation ordinary mountain highway boronia vic australia burroughs wellcome co bangladesh limited ordinary fouzderhat industrial area dhaka trunk road north kattali chittagong bangladesh burroughs wellcome international limited ordinary great west road brentford middlesex tw gs england cascan gmbh co kg partnership capital industriestrasse bad oldesloe germany castleton investment ltd vi ordinary co dtos cybercity th floor standard chartered tower ebene mauritius cellzome gmbh ordinary meyerhofstrasse heidelberg germany cellzome limited ordinary great west road brentford middlesex tw gs england cellzome therapeutics inc iv ordinary corporation service company little falls drive wilmington delaware united states cellzome inc ordinary corporation service company little falls drive wilmington series preferred delaware united states series b preferred series c convertible preferred series c convertible preferred charles midgley limited iv ordinary cumulative preference great west road brentford middlesex tw gs england chiron behring vaccines private limited ordinary wing th floorfloral deck plaza opp rolta bhavan central midc road mumbai andheri e india clarges pharmaceuticals limited ordinary preference great west road brentford middlesex tw gs england colleen corporation common par value corporation service company little falls drive wilmington delaware united states corixa corporation common corporation service company little falls drive wilmington delaware united states coulter pharmaceutical inc iv common corporation service company little falls drive wilmington delaware united states dealcyber limited ordinary great west road brentford middlesex tw gs england desarrollo energia solar alternativa sl ordinary severo ochoa parque tecnologico de madrid tres cantos madrid spain gsk annual report strategic report governance remuneration financial statements investor information group companies continued name security registered address wholly owned subsidiaries continued domantis limited ordinary great west road brentford middlesex tw gs england duncan flockhart australia pty limited iv vi ordinary mountain highway boronia vic australia edinburgh pharmaceutical industries limited iv ordinary preference shewalton road irvine ayrshire ka ap scotland eskaylab limited p ordinary great west road brentford middlesex tw gs england etex farmacutica limitada social capital avenida andres bello piso las condes santiago cp chile fipar thailand ltd liquidation ordinary th floor wave place wireless road lumpini pathumwan bangkok thailand genelabs technologies inc common corporation service company gateway oaks drive suite n sacramento california united states glaxo iv ordinary klaus torgrds vei oslo norway glaxo group limited ordinary great west road brentford middlesex tw gs england glaxo kabushiki kaisha iv ordinary asasaka minatoku tokyo japan glaxo laboratories nigeria limited iv ordinary marine road apapa lagos nigeria glaxo laboratories limited iv ordinary great west road brentford middlesex tw gs england glaxo new zealand pension plan trustee limited ordinary level zurich house queen street auckland new zealand glaxo operations uk limited ordinary great west road brentford middlesex tw gs england glaxo properties bv ordinary huis ter heideweg lz zeist netherlands glaxo verwaltungs gmbh ordinary industriestrasse bad oldesloe germany glaxo wellcome australia pty ltd iv vi ordinary mountain highway boronia vic australia glaxo wellcome farmaceutica limitada ordinary quota rua dr antonio loureiro borges arquiparque miraflores alges portugal glaxo wellcome international bv v ordinary huis ter heideweg lz zeist netherlands glaxo wellcome manufacturing pte ltd ordinary pioneer sector jurong industrial estate jurong singapore glaxo wellcome production sas ordinary rue franois jacob rueilmalmaison france glaxo wellcome pst pty ltd liquidation ordinary mountain highway boronia vic australia glaxo wellcome uk limited ordinary great west road brentford middlesex tw gs england glaxo wellcome vidhyasom limited iv ordinary th floor wave place wireless road lumpini pathumwan bangkok thailand glaxo wellcome sa ordinary poligono industrial allendeduero avenida de extremadura aranda de duero burgos spain glaxo sa ordinary severo ochoa parque tecnologico de madrid tres cantos madrid spain glaxoallenburys nigeria limited iv ordinary creek road apapa lagos pmb nigeria glaxochem uk unlimited ordinary great west road brentford middlesex tw gs england ordinary b ordinary c glaxochem pte ltd v ordinary rochester park singapore glaxosmithkline produtos farmaceuticos limitada ordinary quota rua dr antonio loureiro borges arquiparque miraflores alges portugal glaxosmithkline cambodia co ltd ordinary th floor dksh building preah monivong boulevard corner street sangkat phsar deum thakov khan chamkarmon phnom penh cambodia glaxosmithkline china investment co ltd ordinary room building ocean international center mid th east ring road bejing chaoyang district china glaxosmithkline china rd company limited equity building halei road zhang jiang hi tech park pudong new area shanghai china glaxosmithkline cyprus limited ordinary arch makariou iii capital center th floor nicosia pc cyprus glaxosmithkline gsk srl ordinary costache negri street opera center one th th floors zone district bucharest romania glaxosmithkline ireland limited ii ordinary riverwalk citywest business campus dublin ireland glaxosmithkline israel ltd ordinary basel street po box petachtikva israel glaxosmithkline malta limited ordinary first floor de la cruz avenue qormi qrm malta glaxosmithkline private limited iv ordinary unit anthony road msasa harare zimbabwe glaxosmithkline thailand limited ordinary th floor wave place wireless road lumpini pathumwan bangkok thailand glaxosmithkline aebe ordinary kifissias avenue halandri athens greece glaxosmithkline ab ordinary hemvarnsg solna sweden glaxosmithkline ag ordinary talstrasse muenchenbuchsee switzerland glaxosmithkline angola unipessoal limitada quotas bollore africa logistics angola estrada de cacuaco n cp bairro petrangol luanda angola gsk annual report statutory disclosures continued group companies continued name security registered address wholly owned subsidiaries continued glaxosmithkline argentina sa ordinary tucumn piso buenos aires caaa argentina glaxosmithkline ordinary klaus torgrds vei oslo norway glaxosmithkline asia pvt limited equity patiala road nabha dist patiala punjab india glaxosmithkline australia pty ltd ordinary mountain highway boronia vic australia glaxosmithkline bv ordinary huis ter heideweg lz zeist netherlands glaxosmithkline beteiligungs gmbh ordinary prinzregentenplatz mnchen germany glaxosmithkline biologicals shanghai ltd ordinary niudun road zhangjiang hiteck park shanghai china glaxosmithkline biologicals kft ordinary gdll homoki nagy istvn utca hungary glaxosmithkline biologicals sas ordinary rue des aulnois saintamand les eaux france glaxosmithkline biologicals sa ordinary preference rue de l'institut b rixensart belgium glaxosmithkline brasil limitada quotas estrada dos banderiantes rio de janeiro brazil glaxosmithkline capital inc ordinary wilmington trust sp services inc north market street suite wilmington delaware united states glaxosmithkline capital plc ordinary great west road brentford middlesex tw gs england glaxosmithkline caribbean limited ordinary great west road brentford middlesex tw gs england glaxosmithkline chile farmaceutica limitada social capital avenida andres bello piso las condes santiago cp chile glaxosmithkline colombia sa ordinary avenida el dorado bpiso bogota colombia glaxosmithkline consumer healthcare investments ireland ordinary cork airport business park kinsale road cork county cork limited ii iv v ireland glaxosmithkline consumer healthcare ireland ip limited ii v ordinary currabinny carrigaline county cork ireland glaxosmithkline consumer holding bv iv ordinary huis ter heideweg lz zeist netherlands glaxosmithkline doo quotas zmja od bosne broj sarajevo bosnia herzegovina glaxosmithkline doo equity capital ulica damira tomljanovica gavrana zagreb croatia glaxosmithkline doo beograd ordinary omladinskih brigada new belgrade city belgrade serbia glaxosmithkline ecuador sa ordinary av de agosto n naciones unidas edificio electroectuatoriana piso quito ecuador glaxosmithkline eesti ou ordinary ltsa tallinn estonia glaxosmithkline ehf iv vi dissolved january ordinary thverholt reykjavik iceland glaxosmithkline el salvador sa de cv ordinary avenida el boqueron calle izalco parque industrial el boqueron santa elen antiguo custatlan la libertad el salvador glaxosmithkline eood ordinary g tsarigradsko shose blvd floor mladost region sofia bulgaria glaxosmithkline export limited ordinary great west road brentford middlesex tw gs england glaxosmithkline export panama sa ordinary panama city republic panama panama glaxosmithkline far east bv ordinary huis ter heideweg lz zeist netherlands glaxosmithkline finance plc ordinary great west road brentford middlesex tw gs england glaxosmithkline gmbh co kg partnership capital prinzregentenplatz mnchen germany glaxosmithkline guatemala sa ordinary novena avenida zona guatemala city guatemala glaxosmithkline holding ordinary klaus torgrds vei oslo norway glaxosmithkline holdings americas inc common par value wilmington trust sp services inc north market street suite wilmington delaware united states glaxosmithkline holdings ireland limited ordinary deferred great west road brentford middlesex tw gs england glaxosmithkline holdings one limited ordinary great west road brentford middlesex tw gs england glaxosmithkline holdings limited ordinary great west road brentford middlesex tw gs england glaxosmithkline holdings pty ltd ordinary mountain highway boronia vic australia glaxosmithkline honduras sa ordinary tegucigalpa mdc honduras glaxosmithkline ihc limited ordinary great west road brentford middlesex tw gs england glaxosmithkline ilaclari sanayi ticaret nominative bykdere caddesi levent plaza b blok levent istanbul turkey glaxosmithkline inc class common class c preference mississauga road north mississauga ln l canada glaxosmithkline insurance ltd ordinary parlaville road hamilton hm bermuda glaxosmithkline intellectual property limited ordinary great west road brentford middlesex tw gs england glaxosmithkline intellectual property development limited ordinary great west road brentford middlesex tw gs england glaxosmithkline intellectual property holdings limited ordinary b ordinary great west road brentford middlesex tw gs england glaxosmithkline intellectual property limited ordinary deferred great west road brentford middlesex tw gs england glaxosmithkline intellectual property management limited ordinary great west road brentford middlesex tw gs england glaxosmithkline international limited ordinary great west road brentford middlesex tw gs england glaxosmithkline investigacin desarrollo sl ordinary severo ochoa parque tecnolgico de madrid tres cantos madrid spain gsk annual report strategic report governance remuneration financial statements investor information group companies continued name security registered address wholly owned subsidiaries continued glaxosmithkline investment holdings limited ordinary great west road brentford middlesex tw gs england glaxosmithkline investment services limited ordinary great west road brentford middlesex tw gs england glaxosmithkline investments ireland limited ii v ordinary currabinny carrigaline county cork ireland glaxosmithkline investments pty ltd ordinary mountain highway boronia vic australia glaxosmithkline kk ordinary asasaka minatoku tokyo japan glaxosmithkline korea limited ordinary f ls yongsan tower hangangdaero yongsangu seoul republic korea glaxosmithkline latin america sa ordinary panama city republic panama panama glaxosmithkline latvia sia ordinary duntes iela riga latvia glaxosmithkline lietuva uab ordinary ukmerges st vilnius lt lithuania glaxosmithkline limited ordinary units f tower gateway canton road harbour city tsimshatsui kowloon hong kong glaxosmithkline llc llc interests corporation service company little falls drive wilmington delaware united states glaxosmithkline manufacturing spa ordinary via alessandro fleming verona italy glaxosmithkline maroc sa ordinary angle bd rachidi et abou hamed el glaza casablanca morocco glaxosmithkline medical healthcare products limited ordinary h csorsz utca budapest hungary glaxosmithkline mercury limited ordinary great west road brentford middlesex tw gs england glaxosmithkline mexico sa de cv ordinary calzada mexicoxochimilco colonia san lorenzo huipulco delegacion tlalpan mexico glaxosmithkline nz limited ordinary level zurich house queen street auckland new zealand glaxosmithkline oy ordinary piispansilta po box espoo fin finland glaxosmithkline peru sa ordinary av javier prado oeste san isidro lima peru glaxosmithkline pharma ordinary nykaer brondby dk denmark glaxosmithkline pharma gmbh ordinary wagenseilgasse euro plaza gebude stock vienna austria glaxosmithkline pharmaceutical kenya limited ordinary lr th floor icea lion centre riverside park west wing chiromo road westlands po box nairobi kenya glaxosmithkline pharmaceutical nigeria limited ordinary industrial avenue ilupeju ikeja lagos pm b nigeria glaxosmithkline pharmaceutical sdn bhd ordinary level quill jalan semangat petaling jaya selangor darul ehsan malaysia glaxosmithkline pharmaceuticals pvt ltd ordinary galle road kaldemulla moratuwa sri lanka glaxosmithkline pharmaceuticals suzhou limited ordinary su hong xi road suzhou industrial park suzhou china glaxosmithkline pharmaceuticals costa rica sa ordinary metros al este de la rotonda de la betania mercedes de montes de oca sabanilla montes de oca san jose costa rica glaxosmithkline pharmaceuticals sa ordinary ul grunwaldzka poznan poland ordinary b ordinary c ordinary glaxosmithkline pharmaceuticals sa ordinary site apollo avenue pascal wavre belgium glaxosmithkline pharmaceuticals ukraine llc chartered capital pavla tychyny avenue v kiev ukraine glaxosmithkline pte ltd ordinary rochester park singapore glaxosmithkline puerto rico inc common centro internacional de mercadeo road tower ii suite guaynabo puerto rico glaxosmithkline republica dominicana sa ordinary ave lope de vega torre novocentro local santo domingo dominican republic glaxosmithkline research development limited ordinary great west road brentford middlesex tw gs england glaxosmithkline sa ordinary severo ochoa parque tecnologico de madrid tres cantos madrid spain glaxosmithkline spa ordinary via alessandro fleming verona italy glaxosmithkline sro ordinary hvezdova c prague czech republic glaxosmithkline services gmbh co kg partnership capital prinzregentenplatz mnchen germany glaxosmithkline services inc iv common corporation service company little falls drive wilmington delaware united states glaxosmithkline services unlimited ordinary great west road brentford middlesex tw gs england glaxosmithkline sl holdings llc llc interests corporation service company little falls drive wilmington delaware united states glaxosmithkline sl llc llc interests corporation service company little falls drive wilmington delaware united states glaxosmithkline sl lp iv partnership great west road brentford middlesex tw gs england glaxosmithkline slovakia sro ordinary galvaniho bratislava slovakia gsk annual report statutory disclosures continued group companies continued name security registered address wholly owned subsidiaries continued glaxosmithkline south africa pty limited ordinary flushing meadows building campus sloane street bryanston south africa glaxosmithkline superannuation company pty ltd ordinary mountain highway boronia vic australia liquidation glaxosmithkline trading services limited ii v ordinary currabinny carrigaline county cork ireland glaxosmithkline trading zao ordinary yakimanskaya nab moscow russian federation glaxosmithkline tunisia sarl ordinary immeuble les quatres r rue du lac lochness berges du lac tunis tunisia glaxosmithkline uk limited ordinary great west road brentford middlesex tw gs england glaxosmithkline uruguay sa registered shares provisory stock salto cp montevideo uruguay glaxosmithkline venezuela ca ordinary urbanizacion la trinidad calle luis de camoems edif apatado posta caracas venezuela glaxosmithkline vietnam limited liability company iv vi equity capital metropolitan dong khoi street district th floor unit ho chi minh city viet nam glycovaxyn ag vi common preferred grabenstrasse schlieren switzerland preferred b preferred c group laboratories south africa pty limited iv vi ordinary flushing meadows building campus sloane street bryanston south africa groupe glaxosmithkline sas ordinary rue franois jacob rueilmalmaison france gsk business service centre sdn bhd ordinary level quill jalan semangat petaling jaya selangor darul ehsan malaysia gsk capital kk ordinary asasaka minatoku tokyo japan gsk ch argentina sa nominative non endorseable ordinary shares tucumn piso buenos aires caaa argentina gsk commercial sp z oo ordinary ul rzymowskiego warsaw poland gsk doo ljubljana ordinary amerika ulica ljubljana slovenia gsk kazakhstan llp charter capital furmanov street almaty medeu district kazakhstan gsk pharmaceutical trading sa ordinary poienelor street brasov romania gsk services sp z oo ordinary ul grunwaldzka poznan poland gsk vaccines bv iv ordinary hullenbergweg amsterdam cl netherlands gsk vaccines gmbh ordinary emilvonbehringstr marburg germany gsk vaccines institute global health srl quotas via fiorentina siena italy gsk vaccines srl quotas via fiorentina siena italy gsk vaccines vertriebs gmbh ordinary rudolfdieselring holzkirchen germany hgs france sarl iv vi ordinary rue de la belle feuille boulognebillancourt france horlicks limited ordinary great west road brentford middlesex tw gs england human genome sciences pacific pty ltd liquidation ordinary mountain highway boronia vic australia human genome sciences inc common corporation service company little falls drive wilmington delaware united states id biomedical corporation quebec common du parc technologique qubec pq gp r canada id biomedical corporation washington iv common corporation service company little falls drive wilmington delaware united states instituto luso farmaco limitada iv quotas rua dr antonio loureiro borges arquiparque miraflores alges portugal interpharma dienstleistungen gmbh quotas wagenseilgasse euro plaza gebude stock vienna austria jj technologies lc iv llc interests corporation service company shockoe slip nd floor richmond va united states laboratoire glaxosmithkline ordinary rue franois jacob rueilmalmaison france laboratoire pharmaceutique algrien lpa production spa ordinary zone industrielle est boudouaou boumerdes algeria laboratoire pharmaceutique algrien spa ordinary zone industrielle est boudouaou boumerdes algeria laboratoires paucourt iv ordianry rue franois jacob rueilmalmaison france laboratoires saintgermain iv ordianry rue franois jacob rueilmalmaison france laboratorios dermatologicos darier sa de cv ordianry calzada mexico xochimilco san lorenzo huipulco district federal mexico mexico laboratorios farmaceuticos stiefel portugal ltda iv ordinary rua dr antonio loureiro borges arquiparque miraflores alges portugal laboratorios stiefel de chile compaa limitada vi social capital avenida andres bello piso las condes santiago cp chile laboratorios stiefel de venezuela sa vi ordinary urbanizacion la trinidad calle luis de camoems edif apatado posta caracas venezuela laboratorios stiefel ltda ordinary rua professor joao c salem guarulhos sao paulo brazil gsk annual report strategic report governance remuneration financial statements investor information group companies continued name security registered address wholly owned subsidiaries continued laboratorios wellcome de portugal limitada iv ordinary quota rua dr antonio loureiro borges arquiparque miraflores alges portugal maxinutrition limited liquidation ordinary baker street london wu eu england mixis genetics limited ordinary ordinary euro great west road brentford middlesex tw gs england montrose fine chemical company ltd ordinary shewalton road irvine ayrshire ka ap scotland montrose pharma company limited iv vi ordinary quota h csorsz utca budapest hungary novartis vaccines diagnostics ag liquidation ordinary co obc suisse ag aeschenvorstadt basel switzerland novartis vaccines diagnostics pty ltd iv vi ordinary mountain highway boronia vic australia okairos ag liquidation common co obc suisse ag aeschenvorstadt basel switzerland preferred preferred b penn labs inc iv common corporation service company little falls drive wilmington delaware united states sr one international bv ordinary huis ter heideweg lz zeist netherlands sr one limited units common corporation service company interstate drive suite harrisburg pennsylvania united states setfirst limited ordinary great west road brentford middlesex tw gs england smith kline french laboratories limited ordinary great west road brentford middlesex tw gs england smith kline french portuguesaprodutos ordinary rua dr antonio loureiro borges arquiparque miraflores alges farmaceuticos lda iv portugal smithkline beecham australia pty ltd liquidation ordinary mountain highway boronia vic australia smithkline beecham bangladesh private limited iv ordinary topkhana road segunbagicha dhaka bangladesh smithkline beecham cork limited ii ordinary currabinny carrigaline county cork ireland smithkline beecham export limited ordinary great west road brentford middlesex tw gs england smithkline beecham h limited noncumulative nonredeemables ordinary great west road brentford middlesex tw gs england smithkline beecham investments limited ordinary great west road brentford middlesex tw gs england smithkline beecham manufacturing limited ii ordinary currabinny carrigaline county cork ireland smithkline beecham swg limited ordinary great west road brentford middlesex tw gs england smithkline beecham biologicals us partnership partnership interest corporation service company little falls drive wilmington delaware united states smithkline beecham egypt llc quotas amoun street el salam city cairo egypt smithkline beecham farma sa ordinary severo ochoa parque tecnologico de madrid tres cantos madrid spain smithkline beecham holdings australia pty limited ordinary mountain highway boronia vic australia liquidation smithkline beecham interamerican corporation iv common corporation service company little falls drive wilmington delaware united states smithkline beecham limited ordinary p great west road brentford middlesex tw gs england smithkline beecham marketing technical services limited ordinary great west road brentford middlesex tw gs england smithkline beecham nominees limited ordinary great west road brentford middlesex tw gs england smithkline beecham overseas limited ordinary great west road brentford middlesex tw gs england smithkline beecham pension plan trustee limited iv ordinary great west road brentford middlesex tw gs england smithkline beecham pension trustees limited iv ordinary great west road brentford middlesex tw gs england smithkline beecham pharma gmbh co kg partnership capital prinzregentenplatz mnchen germany smithkline beecham pharma verwaltungs gmbh ordinary prinzregentenplatz mnchen germany smithkline beecham pharmaceuticals pty limited iv vi ordinary flushing meadows building campus sloane street bryanston south africa smithkline beecham pharmaceuticals co common corporation service company little falls drive wilmington delaware united states smithkline beecham port louis limited vi ordinary co cim corporate services ltd les cascades building edith cavell street port louis mauritius smithkline beecham retirement plan nominees pty limited ordinary mountain highway boronia vic australia liquidation smithkline beecham senior executive pension plan trustee ordinary great west road brentford middlesex tw gs england limited iv stiefel distributors ireland limited ii iv ordinary finisklin business park sligo ireland stiefel dominicana srl iv vi ordinary ave lope de vega torre novocentro local santo domingo dominican republic stiefel farma sa ordinary severo ochoa parque tecnologico de madrid tres cantos madrid spain stiefel gmbh co kg partnership capital industriestrasse bad oldesloe germany gsk annual report statutory disclosures continued group companies continued name security registered address wholly owned subsidiaries continued stiefel india private limited equity wing th floor floral deck plaza opp rolta bhavan central midc road mumbai andheri e india stiefel laboratories maidenhead ltd ordinary eurasia headquarters concorde road maidenhead berkshire sl england stiefel laboratories uk ltd ordinary eurasia headquarters concorde road maidenhead berkshire sl england stiefel laboratories legacy ireland limited ii ordinary finisklin business park sligo ireland stiefel laboratories limited iv ordinary eurasia headquarters concorde road maidenhead berkshire sl england stiefel laboratories pte limited vi ordinary gul circle singapore stiefel laboratories pty ltd liquidation ordinary mountain highway boronia vic australia stiefel laboratories inc common corporation service company little falls drive wilmington delaware united states stiefel maroc sarl ordinary boulevard zerktouni casablanca morocco stiefel research australia holdings pty ltd vi ordinary mountain highway boronia vic australia stiefel research australia pty ltd vi ordinary mountain highway boronia vic australia stiefel west coast llc llc interests corporation service company little falls drive wilmington delaware united states strebor inc common corporation service company little falls drive wilmington delaware united states tempero pharmaceuticals inc series preference corporation service company little falls drive wilmington series b preference common delaware united states sydney ross co iv ordinary corporation service company princeton south corporate center suite charles ewing blvd ewing new jersey united states wellcome foundation limited ordinary great west road brentford middlesex tw gs england ucb pharma asia pacific sdn bhd iv ordinary level symphony house pusat dagangan dana jalan pju petaling jaya selangor darul ehsan malaysia wellcome consumer healthcare limited iv ordinary great west road brentford middlesex tw gs england wellcome consumer products limited iv ordinary great west road brentford middlesex tw gs england wellcome developments pty ltd iv vi ordinary mountain highway boronia vic australia wellcome limited ordinary great west road brentford middlesex tw gs england wellcome operations pty ltd iv vi ordinary mountain highway boronia vic australia effective name security ownership registered address subsidiaries effective interest less amoun pharmaceutical industries co sae new monetary shares el salam city po box cairo egypt beecham enterprises inc iv common corporation service company little falls drive wilmington delaware united states block drug company inc common corporation service company princeton south corporate center suite charles ewing blvd ewing new jersey united states block drug corporation iv common corporation service company princeton south corporate center suite charles ewing blvd ewing new jersey united states british pharma group limited captial great west road brentford middlesex tw gs england de micln ordinary priemyselny park gena ul e sachsa levice slovakia duncan consumer healthcare philippines inc common chino roces avenue makati city philippines duncan pharmaceuticals philippines inc common chino roces avenue makati city philippines exlax inc common prentice hall corporation system puerto rico inc co fast solutions llc citi tower ponce de leon avenue floor san juan puerto rico galvani bioelectronics inc common corporation service company little falls drive wilmington delaware united states galvani bioelectronics limited ordinary great west road brentford middlesex tw gs england b ordinary glaxo saudi arabia limited ordinary po box area warehouse city first stage al khomrah jeddah saudi arabia gsk annual report strategic report governance remuneration financial statements investor information group companies continued effective name security ownership registered address subsidiaries effective interest less continued glaxo wellcome ceylon limited ordinary galle road kaldemulla moratuwa sri lanka ordinary b glaxosmithkline tianjin co ltd ordinary fifth avenue tai feng industrial park tianjin economic technolog tianjin china glaxosmithkline algrie spa ordinary zone industrielle est boudouaou wilaya de boumerdes algeria glaxosmithkline bangladesh limited ordinary fouzderhat industrial area dhaka trunk road north kattali chittagong bangladesh glaxosmithkline brasil produtos para consumo e saude ltda quotas bl vitor civita street barra tijuca rio de janeiro brazil glaxosmithkline consumer healthcare china co ltd ordinary rooms b f headquarters building tibet road shanghai china glaxosmithkline consumer healthcare hong kong limited ordinary units f tower gateway canton road harbour city tsimshatsui kowloon hong kong glaxosmithkline consumer healthcare ireland limited ii ordinary riverwalk citywest business campus dublin ireland glaxosmithkline consumer healthcare overseas limited ordinary great west road brentford middlesex tw gs england glaxosmithkline consumer healthcare thailand limited ordinary th floor unit wave place wireless road lumpini pathumwan bangkok thailand glaxosmithkline consumer healthcare uk ip limited ordinary great west road brentford middlesex tw gs england glaxosmithkline consumer healthcare uk trading limited ordinary great west road brentford middlesex tw gs england glaxosmithkline consumer healthcare us ip llc llc interests corporation service company little falls drive wilmington delaware united states glaxosmithkline consumer healthcare ordinary nykaer brondby dk denmark glaxosmithkline consumer healthcare ab vii ordinary nykaer dk brondby denmark glaxosmithkline consumer healthcare australia pty ltd ordinary hughes avenue ermington nsw australia glaxosmithkline consumer healthcare bv ordinary huis ter heideweg lz zeist netherlands glaxosmithkline consumer healthcare colombia sas ordinary avenida el dorado bpiso bogota colombia glaxosmithkline consumer healthcare czech republic sro ordinary hvezdova c prague czech republic glaxosmithkline consumer healthcare finance limited ordinary great west road brentford middlesex tw gs england glaxosmithkline consumer healthcare finance limited ordinary great west road brentford middlesex tw gs england glaxosmithkline consumer healthcare finland oy ordinary piispansilta fin espoo finland glaxosmithkline consumer healthcare gmbh ordinary wagenseilgasse euro plaza gebude stock vienna austria glaxosmithkline consumer healthcare gmbh co kg partnership capital barthstr mnchen germany glaxosmithkline consumer healthcare greece societe ordinary kifissias avenue halandri athens greece anonyme glaxosmithkline consumer healthcare holdings us llc llc interests corporation service company little falls drive wilmington delaware united states glaxosmithkline consumer healthcare holdings limited ordinary great west road brentford middlesex tw gs england ordinary b glaxosmithkline consumer healthcare inc common mississauga road north mississagua ln l canada glaxosmithkline consumer healthcare investments ireland ordinary knockbrack dungarvan co waterford x ry ireland limited ii v glaxosmithkline consumer healthcare investments ireland ordinary knockbrack dungarvan co waterford x ry ireland unlimited company ii iv v glaxosmithkline consumer healthcare japan kk ordinary asasaka minatoku tokyo japan glaxosmithkline consumer healthcare korea co ltd ordinary f ls yongsan tower hangangdaero yongsangu seoul republic korea glaxosmithkline consumer healthcare llc llc interests corporation service company interstate drive suite harrisburg pennsylvania united states glaxosmithkline consumer healthcare limited equity patiala road nabha dist patiala punjab india glaxosmithkline consumer healthcare mexico ordinary calzada mexicoxochimilco colonia san lorenzo huipulco de rl de cv delegacion tlalpan mexico df mexico glaxosmithkline consumer healthcare new zealand limited ordinary level zurich house queen street auckland new zealand glaxosmithkline consumer healthcare norway ordinary klaus torgrds vei oslo norway glaxosmithkline consumer healthcare pakistan limited ordinary sykes building dockyard road west wharf karachi pakistan glaxosmithkline consumer healthcare philippines inc common chino roces avenue makati city philippines glaxosmithkline consumer healthcare pte ltd ordinary rochester park singapore glaxosmithkline consumer healthcare sa ordinary site apollo avenue pascal wavre belgium glaxosmithkline consumer healthcare sa ordinary severo ochoa parque tecnologico de madrid tres cantos madrid spain gsk annual report statutory disclosures continued group companies continued effective name security ownership registered address subsidiaries effective interest less continued glaxosmithkline consumer healthcare spa ordinary via zambeletti snc baranzate milan italy glaxosmithkline consumer healthcare sdn bhd ordinary lot jalan enggang ampangulu kelang industrial estate selangor malaysia glaxosmithkline consumer healthcare slovakia r ownership interest galvaniho bratislava slovakia glaxosmithkline consumer healthcare south africa pty ltd ordinary flushing meadows building campus sloane street bryanston south africa glaxosmithkline consumer healthcare spzoo common ul rzymowskiego warsaw poland glaxosmithkline consumer healthcare sri lanka ordinary great west road brentford middlesex tw gs england holdings limited glaxosmithkline consumer healthcare srl ordinary costache negri street opera center one th floor zone district bucharest romania glaxosmithkline consumer healthcare vietnam charter capital floor metropolitan dong khoi ben nghe ward district company limited ho chi minh city viet nam glaxosmithkline consumer healthcare lp partnership interest corporation service company little falls drive wilmington delaware united states glaxosmithkline consumer healthcare produtos para ordinary quota rua dr antonio loureiro borges arquiparque miraflores alges saude e higiene lda portugal glaxosmithkline consumer nigeria plc iii ordinary industrial avenue ilupeju ikeja lagos pm b nigeria glaxosmithkline consumer private limited equity patiala road nabha dist patiala punjab india glaxosmithkline consumer trading services limited ordinary great west road brentford middlesex tw gs england glaxosmithkline costa rica sa ordinary san jose este de la rotonda betania carretera sabanilla costa rica glaxosmithkline dungarvan limited ii ordinary knockbrack dungarvan co waterford x ry ireland glaxosmithkline healthcare ao ordinary presnenskaya nab moscow glaxosmithkline healthcare gmbh ordinary barthstr mnchen germany glaxosmithkline healthcare ukraine ooo ownership interest pavla tychyny avenue v kiev ukraine glaxosmithkline limited ordinary likoni road po box nairobi kenya glaxosmithkline otc pvt limited ordinary sykes building dockyard road west wharf karachi pakistan glaxosmithkline pakistan limited ordinary sykes building dockyard road west wharf karachi pakistan glaxosmithkline panama sa ordinary panama city republic panama panama glaxosmithkline paraguay sa ordinary oficial gilberto aranda planta alta casi salvador del mundo asuncion paraguay glaxosmithkline pharmaceuticals limited equity dr annie besant road mumbai india glaxosmithkline philippines inc common chino roces avenue makati city philippines glaxosmithkline sae ordinary boomerang office building land zone j st district town center th tagammoe new cairo city egypt glaxosmithkline sante grand public sas ordinary rue franois jacob rueilmalmaison france glaxosmithkline tuketici sagligi anonim sirketi nominative bykdere caddesi levent plaza b blok levent istanbul turkey glaxosmithklineconsumer hungary limited liability company membership h csorsz utca budapest hungary gsk ch kazakhstan llp charter capital manasa str bostandyk district almaty kazakhstan gsk consumer health inc common corporation service company little falls drive wilmington delaware united states gsk consumer healthcare israel ltd iv ordinary basel street petech tikva israel gsk consumer healthcare schweiz ag ordinary suurstoffi rotkreuz switzerland gsk consumer healthcare services inc common corporation service company little falls drive wilmington delaware united states gsk consumer healthcare singapore pte ltd ordinary rochester park singapore gskgebro consumer healthcare gmbh ordinary bahnhofbichl fieberbrunn kitzbhel austria iodosan spa ordinary via zambeletti sncbaranzate milan italy kuhs gmbh ordinary barthstr mnchen germany laboratorios viiv healthcare sl ordinary severo ochoa parque tecnologico de madrid tres cantos madrid spain modern pharma trading company llc quotas amoun street po box el salam city cairo egypt nch nutrition consumer health ltd vi ordinary hamephalsim st petach tikva israel novartis consumer health australasia pty ltd iv vi ordinary hughes avenue ermington nsw australia redeemable preference novartis consumer health gmbh ordinary barthstr mnchen germany gsk annual report strategic report governance remuneration financial statements investor information group companies continued effective name security ownership registered address subsidiaries effective interest less continued novartis consumer health sa ordinary route de i'etraz prangins switzerland novartis consumer health uk limited ordinary park view riverside way watchmoor park camberley surrey gu yl england pt smithkline beecham pharmaceuticals shares jl pulobuaran raya kav iii dd kawasan industri pulogadung b shares jakarta indonesia pt sterling products indonesia shares graha paramita building th f jalan denpasar raya blok jakarta b shares indonesia panadol gmbh ordinary barthstr mnchen germany phivco jersey ii limited iv v ordinary castle street st helier je ut jersey phivco jersey limited iv v ordinary castle street st helier je ut jersey phivco uk ii limited ordinary great west road brentford middlesex tw gs england phivco uk limited ordinary great west road brentford middlesex tw gs england phivco llc llc interests corporation service company little falls drive wilmington delaware united states phivco llc llc interests corporation service company little falls drive wilmington delaware united states pt glaxo wellcome indonesia shares jl pulobuaran raya kav iii dd kawasan industri pulogadung timur b shares jakarta indonesia pt gsk consumer healthcare indonesia ordinary graha paramita b floor jl denpasar raya blok kuningan jakarta indonesia pt bina dentalindo liquidation ordinary gedung graha ganesha lantai jl raya bekasi km jakarta timur indonesia shionogiviiv healthcare llc iv common interests corporation service company little falls drive wilmington delaware united states sinoamerican tianjin smith kline french laboratories ltd ordinary cheng lin zhuang industrial zone dong li district tianjin china smithkline beecham private limited ordinary world trade center level west tower echelon square colombo sri lanka smithkline beecham research limited ordinary great west road brentford middlesex tw gs england smithkline beecham sa ordinary ctra de ajalvir km alcala de henares madrid spain smithkline beechambiomed ooo participation interest krylatskaya str moscow russian federation staffordmiller ireland limited ii ordinary clocherane youghal road dungarvan co waterford ireland staffordmiller limited ordinary great west road brentford middlesex tw gs england noncumulative non redeemable preference sterling drug malaya sdn berhad ordinary lot jalan enggang ampangulu kelang industrial estate selangor malaysia sterling products international incorporated iv common corporation service company little falls drive wilmington delaware united states stiefel consumer healthcare uk limited ordinary great west road brentford middlesex tw gs england stiefel egypt llc iv quota amoun street el salam city cairo egypt stiefel laboratories ireland limited ii ordinary finisklin business park county sligo ireland viiv healthcare south africa proprietary limited ordinary flushing meadows building campus sloane street bryanston south africa viiv healthcare bv ordinary huis ter heideweg lz zeist netherlands viiv healthcare company common corporation service company little falls drive wilmington delaware united states viiv healthcare finance limited ordinary great west road brentford middlesex tw gs england viiv healthcare finance limited ordinary great west road brentford middlesex tw gs england viiv healthcare finance limited ordinary great west road brentford middlesex tw gs england redeemable preference viiv healthcare gmbh ordinary prinzregentenplatz mnchen germany viiv healthcare gmbh ordinary talstrasse muenchenbuchsee switzerland viiv healthcare hong kong limited ordinary f tower gateway canton road harbour city tsimshatsui kowloon hong kong viiv healthcare kabushiki kaisha ordinary asasaka minatoku tokyo japan viiv healthcare limited class shares deferred great west road brentford middlesex tw gs england class b shares class c shares class class class e cumulative preference gsk annual report statutory disclosures continued group companies continued effective name security ownership registered address subsidiaries effective interest less continued viiv healthcare overseas limited ordinary great west road brentford middlesex tw gs england viiv healthcare pty ltd ordinary mountain highway boronia vic australia viiv healthcare puerto rico llc llc interests centro international de mercadeo carr torre suite guaynabo puerto rico viiv healthcare srl quota via alessandro fleming verona italy viiv healthcare sas ordinary rue franois jacob rueilmalmaison france viiv healthcare sprl ordinary site apollo avenue pascal wavre belgium viiv healthcare trading llc iv participation interest krylatskaya str moscow russian federation viiv healthcare trading services uk limited ordinary great west road brentford middlesex tw gs england viiv healthcare uk limited v ordinary castle street st helier je ut jersey viiv healthcare uk limited ordinary great west road brentford middlesex tw gs england viiv healthcare uk limited ordinary great west road brentford middlesex tw gs england viiv healthcare uk limited ordinary great west road brentford middlesex tw gs england viiv healthcare uk limited ordinary great west road brentford middlesex tw gs england viiv healthcare ulc common nd street sw calgary ab tp j canada viiv healthcare venture llc llc interests corporation service company little falls drive wilmington delaware united states viivhiv healthcare unipessoal lda quota rua dr antonio loureiro borges arquiparque miraflores alges portugal winster pharmaceuticals limited iv ordinary association avenue ilupeju industrial estate lagos po box nigeria zhejiang tianyuan biopharmaceutical co ltd ordinary tian road yuhang economic development zone hangzhou zhejiang province china associates apollo therapeutics llp partnership interest calci medica inc series junior preferred glaxosmithkline landholding company inc common index ventures life vi jersey lp partnership interest innoviva inc common japan vaccine distribution co ltd ordinary kurma biofund ii fcpr partnership interest longwood founders fund lp partnership interest medicxi ventures lp partnership interest joint ventures chiron panacea vaccines private limited liquidation th floor wing sagar tech plaza saki naka andheri east mumbai maharashtra india japan vaccine co ltd yonbancho chiyodaku tokyo japan qualivax pte limited robinson road singapore qura therapeutics llc corporation service company little falls drive wilmington delaware united states key directly owned glaxosmithkline plc iv dormant company ii e xempt provisions section companies act v tax resident uk ireland accordance exemptions noted section act vi entity expected disposed removed iii c onsolidated subsidiary accordance section vii incorporated sweden companies act grounds dominant influence gsk annual report strategic report governance remuneration financial statements investor information glossary terms terms used annual report us equivalent brief description accelerated capital allowances tax allowance excess depreciation arising purchase fixed assets delay charging payment tax equivalent tax depreciation american depositary receipt adr receipt evidencing title ads gsk adr represents two ordinary shares american depositary shares ads listed new york stock exchange represents two ordinary shares basic earnings per share basic income per share called share capital ordinary shares issued fully paid cer growth growth constant exchange rates company glaxosmithkline plc currency swap exchange two currencies coupled subsequent reexchange currencies agreed exchange rates dates defined benefit plan pension plan specific employee benefits often called final salary scheme defined contribution plan pension plan specific contributions level pension dependent upon growth pension fund derivative financial instrument financial instrument derives value price rate underlying item diluted earnings per share diluted income per share employee share ownership plan trusts trusts established group satisfy sharebased employee incentive plans equity shareholders funds shareholders equity finance lease capital lease freehold ownership absolute rights perpetuity group glaxosmithkline plc subsidiary undertakings gsk glaxosmithkline plc subsidiary undertakings hedging reduction risk normally relation foreign currency interest rate movements making offsetting commitments intangible fixed assets assets without physical substance computer software brands licences patents knowhow marketing rights purchased outside parties novartis transaction threepart interconditional transaction novartis ag involving consumer healthcare vaccines oncology businesses completed march ordinary share fully paid ordinary share capital company profit income profit attributable shareholders net income share capital ordinary shares capital stock common stock issued fully paid share option stock option share premium account additional paidup capital paidin surplus distributable shares issue number shares outstanding subsidiary entity gsk exercises control treasury share treasury stock turnover revenue uk corporate governance code required uk listing authority company disclosed annual report applied best practice corporate governance provisions financial reporting councils uk corporate governance code gsk annual report index access highquality products investments associates joint ventures accountability investor relations accounting principles policies key accounting judgements estimates acquisitions disposals key performance indicators adjustments reconciling profit tax operating leadership effectiveness cash flows legal proceedings annual general meeting major restructuring costs approach brexit modern employer approach tax movements equity assets held sale net debt associates joint ventures new accounting requirements audit risk committee report nominations committee report cash cash equivalents noncontrolling interests ceos statement noncontrolling interests viiv healthcare chairmans statement nonexecutive directors fees chairmans governance statement notes financial statements chairmans remuneration annual statement operating profit commitments intangible assets consolidated balance sheet investments consolidated cash flow statement noncurrent assets consolidated income statement noncurrent liabilities consolidated statement changes equity operating income consolidated statement comprehensive income provisions consumer healthcare board consumer healthcare products competition longterm priorities contingent consideration liabilities pay performance contingent liabilities pensions postemployment benefits corporate executive team pharmaceuticals corporate governance pharmaceuticals products competition corporate responsibility committee report intellectual property critical accounting policies pipeline directors senior management presentation financial statements directors interests shares principal group companies directors statement responsibilities principal risks uncertainties dividends property plant equipment donations political organisations quarterly trend political expenditure reconciliation net cash flow movement net debt earnings per share registrar employee costs related party transactions employee share schemes relations stakeholders ethical conduct environmental sustainability remuneration governance exchange rates remuneration policy summary executive director remuneration remuneration report finance expense reporting framework finance income science committee report financial calendar segment information financial instruments related disclosures share capital control financial position resources share capital share premium account financial statements glaxosmithkline plc prepared share price uk gaap shareholder information five year record shareholder services contacts global health science taxation glossary terms tax information shareholders goodwill trade payables group companies trade receivables group financial review treasury policies create longterm value trust manage risk us law regulation independent auditors report vaccines industry trends vaccines products competition intellectual property inventories viability statement gsk annual report gsk glaxosmithkline plc incorporated english brand names brand names appearing italics throughout report public limited company december trade marks either owned andor licensed gsk associated companies exception edurant formed merger glaxo wellcome plc owned janssen cialis owned eli lilly company rituxan owned biogen inc zofran owned smithkline beecham plc gsk acquired two novartis ag trumenba owned pfizer inc english companies december part acknowledgements design merger arrangements friend wwwfriendstudiocom printing pureprint group iso shares listed london stock exchange fsc certified carbon neutral new york stock exchange paper annual report printed revive silk recycled paper full fsc certification pulps used made deinked paper waste elemental chlorine free manufacturing mill holds iso eu ecolabel certificates environmental management read wwwgskcom download pdfs annual report form f responsible business supplement cautionary statement regarding number adjusted measures used report given potential development options groups forwardlooking statements performance business measures defined pipeline outlook may affected additional groups reports filed furnished us reconciliation adjusted results total datadriven rd investment decisions expectations securities exchange commission sec including results set given constant currency basis outlook f e sdh txf rea ps r n ch w e ed te cm lao f ytg yr ac e otu n r hio om l ho es u n e sop sm en k oo sn rrda tg ia cfen oy ts ad e rtt lc e maow oo ct rer en hi n cmt set ute e rp nn n r b ou etfi yo sn b f n f r fl ttgo u w hc fir aev um ce n r r fd tae stt ch hi elo tee tv n e hgf h u k nr eae rt ytn ou sl e g tur u h ea p sas e eb nt ye ay wd dict neo ou ov mro r nr dor e se sno n tn r stb ra r ue el c c lh aa ha tn elf p u pfh l nvcfe oe e n nr ui n r tt ao mf lo n rs e r e n ein l g pla v ao u ot iti c iro ra ttan ei v sn htn tn oi e uv fh uri li ta p un bd rdio e eo su n c p cc u pt e oeom e r nm frb soe fe tu r rn r ut ed ato dho n n ce e acr es n se e gn ncao pon agt r n tec g ohn fin noln gt ax f obt n ii n rt es yu e tm rot chee aii lh st ia sh e en tdk r line r aen n se agd n td mi ho af iuo e gc l rl geo eoe mf w r ir noe ei f n r un g p ts r mst beu h f aabb e f tse ej ie oe ec soc nn dt tf v e ooat ec nnd im tja tmu hhxea ea e n rt e e dit e n tr eo sei fa tf p ail ru r f ic l os eteh hfi dxa et tt p n ia oe ig x p nc te r p pt cs e la iif u csdoi cn r r ri nm e tt ih c n fe b n lu eh yr p op e sr fn oo v g trd haahru ext lo e aec ru u bst e p l sm f e os r x anticipate estimate expect intend project assumptions related outlook tax cuts jobs act becomes available assumptions plan believe words terms similar underlying estimates could change consequent meaning connection discussion future outlining expectations fiveyear adjustments charges taken could material operating financial performance particular period group made certain impact results group assumptions healthcare sector different include statements relating future actions prospective markets group operates delivery notice regarding limitations products product approvals future performance revenues financial benefits current portfolio director liability english law results current anticipated products sales efforts expenses outcome contingencies legal pipeline restructuring programmes uk companies act safe harbour limits proceedings financial results group specifically period gsk liability directors respect statements accordance legal regulatory obligations expects declines sales seretideadvair omissions directors report see including uk listing rules disclosure introduction generic alternative advair us strategic report remuneration report transparency rules financial conduct factored groups assessment future english law directors would liable authority group undertakes obligation update performance group assumes premature loss company third party one forwardlooking statements whether result exclusivity key products period group reports contained errors result recklessness new information future events otherwise reader expects least billion revenues per annum cer knowing misstatement dishonest concealment however consult additional disclosures basis products launched since including material fact would otherwise liable pages group may make documents publishes contributions shingrix inclusive comprise andor files sec readers wherever located directors report pages inclusive comprise take note disclosures accordingly assumptions groups revenue earnings strategic report pages inclusive comprise assurance given particular expectation expectations assume material interruptions supply remuneration report drawn met shareholders cautioned place groups products material mergers acquisitions presented accordance reliance upon undue reliance forwardlooking statements disposals litigation costs share repurchases english company law liabilities directors company change groups shareholdings connection reports shall subject forwardlooking statements subject assumptions viiv healthcare consumer healthcare also assume limitations restrictions provided law inherent risks uncertainties many relate material changes macroeconomic healthcare factors beyond groups control precise environment guidance outlook website estimate group cautions investors number factored divestments product exits since gsks website wwwgskcom gives additional information important factors including document could including divestment exit group notwithstanding references make cause actual results differ materially expressed noncore tail brands billion annual sales annual report gsks website none implied forwardlooking statement announced july information made available website constitutes part annual report shall deemed incorporated factors include limited discussed groups expectations assume successful delivery reference herein principal risks uncertainties pages groups integration restructuring plans period annual report forwardlooking statements including extension enhancement made behalf group speak date combined programme announced july material made based upon knowledge costs investment new product launches rd information available directors date factored expectations given annual reporthead office registered office glaxosmithkline plc great west road brentford middlesex tw gs united kingdom tel search us registered number wwwgskcom